0001043961-16-000037.txt : 20161114 0001043961-16-000037.hdr.sgml : 20161111 20161114143110 ACCESSION NUMBER: 0001043961-16-000037 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161114 DATE AS OF CHANGE: 20161114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRANSGENOMIC INC CENTRAL INDEX KEY: 0001043961 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 911789357 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36439 FILM NUMBER: 161993739 BUSINESS ADDRESS: STREET 1: 12325 EMMET ST CITY: OMAHA STATE: NE ZIP: 68164 BUSINESS PHONE: 4027385480 MAIL ADDRESS: STREET 1: 12325 EMMET STREET CITY: OMAHA STATE: NE ZIP: 68164 10-Q 1 tbio-20160930x10q.htm 10-Q Document

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 _______________________________
 FORM 10-Q
 _______________________________

(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended September 30, 2016
OR 
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from _____ to _____
Commission File Number: 000-30975
 _______________________________
TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)
 _______________________________

Delaware
 
91-1789357
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
 
 
12325 Emmet Street, Omaha, Nebraska
 
68164
(Address of principal executive offices)
 
(Zip Code)
(402) 452-5400
(Registrant’s telephone number, including area code)
 _______________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   x No   o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes   x No   o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
 
o
Accelerated filer
 
o
Non-accelerated filer
 
o  (Do not check if a smaller reporting company)
Smaller reporting company
 
x
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes   o    No   x
As of October 31, 2016, the number of shares of common stock outstanding was 24,786,244.


TRANSGENOMIC, INC.
INDEX
 
 
 
 
 
 
 
 
Page No.    
 
 
 
 
PART I.
 
 
 
 
 
Item 1.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8
 
 
 
 
Item 2.
 
 
 
 
 
Item 3.
 
Quantitative and Qualitative Disclosures About Market Risk
 
 
 
 
Item 4.
 
 
 
 
 
PART II.
 
 
 
 
 
Item 1.
 
 
 
 
 
Item 1A.
 
 
 
 
 
Item 6.
 
 
 
 
 

2

PART I. FINANCIAL INFORMATION 
Item 1.
Financial Statements
TRANSGENOMIC, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except per share data)
 
September 30,
 
 
 
2016
 
December 31,
 
(unaudited)
 
2015
ASSETS
 
 
 
CURRENT ASSETS:
 
 
 
Cash and cash equivalents
$
71

 
$
444

Accounts receivable, net
180

 
264

Inventories, net
36

 
50

Other current assets
314

 
537

Assets held for sale
265

 
1,987

Total current assets
866

 
3,282

PROPERTY AND EQUIPMENT:
 
 
 
Equipment
5,592

 
5,593

Furniture, fixtures & leasehold improvements
1,565

 
1,565

 
7,157

 
7,158

Less: accumulated depreciation
(6,985
)
 
(6,899
)
 
172

 
259

OTHER ASSETS:
 
 
 
Intangibles, net
982

 
1,170

Other assets
58

 
105

 
$
2,078

 
$
4,816

LIABILITIES AND STOCKHOLDERS’ DEFICIT
 
 
 
CURRENT LIABILITIES:
 
 
 
Current maturities of long-term debt
$
7,814

 
$
7,596

Accounts payable
6,273

 
3,781

Accrued compensation
225

 
321

Accrued expenses
2,704

 
3,734

Deferred revenue
176

 
217

Other liabilities
1,068

 
1,068

Liabilities held for sale
—

 
264

Total current liabilities
18,260

 
16,981

LONG TERM LIABILITIES:
 
 
 
Common stock warrant liability
1,430

 
350

Other long-term liabilities
212

 
305

Total liabilities
19,902

 
17,636

STOCKHOLDERS’ DEFICIT:
 
 
 
Convertible preferred stock, $0.01 par value, 15,000,000 shares authorized, 214,705 and 4,029,502 shares issued and outstanding, respectively
2

 
40

Common stock, $0.01 par value, 150,000,000 shares authorized, 24,139,130 and 13,915,691 shares issued and outstanding, respectively
241

 
139

Additional paid-in capital
201,522

 
200,403

Accumulated other comprehensive income
—

 
10

Accumulated deficit
(219,589
)
 
(213,412
)
Total stockholders’ deficit
(17,824
)
 
(12,820
)
 
$
2,078

 
$
4,816


See notes to unaudited condensed consolidated financial statements.

3

TRANSGENOMIC, INC. AND SUBSIDIARY
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Dollars in thousands, except per share data)
 
 
Three Months Ended
 
Nine Months Ended
 
September 30,
 
September 30,
 
2016
 
2015
 
2016
 
2015
NET SALES
$
457

 
$
330

 
$
1,198

 
$
1,522

COST OF GOODS SOLD
430

 
445

 
1,477

 
1,375

Gross profit
27

 
(115
)
 
(279
)
 
147

OPERATING EXPENSES:
 
 
 
 
 
 
 
Selling, general and administrative
1,252

 
1,686

 
4,392

 
5,398

Research and development
393

 
455

 
1,065

 
1,374

 
1,645

 
2,141

 
5,457

 
6,772

OPERATING LOSS FROM CONTINUING OPERATIONS
(1,618
)
 
(2,256
)
 
(5,736
)
 
(6,625
)
OTHER INCOME (EXPENSE):
 
 
 
 
 
 
 
Interest expense, net
(285
)
 
(174
)
 
(782
)
 
(550
)
Warrant revaluation
12

 
385

 
357

 
(30
)
Other, net
(1
)
 
(6
)
 
(1
)
 
(19
)
 
(274
)
 
205

 
(426
)
 
(599
)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES
(1,892
)
 
(2,051
)
 
(6,162
)
 
(7,224
)
INCOME TAX BENEFIT
—

 
—

 
—

 
(1
)
LOSS FROM CONTINUING OPERATIONS
(1,892
)
 
(2,051
)
 
(6,162
)
 
(7,223
)
LOSS FROM DISCONTINUED OPERATIONS, NET OF TAXES
(34
)
 
(5,248
)
 
(25
)
 
(6,392
)
NET LOSS
(1,926
)
 
(7,299
)
 
(6,187
)
 
(13,615
)
 
 
 
 
 
 
 
 
PREFERRED STOCK DIVIDENDS
—

 
(331
)
 
(21
)
 
(993
)
 
 
 
 
 
 
 
 
NET LOSS FROM CONTINUING OPERATIONS AVAILABLE TO COMMON STOCKHOLDERS
(1,892
)
 
(2,382
)
 
(6,183
)
 
(8,216
)
NET LOSS FROM DISCONTINUED OPERATIONS AVAILABLE TO COMMON STOCKHOLDERS
(34
)
 
(5,248
)
 
(25
)
 
(6,392
)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS
$
(1,926
)
 
$
(7,630
)
 
$
(6,208
)
 
$
(14,608
)
 
 
 
 
 
 
 
 
BASIC AND DILUTED LOSS PER COMMON SHARE FROM CONTINUING OPERATIONS
$
(0.08
)
 
$
(0.17
)
 
$
(0.28
)
 
$
(0.70
)
BASIC AND DILUTED LOSS PER COMMON SHARE FROM DISCONTINUED OPERATIONS
$
—

 
$
(0.38
)
 
$
—

 
$
(0.54
)
BASIC AND DILUTED LOSS PER COMMON SHARE
$
(0.08
)
 
$
(0.55
)
 
$
(0.28
)
 
$
(1.24
)
BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING
23,551,869

 
13,763,240

 
21,896,943

 
11,784,583


See notes to unaudited condensed consolidated financial statements.

4

TRANSGENOMIC, INC. AND SUBSIDIARY
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Dollars in thousands)

 
Three Months Ended  
 September 30,
 
Nine Months Ended 
 September 30,
 
2016
 
2015
 
2016
 
2015
Net Loss
$
(1,926
)
 
$
(7,299
)
 
$
(6,187
)
 
$
(13,615
)
Other comprehensive loss - foreign currency translation adjustment
—

 
(22
)
 
—

 
(14
)
Comprehensive Loss
$
(1,926
)
 
$
(7,321
)
 
$
(6,187
)
 
$
(13,629
)
 
 
 
 
 
 
 
 

 See notes to unaudited condensed consolidated financial statements.



5

TRANSGENOMIC, INC. AND SUBSIDIARY
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
Nine Months Ended 
 September 30, 2016
(Dollars in thousands, except share data)
 


 
Preferred Stock

Common Stock

 

 

 

 
 
Outstanding
Shares

Par
Value

Outstanding
Shares

Par
Value

Additional
Paid-in
Capital

Accumulated
Deficit

Accumulated
Other
Comprehensive
Income

Total
Balance, December 31, 2015
4,029,502

 
$
40

 
13,915,691


$
139


$
200,403


$
(213,412
)

$
10


$
(12,820
)
Net loss
—


—


—


—


—


(6,187
)

—


(6,187
)
Foreign currency translation adjustment
—


—


—


—


—


10


(10
)

—

Stock-based compensation
—


—


—


—


140


—


—


140

Issuance of common shares
—

 
—

 
1,292,722

 
12

 
488

 
—

 
—

 
500

Private placement, net
2,365,243

 
24


—


—


519


—


—


543

Dividends on preferred stock
—


—


—


—


(4,475
)

—


—


(4,475
)
Conversion of preferred stock and preferred stock dividends
(6,180,040
)
 
(62
)
 
8,930,717

 
90

 
4,447

 
—

 
—

 
4,475

Balance, September 30, 2016
214,705


$
2


24,139,130


$
241


$
201,522


$
(219,589
)

$
—


$
(17,824
)

See notes to unaudited condensed consolidated financial statements.


6

TRANSGENOMIC, INC. AND SUBSIDIARY
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in thousands) 
 
Nine Months Ended 
 September 30,
 
2016
 
2015
CASH FLOWS USED IN OPERATING ACTIVITIES:
 
 
 
Net loss
$
(6,187
)
 
$
(13,615
)
Less loss from discontinued operations, net of tax
(25
)
 
(6,392
)
Loss from continuing operations
(6,162
)
 
(7,223
)
 
 
 
 
Adjustments to reconcile net loss to net cash flows used in operating activities:
 
 
 
Depreciation and amortization
264

 
343

Stock-based compensation
111

 
489

Provision for losses on doubtful accounts
72

 
—

Warrant revaluation
(357
)
 
30

Loss on sale of fixed assets
—

 
14

Deferred interest
47

 
61

Deferred tax provision
—

 
—

Changes in operating assets and liabilities:
 
 
 
Accounts receivable
12

 
158

Inventories
14

 
—

Other current assets
280

 
(214
)
Accounts payable
2,492

 
(162
)
Accrued expenses and other liabilities
(728
)
 
78

Net cash used in continuing operations
(3,955
)
 
(6,426
)
Net cash provided by (used in) discontinued operations
381

 
(3,010
)
Net cash used in operating activities
(3,574
)
 
(9,436
)
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment
(19
)
 
(280
)
Other assets
(27
)
 
(9
)
Net cash used in continuing operations
(46
)
 
(289
)
Net cash provided by discontinued operations
1,052

 
1,910

Net cash provided by investing activities
1,006

 
1,621

CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:
 
 
 
Principal payments on capital lease obligations
(2
)
 
(35
)
Issuance of preferred stock, net
1,779

 
—

Issuance of common stock, net
468

 
8,977

Proceeds from borrowings
500

 
923

Principal payment on note payable
(550
)
 
(874
)
Net cash flows provided by financing activities
2,195

 
8,991

EFFECT OF FOREIGN CURRENCY EXCHANGE RATE CHANGES ON CASH
—

 
2

NET CHANGE IN CASH AND CASH EQUIVALENTS
(373
)
 
1,178

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD
444

 
1,609

CASH AND CASH EQUIVALENTS AT END OF PERIOD
$
71

 
$
2,787

SUPPLEMENTAL CASH FLOW INFORMATION
 
 
 
Cash paid during the period for:
 
 
 
Interest
$
—

 
$
365

See notes to unaudited condensed consolidated financial statements.

7


TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Three and Nine Months Ended September 30, 2016 and 2015

1. BUSINESS DESCRIPTION
Business Description.

Transgenomic, Inc. (“we”, “us”, “our”, the “Company” or “Transgenomic”) is a biotechnology company advancing personalized medicine for the detection and treatment of cancer and inherited diseases through our proprietary molecular technologies and clinical and research services. A key goal is to bring our Multiplexed ICE COLD-PCR (“MX-ICP”) product to the clinical market through strategic partnerships and licensing agreements, enabling the use of blood and other bodily fluids for more effective and patient-friendly diagnosis, monitoring and treatment of cancer.

MX-ICP is technology proprietary to Transgenomic. It is a reagent that improves the ability to detect genetic mutations. This technology has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing and Digital PCR. By enhancing the level of detection of genetic mutations and suppressing the normal or wild-type DNA, several benefits are provided.

Historically, our operations were organized and reviewed by management along our major product lines and presented in two business segments: Laboratory Services and Genetic Assays and Platforms. Beginning with the quarter ended September 30, 2015, our operations are now organized as one business segment, our Laboratory Services segment, and during the second half of 2015, we began presenting our Genetic Assays and Platforms segment and a portion of our Laboratory Services segment in discontinued operations.

Our current Laboratory Services business consists of our laboratory in Omaha, Nebraska, which is focused on providing genetic analytical services related to Oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. Our laboratory employs a variety of genomic testing service technologies, including our proprietary MX-ICP technology. Our laboratory in Omaha is certified under the Clinical Laboratory Improvement Amendments (“CLIA”) as a high complexity laboratory and is accredited by the College of American Pathologists.

Our condensed consolidated balance sheets, statements of operations and statements of cash flows for all periods presented reflect our former Genetic Assays and Platforms activities and Patient Testing business as discontinued operations (See Note 3 - “Discontinued Operations”).

Going Concern.

The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (“GAAP”) applicable for a going concern, which assume that we will realize our assets and discharge our liabilities in the ordinary course of business. We have incurred substantial operating losses and have used cash in our operating activities for the past few years. As of September 30, 2016, we had negative working capital of $17.4 million. Our ability to continue as a going concern is dependent upon a combination of generating additional revenue, improving cash collections, potentially selling underutilized assets and, if necessary, raising additional financing to meet our obligations and pay our liabilities arising from normal business operations when they come due. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. We cannot be certain that additional financing will be available on acceptable terms, or at all, and our failure to raise capital when needed could limit our ability to continue our operations.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation.
The accompanying condensed consolidated financial statements are presented in conformity with GAAP. All amounts are presented in U.S. Dollars (“$”). Supplemental cash flows from discontinued operations are presented in Note 3 - “Discontinued Operations”. We have evaluated events occurring subsequent to September 30, 2016 for potential recognition or disclosure in the consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.

8
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


The condensed consolidated balance sheet as of December 31, 2015 was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2015. The accompanying condensed consolidated financial statements as of and for the three and nine months ended September 30, 2016 and 2015 are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2015 contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on April 14, 2016. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2016.
Certain prior year amounts have been reclassified to conform to the current year presentation in our condensed consolidated financial statements, which consists of the effects of reclassifications from the presentation of our discontinued operations.
Principles of Consolidation.
The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.
Risks and Uncertainties.
Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.
Use of Estimates.
The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. In addition, estimates and assumptions associated with the determination of the fair value of certain assets and related impairments require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these condensed consolidated financial statements.
Fair Value.
Unless otherwise specified, book value approximates fair market value. The common stock warrant liability is recorded at fair value. See Note 9 - “Fair Value” for additional information.
Cash and Cash Equivalents and Other Current Assets.
Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less. Other current assets as of September 30, 2016 of $0.3 million include prepaid assets of $0.1 million and other receivables of $0.2 million.
Concentrations of Cash.
From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits. We have not experienced any losses on such accounts as of September 30, 2016.
Accounts Receivable.
The following is a summary of activity for the allowance for doubtful accounts from continuing operations during the three and nine months ended September 30, 2016 and 2015: 

9
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended September 30, 2016
$
157

 
$
2

 
$
(19
)
 
$
140

Three Months Ended September 30, 2015
$
20

 
$
50

 
$
—

 
$
70

Nine Months Ended September 30, 2016
$
87

 
$
72

 
$
(19
)
 
$
140

Nine Months Ended September 30, 2015
$
20

 
$
50

 
$
—

 
$
70

While payment terms are generally 30 days, we have also provided extended payment terms in certain cases. Accounts receivable are carried at original invoice amount and shown net of allowance for doubtful accounts. The estimate made for doubtful accounts is based on a review of all outstanding amounts on a quarterly basis. We determine the allowance for doubtful accounts by regularly evaluating individual payor receivables and considering a payor’s financial condition, credit history, reimbursement rates and current economic conditions. Accounts receivable are written off when deemed uncollectible and after all collection efforts have been exhausted. Recoveries of accounts receivable previously written off are recorded as a reduction in bad debt expense when received.
Inventories.
Inventories are stated at the lower of cost or market net of allowance for obsolete inventory. Cost is computed using standard costs for finished goods and average or latest actual cost for raw materials and work in process, which approximates the first-in, first-out (FIFO) method. At September 30, 2016, our net inventories were less than $0.1 million and were comprised predominantly of raw materials.
 
The following is a summary of activity for the allowance for obsolete inventory during the three and nine months ended September 30, 2016 and 2015: 
 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended September 30, 2016
$
63

 
$
—

 
$
—

 
$
63

Three Months Ended September 30, 2015
$
—

 
$
—

 
$
—

 
$
—

Nine Months Ended September 30, 2016
$
63

 
$
—

 
$
—

 
$
63

Nine Months Ended September 30, 2015
$
—

 
$
—

 
$
—

 
$
—

We determine the allowance for obsolescence by evaluating inventory quarterly for items deemed to be slow moving or obsolete.
Property and Equipment.
Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets as follows:
 
Leasehold improvements
1 to 10 years
Furniture and fixtures
3 to 7 years
Production equipment
3 to 7 years
Computer equipment
3 to 7 years
Research and development equipment
2 to 7 years
Depreciation expense in continuing operations related to property and equipment was less than $0.1 million for each of the three month periods ended September 30, 2016 and 2015. Depreciation expense was $0.1 million and $0.2 million for the nine month periods ended September 30, 2016 and 2015, respectively. Depreciation expense during each period includes depreciation related to equipment acquired under capital leases.
Intangible Assets.
Intangible assets include intellectual property and patents.

10
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


1. Intellectual Property.    Initial costs paid to license intellectual property from independent third parties are capitalized and amortized using the straight-line method over the license period. Ongoing royalties related to such licenses are expensed as incurred.
2. Patents.    We capitalize legal costs, filing fees and other expenses associated with obtaining patents on new discoveries and amortize these costs using the straight-line method over the shorter of the legal life of the patent or its economic life beginning on the date the patent is issued.
Stock-Based Compensation.
All stock-based awards to date have exercise prices equal to the market value of the shares at the date of grant and have 10-year contractual terms. Unvested awards as of September 30, 2016 had vesting periods of up to three years from the date of grant. None of the awards outstanding at September 30, 2016 are subject to performance or market-based vesting conditions.
We measure and recognize compensation expense for all stock-based awards made to employees and directors. Compensation expense, net of estimated forfeitures, is based on the calculated fair value of the awards as measured at the grant date and is expensed over the service period of the awards.
During the three and nine months ended September 30, 2016, we recorded compensation expense for all stock awards of zero and $0.1 million, respectively, within selling, general and administrative expense. During the three and nine months ended September 30, 2015, we recorded compensation expense for all stock awards of $0.2 million and $0.5 million, respectively. As of September 30, 2016, the unrecognized compensation expense related to unvested stock awards was $0.1 million, which is expected to be recognized over a weighted-average period of 1.1 years.
We granted stock options to purchase an aggregate of 11,250 and 25,250 shares of our common stock during the three and nine months ended September 30, 2016, respectively. The fair value of the stock options granted during the year was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions: risk-free interest rates of 1.56% based on the U.S. Treasury yield in effect at the time of grant; dividend yields of zero percent; expected lives of 6.00 years, based on expected exercise activity behavior; and volatility of 85% based on the historical volatility of our common stock over a time that is consistent with the expected life of the options.
Included in our stock awards outstanding as of September 30, 2016 were stock appreciation rights (“SARs”) to purchase 98,333 shares of our common stock. The SARs were issued solely to our executive officers and will vest over three years from the date of grant.
Net Sales Recognition.
Revenue is realized and earned when all of the following criteria are met:
•
Persuasive evidence of an arrangement exists;
•
Delivery has occurred or services have been rendered;
•
The seller’s price to the buyer is fixed or determinable; and
•
Collectability is reasonably assured.

In our Biomarker Identification laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year. At each of September 30, 2016 and December 31, 2015, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue was $0.2 million.

Net sales from Patient Testing laboratories, reported as part of discontinued operations, are recognized on an individual test basis and take place when the test report is completed, reviewed and sent to the client less the reserve for insurance, Medicare and Medicaid contractual adjustments. There are no deferred net sales associated with our Patient Testing services. Adjustments to the allowances, based on actual receipts from third party payers, are reflected in the estimated contractual allowance applied prospectively. In the fourth quarter of 2015, we adjusted our contractual allowance rates to better reflect the reimbursement level we expect to achieve on Patient Testing billings. The adjustment negatively impacted our Patient Testing revenues for all periods after the third quarter of 2015. (See Note 3 - “Discontinued Operations”).

Net sales of Genetic Assays and Platforms products, reported as discontinued operations (See Note 3 - “Discontinued Operations”) are recognized in accordance with the terms of the sales arrangement. Such recognition is based on receipt of an

11
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


unconditional customer order and transfer of title and risk of ownership to the customer, typically upon shipment of the product under a purchase order. Our sales terms do not provide for the right of return unless the product is damaged or defective. Net sales from certain services associated with the analytical instruments, to be performed subsequent to shipment of the products, is deferred and recognized when the services are provided. Such services, mainly limited to installation and training services that are not essential to the functionality of the instruments, typically are performed in a timely manner subsequent to shipment of the instrument. We also enter into various service contracts that cover installed instruments. These contracts cover specific time periods and net sales associated with these contracts are deferred and recognized ratably over the service period.
Common Stock Warrants.
Certain of our issued and outstanding warrants to purchase common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability (“Common Stock Warrant Liability”). We are required to present these instruments at fair value at each reporting date and any changes in fair values are recorded as an adjustment to earnings. The Common Stock Warrant Liabilities are considered Level Three financial instruments for purposes of fair value measurement. See Note 9 - “Fair Value” for additional information.
Loss Per Share.
Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to 10,701,453 and 10,392,728 shares of our common stock have been excluded from the computation of diluted loss per share at September 30, 2016 and 2015, respectively, because the effect is anti-dilutive due to the net loss.
Recent Accounting Pronouncements.
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“ASU No. 2014-09”). This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year. As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40)(“ASU No. 2014-15”). This guidance addresses management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted. We do not expect to early adopt this guidance and do not believe that the adoption of this guidance will have a material impact on our consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016; however, early adoption is permitted. We do not expect to early adopt this guidance and are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

12
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015



3. DISCONTINUED OPERATIONS

On September 8, 2015, we entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Edge BioSystems, Inc. (“Edge Bio”), pursuant to which we sold our manufacturing, marketing and selling of high quality polymer and silica based beads and resin and chromatography columns business (collectively, the “Columns Business”). The Columns Business was part of our former segment, Genetic Assays and Platforms. Pursuant to the Asset Purchase Agreement, Edge Bio acquired substantially all of the assets used solely in connection with the Columns Business and assumed certain liabilities of the Columns Business for a total cash purchase price of approximately $2.1 million (the “Asset Sale”), which was paid on September 8, 2015 upon the closing of the Asset Sale. During the year ended December 31, 2015, we recorded a gain on the sale of the Columns Business of $1.5 million.

On November 25, 2015, we entered into an Asset Purchase Agreement (the “Purchase Agreement”) with ADSTEC Corporation (“ADSTEC”) and ADS Biotec Inc., a wholly-owned subsidiary of ADSTEC (“Buyer”), pursuant to which we sold (1) to ADSTEC our facilities located in Glasgow, Scotland and on Irvington Road in Omaha, Nebraska (together, the “Facilities”) and all of our stock, inventory and raw materials located at the Facilities (collectively, the “Inventory”), and (2) to Buyer (a) all of the remaining assets relating to our Genetic Assays and Platforms business segment (the “Business”), other than the Inventory (the “Purchased Assets”), and (b) all of the ordinary shares of Transgenomic Limited, a wholly-owned subsidiary of ours (the “Shares”).

Pursuant to the Purchase Agreement, ADSTEC and Buyer acquired the Facilities, the Inventory, the Purchased Assets and the Shares for an aggregate purchase price of approximately $300,000, and Buyer assumed our financial and human resources commitments related to the Business (the “Transaction”). During the year ended December 31, 2015, we recorded a loss on the Transaction of $1.7 million.

Together, the Asset Sale and the Transaction represent the divestiture of our Genetic Assays and Platforms business, resulting in a strategic shift that had a major effect on our operations and financial results. Therefore, the divested operations of our Genetic Assays and Platforms business meet the criteria to be reported as discontinued operations.
During the fourth quarter of 2015, our Board of Directors took actions to begin the process of divesting our Patient Testing business in New Haven, Connecticut. In March 2016, we announced that we had suspended testing services in our Patient Testing laboratory as we review and evaluate various strategic alternatives for that business. As a result of these actions, as of December 31, 2015, our Patient Testing business met the criteria to be reported as discontinued operations. We anticipate that we will complete the divestiture of the Patient Testing business during 2016.
The related assets, liabilities, results of operations and cash flows for both the Genetic Assays and Platforms business and Patient Testing business are classified as assets held for sale, liabilities held for sale and discontinued operations for all periods presented.

13
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


Results of the discontinued operations consisted of the following:
 
Three months ended September 30,
 
Nine months ended September 30,
(Dollars in thousands)
2016
 
2015
 
2016
 
2015
Net sales
$
283

 
$
5,507

 
$
1,960

 
$
17,868

Cost of goods sold
57

 
3,203

 
1,251

 
9,980

Gross profit
226

 
2,304

 
709

 
7,888

Selling, general and administrative expense
252

 
1,910

 
1,621

 
8,325

Research and development expense
98

 
106

 
166

 
330

Impairment of long-lived assets
—

 
7,024

 
—

 
7,024

Operating income (loss) from discontinued operations
(124
)
 
(6,736
)
 
(1,078
)
 
(7,791
)
Gain on sale of business/assets
90

 
1,532

 
1,053

 
1,532

Income (loss) from discontinued operations before income taxes
(34
)
 
(5,204
)
 
(25
)
 
(6,259
)
Income tax expense
—

 
44

 
—

 
133

Income (loss) from discontinued operations, net of taxes
$
(34
)
 
$
(5,248
)
 
$
(25
)
 
$
(6,392
)

The loss from discontinued operations for the nine month period ended September 30, 2016, includes approximately $1.1 million in proceeds received from the sale of assets of our discontinued Patient Testing business.
Assets and liabilities of the discontinued operations are classified as assets held for sale and liabilities held for sale in the condensed consolidated balance sheets and consisted of the following:
 
Dollars in Thousands
 
September 30,
2016
 
December 31,
2015
ASSETS
 
 
 
Accounts receivable, net
$
244

 
$
1,905

Other current assets
21

 
82

Total Assets
$
265

 
$
1,987

 
 
 
 
LIABILITIES
 
 
 
Accrued compensation
$
—

 
$
264

Total Liabilities
$
—

 
$
264

 
 
 
 

The following is a summary of activity for the allowance for doubtful accounts from discontinued operations during the three and nine months ended September 30, 2016 and 2015. The allowance for doubtful accounts from discontinued operations is included in the assets held for sale in the condensed consolidated balance sheets.

14
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended September 30, 2016
$
10,462

 
$
—

 
$
(5,192
)
 
$
5,270

Three Months Ended September 30, 2015
$
8,406

 
$
1,052

 
$
(168
)
 
$
9,290

Nine Months Ended September 30, 2016
$
14,664

 
$
—

 
$
(9,394
)
 
$
5,270

Nine Months Ended September 30, 2015
$
7,927

 
$
3,782

 
$
(2,419
)
 
$
9,290


4. INTANGIBLES AND OTHER ASSETS
We review our amortizable long-lived assets for impairment annually or whenever events indicate that the carrying amount of the asset (group) may not be recoverable. An impairment loss may be needed if the sum of the future undiscounted cash flows is less than the carrying amount of the asset (group). The amount of the loss would be determined by comparing the fair market value of the asset to the carrying amount of the asset (group).
Long-lived intangible assets as of September 30, 2016 and December 31, 2015 consisted of the following:
 
Dollars in Thousands
 
September 30, 2016
 
Cost
 
Accumulated
Amortization
 
Net Book
Value
Patents
680

 
80

 
600

Intellectual property
672

 
290

 
382

 
$
1,352

 
$
370

 
$
982



 
Dollars in Thousands
 
December 31, 2015
 
Cost
 
Accumulated
Amortization
 
Net Book
Value
Patents
980

 
274

 
706

Intellectual property
671

 
207

 
464

 
$
1,651

 
$
481

 
$
1,170


 
 
 
Estimated Useful Life
Patents
Life of the patent
Intellectual property
7 years
Other assets include U.S. security deposits and deferred tax assets, net of applicable valuation allowances.
Amortization expense for intangible assets was $0.2 million and $0.1 million during the nine month periods ended September 30, 2016 and 2015, respectively. Amortization expense for intangible assets is expected to be $0.1 million for each of the years ending December 31, 2016, 2017, 2018, 2019 and 2020.










15
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


5.         DEBT
 
 
Dollars in Thousands
 
 
September 30, 2016
 
December 31, 2015
Revolving Line of Credit(1)
 
$
3,243

 
$
3,025

Term Loan(2)
 
4,000

 
4,000

Convertible Promissory Notes (3)
 
571

 
571

Total debt
 
7,814

 
7,596

Current portion of long-term debt
 
(7,814
)
 
(7,596
)
Long-term debt, net of current maturities
 
$
—

 
$
—

 
(1)
Revolving Line of Credit. Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) 6.25% or (b) the Wall Street Journal prime rate plus 3%. The current interest rate is 6.50%. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of $20,000 on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line. In addition, a fee of 0.5% per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on November 1, 2017.

(2)
Term Loan. We received $4.0 million under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is 9.1%.

We will pay the Lenders an additional final payment of $120,000 at maturity or prepayment of the Term Loan. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of 1% of the total outstanding balance under the Term Loan.

Additional Terms.
The Loan Agreement contains affirmative and negative covenants. Under the Term Loan, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders’ consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of September 30, 2016, we were not in compliance with the Loan Agreement, as amended by the Ninth Amendment, due to the fact that we did not make the required monthly interest payments during the third quarter and have not received a waiver for the non-compliance and as such all debt has been classified as current at September 30, 2016.

To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by 5% and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. As of the date these financials were available for release, the Lenders have not exercised the remedies under the Loan Agreement.

(3) Convertible Promissory Notes. The Notes accrue interest at a rate of 6% per year and mature on December 31, 2016.

Revolving Line and Term Loan.

On March 13, 2013 (the “Effective Date”), we entered into a Loan and Security Agreement with affiliates of Third Security, LLC (the “Lenders”) for (a) a revolving line of credit (the “Revolving Line”) with borrowing availability of up to $4.0 million, subject to reduction based on our eligible accounts receivable, and (b) a term loan (the “Term Loan” and, together with the Revolving Line, the “Loan Agreement”) of $4.0 million. Proceeds were used to pay off a three year senior secured promissory note payable to PGxHealth, LLC, which was entered into on December 29, 2010 in conjunction with our acquisition of the FAMILION family of genetic tests, and for general corporate and working capital purposes.

16
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


On August 2, 2013, we entered into an amendment to the Loan Agreement (the “Amendment”). The Amendment, which became effective as of June 30, 2013, reduced our future minimum revenue covenants under the Loan Agreement and modified the interest rates applicable to the amounts advanced under the Revolving Line.

On November 14, 2013, we entered into a second amendment to the Loan Agreement (the “Second Amendment”). The Second Amendment, which became effective as of October 31, 2013, reduced our future minimum revenue covenants under the Loan Agreement.

On January 27, 2014, we entered into a third amendment to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment, the Lenders agreed to waive certain events of default under the Loan Agreement, and the parties amended certain provisions of the Loan Agreement, including the minimum liquidity ratio that we must maintain during the term of the Loan Agreement.

On March 3, 2014, we entered into a fourth amendment to the Loan Agreement (the “Fourth Amendment”). Pursuant to the terms of the Fourth Amendment, we were not required to make any principal or interest payments under the Term Loan for the period from March 1, 2014 through March 31, 2015. The interest on the debt that was deferred and not paid was capitalized as part of the Term Loan. The amount of interest that was capitalized from March 1, 2014 to March 31, 2015 was $0.4 million.

On October 22, 2014, we entered into a fifth amendment to the Loan Agreement (the “Fifth Amendment”). Pursuant to the Fifth Amendment, the parties amended certain provisions of the Loan Agreement, including reducing the minimum liquidity and revenue covenants under the Loan Agreement. The Fifth Amendment also reduced the aggregate amount that we may borrow under the Revolving Line from $4.0 million to $3.0 million.

On April 1, 2015, we entered into a sixth amendment to the Loan Agreement (the “Sixth Amendment”). Pursuant to the Sixth Amendment, among other things, (a) the Lenders waived specified events of default under the terms of the Loan Agreement, (b) commencing April 1, 2015, we began making monthly interest payments with respect to the Term Loan to the Lenders, (c) we were not be obligated to make monthly payments of principal under the Term Loan to the Lenders until April 1, 2016, (d) we made an initial prepayment of a portion of the Term Loan balance in the amount of approximately $148,000 on April 1, 2015 and will make one or more additional prepayments to the Lenders under the Loan Agreement upon the occurrence of certain events, as defined in the Loan Agreement, and (e) we were not required to comply with the minimum liquidity ratio under the terms of the Loan Agreement until the earliest to occur of a specified event, as defined in the Loan Agreement, or March 31, 2016. The Sixth Amendment also extends the time period in which we must provide certain reports and statements to the Lenders and amends the circumstances pursuant to which we may engage in certain sales or transfers of our business or property without the consent of the Lenders.
As of June 30, 2015, we were in compliance with all financial covenants of the Loan Agreement, but were not in compliance with the restrictions limiting the amount that we may borrow under the Revolving Line. Accordingly, on August 10, 2015, we received a waiver from the Lenders relating to this non-compliance and paid the Lenders an aggregate of $0.7 million, which brought us back into compliance with the terms of the Revolving Line.

On September 4, 2015, we entered into a seventh amendment to the Loan Agreement (the “Seventh Amendment”). The Seventh Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) reduced our borrowing availability under the Revolving Line to approximately $2.3 million, and (d) limited our borrowing base under the Loan Agreement to the amount of the Revolving Line.

On January 6, 2016, we entered into an eighth amendment to the Loan Agreement (the “Eighth Amendment”). The Eighth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) extended the maturity date of the Loan Agreement until November 1, 2017, and (d) provided for the repayment of an overadvance of $750,000 previously provided by the Lenders to us pursuant to the Loan Agreement.

On June 6, 2016, we entered into a ninth amendment to the Loan Agreement (the “Ninth Amendment”). The Ninth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) amended the prepayment terms of the Loan Agreement, (c) provided for the reduction of amounts available under the Revolving Line upon the prepayment or repayment of certain amounts by us, (d) removed the minimum liquidity ratio and minimum net revenue financial covenants applicable to us under the Loan Agreement, (e) amended the circumstances pursuant to which we may

17
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


engage in certain sales or transfers of our business or property without the consent of the Lenders, and (f) capitalized certain amounts owed by us to the Lenders and added such overdue amounts to the outstanding principal amount of the Revolving Line.
 
As a result of the Ninth Amendment, the overadvance that existed at March 31, 2016 was added to the outstanding principal amount of the Revolving Line and no overadvance existed as of September 30, 2016.

Convertible Promissory Notes.

On December 31, 2014, we entered into an Unsecured Convertible Promissory Note Purchase Agreement (the “Note Purchase Agreement”) with an accredited investor (the “Investor”), pursuant to which we agreed to issue and sell to the Investor in a private placement an unsecured convertible promissory note (the “Initial Note”). We issued the Initial Note in the aggregate principal amount of $750,000 to the Investor on December 31, 2014. Pursuant to the terms of the Initial Note, interest accrued at a rate of 6% per year and the Initial Note was set to mature on December 31, 2016. Under the Initial Note, the outstanding principal and unpaid interest accrued was convertible into shares of our common stock as follows: (i) commencing upon the date of issuance of the Initial Note (but no earlier than January 1, 2015), the Investor was entitled to convert, on a one-time basis, up to 50% of the outstanding principal and unpaid interest accrued under the Initial Note, into shares of our common stock at a conversion price equal to the lesser of (a) the average closing price of the common stock on the principal securities exchange or securities market on which our common stock is then traded (the “Market”) for the 20 consecutive trading days immediately preceding the date of conversion, and (b) $2.20 (subject to adjustment for stock splits, stock dividends, other distributions, recapitalizations and the like); and (ii) commencing February 15, 2015, the Investor was entitled to convert, on a one-time basis, any or all of the remaining outstanding principal and unpaid interest accrued under the Initial Note, into shares of our common stock at a conversion price equal to 85% of the average closing price of our common stock on the Market for the 15 consecutive trading days immediately preceding the date of conversion. The Initial Note has been converted in full into 502,786 shares of our common stock, in accordance with the terms of the Initial Note.

On January 15, 2015, we entered into the Note Purchase Agreement with seven accredited investors (the “Additional Investors”) and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, notes (the “Additional Notes”) in an aggregate principal amount of $925,000. The Additional Notes have the same terms and conditions as the Initial Note. As of September 30, 2016, $400,000 of the aggregate principal amount of the Additional Notes, and accrued interest thereon, has been converted into an aggregate of 281,023 shares of our common stock.

6. COMMITMENTS AND CONTINGENCIES
We are subject to a number of claims of various amounts that arise out of the normal course of our business. In our opinion, the disposition of pending claims, in excess of recorded accruals, could have a material adverse effect on our financial position, results of operations or cash flows. On February 25, 2016, the Board of Regents of the University of Nebraska (“UNMC”) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of $0.7 million owed by us to UNMC. We and UNMC are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A $0.7 million liability has been recorded at December 31, 2015 and September 30, 2016.
In addition, on April 13, 2016, Fox Chase Cancer Center (“Fox Chase”) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the “Court of Common Pleas”), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the “License Agreement”), as well as the assignment of certain of our rights under the License Agreement to Integrated DNA Technologies, Inc. (“IDT”) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the “IDT Agreement”). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase’s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney’s fees.  Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. We are unable to determine whether any loss will occur or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by us as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.

18
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


On June 23, 2016, the Icahn School of Medicine at Mount Sinai (“Mount Sinai”) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of $0.7 million owed by us to Mount Sinai for services rendered. We and Mount Sinai are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A $0.7 million liability has been recorded at December 31, 2015 and September 30, 2016.
The outcome of legal proceedings and claims brought against us are subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts in excess of management’s expectations, our financial statements for such reporting period could be materially adversely affected. In general, the resolution of a legal matter could prevent us from offering our services or products to others, could be material to our financial condition or cash flows, or both, or could otherwise adversely affect our operating results.
We lease certain equipment, vehicles and operating facilities under non-cancellable operating leases that expire on various dates through 2022. The future minimum lease payments required under these leases are $0.2 million for the remainder of 2016, $0.7 million in 2017, $0.7 million in 2018, $0.7 million in 2019, $0.7 million in 2020 and $0.4 million thereafter. Rent expense for each of the nine month periods ended September 30, 2016 and 2015 was $0.2 million. At September 30, 2016, firm commitments to vendors totaled $0.1 million.

7. INCOME TAXES

Annually, we file U.S. Federal, state and foreign income tax returns.  All U.S. Federal and most state loss carryforwards remain subject to adjustment in the event of an income tax examination.
Income tax expense from continuing operations was zero for the three and nine months ended September 30, 2016. Income tax expense was zero for the three months ended September 30, 2015 and for the nine months ended September 30, 2015, we had an income tax benefit of approximately one thousand dollars. We maintain a full valuation allowance on our net deferred tax assets, having concluded that we are not more likely than not going to realize the benefit of our deferred tax assets, including our net operating loss carryforwards.
During each of the three and nine month periods ended September 30, 2016 and 2015, there were no material changes to the liability for uncertain tax positions.

8. STOCKHOLDERS’ EQUITY
Common Stock.

Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have 150,000,000 shares of common stock authorized for issuance.
On February 2, 2012, we entered into definitive agreements with institutional and other accredited investors and raised approximately $22.0 million in a private placement financing (the “Private Placement”), which included an aggregate of $3.0 million in convertible notes issued in December 2011 to entities affiliated with Third Security, LLC, a related party, that automatically converted into shares of our common stock and warrants to purchase such common stock on the same terms as all investors in the Private Placement. Pursuant to the purchase agreement, we issued an aggregate of 1,583,333 shares of our common stock at a price per share of $12.00, as well as five-year warrants to purchase up to an aggregate of 823,333 shares of our common stock with an exercise price of $15.00 per share. In connection with the conversion of the convertible notes issued by us to the entities affiliated with Third Security, LLC, the entities received an aggregate of 250,000 shares of our common stock and 125,000 warrants on the same terms as all investors in the Private Placement. Craig-Hallum Capital Group LLC (“Craig-Hallum”) served as the sole placement agent for the offering. In consideration for services rendered as the placement agent in the offering, we agreed to (a) pay to the placement agent cash commissions equal to $1,330,000, or 7.0% of the gross proceeds received in the offering; (b) issue to the placement agent a five-year warrant to purchase up to 31,666 shares of our common stock (representing 2% of the shares sold in the Private Placement) with an exercise price of $15.00 per share and other terms that are the same as the terms of the warrants issued in the Private Placement; and (c) reimburse the placement agent for reasonable out-of-pocket expenses, including fees paid to the placement agent’s legal counsel, incurred in connection with the offering, which reimbursable expenses were not to exceed $125,000. The costs incurred to complete the Private Placement were recorded as a reduction in equity in the amount of $1.5 million. Net proceeds from this offering were used for general corporate and working capital purposes, primarily to accelerate development of several of our key initiatives.

19
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


On January 24, 2013, we entered into a Securities Purchase Agreement with certain institutional and other accredited investors pursuant to which we: (a) sold to the investors an aggregate of 1,383,333 shares of our common stock at a price per share of $6.00 for aggregate gross proceeds of approximately $8.3 million; and (b) issued to the investors warrants to purchase up to an aggregate of 691,655 shares of our common stock with an exercise price of $9.00 per share (the “2013 Offering”). The warrants may be exercised, in whole or in part, at any time from January 30, 2013 until January 30, 2018 and contain both cash and “cashless exercise” features. Affiliates of Third Security, LLC purchased an aggregate of 500,000 shares of common stock and warrants to purchase an aggregate of 250,000 shares of common stock in the 2013 Offering on the same terms as the other investors. Net proceeds from the 2013 Offering were used for general corporate and working capital purposes.
In connection with the 2013 Offering, we entered into a registration rights agreement with the investors (the “Registration Rights Agreement”). The Registration Rights Agreement required that we file with the SEC a registration statement to register for resale the shares of common stock sold and the shares of common stock issuable upon exercise of the warrants (the “Warrant Shares”) by March 16, 2013. The registration statement was filed with the SEC on March 15, 2013 and was declared effective by the SEC on March 29, 2013.
The 2013 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of the warrants decreased from $15.00 per share to $12.96 per share and the number of shares issuable upon exercise of the warrants increased from 948,333 to 1,097,600.
On October 22, 2014, we entered into a Securities Purchase Agreement with certain accredited investors (the “October 2014 Investors”), pursuant to which we, in a private placement, issued and sold to the October 2014 Investors (the “2014 Private Placement”) an aggregate of 730,776 shares of our common stock at a price per share of $3.25 for an aggregate purchase price of approximately $2.4 million, and warrants to purchase up to an aggregate of 365,388 shares of our common stock with an initial exercise price of $4.00 per share that are exercisable for the period from April 22, 2015 through April 22, 2020. In connection with the 2014 Private Placement, we also issued a warrant to purchase up to an aggregate of 9,230 shares of our common stock to one advisor. The warrants issued in the 2014 Private Placement include both cash and “cashless exercise” features.
The 2014 Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale. The exercise price of the warrants decreased from $11.73 per share to $10.86 per share and the number of shares issuable upon exercise of the warrants increased from 1,212,665 to 1,309,785.
On December 31, 2014, we entered into the Note Purchase Agreement with the Investor pursuant to which we agreed to issue and sell the Initial Note to the Investor (the “Note Private Placement”). See Note 5 - “Debt-Convertible Promissory Notes” for additional information regarding the terms of the Initial Note. Pursuant to the terms of the Note Purchase Agreement, we are subject to certain registration obligations and we may be required to effect one or more other registrations to register for resale the shares of our common stock issued or issuable under the Initial Note in connection with certain “piggy-back” registration rights granted to the Investor.

The Note Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale. The exercise price of the 2012 warrants decreased from $10.86 per share to $10.25 per share and the number of shares issuable upon exercise of the warrants increased from 1,309,785 to 1,387,685.

On January 15, 2015, we entered into the Note Purchase Agreement with the Additional Investors and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, the Additional Notes in an aggregate principal amount of $925,000 (the “Additional Note Private Placement”). The Additional Notes have the same terms and conditions as the Initial Note.

Craig-Hallum acted as the sole placement agent for the sale and issuance of the Additional Notes. In connection with the sale and issuance of the Additional Notes, we issued to Craig-Hallum an unsecured convertible promissory note, upon the same terms and conditions as the Notes, in an aggregate principal amount equal to 5% of the proceeds received by us pursuant to the sale and issuance of the Additional Notes, or $46,250 (the “Placement Agent Note”). As of the date of filing of this Quarterly Report on form 10-Q, the Placement Agent Note remains outstanding.

The Additional Note Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from $10.25 per share to $9.59 per share and the number of shares issuable upon exercise of the warrants increased from 1,387,685 to 1,483,161.


20
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


On February 27, 2015, we entered into a purchase agreement with Craig-Hallum (the “Underwriter”) relating to our sale and issuance of 3,573,899 shares of our common stock and corresponding warrants to purchase up to 714,780 shares of our common stock (the “February 2015 Offering”). Each share of common stock was sold in combination with a warrant to purchase 0.20 of a share of common stock. The purchase price to the public for each share of common stock and accompanying warrant was $1.95.
The purchase price paid by the Underwriter to us for the common stock and accompanying warrants was $1.8135. The net proceeds from the February 2015 Offering, after deducting the Underwriter’s discount and other estimated February 2015 Offering expenses, were approximately $6.2 million.
The accompanying warrants are exercisable immediately upon their initial issuance date at an exercise price of $2.24 per share and will expire five years from the date of issuance. The exercise price will also be subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock.
The February 2015 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from $9.59 per share to $7.56 per share and the number of shares issuable upon exercise of the warrants increased from 1,483,161 to 1,881,396.
On June 30, 2015, we entered into a Securities Purchase Agreement with certain accredited investors (the “July 2015 Investors”) pursuant to which, on July 7, 2015, we sold to the July 2015 Investors (a) an aggregate of approximately 1.5 million shares of our common stock at a price per share of $1.42, (b) warrants (the “Series B Warrants”) to purchase up to an aggregate of 0.7 million shares of our common stock with an exercise price of $0.01 per share, and (c) warrants (the “Series A Warrants” and, together with the Series B Warrants, the “July 2015 Warrants”) to purchase up to an aggregate of 1.2 million shares of our common stock, with an exercise price of $1.66 per share (collectively, the “July 2015 Offering”). Each of the July 2015 Warrants has a term of 5 and 1/2 years. The Series B Warrants were immediately exercisable upon issuance. The Series A Warrants became exercisable on January 7, 2016, six months from the date of issuance. The aggregate gross proceeds to us from the July 2015 Offering were approximately $3.0 million.
Craig-Hallum (the “2015 Placement Agent”) served as the sole placement agent for the July 2015 Offering. In consideration for services rendered as the placement agent in the July 2015 Offering, we (a) paid to the 2015 Placement Agent cash commissions equal to approximately $212,783, or 7.0% of the gross proceeds received in the July 2015 Offering; (b) issued to the 2015 Placement Agent a five-year warrant to purchase up to 107,033 shares of our common stock with an exercise price of $1.66 per share and which is subject to other terms that are the same as the terms of the Series A Warrants; and (c) reimbursed the 2015 Placement Agent for reasonable out-of-pocket expenses, including fees paid to the 2015 Placement Agent’s legal counsel, incurred in connection with the July 2015 Offering, which reimbursable expenses did not exceed $50,000.
The July 2015 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from $7.56 per share to $6.50 per share and the number of shares issuable upon exercise of the warrants increased from 1,881,396 to 2,188,177.
On January 6, 2016, we entered into a Securities Purchase Agreement (the “SPA”) with certain accredited investors (the “2016 Investors”), pursuant to which, on January 8, 2016, we sold to the 2016 Investors, and the 2016 Investors purchased from us (the “January 2016 Offering”), an aggregate of approximately $2.2 million of units (the “Units”) consisting of (a) an aggregate of 2,365,243 shares (the “A-1 Preferred Shares”) of our Series A-1 Convertible Preferred Stock (the “A-1 Preferred”), and (b) warrants (the “2016 Warrants”) to purchase up to an aggregate of 1,773,929 shares of our common stock. Each Unit was sold to the 2016 Investors at a purchase price of $0.93 per Unit. The A-1 Preferred Shares are convertible into shares of our common stock at an initial rate of 1-for-1, which conversion rate is subject to further adjustment as set forth in our Certificate of Designation of Series A-1 Convertible Preferred Stock, which was filed with the Secretary of State of the State of Delaware on January 8, 2016 (the “Series A-1 Certificate of Designation”). Pursuant to the terms of the Series A-1 Certificate of Designation, the holders of the A-1 Preferred Shares will generally be entitled to that number of votes as is equal to the product obtained by multiplying: (i) the number of whole shares of our common stock into which the A-1 Preferred may be converted as of the record date of such vote or consent, by (ii) 0.93, rounded down to the nearest whole number. Therefore, every 1.075269 shares of A-1 Preferred will generally initially be entitled to one vote. In May 2016, 2,150,538 of the A-1 Preferred Shares were converted into 2,150,538 shares of our common stock. At June 30, 2016, there were 214,705 A-1 Preferred Shares outstanding.

The 2016 Warrants were immediately exercisable upon issuance, have a term of five years and have an exercise price of $1.21 per share of our common stock. Each 2016 Warrant includes both cash and “cashless exercise” features and an exchange feature whereby the holder of the 2016 Warrant may exchange (the “Exchange Right”) all or any portion of the 2016 Warrant for a number of shares of our common stock equal to the quotient obtained by dividing the “Exchange Amount” by the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged (the “Exchange Price”).

21
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


Under the 2016 Warrants, the “Exchange Amount” is based upon a Black Scholes option pricing model, and the aggregate Exchange Amount under all of the 2016 Warrants will be $1,436,882, subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged. Each 2016 Warrant provides that the number of shares that may be issued upon exercise of the Exchange Right is limited to the number of shares that may be purchased pursuant to the terms of the 2016 Warrant, unless we have previously obtained stockholder approval or approval from The Nasdaq Stock Market LLC to issue any additional shares of our common stock (the “Additional Shares”) pursuant to the Exchange Right (the “Required Approvals”). For any Exchange Right exercised more than 90 days following the issuance of the 2016 Warrants, if we have not obtained either of the Required Approvals, we will be required to pay the 2016 Warrant holder an amount in cash for any Additional Shares that we cannot issue without the Required Approvals based on the Exchange Amount.

The 2016 Warrants further provide that, to the extent the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged is less than $0.50, the Exchange Price will be deemed to be equal to $0.50, and, in addition to issuing shares of our common stock based on this Exchange Price, we will be required to pay to the 2016 Warrant holder an amount in cash equal to the product obtained by multiplying (a) $0.50 minus the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the 2016 Warrant holder by the Company in such exchange at an Exchange Price equal to $0.50. Therefore, if the Required Approvals are obtained, based on the Exchange Amount of $1,436,882 (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of the issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the 2016 Warrants will be 2,873,765. In addition, if, for example, assuming an Exchange Amount of $1,436,882, the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrants are exchanged is $0.25, we would be required to pay to the 2016 Warrant holders cash in an aggregate amount of $718,441 in addition to issuing the 2016 Warrant holders 2,873,765 shares.

In accordance with the terms of the SPA, we amended that certain Series A Warrant to purchase up to an aggregate of 1,161,972 shares of our common stock previously issued by us to an affiliate of one of the 2016 Investors on July 7, 2015 (the “Original Warrant”), as previously reported by us on our Amendment No. 1 to Current Report on Form 8-K/A, filed with the SEC on July 7, 2015 (as so amended, the “Amended Warrant”). The Amended Warrant amends the Original Warrant to provide that the Amended Warrant is subject to the same terms and conditions as the 2016 Warrants and, therefore, includes both cash and “cashless exercise” features and an Exchange Right whereby the number of shares issuable pursuant to the Exchange Right is equal to the “Amended Warrant Exchange Amount”, which is based on a Black Scholes option pricing model, and will be $941,197, subject to adjustment to the extent that the risk-free U.S. treasury rate fluctuates between the date of issuance of the Amended Warrant and the date the Amended Warrant is exchanged. The Amended Warrant is exercisable for up to 1,161,972 shares of our common stock in the event we have obtained either of the Required Approvals with respect to the Amended Warrant. In the event the Amended Warrant holder exercises the Amended Warrant more than 90 days following the issuance of the Amended Warrant, if we have not obtained either of the Required Approvals, we will be required to pay the Amended Warrant holder an amount in cash for the shares of our common stock that we cannot issue under the Amended Warrant pursuant to such exercise without the Required Approvals based on the Amended Warrant Exchange Amount.

The Amended Warrant also provides that, to the extent the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is less than $0.50, the Exchange Price will be deemed to be equal to $0.50, and, in addition to issuing shares of our common stock based on this Exchange Price (assuming receipt of the Required Approvals), we will be required to pay to the Amended Warrant holder an amount in cash equal to the product obtained by multiplying (a) $0.50 minus the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the Amended Warrant holder by us in such exchange at an Exchange Price equal to $0.50. Therefore, if the Required Approvals are obtained, based on the Amended Warrant Exchange Amount of $941,197 (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the issuance of the Amended Warrant and the date the Amended Warrant is exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the Amended Warrant will be 1,882,395. In addition, if, for example, assuming an Amended Warrant Exchange Amount of $941,197, the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is $0.25, we would be required to pay to the Amended Warrant holder cash in an aggregate amount of $470,599 in addition to issuing the Amended Warrant holder 1,882,395 shares.

In connection with entering into the SPA, we also entered into a Registration Rights Agreement, dated January 8, 2016, with the 2016 Investors. Pursuant to the terms of the Registration Rights Agreement, we were required to file with the SEC a registration statement to register for resale the shares of our common stock issuable upon conversion of the A-1 Preferred Shares and the shares

22
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


of our common stock issuable upon exercise of the 2016 Warrants and the Amended Warrant by January 25, 2016. We filed the required registration statement with the SEC on January 25, 2016.

Craig-Hallum (the “Placement Agent”) served as the sole placement agent for the January 2016 Offering. In consideration for services rendered as the Placement Agent in the January 2016 Offering, we (1) paid to the Placement Agent cash commissions equal to approximately $140,000, or 7.0% of the gross proceeds received in the January 2016 Offering, excluding any proceeds received from Third Security, LLC or any of its affiliates; (2) issued to the Placement Agent, for a price of $50, a five-year warrant to purchase up to 107,527 shares of our common stock at an exercise price of $1.21 per share (the “Agent Warrant”), which is subject to the same terms as the 2016 Warrants except that the Agent Warrant was not exercisable until July 8, 2016 and does not contain the Exchange Right; and (3) reimbursed the Placement Agent for reasonable out-of-pocket expenses, including fees paid to the Placement Agent’s legal counsel, incurred in connection with the January 2016 Offering, which reimbursable expenses did not exceed $50,000.

The January 2016 Offering and the payment of all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock in the form of shares of our common stock at a rate of $1.00 per share of our common stock discussed under “-Conversion of Preferred Stock” below required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased to $4.39 per share and the number of shares issuable upon exercise of the warrants increased from 2,188,177 to 3,239,827.

On May 31, 2016, we issued to a vendor an aggregate of 78,000 shares of our common stock and, on June 14, 2016, we issued to a second vendor an aggregate of 64,153 shares of our common stock. Such shares of common stock were issued to the vendors in lieu of an aggregate cash amount of approximately $89,000 owed by us to such vendors for services previously performed by such vendors. We issued the shares to the vendors in transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The offering of the shares to the vendors did not involve a public offering, and no general solicitation or advertisement was made in connection with the offering of the shares to the vendors.

On June 7, 2016, we entered into an At the Market Offering Agreement (the “ATM Agreement”) with Craig-Hallum, as sales agent, pursuant to which we may offer and sell, from time to time, through Craig-Hallum, up to $3,500,000 of shares (the “Shares”) of our common stock. Any Shares offered and sold in the offering will be issued pursuant to our effective shelf registration statement on Form S-3 (File No. 333-201907) and the related prospectus previously declared effective by the SEC on February 13, 2015, as supplemented by a prospectus supplement, dated June 7, 2016, that we filed with the SEC pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the “Securities Act”). The number of shares eligible for sale under the ATM Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3.

Under the terms of the ATM Agreement, we will pay Craig-Hallum a placement fee of 3.25% of the gross sales price of the Shares, unless Craig-Hallum acts as principal, in which case we may sell Shares to Craig-Hallum as principal at a price to be agreed upon by us and Craig-Hallum. We will also reimburse Craig-Hallum for certain expenses incurred in connection with the ATM Agreement, and agreed to provide indemnification and contribution to Craig-Hallum with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended.
 
During the three and nine months ended September 30, 2016, we sold 1,035,255 and 1,150,569 shares under the ATM Agreement.  For the nine months ended September 30, 2016, the average sales price per common share was $0.42 and the aggregate net proceeds from the sales totaled $0.5 million.    

During the three months ended September 30, 2016, the sale of shares under the ATM Agreement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased to $4.23 per share and the number of shares issuable upon exercise of the warrants increased from 3,262,088 to 3,362,276.
Common Stock Warrants.
During the nine months ended September 30, 2016 and 2015, we issued warrants to purchase 3,055,555 and 3,466,841 shares of common stock, respectively. None of the issued warrants were exercised during such periods. The warrants issued in the nine months ended September 30, 2016 included 1,174,099 warrants issued due to repricing requirements of the Private Placement and 1,881,456 warrants issued in connection with the January 2016 Offering. The warrants issued in the nine months ended September

23
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


30, 2015 included 800,492 warrants issued due to repricing requirements of the Private Placement and 2,666,349 warrants issued in connection with the February 2015 Offering and the July 2015 Offering. Warrants to purchase an aggregate of 8,976,354 shares of common stock were outstanding at September 30, 2016.
 
Warrant Holder
 
Issue Year
 
Expiration
 
Underlying
Shares
 
Exercise
Price
Various Institutional Holders(1)
 
2012
 
February 2017
 
2,919,043
 
$4.23
Affiliates of Third Security, LLC(1)
 
2012
 
February 2017
 
443,233
 
$4.23
Various Institutional Holders(2)
 
2013
 
January 2018
 
441,655
 
$9.00
Affiliates of Third Security, LLC(2)
 
2013
 
January 2018
 
250,000
 
$9.00
Various Institutional Holders(3)
 
2014
 
April 2020
 
374,618
 
$4.00
Various Institutional Holders(4)
 
2015
 
February 2020
 
714,780
 
$2.24
Various Institutional Holders(5)
 
2015
 
December 2020
 
122,433
 
$1.66
Various Institutional Holders(5)
 
2015
 
December 2020
 
667,164
 
$0.01
Various Institutional Holders(6)
 
2015
 
January 2021
 
1,161,972
 
$1.21
Affiliates of Third Security, LLC(7)
 
2016
 
January 2021
 
161,026
 
$1.21
Various Institutional Holders(7)
 
2016
 
January 2021
 
1,720,430
 
$1.21
 
 
 
 
 
 
8,976,354
 
 

(1)
These warrants were issued in connection with the Private Placement completed in February 2012 and are classified as a liability in our financial statements. See Note 9 - “Fair Value” for additional information. These warrants also contain certain anti-dilution provisions that provide for an adjustment to the exercise price and number of shares issuable upon exercise of the warrant in the event that we engage in certain issuances of shares of our common stock at a price lower than the exercise price of the warrant.
(2)
These warrants were issued in connection with the 2013 Offering, which was completed in January 2013.
(3)
These warrants were issued in connection with the 2014 Private Placement, which was completed in October 2014.
(4)
These warrants were issued in connection with the February 2015 Offering, which was completed in February 2015.
(5)
These warrants were issued in connection with the July 2015 Offering, which was completed in July 2015.
(6)
These warrants were originally issued in connection with the July 2015 Offering, which was completed in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.
(7)
These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.
Issuance of Series B Preferred Stock.

On March 5, 2014, we entered into a Series B Convertible Preferred Stock Purchase Agreement (the “Series B Purchase Agreement”) with affiliates of Third Security, LLC (the “2014 Third Security Investors”), pursuant to which we, in a private placement, sold and issued an aggregate of 1,443,297 shares of our Series B Preferred Stock, par value $0.01 per share (the “Series B Preferred Stock”), at a price per share of $4.85 for an aggregate purchase price of approximately $7.0 million. Each share of Series B Preferred Stock issued pursuant to the Series B Purchase Agreement was initially convertible into shares of our common stock at a rate of 1-for-1, which conversion rate was subject to further adjustment as set forth in the Certificate of Designation of Series B Convertible Preferred Stock.

In connection with the Series B financing, we also entered into a Registration Rights Agreement, dated March 5, 2014, with the 2014 Third Security Investors, pursuant to which we granted certain demand, “piggy-back” and S-3 registrations rights covering the resale of the shares of common stock underlying the Series B Preferred Stock issued pursuant to the Series B Purchase Agreement and all shares of common stock issuable upon any dividend or other distribution with respect thereto.


24
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


The Series B financing required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of the warrants decreased from $12.96 per share to $11.73 per share and the number of shares issuable upon exercise of the warrants increased from 1,097,600 to 1,212,665.

Conversion of Preferred Stock.

On January 6, 2016, the Company entered into a Conversion Agreement (the “Conversion Agreement”) with the holders (the “Preferred Holders”) of all of the Company’s outstanding shares of Series A Convertible Preferred Stock, par value $0.01 per share (the “Series A Preferred Stock”), and Series B Preferred Stock, pursuant to which, among other things, the Preferred Holders: (a) elected to convert all of the outstanding shares of Series A Preferred Stock and Series B Preferred Stock into shares of our common stock, in each case in accordance with the terms thereof, and (b) agreed that all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock would be paid by the Company in shares of our common stock at a rate of $1.00 per share of our common stock (collectively, the “Conversion”).

The outstanding shares of Series A Preferred Stock were convertible into shares of our common stock at a rate of 1-for-3, and the outstanding shares of Series B Preferred Stock were convertible into shares of our common stock at a rate of 1-for-1. Prior to the entry into the Conversion Agreement, there were 2,586,205 shares of Series A Preferred Stock outstanding, which were converted into 862,057 shares of our common stock, and 1,443,297 shares of Series B Preferred Stock outstanding, which were converted into 1,443,297 shares of our common stock, for an aggregate of 2,305,354 shares of our common stock issued upon conversion of the Series A Preferred Stock and Series B Preferred Stock (the “Conversion Shares”). At the time of the entry into the Conversion Agreement, there were $3,681,591.90 in accrued and unpaid dividends on the outstanding shares of Series A Preferred Stock, which were converted, in accordance with the Conversion Agreement, into 3,681,590 shares of our common stock, and $793,236.17 in accrued and unpaid dividends on the outstanding shares of Series B Preferred Stock, which were converted, in accordance with the terms of the Conversion Agreement, into 793,235 shares of our common stock, for an aggregate of 4,474,825 shares of our common stock issued pursuant to the accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock. Therefore, in connection with the full conversion of the Series A Preferred Stock and Series B Preferred Stock, plus the conversion of all accrued and unpaid dividends thereon, we issued an aggregate of 6,780,179 shares of our common stock to the Preferred Holders on January 6, 2016.

Following the conversion of the shares of Series A Preferred Stock and Series B Preferred Stock into common stock, no shares of Series A Preferred Stock or Series B Preferred Stock remain outstanding.
Preferred Stock Dividends.
We had cumulative undeclared dividends on our Series A Preferred Stock and Series B Preferred Stock of zero and $4.4 million at September 30, 2016 and December 31, 2015, respectively. Since dividends should generally not be recognized as a liability until declared, we had a recorded liability of zero for these undeclared dividends.
We had no undeclared dividends for the three months ended September 30, 2016. For the three months ended September 30, 2015 and the nine months ended September 30, 2016 and 2015, we had undeclared dividends. In accordance with the FASB’s Accounting Standards Codification Topic 260-10-45-11, “Earnings per Share”, these dividends were added to the net loss per share calculation.

9. FAIR VALUE

FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our consolidated financial statements.
FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:
Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2—Observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets; and

25
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


Level 3—Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.

Debt.
Our long term debt book value approximates fair market value due to the variable interest rate it bears.

Common Stock Warrant Liabilities.

Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.

2012 Warrant Liability
The 2012 Warrant Liability represents the fair value of the 1.2 million warrants issued in February 2012, which, through a series of changes in exercise price since February 2012, are now exercisable for 3.4 million shares of common stock. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our Statement of Operations. Management does not believe that this liability will be settled by a use of cash.
The 2012 Warrant Liability is considered a Level 3 financial instrument and is valued using a Monte Carlo simulation model. This method is well suited to valuing options with non-standard features, such as anti-dilution protection. A Monte Carlo simulation model uses repeated random sampling to simulate significant uncertainty in inputs. Assumptions and inputs used in the valuation of the common stock warrants are broken down into four sections: Static Business Inputs; Static Technical Inputs; Simulated Business Inputs; and Simulated Technical Inputs.
Static Business Inputs include: our equity value, which was estimated using our stock price of $0.28 as of September 30, 2016; the amount of the down-round financing; the timing of the down-round financing; and the expected exercise period of 0.41 years from the valuation date.
Static Technical Inputs include: volatility of 67% and the risk-free interest rate of 0.42% based on the 1-year U.S. Treasury yield interpolated from the six-month and one-year U.S. Treasury bonds.
Simulated Business Inputs include: the probability of down-round financing, which was estimated to be 100% for simulated equity values below the down-round financing cut-off point.
Simulated Technical Inputs include: our equity value follows a geometric Brownian motion and is simulated over weekly periods; and a down-round financing event that was randomly simulated in an iteration based on the 100% discrete probability of a down-round financing for those iterations where our simulated equity value at the expected timing of a down-round financing event was below the down-round financing cut-off point.

During the three and nine months ended September 30, 2016 and 2015, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:
 
 
Dollars in Thousands
 
 
For the Three Months Ended
 
 
September 30, 2016
 
September 30, 2015
Beginning balance at July 1
 
$
—

 
$
560

Total (gains) or losses:
 

 
 
Recognized in earnings
 
—

 
(385
)
Balance at September 30
 
$
—

 
$
175



26
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


 
 
Dollars in Thousands
 
 
For the Nine Months Ended
 
 
September 30, 2016
 
September 30, 2015
Beginning balance at January 1
 
$
350

 
$
145

Total (gains) or losses:
 
 
 
 
Recognized in earnings
 
(350
)
 
30

Balance at September 30
 
$
—

 
$
175


2016 Warrant Liability
The 2016 Warrant Liability represents the fair value of the 1.8 million warrants issued in January 2016. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our Statement of Operations.
The Common Stock Warrant Liability is considered a Level 3 financial instrument and is valued using a binomial lattice simulation model. This method is well suited to valuing options with non-standard features. Assumptions and inputs used in the valuation of the common stock warrants include; our equity value, which was estimated using our stock price of $0.28 as of September 30, 2016; volatility of 86%; and a risk-free interest rate of 1.04%.
During the three and nine months ended September 30, 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:
 
 
Dollars in Thousands
 
 
 
For the Three Months Ended
 
 
 
September 30, 2016
 
Beginning balance at July 1
 
$
1,442

 
Total (gains) or losses:
 
 
 
Recognized in earnings
 
(12
)
 
Balance at September 30
 
$
1,430

 
 
 
Dollars in Thousands
 
 
 
For the Nine Months Ended
 
 
 
September 30, 2016
 
Beginning balance at January 1
 
$
—

 
Additions
 
1,437

 
Total (gains) or losses:
 
 
 
Recognized in earnings
 
(7
)
 
Balance at September 30
 
$
1,430

 
The change in unrealized gains or losses of Level 3 liabilities was included in earnings and was reported in other income (expense) in our Statement of Operations.


10. STOCK OPTIONS
 
Stock Options.


27
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


The following table summarizes stock option activity during the nine months ended September 30, 2016:
 
 
Number of
Options
 
Weighted-Average
Exercise Price
Outstanding at January 1, 2016
1,107,794

 
$
3.45

Granted
25,250

 
0.84

Forfeited
(252,589
)
 
3.28

Outstanding at September 30, 2016
880,455

 
$
3.39

Exercisable at September 30, 2016
574,650

 
$
4.08

    
During the nine months ended September 30, 2016, we granted options to purchase 25,250 shares of our common stock at a weighted-average exercise price of $0.84 per share under our 2006 Equity Incentive Plan, as amended (the “Plan”). Options to purchase an aggregate of 641,560 shares of our common stock were granted during the nine months ended September 30, 2015.

As of September 30, 2016, there were 574,650 options exercisable and 860,411 options that were vested or expected to vest with an aggregate intrinsic value of zero.

Stock Appreciation Rights (“SARs”)

The following table summarizes SARs activity under the Plan during the nine months ended September 30, 2016:
 
Number of
SARs
 
Weighted-Average
Exercise Price
Outstanding at January 1, 2016
98,333

 
$
4.14

Outstanding at September 30, 2016
98,333

 
$
4.14

Exercisable at September 30, 2016
92,558

 
$
4.20


All outstanding SARs were issued solely to our executive officers.

As of September 30, 2016, 92,558 shares subject to outstanding SARs were exercisable and 98,333 shares were vested or expected to vest. The weighted-average exercise price of these SARs was $4.14 per share and the aggregate intrinsic value was zero.

11. SUBSEQUENT EVENTS

Merger Agreement

On October 12, 2016, Transgenomic, New Haven Labs Inc., a wholly owned subsidiary of Transgenomic (“Merger Sub” and, together with Transgenomic, the “Transgenomic Parties”), and Precipio Diagnostics, LLC (“Precipio”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which Precipio will become a wholly owned subsidiary of Transgenomic (the “Merger”), on the terms and subject to the conditions set forth in the Merger Agreement. Following the Merger, Transgenomic will change its name to Precipio, Inc. (“New Precipio”). The parties expect the Merger to close in 2016.
 
When the Merger is completed, (i) each outstanding common unit of Precipio will be converted into the right to receive an amount of shares of New Precipio common stock based on an exchange ratio set forth in the Merger Agreement, which is dependent on the relative amount of outstanding liabilities of each of the parties at the time of the Merger, together with cash in lieu of fractional units, which will result in Precipio unit holders owning between 62% and 80% of the outstanding shares of New Precipio common stock (not taking into account the issuance of New Precipio preferred stock in the Merger or the private placement discussed below) and (ii) each outstanding preferred unit of Precipio will be converted into the right to receive shares of New Precipio preferred stock in an aggregate amount equal to $3 million.

In connection with the Merger, at the effective time of the Merger, New Precipio also will issue shares of New Precipio preferred stock in a private placement, whereby:


28
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


•
holders of indebtedness of Transgenomic will receive $3 million in New Precipio preferred stock in exchange for such indebtedness; and

•
New Precipio will issue for cash up to $7 million in New Precipio preferred stock to investors in a private placement.

New Precipio preferred stock will be issued based on a pre-money valuation of New Precipio of $25 million and will represent, in the aggregate, approximately 34% of the outstanding shares of New Precipio common stock on an as-converted basis, including New Precipio preferred stock issued in the Merger and the private placement.

The board of managers of Precipio and the boards of directors of Transgenomic and Merger Sub, and Transgenomic, in its capacity as the sole stockholder of Merger Sub, have each approved the Merger Agreement and the board of managers of Precipio and the board of directors of Transgenomic have each recommended that their respective equity holders approve the transactions contemplated by the Merger Agreement. Transgenomic will hold a special meeting of its stockholders to approve the issuance of shares of Transgenomic common stock pursuant to the Merger, as required by Nasdaq Listing Rules, as well as certain other matters (the “Special Meeting”).
 
The Merger Agreement contains various representations, warranties and covenants of the Transgenomic Parties and Precipio, including, among others, covenants (i) by each of Precipio and Transgenomic to operate its business in the ordinary course, (ii) by each of Precipio and Transgenomic not to engage in certain kinds of transactions during the period between the execution of the Merger Agreement and the completion of the Merger, (iii) by Precipio to have its members approve the Merger and (iv) by Transgenomic to hold the Special Meeting.
 
Under the Merger Agreement, Precipio and Transgenomic are subject to customary “no shop” provisions that limit their respective abilities to solicit alternative acquisition proposals from third parties or to provide confidential information to third parties, subject to a “fiduciary out” provision that allows Precipio and Transgenomic to provide information and participate in discussions with respect to certain unsolicited written proposals and to terminate the Merger Agreement and enter into an acquisition agreement with respect to a superior proposal in compliance with the terms of the Merger Agreement (a “Superior Proposal”).
 
Completion of the Merger is subject to various conditions, including, among others: (i) approval of the holders of a majority of Transgenomic’s shares of outstanding common stock, (ii) approval of the requisite amount of the members of Precipio, (iii) approval of an amendment to the Certificate of Incorporation of Transgenomic contemplating the New Preferred Stock Financing (described below) and changing the name of Transgenomic to Precipio, Inc. or such other name as determined by Precipio, (iv) obtaining certain third party consents, (v) the absence of any judgment, injunction, order or decree prohibiting or enjoining the completion of the Merger, (vi) consummation of the New Preferred Stock Financing, (vii) approval of listing of the Parent Common Stock on NASDAQ, (viii) completion of the Common Unit Recapitalization (described above), (ix) increase in the size of the Transgenomic board by two members and the appointment of designees in accordance with the Merger Agreement and (x) the lock-up of certain Transgenomic stockholders and Precipio members.
 
In addition, the obligation of the parties to complete the Merger is subject to certain other conditions, including (i) subject to the standards set forth in the Merger Agreement, the accuracy of the representations and warranties of the other party, (ii) compliance of each party with its covenants in all material respects and (iii) no material adverse effect of either party.
 
The Merger Agreement contains certain termination rights for both the Transgenomic Parties and Precipio. Either may terminate the Merger Agreement if the Merger is not completed on or before the date that is six months following the date of the Merger Agreement. Moreover, either party may terminate the Merger Agreement if the other party changes its recommendation to its security holders to approve the Merger and the related transactions or enter into an agreement with a third party regarding a Superior Proposal (as defined in the Merger Agreement).
 
The Merger Agreement also provides that, upon termination of the Merger Agreement under certain circumstances, Transgenomic will be required to pay to Precipio a termination payment of $256,500. If the Merger Agreement is terminated for certain other reasons, Precipio will be required to pay Transgenomic a termination payment of $256,500.
 
The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, which is attached hereto as Exhibit 2.1 and incorporated by reference herein. The Merger Agreement has been included as an exhibit hereto solely to provide investors and security holders with information regarding its terms. It is not intended to be a source of financial, business or operational information about Transgenomic, Precipio or their respective subsidiaries or affiliates. The representations, warranties and covenants contained in the Merger Agreement are made only for purposes of the Merger Agreement and are made as of specific dates; are solely for the benefit of the parties; may be subject to

29
TRANSGENOMIC, INC. AND SUBSIDIARY
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Three and Nine Months Ended September 30, 2016 and 2015


qualifications and limitations agreed upon by the parties in connection with negotiating the terms of the Merger Agreement, including being qualified by confidential disclosures made for the purpose of allocating contractual risk between the parties rather than establishing matters as facts; and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors or security holders. Investors and security holders should not rely on the representations, warranties and covenants or any description thereof as characterizations of the actual state of facts or condition of Transgenomic, Precipio or their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in public disclosures.
 
In connection with the Merger, the Supporting Stockholders and Supporting Members (as defined in the Merger Agreement) are obligated to enter into a lock-up agreement with the combined company at the Effective Time pursuant to which the Supporting Stockholders will agree, among other things, not to sell shares of Transgenomic common stock for the six month period beginning at the Effective Time.
 
The Merger Agreement also provides that the combined company will enter into employment agreements with certain employees of Precipio at the Effective Time and that the officers of the combined company will be agreed to by the parties prior to the Effective Time.

Special Meeting of Stockholders
At our 2016 Special Meeting of Stockholders (the “Special Meeting”) held on October 31, 2016, our stockholders approved the proposal to authorize our Board of Directors to, in its discretion, amend our Third Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio of between one-for-ten to one-for-thirty, such ratio to be determined by our Board of Directors (the “Reverse Split Proposal”). The Reverse Split Proposal was described in detail in our definitive proxy statement filed with the Securities and Exchange Commission on September 22, 2016, as supplemented on October 13, 2016.
The approval of the Reverse Split Proposal by our stockholders provides our Board of Directors with the authority to carry out the reverse stock split, but our Board of Directors is not obligated to do so. If our Board of Directors determines to effect the reverse stock split, it intends to select a reverse stock split ratio that it believes would be most likely to achieve the anticipated benefits of the reverse stock split. Notwithstanding approval of the Reverse Split Proposal by our stockholders, our Board of Directors may, in its sole discretion, abandon the Reverse Split Proposal and determine, prior to the effectiveness of any filing with the Secretary of State of the State of Delaware, not to effect the reverse stock split. If our Board of Directors fails to implement the reverse stock split on or prior to the first anniversary date of the Special Meeting, stockholder approval again would be required prior to implementing any reverse stock split.

Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Information
This Quarterly Report on Form 10-Q, including this Management’s Discussion and Analysis, contains forward-looking statements. These statements are based on management’s current views, assumptions or beliefs of future events and financial performance and are subject to uncertainty and changes in circumstances. Readers of this report should understand that these statements are not guarantees of performance or results. Many factors could affect our actual financial results and cause them to vary materially from the expectations contained in the forward-looking statements. These factors include, among other things: our expected revenue, income (loss), receivables, operating expenses, supplier pricing, availability and prices of raw materials, insurance reimbursements, product pricing, sources of funding operations and acquisitions, our ability to raise funds, sufficiency of available liquidity, future interest costs, future economic circumstances, business strategy, industry conditions, our ability to execute our operating plans, the success of our cost savings initiatives, competitive environment and related market conditions, expected financial and other benefits from our organizational restructuring activities, actions of governments and regulatory factors affecting our business, retaining key employees and other risks as described in our reports filed with the Securities and Exchange Commission. In some cases these statements are identifiable through the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “target,” “can,” “could,” “may,” “should,” “will,” “would” or the negative versions of these terms and other similar expressions.
You are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements we make are not guarantees of future performance and are subject to various assumptions, risks and other factors that could cause actual results to differ materially from those suggested by these forward-looking statements. Actual results may differ materially from those suggested by the forward-looking statements that we make for a number of reasons, including those described in Part

30

II, Item 1A, “Risk Factors,” of this Quarterly Report on Form 10-Q and in Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, which we filed with the Securities and Exchange Commission on April 14, 2016.
We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
The following discussion should be read together with our financial statements and related notes contained in this Quarterly Report on Form 10-Q and with the financial statements, related notes and Management’s Discussion and Analysis included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, which we filed with the Securities and Exchange Commission on April 14, 2016. Results for the three and nine months ended September 30, 2016 are not necessarily indicative of results that may be attained in the future.

Overview

Transgenomic, Inc. (“we”, “us”, “our”, the “Company” or “Transgenomic”) is a biotechnology company advancing personalized medicine for the detection and treatment of cancer and inherited diseases through our proprietary molecular technologies and clinical and research services. A key goal is to bring our Multiplexed ICE COLD-PCR (“MX-ICP”) product to the clinical market through strategic partnerships and licensing agreements, enabling the use of blood and other bodily fluids for more effective and patient-friendly diagnosis, monitoring and treatment of cancer.

MX-ICP is technology proprietary to Transgenomic. It is a reagent that improves the ability to detect genetic mutations by 100 - 400 fold over existing technologies. This technology has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing and Digital PCR. By enhancing the level of detection of genetic mutations and suppressing the normal, or wild-type, DNA, several benefits are provided. It is generally understood that most current technologies are unable to consistently identify mutations that occur in less than approximately 5% of a sample. However, many mutations found at much lower levels, even as low as 0.01%, are known to be clinically relevant and can have significant consequences to a patient: both in terms of how they will respond to a given drug or treatment and how a given tumor is likely to change over time. More importantly, in our view, is the ability to significantly improve the level of detection while using blood, saliva and even urine as a source for DNA, rather than depending on painful, expensive and potentially dangerous tumor biopsies. We believe that this is an important advancement in patient care with respect to cancer detection, treatment and monitoring and can result in significant cost savings for the healthcare system by replacing invasive procedures with the simple collection of blood or other bodily fluids. By broadening the types of samples that can be used for testing and allowing all sequencing platforms to provide improved identification of low level mutations, MX-ICP has the potential to make testing more readily available and more patient friendly, enable genetic monitoring of disease progression, effectively guide treatment protocols, and reduce the overall cost of diagnosis and monitoring while significantly improving patient outcomes.

Historically, our operations were organized and reviewed by management along our major product lines and presented in two business segments: Laboratory Services and Genetic Assays and Platforms. Beginning with the quarter ended September 30, 2015, our operations are now organized as one business segment, our Laboratory Services segment, and during the fourth quarter of 2015, we began including a portion of our Laboratory Services segment as discontinued operations.

Our laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. Our laboratory employs a variety of genomic testing service technologies, including our proprietary MX-ICP technology. ICE COLD-PCR is a proprietary ultra-high sensitivity platform technology with breakthrough potential to enable wide adoption of personalized, precision medicine in cancer and other diseases. It can be run in any laboratory that contains standard PCR systems. MX-ICP enables detection of multiple known and unknown mutations from virtually any sample type, including tissue biopsies, blood, urine, saliva, cell-free DNA (“cfDNA”) and circulating tumor cells (“CTCs”) at levels greater than 1,000-fold higher than standard DNA sequencing techniques. It is easy to implement and use within existing workflows. Our laboratory in Omaha is certified under the Clinical Laboratory Improvement Amendments (“CLIA”) as a high complexity laboratory and is accredited by the College of American Pathologists.

Our condensed consolidated balance sheets, statements of operations and statements of cash flows for all periods presented reflect our former Genetic Assays and Platforms activities and Patient Testing business as discontinued operations (See Note 3 - “Discontinued Operations” in the Notes to Unaudited Condensed Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q).



31

Third Quarter 2016 Overview and Recent Highlights

Below is a summary of our most recent business activities:

•
Signed Data Sharing Agreement with Ventana Medical Systems, Inc. - In September 2016, we signed a data sharing agreement with Ventana Medical Systems, Inc., a subsidiary of Roche Holdings (“Ventana”). The agreement allows Ventana to access DNA test results from an existing research agreement between us and the University of Melbourne in Australia. As part of this research agreement, the University of Melbourne is conducting additional clinical validation studies of our MX-ICP technology.
•
Added New Distributors in China and India for our ICEme Kits that Enable Liquid Biopsy Cancer Testing on Existing Platforms - In September 2016, we signed agreements with two additional distributors in China and India for our ICEme™ Mutation Enrichment Kits for cancer genomic testing. The kits incorporate our MX-ICP technology and are designed to enable virtually any laboratory to conduct high quality DNA mutation detection in cancer patients using plasma, blood or tissue samples and existing sequencing platforms. The new distributors, Joying Bio in China and Biotron Healthcare in India, are important suppliers of advanced life science products in their respective markets.
Uncertainties
We have historically operated at a loss and have not consistently generated sufficient cash from operating activities to cover our operating and other cash expenses. We have been able to historically finance our operating losses through borrowings or from the issuance of additional equity. At September 30, 2016, we had cash and cash equivalents of $0.1 million. Our ability to continue as a going concern is dependent upon a combination of generating additional revenue, improving cash collections, potentially selling underutilized assets and, if necessary, raising additional financing to meet our obligations and pay our liabilities arising from normal business operations when they come due. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern.

Results of Continuing Operations

Three Months Ended September 30, 2016 and 2015
Net Sales. Net sales were as follows:
 
Dollars in Thousands
 
Three Months Ended
 
 
 
September 30,
 
Change
 
2016
 
2015
 
$    
 
%
Total Net Sales
$
457

 
$
330

 
$
127

 
38
%
Net sales increased by $0.1 million, or 38%, during the three months ended September 30, 2016 as compared to the same period in 2015. Sales of our contract laboratory services were flat year over year. The slight increase in total net sales for the current year period reflects higher grant revenues.
Cost of Goods Sold. Cost of goods sold includes material costs for the products that we sell and other direct costs (primarily personnel costs, rent, supplies and depreciation) associated with the operations of our laboratories.
Gross Profit. Gross profit and gross margins were as follows:
 
Dollars in Thousands
 
Three Months Ended
 
 
 
September 30,
 
Margin %
 
2016
 
2015
 
2016
 
2015
Gross Profit
$
27

 
$
(115
)
 
6
%
 
(35
)%
Gross profit was $27,000, or 6% of total net sales, during the third quarter of 2016, compared to negative $115,000, or (35)% of total net sales, during the same quarter of 2015. The increased gross profit during the three months ended September 30, 2016 as compared to the same period of 2015 is due to increased revenues.
Selling, General and Administrative Expenses. Selling, general and administrative expenses primarily consist of personnel costs, marketing, travel costs, professional fees, facility costs and bad debt provisions. Our selling, general and administrative

32

costs decreased by $0.4 million to $1.3 million during the three month period ended September 30, 2016 as compared to the same period in 2015. This decrease was due to lower professional and lower stock compensation costs in the third quarter of 2016 as compared to the third quarter of 2015.
Research and Development Expenses. Research and development expenses primarily include personnel costs, intellectual property fees, patent costs, outside services, laboratory supplies and facility costs and are expensed in the period in which they are incurred. For the three months ended September 30, 2016, research and development expenses totaled $0.4 million as compared to $0.5 million for the three months ended September 30, 2015. Research and development expenses totaled 86% and 138% of net sales during the three months ended September 30, 2016 and 2015, respectively.
Other Income (Expense). Other expense for the three months ended September 30, 2016 and 2015 includes interest expense of $0.3 million and $0.2 million, respectively. In addition, we recorded less than $0.1 million of other income for the three months ended September 30, 2016 and other income of $0.4 million for the three months ended September 30, 2015 for the revaluation of common stock warrants, which was due to the change in fair value of the common stock warrant liability. The income and expense associated with the change in fair value of the warrants is a non-cash item.

Nine Months Ended September 30, 2016 and 2015
Net Sales. Net sales were as follows:
 
Dollars in Thousands
 
Nine Months Ended
 
 
 
September 30,
 
Change
 
2016
 
2015
 
$    
 
%
Total Net Sales
$
1,198

 
$
1,522

 
$
(324
)
 
(21
)%
Net sales decreased by $0.3 million, or 21%, during the nine months ended September 30, 2016 as compared to the same period in 2015. The decrease reflects fewer sales of our contract laboratory services as a result of fewer customers with active projects in the current year partially offset by increased grant revenues in the current year.
Cost of Goods Sold. Cost of goods sold includes material costs for the products that we sell and other direct costs (primarily personnel costs, rent, supplies and depreciation) associated with the operations of our laboratories.
Gross Profit. Gross profit and gross margins were as follows:
 
Dollars in Thousands
 
Nine Months Ended
 
 
 
September 30,
 
Margin %
 
2016
 
2015
 
2016
 
2015
Gross Profit
$
(279
)
 
$
147

 
(23
)%
 
10
%
Gross profit was a negative $0.3 million, or (23)% of total net sales, during the first nine months of 2016, compared to $0.1 million, or 10% of total net sales, during the same period of 2015. The decrease in gross profit in the current year is a result of lower revenues during the nine months ended September 30, 2016 as compared to the first nine months of 2015. The negative gross margin in the current year is due to lower revenues that were insufficient to cover our laboratory’s fixed direct costs.
Selling, General and Administrative Expenses. Selling, general and administrative expenses primarily consist of personnel costs, marketing, travel costs, professional fees, facility costs and bad debt provisions. Our selling, general and administrative costs decreased by $1.0 million to $4.4 million during the nine month period ended September 30, 2016 as compared to the same period in 2015. This decrease was due to lower professional fees and lower stock compensation costs in the first nine months of 2016 as compared to the same period of 2015.
Research and Development Expenses. Research and development expenses primarily include personnel costs, intellectual property fees, outside services, collaboration expenses, laboratory supplies and facility costs and are expensed in the period in which they are incurred. For the nine months ended September 30, 2016, research and development expenses totaled $1.1 million as compared to $1.4 million for the nine months ended September 30, 2015. Research and development expenses totaled 89% and 90% of net sales during the nine months ended September 30, 2016 and 2015, respectively.
Other Income (Expense). Other expense for the nine months ended September 30, 2016 and 2015 includes interest expense of $0.8 million and $0.6 million, respectively. In addition, we recorded $0.4 million of other income for the nine months ended September 30, 2016 and other expense of less than $0.1 million for the nine months ended September 30, 2015 for the revaluation

33

of common stock warrants, which was due to the change in fair value of the common stock warrant liability. The income and expense associated with the change in fair value of the warrants is a non-cash item.

Discontinued Operations For The Three and Nine Months Ended September 30, 2016 and 2015

During the third quarter of 2015, we decided to divest our Genetic Assays and Platforms business, resulting in a strategic shift that had a major effect on our operations and financial results. Therefore, the divested Genetic Assays and Platforms operations meet the criteria to be reported as discontinued operations.

During the fourth quarter of 2015, our Board of Directors took actions to begin the process of divesting our Patient Testing business located in New Haven, Connecticut. In March 2016, we announced that we had suspended testing services in our Patient Testing laboratory as we review and evaluate various strategic alternatives for that business. As a result of these actions, our Patient Testing business meets the criteria to be reported as discontinued operations.

The related assets, liabilities, results of operations and cash flows for both the Genetic Assays and Platforms business and Patient Testing business are classified as assets held for sale, liabilities held for sale and discontinued operations for all periods presented.

Net loss from discontinued operations for the three and nine months ended September 30, 2016, includes approximately $0.1 million and $1.1 million, respectively, in proceeds received from the sale of assets of our discontinued Patient Testing business.

Revenues and net loss of the discontinued operations consisted of the following:
 
Three months ended September 30,
 
Nine months ended September 30,
(Dollars in thousands)
2016
 
2015
 
2016
 
2015
Net sales
$
283

 
$
5,507

 
$
1,960

 
$
17,868

Net loss from discontinued operations, before tax
$
(34
)
 
$
(5,204
)
 
$
(25
)
 
$
(6,259
)
Income tax expense
—

 
44

 
—

 
133

Loss from discontinued operations, net of tax
$
(34
)
 
$
(5,248
)
 
$
(25
)
 
$
(6,392
)


Liquidity and Capital Resources
Our working capital positions at September 30, 2016 and December 31, 2015 were as follows: 
 
Dollars in Thousands
 
September 30,
2016
 
December 31,
2015
 
Change
Current assets (including cash and cash equivalents of $71 and $444, respectively)
$
866

 
$
3,282

 
$
(2,416
)
Current liabilities
18,260

 
16,981

 
1,279

Working capital
$
(17,394
)
 
$
(13,699
)
 
$
(3,695
)

Conversion Agreement

On January 6, 2016, we entered into a Conversion Agreement (the “Conversion Agreement”) with the holders (the “Preferred Holders”) of all of our outstanding shares of Series A Convertible Preferred Stock (the “Series A Preferred”), and Series B Convertible Preferred Stock (the “Series B Preferred”), pursuant to which, among other things, the Preferred Holders: (1) elected to convert all of the outstanding shares of Series A Preferred and Series B Preferred into shares of our common stock in each case in accordance with the terms thereof, and (2) agreed that all accrued and unpaid dividends on the Series A Preferred and Series B Preferred would be paid by us in shares of common stock at a rate of $1.00 per share of common stock (collectively, the “Conversion”).


34

The outstanding shares of Series A Preferred were convertible into shares of common stock at a rate of 1-for-3, and the outstanding shares of Series B Preferred were convertible into shares of common stock at a rate of 1-for-1. Prior to the entry into the Conversion Agreement, there were 2,586,205 shares of Series A Preferred outstanding, which were converted into 862,057 shares of common stock, and 1,443,297 shares of Series B Preferred outstanding, which were converted into 1,443,297 shares of common stock, for an aggregate of 2,305,354 shares of common stock issued upon conversion of the Series A Preferred and Series B Preferred. At the time of the entry into the Conversion Agreement, there were $3,681,591 in accrued and unpaid dividends on the outstanding shares of Series A Preferred, which were converted, in accordance with the Conversion Agreement, into 3,681,590 shares of common stock, and $793,236 in accrued and unpaid dividends on the outstanding shares of Series B Preferred, which were converted, in accordance with the terms of the Conversion Agreement, into 793,235 shares of common stock, for an aggregate of 4,474,825 shares of our common stock issued pursuant to the accrued and unpaid dividends on the Series A Preferred and Series B Preferred. Therefore, in connection with the full conversion of the Series A Preferred and Series B Preferred, plus the conversion of all accrued and unpaid dividends thereon, we issued an aggregate of 6,780,179 shares of common Stock to the Preferred Holders on January 6, 2016.

January 2016 Private Placement

On January 6, 2016, we entered into a Securities Purchase Agreement (the “A-1 Preferred Purchase Agreement”) with certain accredited investors (the “A-1 Preferred Investors”), pursuant to which, on January 8, 2016, we sold to the A-1 Preferred Investors, and the A-1 Preferred Investors purchased from us (the “A-1 Preferred Offering”), an aggregate of approximately $2.2 million of units (the “Units”) consisting of (1) an aggregate of 2,365,243 shares (the “A-1 Preferred Shares”) of our Series A-1 Convertible Preferred Stock (the “A-1 Preferred”), and (2) warrants (the “Warrants”) to purchase up to an aggregate of 1,773,929 shares of our common stock. Each Unit was sold to the A-1 Preferred Investors at a purchase price of $0.93 per Unit. The A-1 Preferred Shares are convertible into shares of common stock at an initial rate of 1-for-1, which conversion rate is subject to further adjustment as set forth in our Certificate of Designation of Series A-1 Convertible Preferred Stock, which was filed with the Secretary of State of the State of Delaware on January 8, 2016 (the “Series A-1 Certificate of Designation”). Pursuant to the terms of the Series A-1 Certificate of Designation, the holders of the A-1 Preferred Shares will generally be entitled to that number of votes as is equal to the product obtained by multiplying: (a) the number of whole shares of common stock into which the A-1 Preferred may be converted as of the record date of such vote or consent, by (b) 0.93, rounded down to the nearest whole number. Therefore, every 1.075269 shares of A-1 Preferred will generally initially be entitled to one vote.

The Warrants were immediately exercisable upon issuance, have a term of five years and have an exercise price of $1.21 per share of common stock. Each Warrant also includes both cash and cashless exercise features and an exchange feature whereby the holder of the Warrant may exchange all or any portion of the Warrant for a number of shares of our common stock equal to the quotient obtained by dividing the “Exchange Amount” by the closing bid price of our common stock on the second trading day prior to the date the Warrant is exchanged (the “Exchange Right”). Under the Warrants, the “Exchange Amount” is based upon a Black Scholes option pricing model, and the aggregate Exchange Amount under all of the Warrants will be $1,436,882, subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of issuance of the Warrants and the date the Warrants are exchanged. Each Warrant provides that the number of shares that may be issued upon exercise of the Exchange Right is limited to the number of shares that may be purchased pursuant to the terms of the Warrant, unless we have previously obtained stockholder approval or approval from The Nasdaq Stock Market LLC to issue any additional shares of our common stock (the “Additional Shares”) pursuant to the Exchange Right (the “Required Approvals”). For any Exchange Right exercised more than 90 days following the issuance of the Warrants, if we have not obtained either of the Required Approvals, we will be required to pay the Warrant holder an amount in cash for any Additional Shares that we cannot issue without the Required Approvals based on the Exchange Amount.

At the Market Offering

On June 7, 2016, we entered into an At the Market Offering Agreement (the “ATM Agreement”) with Craig-Hallum Capital Group LLC, as sales agent (“Craig-Hallum”), pursuant to which we may offer and sell, from time to time, through Craig-Hallum, up to $3,500,000 of shares (the “Shares”) of our common stock. Any Shares offered and sold in the offering will be issued pursuant to our effective shelf registration statement on Form S-3 (File No. 333-201907) and the related prospectus previously declared effective by the Securities and Exchange Commission (the “SEC”) on February 13, 2015, as supplemented by a prospectus supplement, dated June 7, 2016, that we filed with the SEC pursuant to Rule 424(b)(5) under the Securities Act. The number of shares eligible for sale under the ATM Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3. During the nine months ended September 30, 2016, we sold 1,150,569 shares under the ATM Agreement.  The average sales price per common share was $0.42 and the aggregate net proceeds from the sales totaled $0.5 million.

35

Please see Note 5 - “Debt” and Note 6 - “Commitments and Contingencies” in the Notes to Unaudited Condensed Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q for additional information regarding our outstanding debt and debt servicing obligations.
At September 30, 2016, we had cash on hand of $0.1 million. Our current operating plan projects improved operating results and monetization of underutilized assets. As with any operating plan, there are risks associated with our ability to execute it. Therefore, there can be no assurance that we will be able to satisfy our obligations, or achieve the operating improvements as contemplated by the current operating plan. If we are unable to execute this plan, we will need to find additional sources of cash not contemplated by the current operating plan and/or raise additional capital to sustain continuing operations as currently contemplated. We could raise additional funds through various potential sources such as through the sale of assets or sale of debt or equity securities. However, there can be no assurance that the additional funding sources will be available to us at reasonable terms or at all. If we are unable to achieve our operating plan or obtain additional financing, our business would be jeopardized and we may not be able to continue as a going concern.

Analysis of Cash Flows - Nine Months Ended September 30, 2016 and 2015
Net Change in Cash and Cash Equivalents. Cash and cash equivalents decreased by $0.4 million during the nine months ended September 30, 2016, compared to an increase of $1.2 million during the nine months ended September 30, 2015. These amounts include cash provided by discontinued operations of $1.4 million and cash used in discontinued operations of $1.1 million, for the nine months ended September 30, 2016 and 2015, respectively.
Cash Flows From Continuing Operations
Cash Flows Used in Operating Activities. The cash flows used in operating activities of $4.0 million during the nine months ended September 30, 2016 included a net loss of $6.2 million and a decrease in accrued expenses of $0.7 million. These were partially offset by an increase in accounts payable of $2.5 million and a decrease in other current assets of $0.3 million. The cash flows used in operating activities in the first nine months of 2015 included the net loss of $7.2 million, a decrease in accounts payable of $0.2 million and an increase in other current assets of $0.2 million. These were partially offset by a decrease in accounts receivable of $0.2 million and other non-cash adjustments of $0.9 million.
Cash Flows Used in Investing Activities. Cash flows used in investing activities for continuing operations were $0.1 million and $0.3 million for the nine months ended September 30, 2016 and 2015, respectively.
Cash Flows Provided by Financing Activities. Cash flows provided by financing activities totaled $2.2 million for the nine months ended September 30, 2016, which included net proceeds of approximately $1.8 million from our Unit issuance, $0.5 million from sales under the ATM Agreement and $0.5 million from borrowing on our debt. These proceeds were partially offset by payments on our debt of approximately $0.6 million. Cash flows provided by financing activities during the nine months ended September 30, 2015 included net proceeds of $9.0 million from our common stock offerings and $0.9 million from the issuance of unsecured convertible promissory notes. These were partially offset by payments on our debt and capital lease obligations of $0.9 million.

Off-Balance Sheet Arrangements
At each of September 30, 2016 and December 31, 2015, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Contractual Obligations and Commitments
There have been no material changes to our contractual obligations outside the normal course of business as compared to those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission on April 14, 2016.

Critical Accounting Policies and Estimates
Accounting policies used in the preparation of our consolidated financial statements may involve the use of management judgments and estimates. Certain of our accounting policies are considered critical as they are both important to the portrayal of our financial statements and require significant or complex judgments on the part of management. Our judgments and estimates are based on experience and assumptions that we believe are reasonable under the circumstances. Further, we evaluate our judgments and estimates from time to time as circumstances change. Actual financial results based on judgments or estimates may vary under

36

different assumptions or circumstances. Our critical accounting policies are discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the Securities and Exchange Commission on April 14, 2016.

Recently Issued Accounting Pronouncements
Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the Securities and Exchange Commission on April 14, 2016. There have been no changes to those accounting pronouncements listed except as noted in Note 2 - “Summary of Significant Accounting Policies-Recent Accounting Pronouncements” in the Notes to Unaudited Condensed Consolidated Financial Statements contained in this Quarterly Report on Form 10-Q.

Impact of Inflation
We do not believe that price inflation or deflation had a material adverse effect on our financial condition or results of operations during the periods presented.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide the information required under this item.

Item 4.
Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Management performed, with the participation of our Chief Executive Officer and Interim Chief Financial Officer, an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Interim Chief Financial Officer, to allow timely decisions regarding required disclosures. Based on the evaluation, our Chief Executive Officer and Interim Chief Financial Officer concluded that, as of September 30, 2016, our disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
We have evaluated the changes in our internal control over financial reporting that occurred during the three months ended September 30, 2016 and concluded that there have not been any changes that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

37

PART II. OTHER INFORMATION
 
Item 1.
Legal Proceedings
We are subject to a number of claims of various amounts that arise out of the normal course of our business. In our opinion, the disposition of pending claims, in excess of recorded accruals, could have a material adverse effect on our financial position, results of operations or cash flows. On February 25, 2016, the Board of Regents of the University of Nebraska (“UNMC”) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of $0.7 million owed by us to UNMC. We and UNMC are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A $0.7 million liability has been recorded at December 31, 2015 and September 30, 2016.
In addition, on April 13, 2016, Fox Chase Cancer Center (“Fox Chase”) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the “Court of Common Pleas”), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the “License Agreement”), as well as the assignment of certain of our rights under the License Agreement to Integrated DNA Technologies, Inc. (“IDT”) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the “IDT Agreement”). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase’s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney’s fees.  Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. We are unable to determine whether any loss will occur or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by us as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.
On June 23, 2016, the Icahn School of Medicine at Mount Sinai (“Mount Sinai”) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of $0.7 million owed by us to Mount Sinai for services rendered. We and Mount Sinai are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A $0.7 million liability has been recorded at December 31, 2015 and September 30, 2016.
The outcome of legal proceedings and claims brought against us are subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts in excess of management’s expectations, our financial statements for such reporting period could be materially adversely affected. In general, the resolution of a legal matter could prevent us from offering our services or products to others, could be material to our financial condition or cash flows, or both, or could otherwise adversely affect our operating results.
 
Item 1A.
Risk Factors
Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information in this Quarterly Report on Form 10-Q, before making a decision to invest in our common stock. The risks and uncertainties described below may not be the only ones we face. If any of the risks actually occur, our business, financial condition and results of operations could be materially and adversely affected. In that event, the trading price of our common stock could decline, and you could lose part or all of your investment.
Risk factors marked with an asterisk (*) below include a change from or an update to the risk factors included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed with the Securities and Exchange Commission on April 14, 2016.

*We have a history of operating losses and may incur losses in the future.
We have experienced annual losses from continuing operations since inception of our operations. Our operating loss for the years ended December 31, 2015 and 2014 was $9.2 million and $10.6 million, respectively, and for the nine months ended September 30, 2016 and 2015 was $5.7 million and $6.6 million, respectively. These historical losses have been due principally to the expenses that we have incurred in order to develop and market our products, the fixed nature of our manufacturing costs and merger and acquisition costs.

38

*Recurring operating losses raise substantial doubt about our ability to continue as a going concern.
We have incurred substantial operating losses and have used cash in our operating activities for the past several years. As of September 30, 2016, we had negative working capital of $17.4 million.
The audit report issued by our independent registered public accounting firm for our financial statements for the fiscal year ended December 31, 2015 states that our independent registered public accounting firm has substantial doubt in our ability to continue as a going concern due to the risk that we may not have sufficient cash and liquid assets at December 31, 2015 to cover our operating and capital requirements for the next 12 months. If that is the case, and if sufficient cash cannot be obtained, we would have to substantially alter, or possibly even discontinue, operations. Additionally, as of September 30, 2016, we do not believe that we will have sufficient cash to meet our operating requirements for at least the next 12 months. Our financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q do not include any adjustments that might result from the outcome of this uncertainty.
Our current operating plan is designed to improve operating results, improve collection rates and monetize underutilized assets. There are no guarantees that these efforts will be successful and, if not, we may use more cash than projected and not be able to meet our current obligations. As with any operating plan, there are risks associated with our ability to execute it. Therefore, there can be no assurance that we will be able to satisfy our obligations, or achieve the operating improvements as contemplated by the current operating plan. If we are unable to execute this plan, we will need to find additional sources of cash not contemplated by the current operating plan and/or raise additional capital to sustain continuing operations as currently contemplated. We could seek to raise additional funds through various potential sources such as through the sale of assets or sale of debt or equity securities. However, there can be no assurance that the additional funding sources will be available to us at reasonable terms or at all. If we are unable to achieve our operating plan or obtain additional financing, our business would be jeopardized and we may not be able to continue as a going concern.
*We have substantial debt and other financial obligations and we may incur even more debt, and we are in default under our loan agreement with affiliates of Third Security, LLC, which means that the lenders under the loan agreement have the right to cease making additional advances, accelerate repayment of all sums due and take action to collect the amounts owed to them, including foreclosing on their security interest, each of which could adversely affect us.
Our revolving line of credit and term loan with affiliates of Third Security, LLC, a related party (the “Lenders”), are governed by a Loan and Security Agreement, as amended (the “Loan and Security Agreement”), which contains certain affirmative and negative covenants. As of September 30, 2016, we had borrowings of $7.2 million under the Loan and Security Agreement. Under the term loan, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders’ consent. To secure the repayment of amounts borrowed under the revolving line of credit and term loan, we granted the Lenders a security interest in all of our assets. As of September 30, 2016, we were not in compliance with the Loan and Security Agreement, as amended by the Ninth Amendment, due to the fact that we did not make the required monthly interest payments during the third quarter and have not received a waiver for the non-compliance. We are therefore currently in default under the Loan and Security Agreement. Accordingly, under the terms of the Loan and Security Agreement, the Lenders currently have the right to cease making additional advances, accelerate repayment of all sums due and take action to collect the amounts owed to them, including foreclosing on their security interest or forcing us into bankruptcy, which would have a material adverse effect on our financial condition and results of operations.
We may be required to amend our Loan and Security Agreement, refinance all or part of our existing debt, sell assets, incur additional indebtedness or raise equity. Further, based upon our actual performance levels, our covenants relating to income, debt coverage and cash flow and minimum working capital requirements could limit our ability to incur additional debt, which could hinder our ability to execute on our current business strategy. Our ability to make scheduled payments on our debt and other financial obligations and comply with financial covenants depends on our financial and operating performance. Our financial and operating performance will continue to be subject to prevailing economic conditions and to financial, business and other factors, some of which are beyond our control.
*Our existing indebtedness could adversely affect our ability to fulfill our obligations and may place us at a competitive disadvantage in our industry.
We continue to have substantial debt outstanding and we may incur additional indebtedness from time to time to finance working capital, product development efforts, strategic acquisitions, investments and alliances, capital expenditures or other general corporate purposes, subject to the restrictions contained in our existing indebtedness and in any other agreements under which we incur indebtedness. Our outstanding indebtedness and debt service requirements could adversely affect our ability to operate our

39

business and may limit our ability to take advantage of potential business opportunities. For example, our existing level of indebtedness presents the following risks:
•
we will be required to use a substantial portion of our cash flow from operations to pay principal and interest on our indebtedness, thereby reducing the availability of our cash flow to fund working capital, capital expenditures, product development efforts, acquisitions, investments and strategic alliances and other general corporate requirements;
•
our debt service obligations could limit our flexibility in planning for, or reacting to, changes in our business and our industry and could limit our ability to pursue other business opportunities, borrow more money for operations or capital in the future and implement our business strategies;
•
our level of indebtedness and the covenants within our debt instruments may restrict us from raising additional financing on satisfactory terms to fund working capital, capital expenditures, product development efforts, strategic acquisitions, investments and alliances, and other general corporate requirements; and
•
our outstanding indebtedness may make it difficult for us to attract additional financing when needed.

As of September 30, 2016, we were not in compliance with the Loan and Security Agreement, as amended by the Ninth Amendment, due to the fact that we did not make the required monthly interest payments during the third quarter and we are therefore currently in default under the Loan and Security Agreement. Accordingly, we may be required to attempt to renegotiate the terms of the instruments relating to the indebtedness, seek to refinance all or a portion of the indebtedness or obtain additional financing. There can be no assurance that we will be able to successfully renegotiate such terms, that any such refinancing would be possible or that any additional financing could be obtained on terms that are favorable or acceptable to us.

Our future capital needs are uncertain and we may need to raise additional funds in the future.
Our future capital needs are uncertain and we may need to raise additional funds in the future through debt or equity offerings. Our future capital requirements will depend on many factors, including, but not limited to:
•
Revenue generated by sales of our products;
•
Expenses incurred in manufacturing and selling our products;
•
Costs of developing new products or technologies;
•
Costs associated with capital expenditures;
•
The number and timing of strategic transactions; and
•
Working capital requirements related to growing existing business.

We may need additional capital to finance our growth or to compete, which may cause dilution to existing stockholders or limit our flexibility in conducting our business activities.
We may need to raise additional capital in the future to fund expansion, respond to competitive pressures or acquire complementary businesses, technologies or services. Such additional financing may not be available on terms acceptable to us or at all. To the extent that we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution, and to the extent we engage in additional debt financing, if available, we may become subject to additional restrictive covenants that could limit our flexibility in conducting future business activities. If additional financing is not available or not available on acceptable terms, we may not be able to continue as a going concern, fund our expansion, promote our brands, take advantage of acquisition opportunities, develop or enhance services or respond to competitive pressures.
Governmental payers and health care plans have taken steps to control costs.
Medicare, Medicaid and private insurers have increased their efforts to control the costs of health care services, including clinical testing services. They may reduce fee schedules or limit/exclude coverage for certain types of tests that we perform. Medicaid reimbursement varies by state and is subject to administrative and billing requirements and budget pressures. We expect efforts to reduce reimbursements, impose more stringent cost controls and reduce utilization of testing services will continue. These efforts, including changes in laws or regulations, may have a material adverse impact on our business.
Weakness in U.S. or global economic conditions could have an adverse effect on our businesses.
The economies of the United States and other regions of the world in which we do business have experienced significant weakness, which, in the case of the U.S., has recently resulted in significant unemployment and slower growth in economic activity. A decline in economic conditions may adversely affect demand for our services and products, thus reducing our revenue. These conditions could also impair the ability of those with whom we do business to satisfy their obligations to us. The strengthening of the U.S. dollar has the potential to adversely impact U.S. businesses that operate overseas.

40

Sales have been variable.
Our laboratory performs project-based work that changes from quarter to quarter. Therefore, comparison of the results of successive quarters may not accurately reflect trends or results for the full year due to the fact that ICP is a new product and will enable the liquid biopsy market to evolve rapidly and ensure Precision Medicine is adopted globally. We see the ICP business and revenues growing as our commercial strategy is successful and our partnerships and licensing agreements become profitable.
Changes in payer mix could have a material adverse impact on our net sales and profitability.
Testing services are billed to physicians, patients, government payers such as Medicare, and insurance companies. Tests may be billed to different payers depending on a particular patient’s medical insurance coverage. Government payers have increased their efforts to control the cost, utilization and delivery of health care services as well as reimbursement for laboratory testing services. Further reductions of reimbursement for Medicare and Medicaid services or changes in policy regarding coverage of tests or other requirements for payment, such as prior authorization or a physician or qualified practitioner’s signature on test requisitions, may be implemented from time to time. Reimbursement for the laboratory services component of our business is also subject to statutory and regulatory reduction. Reductions in the reimbursement rates and changes in payment policies of other third party payers may occur as well. Such changes in the past have resulted in reduced payments as well as added costs and have decreased test utilization for the clinical laboratory industry by adding more complex new regulatory and administrative requirements. As a result, increases in the percentage of services billed to government payers could have an adverse impact on our net sales.
We may experience temporary disruptions and delays in processing biological samples at our facilities.
We may experience delays in processing biological samples caused by software and other errors. Any delay in processing samples could have an adverse effect on our business, financial condition and results of operations.
Our laboratories require ongoing CLIA certification.
The CLIA extended federal oversight to virtually all clinical laboratories by requiring that they be certified by the federal government or by a federally-approved accreditation agency. The CLIA requires that all clinical laboratories meet quality assurance, quality control and personnel standards. Laboratories must also undergo proficiency testing and are subject to inspections.
The sanctions for failure to comply with the CLIA requirements include suspension, revocation or limitation of a laboratory’s CLIA certificate, which is necessary to conduct business, cancellation or suspension of the laboratory’s approval to receive Medicare and/or Medicaid reimbursement, as well as significant fines and/or criminal penalties. The loss or suspension of a CLIA certification, imposition of a fine or other penalties, or future changes in the CLIA law or regulations (or interpretation of the law or regulations) could have a material adverse effect on us.
We believe that we are in compliance with all applicable laboratory requirements, but no assurances can be given that our laboratories will pass all future certification inspections.
Failure to comply with HIPAA could be costly.
The Health Insurance Portability and Accountability Act (“HIPAA”) and associated regulations protect the privacy and security of certain patient health information and establish standards for electronic health care transactions in the United States. These privacy regulations establish federal standards regarding the uses and disclosures of protected health information. Our Molecular Labs are subject to HIPAA and its associated regulations. If we fail to comply with these laws and regulations we could suffer civil and criminal penalties, fines, exclusion from participation in governmental health care programs and the loss of various licenses, certificates and authorizations necessary to operate our Patient Testing business. We could also incur liabilities from third party claims.
Our business could be adversely impacted by health care reform.
Government attention to the health care industry in the United States is significant and may increase. The Patient Protection and Affordable Care Act passed by Congress and signed into law by President Obama in March 2010 could adversely impact our business. While certain portions of the legislation have already gone into effect, the ultimate impact of the legislation on the health care industry is still unknown, and the overall impact on our business is likely to be extensive and could result in significant changes to our business and our customers’ businesses.

41

*We are subject to a number of claims of various amounts that arise out of the normal course of our business.
We are subject to a number of claims of various amounts that arise out of the normal course of our business. Specifically, on February 25, 2016, the Board of Regents of the University of Nebraska (“UNMC”) filed a lawsuit against us in the District Court of Douglas County, Nebraska for breach of contract and seeking recovery of $0.7 million owed by us to UNMC. We and UNMC are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A $0.7 million liability has been recorded and is reflected in accrued expenses at December 31, 2015 and September 30, 2016.
In addition, on April 13, 2016, Fox Chase Cancer Center (“Fox Chase”) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the “Court of Common Pleas”), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the “License Agreement”), as well as the assignment of certain rights of our rights under the License Agreement to Integrated DNA Technologies, Inc. (“IDT”), pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the “IDT Agreement”). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase’s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney’s fees.  Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. However, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.
On June 23, 2016, the Icahn School of Medicine at Mount Sinai (“Mount Sinai”) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of $0.7 million owed by us to Mount Sinai for services rendered. We and Mount Sinai are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A $0.7 million liability has been recorded at December 31, 2015 and September 30, 2016.
Our ongoing and future litigation could result in significant additional costs and further divert the attention of our management and key personnel from our business operations and the implementation of our business strategy. In addition, the disposition of any of the pending claims against us, in excess of recorded accruals, could have a material adverse effect on our financial position, results of operations or cash flows.
We may be subject to client lawsuits.
Providers of clinical testing services may be subject to lawsuits alleging negligence or other legal claims. Potential suits could involve claims for substantial damages. Litigation could also have an adverse impact on our client base and our reputation. We maintain liability insurance coverage for certain claims that could result from providing or failing to provide clinical testing services, including inaccurate testing results and other exposures. Our insurance coverage limits our maximum recovery on individual claims and, therefore, there is no assurance that such coverage will be adequate.
*The sale of our products and business operations in international markets subjects us to additional risks.
During the past several years, international sales have represented a significant portion of our total net sales. As a result, a major portion of our net sales are subject to risks associated with international sales and operations. These risks include:
•
Payment cycles in foreign markets are typically longer than in the U.S., and capital spending budgets for research agencies can vary over time with foreign governments;
•
Changes in foreign currency exchange rates can make our products more costly in local currencies because our foreign sales are typically paid for in British Pounds or in Euros;
•
The potential for changes in U.S. and foreign laws or regulations that result in additional import or export restrictions, higher tariffs or other taxes, more burdensome licensing requirements or similar impediments may limit our ability to sell products and services profitably in these markets; and
•
The fluctuation of foreign currency exchange rates to the U.S. Dollar and the Euro to the British Pound can cause our net sales and expenses to increase or decrease, which adds risk to our financial statements.

In addition, many of the countries in which we have sales, including the U.S. and several of the members of the European Union, have experienced and continue to experience uncertain economic conditions resulting from global as well as local factors. For example, on June 23, 2016, the United Kingdom (the “UK”) held a referendum pursuant to which voters elected to leave the

42

European Union, commonly referred to as Brexit. As a result of UK voters’ election to leave the European Union, the British government is expected to begin negotiating the terms of the UK’s future relationship with the European Union. Although the long-term effects of Brexit will depend on any agreements the UK makes to retain access to the European Union markets, Brexit has created additional uncertainties that may ultimately result in new regulatory costs and challenges for companies and increased restrictions on imports and exports throughout Europe, which could adversely affect our ability to conduct and expand our operations in Europe and which may have an adverse effect on our business, financial condition and results of operations. In addition, Brexit may also increase the possibility that other countries may decide to leave the European Union in the future.

Our dependence on our suppliers exposes us to certain risks.
We rely on various suppliers for products and materials to produce our products. In the event that they would be unable to deliver these items due to product shortages or business closures, we may be unable to deliver our products to our customers in a timely manner or may need to increase our prices. The current economy poses the additional risk of our suppliers’ inability to continue their businesses as usual.
Our markets are very competitive.
Many of our competitors have greater resources than we do and may enjoy other competitive advantages. This may allow them to more effectively market their products to our customers or potential customers, to develop products that make our products obsolete or to produce and sell products less expensively than us. As a result of these competitive factors, demand for and pricing of our products and services could be negatively affected.
Our patents may not protect us from others using our technology, which could harm our business and competitive position.
Patent law relating to the scope of claims in the technology fields in which we operate is still evolving. The degree of future protection for our proprietary rights is uncertain. Furthermore, we cannot be certain that others will not independently develop similar or alternative products or technology, duplicate any of our products, or, if patents are issued to us, design around the patented products developed by us. Our patents or licenses could be challenged by litigation and, if the outcome of such litigation were adverse to us, our competitors could be free to use our technology. We may not be able to obtain additional patents for our technology, or if we are able to do so, patents may not provide us with adequate protection or be commercially beneficial. In addition, we could incur substantial costs in litigation if we are required to defend ourselves in patent suits brought by third parties or if we initiate such suits.
We cannot be certain that other measures taken to protect our intellectual property will be effective.
We rely upon trade secrets, copyright and trademark laws, non-disclosure agreements and other contractual confidentiality provisions to protect some of our confidential and proprietary information that we are not seeking patent protection for various reasons. Such measures, however, may not provide adequate protection for our trade secrets or other proprietary information. If such measures do not protect our rights, third parties could use our technology and our ability to compete in the market would be reduced.
We are dependent upon licensed technologies and may need to obtain additional licenses in the future to offer our products and remain competitive.
We have licensed key components of our technologies from third parties. If these agreements were to terminate prematurely due to our breach of the terms of these licenses or we otherwise fail to maintain our rights to such technologies, we may lose the right to manufacture or sell a substantial portion of our products. In addition, we may need to obtain licenses to additional technologies in the future in order to keep our products competitive. If we fail to license or otherwise acquire necessary technologies, we may not be able to develop new products that we need to remain competitive.
The protection of intellectual property in foreign countries is uncertain.
A significant percentage of our sales are to customers located outside the U.S. Patent and other intellectual property laws of some foreign countries may not protect our intellectual property rights to the same extent as U.S. laws. We may need to bring proceedings to defend our patent rights or to determine the validity of our competitors’ foreign patents. These proceedings could result in substantial cost and diversion of our other efforts. Finally, some of the patent protections available to us in the U.S. are not available to us in foreign countries due to the laws of those countries.

43

Our products could infringe on the intellectual property rights of others.
There are a significant number of U.S. and foreign patents and patent applications submitted for technologies in, or related to, our area of business. As a result, our use of our technology could infringe patents or proprietary rights of others. This may lead others to assert patent infringement or other intellectual property claims against us. We could incur substantial costs in litigation if we are required to defend against intellectual property claims by third parties. Additionally, any licenses that we might need as a result of any actual infringement might not be available to us on commercially reasonable terms, if at all.
Our failure to comply with any applicable government laws and regulations or otherwise respond to claims relating to improper handling, storage or disposal of hazardous chemicals that we use may adversely affect our results of operations.
Our research and development and manufacturing activities involve the controlled use of hazardous materials and chemicals. We are subject to federal, state, local and international laws and regulations governing the use, storage, handling and disposal of hazardous materials and waste products. If we fail to comply with applicable laws or regulations, we could be required to pay penalties or be held liable for any damages that result and this liability could exceed our financial resources. We cannot be certain that accidental contamination or injury will not occur. Any such accident could damage our research and manufacturing facilities and operations, resulting in delays and increased costs.
*We may issue a substantial amount of our common stock to holders of options and warrants and this could reduce the market price for our stock.
At September 30, 2016, we had obligations to issue 10,701,453 shares of common stock upon exercise of outstanding stock options, warrants or conversion rights. The issuance of these securities may be dilutive to our current stockholders and could negatively impact the market price of our common stock.
*Our common stock is thinly traded and a large percentage of our shares are held by a small group of unrelated, institutional owners.
At September 30, 2016, we had 24,139,130 shares of common stock outstanding. The sale of a significant number of shares into the public market has the potential to cause significant downward pressure on the price of our common stock. This is particularly the case if the shares being placed into the market exceed the market’s ability to absorb the stock. This presents an opportunity for short sellers to contribute to the further decline of our stock price. If there are significant short sales of our stock, the price decline that would result from this activity will cause the share price to decline more so, which, in turn, may cause long holders of the stock to sell their shares, thereby contributing to sales of our stock in the market. In addition, the large concentration of our shares are held by a small group of stockholders which could result in increased volatility in our stock price due to the limited number of shares available in the market.
We have previously identified material weaknesses and ineffective internal controls could impact our business and financial results.
Our internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud. In the course of auditing our financial statements as of and for the year ended December 31, 2014, our independent registered public accounting firm identified material weaknesses in our internal control over financial reporting relating to proper timing and recognition of revenue and the elements used in our analysis and evaluation of the allowance for doubtful accounts to ensure that the allowance for doubtful accounts is reasonably stated. We remediated these material weaknesses in the year ended December 31, 2015.
Even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. If we fail to maintain the adequacy of our internal controls, including any failure to implement required new or improved controls, or if we experience difficulties in their implementation, our business and financial results could be harmed, we could fail to meet our financial reporting obligations and we may not be able to accurately report financial results or prevent fraud.
*As we are currently not in compliance with the continued listing requirements of The Nasdaq Stock Market LLC (“Nasdaq”), Nasdaq may delist our shares of common stock, which would have an adverse impact on the trading volume, liquidity and market price of our common shares.

On February 23, 2016, we received written notice (the “First Notice”) from Nasdaq indicating that, based on the closing bid price of our common stock for the preceding 30 consecutive business days, we were not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market (the “Minimum Bid Price Requirement”), as set forth

44

in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we had a period of 180 calendar days, or until August 22, 2016, to regain compliance with the Minimum Bid Price Requirement. To have regained compliance, the closing bid price of our common stock must have met or exceeded $1.00 per share for at least ten consecutive business days during this 180 calendar day period.

On April 20, 2016, we received a second written notice (the “Second Notice”) from Nasdaq indicating that, based on the stockholders’ equity reported in our Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on April 14, 2016, we were not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, which requires listed companies to maintain stockholders’ equity of at least $2,500,000 (the “Minimum Stockholders’ Equity Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(2)(C), we had a period of 45 calendar days, or until June 6, 2016, to submit a plan to regain compliance with the Minimum Stockholders’ Equity Requirement. Nasdaq indicated that, if our plan was accepted, Nasdaq may have granted an extension of up to 180 calendar days, or until October 17, 2016, to evidence compliance. We initially submitted our plan to regain compliance with the Minimum Stockholders’ Equity Requirement to Nasdaq on May 31, 2016 and provided Nasdaq with supplemental information on June 22, 2016 and June 29, 2016. On June 30, 2016, based on the information we submitted to Nasdaq, Nasdaq granted us the maximum allowable 180 day extension to October 17, 2016 to evidence compliance with the Minimum Stockholders’ Equity Requirement.

On August 24, 2016, we received a determination letter (the “Determination Letter”) from the staff of Nasdaq stating that we had not regained compliance with the Minimum Bid Price Requirement. The Determination Letter also stated that we were not eligible for an additional 180-day extension to regain compliance with the Minimum Bid Price Requirement because we did not meet the Minimum Stockholders’ Equity Requirement for continued listing on the Nasdaq Capital Market, which requires listed companies to maintain stockholders’ equity of at least $2,500,000 (the “Minimum Stockholders’ Equity Requirement”), as set forth in Nasdaq Listing Rule 5550(b)(1) and as discussed below. In addition, the Determination Letter provided that our common stock would be delisted from the Nasdaq Capital Market at the opening of business on September 2, 2016 unless we requested a hearing before the Nasdaq Hearings Panel (the “Panel”).
 
On August 29, 2016, we requested a hearing before the Panel to appeal the Determination Letter in accordance with Nasdaq rules and as stated in the Determination Letter, and the hearing (the “Hearing”) was held on October 13, 2016. At the Hearing, we asked that the Panel continue our listing through December 31, 2016, to allow us to close the Merger, which we expect to result in a combined entity that will meet all initial listing standards for the Nasdaq Capital Market; however, we noted that we will need to effectuate a reverse stock split to ensure compliance with the Minimum Bid Price Requirement.

On November 1, 2016, we received a decision letter (the “Decision Letter”) from the staff of Nasdaq stating that the Panel had granted our request for continued listing on Nasdaq until December 31, 2016, subject to the following conditions.
.
1.
On or before November 15, 2016 we must report to the Panel, in writing, regarding the status of the reverse stock split, the filing of a definitive proxy for the Merger, and any feedback received from the staff of Nasdaq regarding the prospects of the application of the post-merger entity for listing on the Nasdaq Capital Market.

2.
On or before December 31, 2016, we must have closed the Merger and gained approval from the staff of Nasdaq for listing of the post-merger company on the Nasdaq Capital Market.

In addition, in order to fully comply with the terms of the Decision Letter, we must be able to demonstrate compliance with all requirements for continued listing on Nasdaq, and, in the event that we are unable to do so, our securities may be delisted from Nasdaq in the future.

If we are unable to fully comply with the terms of the Decision Letter and are unable to demonstrate compliance with all requirements for continued listing on Nasdaq, our securities may be delisted from Nasdaq in the future. We intend to monitor the closing bid price of our common stock and consider our available options to resolve our noncompliance with the Minimum Bid Price Requirement and the Minimum Stockholders’ Equity Requirement. There can be no assurance that we will be able to regain compliance with the Minimum Bid Price Requirement or the Minimum Stockholders’ Equity Requirement or will otherwise be in compliance with the other listing standards for the Nasdaq Capital Market. A suspension or delisting of our common stock could adversely affect our relationships with our business partners and suppliers and customers’ and potential customers’ decisions to purchase our products and services, and could have a material, adverse impact on our business and operating results. In addition, a suspension or delisting could impair our ability to raise additional capital through equity or debt financings and our ability to attract and retain employees by means of equity compensation.

Upon a potential delisting from Nasdaq, if our common stock is not then eligible for quotation on another market or exchange, trading of our common stock could be conducted in the over-the-counter market or on an electronic bulletin board

45

established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it is likely that there would be significantly less liquidity in the trading of our common stock; decreases in institutional and other investor demand for our common stock, coverage by securities analysts, market making activity and information available concerning trading prices and volume; and fewer broker-dealers willing to execute trades in our common stock. Also, it may be difficult for us to raise additional capital if we are not listed on a major exchange. The occurrence of any of these events could result in a further decline in the market price of our common stock and could have a material adverse effect on us.

*Failure to complete the Merger and private placement could negatively impact our stock price and our future business and financial results.

Although we have agreed to use reasonable efforts to obtain stockholder approval of the proposal to issue shares of our common stock and preferred stock in connection with the Merger, there is no assurance that these proposals will be approved. If these proposals are not approved, and as a result the Merger is not completed:

•
Our ongoing business may be adversely affected; and
•
We may be required, under certain circumstances, to pay Precipio a termination fee of up to $256,500.

*The announcement and pendency of the Merger may cause disruptions in our business, which could have an adverse effect on our businesses, financial conditions or results of operations.

The announcement and pendency of the Merger could cause disruptions in our business. Specifically:

•
our current and prospective employees may experience uncertainty about their future roles with the combined company following completion of the Merger, which might adversely affect our ability to retain key personnel and attract new personnel;
•
third parties may seek to terminate and/or renegotiate their relationships with us as a result of the transaction; and
•
our management’s attention has been focused on the Merger, which may divert management’s attention from our core business and other opportunities that could have been beneficial to us.

These disruptions could be exacerbated by a delay in the completion of the Merger or termination of the Merger Agreement and could have an adverse effect on our business, financial condition or results of operations prior to the completion of the Merger.

*The Merger is subject to the receipt of consents and approvals that may not be received.

The Merger Agreement provides that the parties cannot complete the Merger unless they receive various consents and approvals from Nasdaq and other third parties. While we believe that we will receive the requisite approvals, there can be no assurance that such approvals will be received.

*While the Merger is pending, we will be subject to contractual limitations that could adversely affect our business.

The Merger Agreement restricts us from taking certain specified actions while the Merger is pending without Precipio’s consent, including incurring indebtedness, making capital expenditures in excess of $5,000, acquiring any assets or selling, leasing or otherwise transferring any assets, and increasing in any material manner the compensation, bonuses or benefits of any directors, officers, employees, former employees or consultants, subject to certain exceptions in the ordinary course of business. These restrictions may prevent us from pursuing otherwise attractive business opportunities that may arise and making other changes to our business prior to the closing of the Merger or termination of the Merger Agreement.

*The Merger Agreement restricts our ability to pursue certain alternatives to the Merger and requires us to pay a reverse termination fee to Precipio if we do.

The Merger Agreement contains non-solicitation provisions that, subject to limited exceptions, restrict our ability to initiate, solicit or encourage or take any action to discuss or accept a competing third-party proposal. Although our Board of Directors is permitted to change its recommendation that stockholders approve the matters relating to the Merger if it determines in good faith that this action is reasonably likely to be required to comply with its fiduciary duties and certain other conditions, doing so in certain situations would require us to pay a termination fee to Precipio of $256,500. Additionally, these non-solicitation provisions could discourage a potential acquiror that might have an interest in acquiring all or a significant part of us from considering or proposing that acquisition, or might result in a potential acquiror proposing to pay a lower per share price to acquire us than it might otherwise have proposed to pay because of the added expense of the termination fee that may become payable to Precipio in certain circumstances.

46


*We have incurred substantial expenses in connection with the Merger.

We have incurred and will incur additional substantial expenses in connection with the Merger, whether or not the Merger is completed. These costs include fees for financial advisors, attorneys and accountants, filing fees and financial printing costs. If the Merger is not consummated, we will be responsible for our own expenses, which are not reimbursable in the event the Merger does not occur.



47

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds

On May 31, 2016, we issued to a vendor an aggregate of 78,000 shares of our common stock and, on June 14, 2016, we issued to a second vendor an aggregate of 64,153 shares of our common stock. Such shares of common stock were issued to the vendors in lieu of an aggregate cash amount of approximately $89,000 owed by us to such vendors for services previously performed by such vendors. We issued the shares to the vendors in transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The offering of the shares to the vendors did not involve a public offering, and no general solicitation or advertisement was made in connection with the offering of the shares to the vendors.

Item 6.
Exhibits
(a)
Exhibits
†2.1

 
Agreement and Plan of Merger, dated October 12, 2016, by and among Transgenomic, Inc., New Haven Labs Inc. and Precipio Diagnostics, LLC (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed on October 13, 2016).
 
 
 
3.1

  
Amended and Restated Bylaws of the Registrant.
 
 
 
 
 
 
31.1

 
Certification of Paul Kinnon, President, Chief Executive Officer and Interim Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended.
 
 
 
32.1

  
Certification of Paul Kinnon, President, Chief Executive Officer and Interim Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended.
 
 
 
99.1

 
Form of Voting Agreement, by and among Transgenomic, Inc., Precipio Diagnostics, LLC, and certain holders of Transgenomic common stock (incorporated by reference to Exhibit 99.1 to the Registrant’s Current Report on Form 8-K filed on October 13, 2016).
 
 
 
99.2

 
Form of Voting Agreement, by and among Transgenomic, Inc., Precipio Diagnostics, LLC, and certain members and warrantholders of Precipio (incorporated by reference to Exhibit 99.2 to the Registrant’s Current Report on Form 8-K filed on October 13, 2016).
 
 
 
101.INS

 
XBRL Instance Document
 
 
 
101.SCH

 
XBRL Taxonomy Extension Schema Document
 
 
 
101.CAL

 
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
 
101.DEF

 
XBRL Taxonomy Extension Definition Linkbase Document
 
 
 
101.LAB

 
XBRL Taxonomy Extension Label Linkbase Document
 
 
 
101.PRE

 
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
 
†


 
Pursuant to Item 601(b)(2) of Regulation S-K, the schedules to this agreement have been omitted. The Registrant agrees to furnish supplementally a copy of any omitted schedule to the Securities and Exchange Commission upon request.
 
 
 

48

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
 
 
TRANSGENOMIC, INC.
 
 
 
 
Date:
November 14, 2016
By:
/S/ PAUL KINNON



Paul Kinnon
President, Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)
 
 
 
 

49
 EX-3.1 2 tbio-ex31_20160930x10q.htm EXHIBIT 3.1 Exhibit

Exhibit 3.1
AMENDED AND RESTATED
BYLAWS OF
TRANSGENOMIC, INC.



TABLE OF CONTENTS
 
 
 
 
 
 
 
 
 
 
Page
ARTICLE I
 
STOCKHOLDERS
Section 1.
 
Time and Place of Meetings
 
1
Section 2.
 
Annual Meetings
 
1
Section 3.
 
Special Meetings
 
1
Section 4.
 
Notice of Meetings
 
1
Section 5.
 
Quorum and Adjournment
 
1
Section 6.
 
Voting
 
2
Section 7.
 
Stockholder Proposals and Nominations of Directors
 
2
Section 8.
 
Inspectors of Elections
 
3
Section 9.
 
Opening and Closing of Polls
 
3
Section 10.
 
Participation in Meetings by Conference Telephone
 
3
 
ARTICLE II
 
DIRECTORS
Section 1.
 
General Powers
 
4
Section 2.
 
Number of Directors; Removal; Qualifications
 
4
Section 3.
 
Vacancies
 
4
Section 4.
 
Regular Meetings
 
5
Section 5.
 
Special Meetings
 
5
Section 6.
 
Quorum
 
5
Section 7.
 
Written Action
 
5
Section 8.
 
Participation in Meetings by Conference Telephone
 
5
Section 9.
 
Committees
 
5
Section 10.
 
Compensation
 
6
Section 11.
 
Regulations; Manner of Acting
 
6
 
ARTICLE III
 
NOTICES
Section 1.
 
Generally
 
6
Section 2.
 
Waivers
 
6
 
 
 
 
 
 


ARTICLE IV
 
OFFICERS
Section 1.
 
Generally
 
7
Section 2.
 
Compensation
 
7
Section 3.
 
Election
 
7
Section 4.
 
Authority and Duties
 
7
Section 5.
 
Removal and Resignation; Vacancies
 
7
Section 6.
 
Chairman
 
7
Section 7.
 
President/Chief Executive Officer
 
7
Section 7A.
 
Chief Operating Officer
 
8
Section 8.
 
Execution of Documents and Action With Respect to Securities of Other Corporations
 
8
Section 9.
 
Vice President
 
8
Section 10.
 
Secretary and Assistant Secretaries
 
8
Section 11.
 
Treasurer and Assistant Treasurers
 
9
 
ARTICLE V
 
INDEMNIFICATION
Section 1.
 
Right to Indemnification
 
9
Section 2.
 
Right of Indemnitee To Bring Suit
 
10
Section 3.
 
Nonexclusivity of Rights
 
10
Section 4.
 
Insurance
 
10
Section 5.
 
Indemnification of Agents of the Corporation
 
10
Section 6.
 
Indemnification Contracts
 
11
Section 7.
 
Effect of Amendment
 
11
 
ARTICLE VI
 
STOCK
Section 1.
 
Certificates
 
11
Section 2.
 
Transfer
 
11
Section 3.
 
Lost, Stolen or Destroyed Certificates
 
11
Section 4.
 
Record Date
 
12


 
 
 
 
 
 
ARTICLE VII
 
GENERAL PROVISIONS
Section 1.
 
Fiscal Year
 
12
Section 2.
 
Corporate Seal
 
12
Section 3.
 
Reliance Upon Books, Reports and Records
 
12
Section 4.
 
Time Periods
 
12
Section 5.
 
Dividends
 
12
Section 6.
 
Exclusive Forum
 
13
Section 7.
 
Severability
 
13
 
ARTICLE VIII
 
 
AMENDMENT OF BYLAWS
 
13
 



BYLAWS
ARTICLE I
STOCKHOLDERS
Section 1. Time and Place of Meetings. All meetings of the stockholders for the election of directors or for any other purpose shall be held at such time and place, within or without the State of Delaware, as may be designated by the Board of Directors, or by the Chairman of the Board, the Chief Executive Officer, the President or the Secretary in the absence of a designation by the Board of Directors, and stated in the notice of the meeting or in a duly executed waiver of notice thereof. [Sections 211(a), (b).]
Section 2. Annual Meetings. An annual meeting of the stockholders shall be held on such date and at such time as shall be designated by the Board of Directors, at which meeting the stockholders shall elect by a plurality vote the directors to succeed those whose terms expire at that meeting and shall transact such other business as may properly be brought before the meeting.
Section 3. Special Meetings. Special meetings of the stockholders, for any purpose or purposes, unless otherwise prescribed by statute or by the Certificate of Incorporation, may only be called (i) by the Chairman of the Board, (ii) by the Board of Directors pursuant to a resolution adopted by a majority of the entire Board of Directors or (iii) by the Chief Executive Officer, if one is appointed, otherwise the President. [Section 211(d).]
Section 4. Notice of Meetings. Written notice of every meeting of the stockholders, stating the place, date and hour of the meeting and, in the case of a special meeting, the purpose or purposes for which the meeting is called, shall be given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote at such meeting, except as otherwise provided herein or by law. When a meeting is adjourned to another place, date or time, written notice need not be given of the adjourned meeting if the place, date and time thereof are announced at the meeting at which the adjournment is taken; provided, however, that if the adjournment is for more than 30 days, or if after the adjournment a new record date is fixed for the adjourned meeting, written notice of the place, date and time of the adjourned meeting shall be given in conformity herewith. At any adjourned meeting, any business may be transacted which might have been transacted at the original meeting. [Section 222.]
Section 5. Quorum and Adjournment. The holders of a majority of the stock issued and outstanding and entitled to vote thereat, present in person or represented by proxy, shall constitute a quorum at all meetings of the stockholders for the transaction of business except as otherwise provided by law or by the Certificate of Incorporation. If, however, such quorum shall not be present or represented at any meeting of the stockholders, the stockholders entitled to vote thereat, present in person or represented by proxy, shall have power to adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present or represented; provided, however, that if the adjournment is for more than 30 days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting, conforming to the requirements of Section 4 of Article I hereof, shall be given to each stockholder of record entitled to vote at such meeting. At any adjourned meeting at


which a quorum is present, any business may be transacted that might have been transacted on the original date of the meeting. [Sections 216, 222(c).]
Section 6. Voting. Except as otherwise provided by law or by the Certificate of Incorporation, each stockholder shall be entitled at every meeting of the stockholders to one vote for each share of stock having voting power standing in the name of such stockholder on the books of the Corporation on the record date for the meeting, and such votes may be cast either in person or by written proxy. Every proxy must be duly executed and filed with the Secretary of the Corporation. A stockholder may revoke any proxy which is not irrevocable by attending the meeting and voting in person or by filing an instrument in writing revoking the proxy or another duly executed proxy bearing a later date with the Secretary of the Corporation. No vote of the stockholders need be taken by written ballot unless otherwise required by law. Any vote which need not be taken by ballot may be conducted in any manner approved by the meeting. Every vote taken by written ballot shall be counted by one or more inspectors of election appointed by the Board of Directors. When a quorum is present at any meeting, the vote of the holders of a majority of the stock which has voting power present in person or represented by proxy shall decide any question properly brought before such meeting, unless the question is one upon which by express provision of law, the Certificate of Incorporation or these Bylaws, a different vote is required, in which case such express provision shall govern and control the decision of such question. [Sections 212, 216.]
Section 7. Stockholder Proposals and Nominations of Directors. Nominations for election to the Board of Directors of the Corporation at a meeting of the stockholders may be made by the Board of Directors, or on behalf of the Board of Directors by a Nominating Committee appointed by the Board of Directors, or by any stockholder of the Corporation entitled to vote for the election of directors at such meeting. Any nominations, other than those made by or on behalf of the Board of Directors, and any proposal by any stockholder to transact any corporate business at an annual or special stockholders meeting, shall be made by notice in writing and mailed by certified mail to the Secretary of the Corporation and (i) in the case of an annual meeting, received no later than 35 days prior to the date of the annual meeting; provided, however, that if less than 35 days’ notice of a meeting of stockholders is given to the stockholders, such notice of proposed business or nomination by such stockholder shall have been made or delivered to the Secretary of the Corporation not later than the close of business on the seventh day following the day on which the notice of a meeting was mailed, and (ii) in the case of a special meeting of stockholders, received not later than the close of business on the tenth day following the day on which notice of the date of the meeting was mailed. A notice of nominations by stockholders shall set forth as to each proposed nominee who is not an incumbent director (i) the name, age, address and principal occupation of each nominee proposed in such notice, (ii) the number of shares of stock of the Corporation which are beneficially owned by each such nominee and the nominating stockholder and (iii) any other information concerning the nominee that must be disclosed regarding nominees in proxy solicitations pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and the rules under such section.
 
The Chairman of the Board, or in his absence the Chief Executive Officer, if one is appointed, otherwise the President or the Secretary, may, if the facts warrant, determine and


declare to the meeting of stockholders that a nomination was not made in accordance with the foregoing procedure and that the defective nomination shall be disregarded.
Section 8. Inspectors of Elections. Preceding any meeting of the stockholders, the Board of Directors may appoint one or more persons to act as Inspectors of Elections and may designate one or more alternate inspectors. In the event either no inspector or alternate is appointed or no inspector or alternate is able to act, the Secretary shall serve as the inspector or the person presiding at the meeting shall appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of the duties of an inspector, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. The inspector shall:
(a) ascertain the number of shares outstanding and the voting power of each;
(b) determine the shares represented at a meeting and the validity of proxies and ballots;
(c) count all votes and ballots;
(d) determine and retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspectors; and
(e) certify his or her determination of the number of shares represented at the meeting and his or her count of all votes and ballots.
The inspector may appoint or retain other persons or entities to assist in the performance of the duties of inspector.
When determining the shares represented and the validity of proxies and ballots, the inspector shall be limited to an examination of the proxies, any envelopes submitted with those proxies, ballots and the regular books and records of the Corporation. The inspector may consider reliable information for the limited purpose of reconciling proxies and ballots submitted by or on behalf of banks, brokers or their nominees or a similar person which represent more votes than the holders of a proxy is authorized by the record owner to cast or more votes than the stockholder holds of record. If the inspector considers other reliable information as outlined in this Section, the inspector, at the time of his or her certification pursuant to (e) of this Section, shall specify the precise information considered, the person or persons from whom the information was obtained, when this information was obtained, the means by which the information was obtained, and the basis for the inspector’s belief that such information is accurate and reliable. [Sections 231(a), (b), (d).]
Section 9. Opening and Closing of Polls. The date and time for the opening and the closing of the polls for each matter to be voted upon at a meeting of stockholders shall be announced at the meeting. The inspector of the election shall be prohibited from accepting any ballots, proxies or votes nor any revocations thereof or changes thereto after the closing of the polls, unless the Court of Chancery upon application by a stockholder shall determine otherwise. [Section 231(c).]
 
Section 10. Participation in Meetings by Conference Telephone. So long as the Corporation has 35 or fewer stockholders, any stockholder may participate in any meeting of


stockholders by conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and such participation shall constitute presence in person at the meeting.
ARTICLE II
DIRECTORS
Section 1. General Powers. The business and affairs of the Corporation shall be managed by or under the direction of its Board of Directors, which may exercise all such powers of the Corporation and do all such lawful acts and things as are not by law or by the Certificate of Incorporation directed or required to be exercised or done by the stockholders. [Section 141(a).]
Section 2. Number of Directors; Removal; Qualifications. (a) The number of directors constituting the initial Board of Directors shall be five and, thereafter, the number of directors shall be fixed from time to time by resolution of the Board of Directors; provided that the number shall at no time be less than three or more than fifteen. In case of any increase in the number of directors in advance of an annual meeting of stockholders, each additional director shall be elected by the directors then in office, although less than a quorum, to hold office until the next annual meeting of shareholders or until his successor is elected. No decrease in the number of directors shall shorten the term of any incumbent director.
(b) The Board of Directors shall be divided into three classes, designated Classes I, II and III, which shall be as nearly equal in number as possible. Directors of Class I shall be elected to hold office for a term expiring at the annual meeting of stockholders to be held in 1998; directors of Class II shall be elected to hold office for a term expiring at the annual meeting of stockholders to be held in 1999; and directors of Class III shall be elected to hold office for a term expiring at the annual meeting of stockholders to be held in 2000. At each succeeding annual meeting of stockholders following such initial classification and election, the respective successors of each class shall be elected for three-year terms.
(c) After the election or appointment of a director, the holders of a majority of the shares then entitled to vote generally for the election of directors may remove such director or the entire Board of Directors, but only for cause.
(d) At any time securities of the Corporation are registered under Section 12 of the Securities Exchange Act of 1934, as amended, no less than two directors shall be persons other than (i) officers or employees of the Corporation or it subsidiaries or (ii) individuals having a relationship which, in the opinion of the Board of Directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Directors need not be shareholders of the Corporation. [Sections 141(b), (k).]
Section 3. Vacancies. Vacancies in the Board of Directors resulting from death, resignation, retirement, disqualification, removal from office or other cause, and newly created directorships resulting from any increase in the authorized number of directors, may be filled only by the affirmative vote of a majority of the remaining directors, though less than a quorum of the Board


of Directors, and directors so chosen shall hold office until the next annual meeting of shareholders or until their successors shall have been duly elected and qualified. [Section 223.]
Section 4. Regular Meetings. Regular meetings of the Board of Directors may be held without notice immediately after the annual meeting of the stockholders and at such other times and places as shall from time to time be determined by the Board of Directors. [Section 141(g).]
Section 5. Special Meetings. Special meetings of the Board of Directors may be called by the Chairman of the Board or the Chief Executive Officer, if one is appointed, otherwise the President or the Secretary on five days’ written notice to each director by whom such notice is not waived, given either personally or by courier, mail, facsimile transmission or telegram, and shall be called by the Chief Executive Officer, President or the Secretary in like manner and on like notice on the written request of any two directors. [Section 141(g).]
Section 6. Quorum. At all meetings of the Board of Directors, a majority of the total number of directors then in office shall constitute a quorum for the transaction of business, and the act of a majority of the directors present at any meeting at which there is a quorum shall be the act of the Board of Directors. If a quorum shall not be present at any meeting of the Board of Directors, the Directors present thereat may adjourn the meeting from time to time to another place, time or date, without notice other than announcement at the meeting, until a quorum shall be present. [Section 141(b).]
Section 7. Written Action. Any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting if all members of the Board or such committee, as the case may be, consent thereto in writing and the writing or writings are filed with the minutes or proceedings of the Board or such committee. [Section 141(f).]
Section 8. Participation in Meetings by Conference Telephone. Members of the Board of Directors, or any committee designated by the Board of Directors, may participate in a meeting of the Board of Directors, or any such committee, by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at the meeting. [Section 141(i).]
Section 9. Committees. The Board of Directors may, by resolution passed by a majority of the entire Board, designate one or more committees, each committee to consist of two or more of the directors of the Corporation and each to have such lawfully delegable powers and duties as the Board may confer. Each such committee shall serve at the pleasure of the Board of Directors. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. Except as otherwise provided by law, any such committee, to the extent provided in the resolution of the Board of Directors, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation and may authorize the seal of the Corporation to be affixed to all papers which may require it. Any committee or committees so designated by the Board shall have such name or names as may be determined from time to time by resolution adopted by the Board of Directors. Unless otherwise prescribed


by the Board of Directors, a majority of the members of the committee shall constitute a quorum for the transaction of business, and the act of a majority of the members present at a meeting at which there is a quorum shall be the act of such committee. Each Committee shall act at meetings held pursuant to duly issued notice as set out in Section 5 of this Article, waivers of notice or unanimous written consent. Each committee shall prescribe its own rules for calling and holding meetings and its method of procedure, subject to any rules prescribed by the Board of Directors, and shall keep a written record of all actions taken by it. No such committee shall have the power or authority:
(a) to amend the Certificate of Incorporation or provide for the issuance of shares of stock or fix the designations and any of the preferences or rights of shares or the conversion into, or the exchange of shares for, shares of any class or classes or any other series of the same of the Corporation or fix the number of shares of any series of stock or authorize the increase or decrease of the shares of any series;
(b) to adopt an agreement of merger or consolidation under Section 251 or Section 252 of the General Corporation Law of the State of Delaware;
(c) to recommend to the stockholders the sale, lease or exchange of all or substantially all of the Corporation’s property and assets;
(d) to recommend to the stockholders a dissolution of the Corporation or a revocation of a dissolution;
(e) to amend the Bylaws of the Corporation; or
(f) to declare a dividend.
Section 10. Compensation. The Board of Directors may establish such compensation for, and reimbursement of the expenses of, directors for attendance at meetings of the Board of Directors or committees, or for other services by directors to the Corporation, as the Board of Directors may reasonably determine. [Section 141(h).]
Section 11. Regulations; Manner of Acting. To the extent consistent with applicable law, the Certificate of Incorporation and these Bylaws, the Board of Directors may adopt such special rules and regulations for the conduct of their meetings and for the management of the property, affairs and business of the Corporation as the Board of Directors may deem appropriate. The directors shall act only as a Board, and the individual directors shall have no power as such.
ARTICLE III
NOTICES
Section 1. Generally. Whenever by law or under the provisions of the Certificate of Incorporation or these Bylaws notice is required to be given to any director or stockholder, it shall not be construed to mean personal notice, but such notice may be given in writing, by mail or national courier service, addressed to such director or stockholder, at his address as it appears on the records of the Corporation, with postage thereon prepaid, and such notice shall be deemed to be given at the time when the same shall be deposited in the United States mail or with such


courier service. Notice to directors may also be given by facsimile transmission, telegram or telephone. [Section 222(b).]
Section 2. Waivers. Whenever any notice is required to be given by law or under the provisions of the Certificate of Incorporation or these Bylaws, a waiver thereof in writing, signed by the person or persons entitled to such notice, whether before or after the time of the event for which notice is to be given, shall be deemed equivalent to such notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. [Section 229.]
ARTICLE IV
OFFICERS
Section 1. Generally. The officers of the Corporation shall be elected by the Board of Directors and shall consist of a Chief Executive Officer, a President, a Chief Operating Officer, a Secretary and a Treasurer. The Board of Directors may also choose any or all of the following: a Chairman of the Board of Directors, one or more Vice Presidents, and one or more Assistant Secretaries and Assistant Treasurers or any other officers deemed necessary by the Board of Directors. Any number of offices may be held by the same person. [Section 142(a).]
Section 2. Compensation. The compensation of the Chief Executive Officer, the President and all officers and agents of the Corporation who are also directors of the Corporation shall be fixed by the Board of Directors. The Board of Directors may delegate the power to fix the compensation of other officers and agents of the Corporation to an officer of the Corporation and, in the absence of any express designation, the Chief Executive Officer, if one is appointed, otherwise the President, shall have the power to fix such amounts.
Section 3. Election. The officers of the Corporation shall hold office until their successors are elected and qualified. Any officer elected or appointed by the Board of Directors may be removed at any time by the affirmative vote of a majority of the directors. Any vacancy occurring in any office of the Corporation may be filled by the Board of Directors. [Section 142(b).]
Section 4. Authority and Duties. Each of the officers of the Corporation shall have such authority and shall perform such duties as are customarily incident to their respective offices or as may be specified from time to time by the Board of Directors in a resolution which is not inconsistent with these Bylaws. [Section 142(a).]
Section 5. Removal and Resignation; Vacancies. Any officer may be removed for or without cause at any time by the Board of Directors. Any officer may resign at any time by delivering a written notice of resignation, signed by such officer, to the Board of Directors or the President. Unless otherwise specified therein, such resignation shall take effect upon delivery. Any vacancy occurring in any office of the Corporation by death, resignation, removal or otherwise shall be filled by the Board of Directors. [Sections 142(b), (e).]
 


Section 6. Chairman. The Chairman of the Board of Directors shall preside at all meetings of the stockholders and of the Board of Directors and shall have such other duties and responsibilities as may be assigned to him or her by the Board of Directors. The Chairman may delegate to any qualified person authority to chair any meeting of the stockholders, either on a temporary or a permanent basis. [Section 142(a).]
Section 7. President/Chief Executive Officer. The President shall be the principal executive officer of the Company unless a separate Chief Executive Officer is appointed by the Board of Directors. The Chief Executive Officer, if one is appointed, otherwise the President, shall carry out and direct the operations of the Company under the direction of the Board of Directors, subject to the specific delegation of any duties to a separate Chief Executive Officer. The President or the Chief Executive Officer, if one is appointed, shall preside at all meetings of the shareholders. The President and the Chief Executive Officer, if one is appointed, shall have general power to execute contracts, notes, bonds and other instruments on behalf of the Company and shall have such other duties and responsibilities as may be prescribed by the Board of Directors from time to time. In the absence of a Secretary, the President shall perform the duties thereof. [Section 142(a).]
Section 7A. Chief Operating Officer. The Chief Operating Officer shall carry out and direct the operations of the Company under the direction of the Chief Executive Officer.
Section 8. Execution of Documents and Action With Respect to Securities of Other Corporations. The Chief Executive Officer, the President, the Chief Operating Officer and the Executive Vice President shall have and are hereby given full power and authority, except as otherwise required by law or directed by the Board of Directors, (a) to execute, on behalf of the Corporation, all duly authorized contracts, agreements, deeds, conveyances or other obligations of the Corporation, applications, consents, proxies and other powers of attorney and other documents and instruments and (b) to vote and otherwise act on behalf of the Corporation, in person or by proxy, at any meeting of stockholders (or with respect to any action of such stockholders) of any other corporation in which the Corporation may hold securities and otherwise to exercise any and all rights and powers which the Corporation may possess by reason of its ownership of securities of such other corporation. In addition, the Chief Executive Officer, if one is appointed, otherwise the President, may delegate to the Secretary or to other officers, employees and agents of the Corporation the power and authority to take any action which the Chief Executive Officer, if one is appointed, otherwise the President, is authorized to take under this Section 8 of this Article IV, with such limitations as the Chief Executive Officer, if one is appointed, otherwise the President, may specify; such authority so delegated by the Chief Executive Officer, if one is appointed, otherwise the President, shall not be redelegated by the person to whom such execution authority has been delegated. [Section 142(a).]
Section 9. Vice President. Each Vice President, however titled, shall perform such duties and services and shall have such authority and responsibilities as shall be assigned to or required from time to time by the Board of Directors or the President. [Section 142(a).]
Section 10. Secretary and Assistant Secretaries. (a) The Secretary shall attend all meetings of the stockholders and all meetings of the Board of Directors and record all proceedings of the meetings of the stockholders and of the Board of Directors and shall perform like duties for the


standing committees when requested by the Board of Directors, the President or the Chairman. The Secretary shall give, or cause to be given, notice of all meetings of the stockholders and meetings of the Board of Directors. The Secretary shall perform such duties as may be prescribed by the Board of Directors or its Chairman or the Chief Executive Officer, if one is appointed, otherwise the President. The Secretary shall have charge of the seal of the Corporation and authority to affix the seal to any instrument. The Secretary or any Assistant Secretary may attest to the corporate seal by handwritten or facsimile signature. The Secretary shall keep and account for all books, documents, papers and records of the Corporation except those for which some other officer or agent has been designated or is otherwise properly accountable. The Secretary shall have authority to sign stock certificates.
(b) Assistant Secretaries, in the order of their seniority, shall assist the Secretary and, if the Secretary is unavailable or fails to act, perform the duties and exercise the authorities of the Secretary. [Section 142(a).]
Section 11. Treasurer and Assistant Treasurers. (a) The Treasurer, if so designated, shall be the Chief Financial Officer of the Corporation and may be known as such. The Treasurer shall have the custody of the funds and securities belonging to the Corporation and shall deposit all moneys and other valuable effects in the name and to the credit of the Corporation in such depositories as may be designated by the Treasurer or the President. The Treasurer shall disburse the funds and pledge the credit of the Corporation and shall render to the Board of Directors and the President, as and when required by them, or any of them, an account of all transactions by the Treasurer.
(b) Assistant Treasurers, in the order of their seniority, shall assist the Treasurer and, if the Treasurer is unable or fails to act, perform the duties and exercise the powers of the Treasurer. [Section 142(a).]
ARTICLE V
INDEMNIFICATION
Section 1. Right to Indemnification. Each person who was or is made a party or is threatened to be made a party to or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (hereinafter a “proceeding”), by reason of the fact that he or she is or was a director or officer of the Corporation or is or was serving at the request of the Corporation as a director, officer or employee of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans (hereinafter an “indemnitee”), whether the basis of such proceeding is alleged action in an official capacity as a director, officer or employee or in any other capacity while serving as a director, officer or employee, shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the General Corporation Law of the State of Delaware, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), against all expense, liability and loss (including attorneys’ fees, judgments, fines,


ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by such indemnitee in connection therewith and such indemnification shall continue as to an indemnitee who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the indemnitee’s heirs, executors and administrators; provided, however, that, except as provided in Section 2 of this Article V with respect to proceedings to enforce rights to indemnification, the Corporation shall indemnify any such indemnitee in connection with a proceeding (or part thereof) initiated by such indemnitee only if such proceeding (or part thereof) was authorized by the Board of Directors of the Corporation. The right to indemnification conferred in this Section 1 of this Article V shall be a contract right and shall include the right to be paid by the Corporation the expenses incurred in defending any such proceeding in advance of its final disposition (hereinafter an “advancement of expenses”); and provided, further, that, if the General Corporation Law of the State of Delaware requires it, an advancement of expenses incurred by an indemnitee in his or her capacity as a director or officer (and not in any other capacity in which service was or is rendered by such indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to the Corporation of an undertaking, by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such indemnitee is not entitled to be indemnified for such expenses under this Article V or otherwise (hereinafter an “undertaking”).
Section 2. Right of Indemnitee To Bring Suit. If a claim under Section 1 of this Article V is not paid in full by the Corporation within 60 days after a written claim has been received by the Corporation, except in the case of a claim for an advancement of expenses, in which case the applicable period shall be 20 days, the indemnitee may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim. If successful in whole or part in any such suit or in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the indemnitee shall be entitled to be paid also the expense of prosecuting or defending such suit. In any suit brought by the indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by the indemnitee to enforce a right to an advancement of expenses), it shall be a defense that the indemnitee has not met the applicable standard of conduct set forth in the General Corporation Law of the State of Delaware. Likewise, in any suit by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the indemnitee has not met such standards. Neither the failure of the Corporation (including its Board of Directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such suit that indemnification of the indemnitee is proper in the circumstances because the indemnitee has met the applicable standard of conduct set forth in the General Corporation Law of the State of Delaware, nor an actual determination by the Corporation (including its Board of Directors, independent legal counsel or its stockholders) that the indemnitee has not met such applicable standard of conduct, shall create a presumption that the indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by indemnitee, be a defense to such suit. In any suit brought by the indemnitee to enforce a right hereunder, or by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the indemnitee is


not entitled to be indemnified or to such advancement of expenses under this Article V or otherwise shall be on the Corporation.
Section 3. Nonexclusivity of Rights. The rights of indemnification and to the advancement of expenses conferred in this Article V shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, bylaw, contract, agreement, vote of stockholders or disinterested directors or otherwise.
 
Section 4. Insurance. The Corporation may maintain insurance, at its expense, to protect itself and any indemnitee against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the General Corporation Law of the State of Delaware.
Section 5. Indemnification of Agents of the Corporation. The Corporation may, to the extent authorized from time to time by the Board of Directors, grant rights to indemnification and to the advancement of expenses to any employee or agent of the Corporation to the fullest extent of the provisions of this Article V or as otherwise permitted under the General Corporation Law of the State of Delaware with respect to the indemnification and advancement of expenses of directors and officers of the Corporation.
Section 6. Indemnification Contracts. The Board of Directors is authorized to enter into a contract with any director, officer, employee or agent of the Corporation, or any person serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including employee benefit plans, providing for indemnification rights equivalent to or, if the Board of Directors so determines, greater than, those provided for in this Article V.
Section 7. Effect of Amendment. Any amendment, repeal or modification of any provision of this Article V by the stockholders or the directors of the Corporation shall not adversely affect any right or protection of a director or officer of the Corporation existing at the time of such amendment, repeal or modification. [Section 145.]
ARTICLE VI
STOCK
Section 1. Certificates. Shares of the Corporation’s stock may be certificated or uncertificated, as provided under Section 158 of the General Corporation Law of the State of Delaware. Certificates representing shares of stock of the Corporation shall be in such form as shall be determined by the Board of Directors, subject to applicable legal requirements. Such certificates shall be numbered and their issuance recorded in the books of the Corporation, and such certificates shall exhibit the holder’s name and the number of shares and shall be signed by, or in the name of the Corporation by, the Chief Executive Officer, if one is appointed, otherwise the President and the Secretary or an Assistant Secretary or the Treasurer or an Assistant Treasurer of the Corporation. Any or all of the signatures and the seal of the Corporation, if any, upon such certificates may be facsimiles, engraved or printed. [Section 158.]


Section 2. Transfer. Transfers of stock shall be made on the books of the Corporation only by the record holder of such stock, or by attorney lawfully constituted in writing, and in the case of stock represented by a certificate, upon surrender of the certificate, duly endorsed or accompanied by proper evidence of succession, assignment or authority to transfer. [Section 151.]
 
Section 3. Lost, Stolen or Destroyed Certificates. The Secretary may direct a new certificate or certificates to be issued in place of any certificate or certificates theretofore issued by the Corporation alleged to have been lost, stolen or destroyed upon the making of an affidavit of that fact, satisfactory to the Secretary, by the person claiming the certificate of stock to be lost, stolen or destroyed. As a condition precedent to the issuance of a new certificate or certificates, the Secretary may require the owner of such lost, stolen or destroyed certificate or certificates to give the Corporation a bond in such sum and with such surety or sureties as the Secretary may direct as indemnity against any claims that may be made against the Corporation with respect to the certificate alleged to have been lost, stolen or destroyed or the issuance of the new certificate. [Section 167.]
Section 4. Record Date. (a) In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 60 nor less than 10 days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.
(b) In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto. [Section 213.]
ARTICLE VII
GENERAL PROVISIONS
Section 1. Fiscal Year. The fiscal year of the Corporation shall be the calendar year or such other annual period as shall be fixed from time to time by the Board of Directors.


Section 2. Corporate Seal. The Board of Directors may adopt a corporate seal and use the same by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise.
Section 3. Reliance Upon Books, Reports and Records. Each director, each member of a committee designated by the Board of Directors, and each officer of the Corporation shall, in the performance of his or her duties, be fully protected in relying in good faith upon the records of the Corporation and upon such information, opinions, reports or statements presented to the Corporation by any of the Corporation’s officers or employees, or committees of the Board of Directors, or by any other person as to matters the director, committee member or officer believes are within such other person’s professional or expert competence and who has been selected with reasonable care by or on behalf of the Corporation. [Section 141(e)]
Section 4. Time Periods. In applying any provision of these Bylaws which requires that an act be done or not be done a specified number of days prior to an event or that an act be done during a period of a specified number of days prior to an event, calendar days shall be used, the day of the doing of the act shall be excluded and the day of the event shall be included.
Section 5. Dividends. The Board of Directors may from time to time declare and the Corporation may pay dividends upon its outstanding shares of capital stock, in the manner and upon the terms and conditions provided by law and the Certificate of Incorporation. [Section 173.]

Section 6. Exclusive Forum. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any current or former director, officer or other employee or agent of the Corporation to the Corporation or the Corporation’s stockholders or debtholders, (iii) any action asserting a claim against the Corporation or any director or officer or other employee of the Corporation arising pursuant to any provision of the Delaware General Corporation Law or the Certificate of Incorporation or Bylaws (in each case, as they may be amended from time to time), (iv) any action asserting a claim against the Corporation or any current or former director or officer or other employee or agent of the Corporation governed by the internal affairs doctrine or (v) any action asserting an “internal corporate claim” as that term is defined in Section 115 of the General Corporation Law of the State of Delaware; provided, however, that in the event that the Court of Chancery of the State of Delaware lacks jurisdiction over any such action or proceeding, the sole and exclusive forum for such action or proceeding shall be another state or federal court located within the State of Delaware.
 
Section 7. Severability. If any provision of these Bylaws shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provision in any other circumstance and of the remaining provisions of these Bylaws (including, without limitation, each portion of any sentence of these Bylaws containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or


unenforceable) and the application of such provision to other persons or entities or circumstances shall not in any way be affected or impaired thereby.
ARTICLE VIII
AMENDMENT OF BYLAWS
In furtherance and not in limitation of the powers conferred upon it by law, the Board of Directors is expressly authorized to adopt, repeal, alter or amend the Bylaws of the Corporation by the affirmative vote of a majority or more of the entire Board of Directors. In addition to any requirements of law and any provision of the Certificate of Incorporation, the stockholders of the Corporation may adopt, repeal, alter or amend any provision of the Bylaws upon the affirmative vote of the holders of a majority or more of the combined voting power of the then outstanding stock of the Corporation entitled to vote generally in the election of directors. [Section 109(a).]
 


 EX-31.1 3 tbio-ex311_20160930x10q.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
I, Paul Kinnon, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Transgenomic, Inc. (the Registrant);
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and I have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiary, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and
5.
I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent function):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.


/s/ PAUL KINNON
 
Paul Kinnon
President, Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)
Date: November 14, 2016


EX-32.1 4 tbio-ex321_20160930x10q.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
In connection with the accompanying Quarterly Report on Form 10-Q of Transgenomic, Inc. for the period ended September 30, 2016, I, Paul Kinnon, Chief Executive Officer and Interim Chief Financial Officer of Transgenomic, Inc., hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:
(1)
Such Quarterly Report on Form 10-Q of Transgenomic, Inc. for the period ended September 30, 2016, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in such Quarterly Report on Form 10-Q of Transgenomic, Inc. for the period ended September 30, 2016, fairly presents, in all material respects, the financial condition and results of operations of Transgenomic, Inc.
 
/s/ PAUL KINNON
 
Paul Kinnon
President, Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)

Date: November 14, 2016
A signed original of the certification required by Section 906 has been provided to Transgenomic, Inc. and will be retained by Transgenomic, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



EX-101.INS 5 tbio-20160930.xml XBRL INSTANCE DOCUMENT 0001043961 2016-01-01 2016-09-30 0001043961 2016-10-31 0001043961 2015-12-31 0001043961 2016-09-30 0001043961 2015-07-01 2015-09-30 0001043961 2015-01-01 2015-09-30 0001043961 2016-07-01 2016-09-30 0001043961 us-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-09-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember 2016-07-01 2016-09-30 0001043961 us-gaap:SegmentContinuingOperationsMember 2016-07-01 2016-09-30 0001043961 us-gaap:SegmentContinuingOperationsMember 2015-01-01 2015-09-30 0001043961 us-gaap:SegmentContinuingOperationsMember 2015-07-01 2015-09-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember 2015-01-01 2015-09-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember 2016-01-01 2016-09-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember 2015-07-01 2015-09-30 0001043961 us-gaap:CommonStockMember 2015-12-31 0001043961 us-gaap:CommonStockMember 2016-01-01 2016-09-30 0001043961 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001043961 us-gaap:PreferredStockMember 2016-01-01 2016-09-30 0001043961 us-gaap:CommonStockMember 2016-09-30 0001043961 us-gaap:PreferredStockMember 2016-09-30 0001043961 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001043961 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0001043961 us-gaap:RetainedEarningsMember 2015-12-31 0001043961 us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember 2016-01-01 2016-09-30 0001043961 us-gaap:RetainedEarningsMember 2016-01-01 2016-09-30 0001043961 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001043961 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-09-30 0001043961 us-gaap:PreferredStockMember 2015-12-31 0001043961 us-gaap:RetainedEarningsMember 2016-09-30 0001043961 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-09-30 0001043961 us-gaap:PrivatePlacementMember 2016-01-01 2016-09-30 0001043961 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember 2016-01-01 2016-09-30 0001043961 2015-09-30 0001043961 2014-12-31 0001043961 2016-06-30 0001043961 2015-06-30 0001043961 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-07-01 2015-09-30 0001043961 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-07-01 2016-09-30 0001043961 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-01-01 2015-09-30 0001043961 us-gaap:ExecutiveOfficerMember 2016-01-01 2016-09-30 0001043961 us-gaap:MaximumMember 2016-01-01 2016-09-30 0001043961 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-09-30 0001043961 tbio:PharmacogenomicServicesMember 2016-09-30 0001043961 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2016-01-01 2016-09-30 0001043961 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember us-gaap:MaximumMember 2016-01-01 2016-09-30 0001043961 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember us-gaap:MinimumMember 2016-01-01 2016-09-30 0001043961 us-gaap:LeaseholdImprovementsMember us-gaap:MaximumMember 2016-01-01 2016-09-30 0001043961 us-gaap:ComputerEquipmentMember us-gaap:MaximumMember 2016-01-01 2016-09-30 0001043961 us-gaap:LeaseholdImprovementsMember us-gaap:MinimumMember 2016-01-01 2016-09-30 0001043961 us-gaap:ComputerEquipmentMember us-gaap:MinimumMember 2016-01-01 2016-09-30 0001043961 us-gaap:OtherMachineryAndEquipmentMember us-gaap:MaximumMember 2016-01-01 2016-09-30 0001043961 us-gaap:OtherMachineryAndEquipmentMember us-gaap:MinimumMember 2016-01-01 2016-09-30 0001043961 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2016-01-01 2016-09-30 0001043961 tbio:PharmacogenomicServicesMember 2015-12-31 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2014-12-31 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2016-09-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2015-01-01 2015-09-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2015-12-31 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2015-09-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2016-01-01 2016-09-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2016-07-01 2016-09-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2015-07-01 2015-09-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2016-06-30 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:GeneticAssaysandPlatformsandPatientTestingMember 2015-06-30 0001043961 tbio:ADSTECCorporationMember tbio:GeneticAssaysAndPlatformsBusinessMember 2015-11-25 0001043961 tbio:GeneticAssaysAndPlatformsBusinessMember 2015-09-08 0001043961 us-gaap:SegmentDiscontinuedOperationsMember tbio:PatientTestingMember 2016-01-01 2016-09-30 0001043961 tbio:GeneticAssaysAndPlatformsBusinessMember 2015-01-01 2015-12-31 0001043961 tbio:ADSTECCorporationMember tbio:GeneticAssaysAndPlatformsBusinessMember 2015-01-01 2015-12-31 0001043961 us-gaap:PatentsMember 2016-09-30 0001043961 us-gaap:IntellectualPropertyMember 2016-09-30 0001043961 us-gaap:PatentsMember 2015-12-31 0001043961 us-gaap:IntellectualPropertyMember 2015-12-31 0001043961 us-gaap:IntellectualPropertyMember 2016-01-01 2016-09-30 0001043961 tbio:TermLoanMember 2015-12-31 0001043961 tbio:TermLoanMember 2016-09-30 0001043961 us-gaap:ConvertibleNotesPayableMember 2015-12-31 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2015-12-31 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2016-09-30 0001043961 us-gaap:ConvertibleNotesPayableMember 2016-09-30 0001043961 tbio:TermLoanMember 2014-03-01 2015-03-31 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember tbio:WallStreetJournalPrimeRateMember 2016-01-01 2016-09-30 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2015-09-04 0001043961 us-gaap:ConvertibleNotesPayableMember 2014-12-31 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2014-10-22 0001043961 us-gaap:ConvertibleNotesPayableMember tbio:AdditionalNotePrivatePlacementMember 2016-01-01 2016-09-30 0001043961 tbio:TermLoanMember 2016-01-01 2016-09-30 0001043961 us-gaap:ConvertibleNotesPayableMember 2016-01-06 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2016-01-01 2016-09-30 0001043961 tbio:DebtInstrumentConversionPeriodTwoMember us-gaap:ConvertibleNotesPayableMember 2014-12-31 2014-12-31 0001043961 us-gaap:ConvertibleNotesPayableMember tbio:AdditionalNotePrivatePlacementMember 2015-01-20 0001043961 tbio:DebtInstrumentConversionPeriodOneMember us-gaap:ConvertibleNotesPayableMember 2014-12-31 0001043961 tbio:DebtInstrumentConversionPeriodOneMember us-gaap:ConvertibleNotesPayableMember 2014-12-31 2014-12-31 0001043961 us-gaap:ConvertibleNotesPayableMember 2016-01-01 2016-09-30 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2015-08-10 2015-08-10 0001043961 tbio:PGxHealthLLCMember us-gaap:SeniorNotesMember 2013-03-13 2013-03-13 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember tbio:TermLoanMember 2013-03-13 0001043961 us-gaap:RevolvingCreditFacilityMember tbio:ThirdSecurityLlcAndAffiliatesMember us-gaap:LineOfCreditMember 2013-03-13 0001043961 tbio:AdditionalNotePrivatePlacementMember 2015-01-15 0001043961 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2014-10-21 0001043961 tbio:TermLoanMember 2015-04-01 0001043961 tbio:UniversityofNebraskaMember us-gaap:ThreatenedLitigationMember us-gaap:PerformanceGuaranteeMember 2016-09-30 0001043961 tbio:IcahnSchoolofMedicineMember us-gaap:ThreatenedLitigationMember us-gaap:PerformanceGuaranteeMember 2016-06-23 2016-06-23 0001043961 tbio:UniversityofNebraskaMember us-gaap:ThreatenedLitigationMember us-gaap:PerformanceGuaranteeMember 2016-02-25 2016-02-25 0001043961 tbio:IcahnSchoolofMedicineMember us-gaap:ThreatenedLitigationMember us-gaap:PerformanceGuaranteeMember 2016-09-30 0001043961 tbio:IcahnSchoolofMedicineMember us-gaap:ThreatenedLitigationMember us-gaap:PerformanceGuaranteeMember 2015-12-31 0001043961 tbio:UniversityofNebraskaMember us-gaap:ThreatenedLitigationMember us-gaap:PerformanceGuaranteeMember 2015-12-31 0001043961 2015-07-07 2015-07-07 0001043961 tbio:SeriesA1ConvertiblePreferredStockMember 2016-09-30 0001043961 us-gaap:PrivatePlacementMember 2016-09-30 0001043961 tbio:TwoThousandFourteenPrivatePlacementMember 2014-10-22 2014-10-22 0001043961 tbio:SeriesA1ConvertiblePreferredStockMember 2016-01-06 0001043961 us-gaap:PrivatePlacementMember 2016-01-06 0001043961 us-gaap:PrivatePlacementMember 2012-02-02 0001043961 tbio:SeriesAWarrantsMember 2015-07-07 2015-07-07 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2014-03-05 0001043961 us-gaap:PrivatePlacementMember 2014-12-31 0001043961 tbio:CraigHallumCapitalGroupLLCMember 2015-07-07 0001043961 2015-07-07 0001043961 us-gaap:PrivatePlacementMember 2012-02-02 2012-02-02 0001043961 tbio:SeriesA1WarrantMember 2016-01-06 0001043961 2016-01-06 2016-01-06 0001043961 tbio:CraigHallumCapitalGroupLLCMember 2016-01-06 2016-01-06 0001043961 us-gaap:SeriesBPreferredStockMember 2016-01-06 2016-01-06 0001043961 tbio:SeriesA1WarrantMember 2016-01-06 2016-01-06 0001043961 tbio:TwoThousandFourteenPrivatePlacementMember 2014-10-22 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember 2014-03-05 0001043961 us-gaap:PrivatePlacementMember 2014-10-22 0001043961 tbio:OfferingMember 2013-01-24 0001043961 tbio:SeriesA1WarrantMember us-gaap:ProFormaMember 2016-01-06 0001043961 tbio:CraigHallumCapitalGroupLLCMember us-gaap:ConvertibleNotesPayableMember tbio:AdditionalNotePrivatePlacementMember 2015-01-15 0001043961 us-gaap:CommonStockMember 2016-05-31 2016-05-31 0001043961 tbio:SeriesAWarrantsMember 2016-01-06 2016-01-06 0001043961 us-gaap:PrivatePlacementMember 2015-02-27 0001043961 us-gaap:PrivatePlacementMember 2015-07-07 0001043961 tbio:SeriesAWarrantsMember us-gaap:MaximumMember 2016-01-06 0001043961 tbio:SeriesA1WarrantMember us-gaap:MaximumMember 2016-01-06 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember us-gaap:PrivatePlacementMember 2012-02-02 0001043961 tbio:SeriesAWarrantsMember us-gaap:ProFormaMember 2016-01-06 0001043961 us-gaap:PrivatePlacementMember 2013-01-24 0001043961 tbio:CraigHallumCapitalGroupLLCMember tbio:TwoThousandFifteenOfferingMember 2015-02-27 0001043961 tbio:CraigHallumCapitalGroupLLCMember tbio:TwoThousandFifteenOfferingMember 2015-02-27 2015-02-27 0001043961 us-gaap:PrivatePlacementMember 2015-01-15 0001043961 us-gaap:CommonStockMember tbio:AttheMarketOfferingMember 2016-07-01 2016-09-30 0001043961 tbio:SeriesAWarrantsMember 2016-01-06 0001043961 tbio:AffiliatesofThirdSecurityLLCJanuary2018Member tbio:OfferingMember 2013-01-24 0001043961 tbio:AttheMarketOfferingMember 2016-07-01 2016-09-30 0001043961 tbio:SeriesBWarrantsMember us-gaap:MaximumMember 2015-07-07 0001043961 tbio:SeriesAWarrantsMember us-gaap:ProFormaMember 2016-01-06 2016-01-06 0001043961 us-gaap:SeriesAPreferredStockMember 2016-01-06 2016-01-06 0001043961 us-gaap:CommonStockMember 2016-05-01 2016-05-31 0001043961 tbio:SeriesBWarrantsMember 2015-07-07 0001043961 us-gaap:PrivatePlacementMember 2016-06-30 0001043961 tbio:OfferingMember 2016-01-01 2016-09-30 0001043961 tbio:SeriesAWarrantCashlessExchangeMember us-gaap:MaximumMember us-gaap:ProFormaMember 2016-01-06 0001043961 tbio:OfferingMember 2013-01-24 2013-01-24 0001043961 tbio:CraigHallumCapitalGroupLLCMember 2015-07-07 2015-07-07 0001043961 tbio:OfferingMember 2015-01-01 2015-09-30 0001043961 us-gaap:SeriesAPreferredStockMember 2016-01-06 0001043961 tbio:SeriesA1ConvertiblePreferredStockMember 2016-05-01 2016-05-31 0001043961 tbio:SeriesAWarrantCashlessExchangeMember us-gaap:MaximumMember 2016-01-06 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember 2013-01-24 0001043961 us-gaap:WeightedAverageMember us-gaap:CommonStockMember tbio:AttheMarketOfferingMember 2016-09-30 0001043961 us-gaap:PrivatePlacementMember 2014-10-21 0001043961 us-gaap:PrivatePlacementMember 2012-12-31 0001043961 tbio:SeriesA1WarrantMember us-gaap:MaximumMember us-gaap:ProFormaMember 2016-01-06 0001043961 us-gaap:SeriesBPreferredStockMember 2015-12-31 0001043961 us-gaap:SeriesAPreferredStockMember 2015-12-31 0001043961 tbio:ThirdSecurityLlcAndAffiliatesMember us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2014-03-05 2014-03-05 0001043961 tbio:SeriesA1ConvertiblePreferredStockandWarrantsMember 2016-01-06 2016-01-06 0001043961 tbio:CraigHallumCapitalGroupLLCMember 2016-01-06 0001043961 tbio:AffiliatesofThirdSecurityLLCJanuary2018Member tbio:OfferingMember 2013-01-24 2013-01-24 0001043961 tbio:SeriesAandSeriesBWarrantsMember 2015-07-07 0001043961 us-gaap:CommonStockMember tbio:AttheMarketOfferingMember 2016-06-07 0001043961 us-gaap:CommonStockMember 2016-06-14 2016-06-14 0001043961 tbio:SeriesA1WarrantMember us-gaap:ProFormaMember 2016-01-06 2016-01-06 0001043961 tbio:TwoThousandFourteenPrivatePlacementMember tbio:AdvisorMember 2014-10-22 0001043961 us-gaap:PrivatePlacementMember 2011-12-01 2011-12-31 0001043961 us-gaap:CommonStockMember 2016-01-06 2016-01-06 0001043961 tbio:SeriesAandSeriesBWarrantsMember us-gaap:MaximumMember 2015-07-07 0001043961 us-gaap:PrivatePlacementMember 2015-01-01 2015-09-30 0001043961 us-gaap:CommonStockMember tbio:AttheMarketOfferingMember 2016-01-01 2016-09-30 0001043961 tbio:CraigHallumCapitalGroupLLCMember us-gaap:CommonStockMember tbio:AttheMarketOfferingMember 2016-06-07 2016-06-07 0001043961 tbio:SeriesA1ConvertiblePreferredStockandWarrantsMember 2016-01-06 0001043961 us-gaap:CommonStockMember 2016-07-01 2016-09-30 0001043961 tbio:VariousInstitutionalHoldersDecember2020TwoMember 2016-09-30 0001043961 tbio:VariousInstitutionalHoldersJanuary2018Member 2016-09-30 0001043961 tbio:VariousInstitutionalHoldersDecember2020OneMember 2016-09-30 0001043961 tbio:VariousInstitutionalHoldersJanuary2021TwoMember 2016-09-30 0001043961 tbio:AffiliatesofThirdSecurityLLCFebruary2017Member 2016-09-30 0001043961 tbio:AffiliatesofThirdSecurityLLCJanuary2021Member 2016-09-30 0001043961 tbio:AffiliatesofThirdSecurityLLCJanuary2018Member 2016-09-30 0001043961 tbio:VariousInstitutionalHoldersJanuary2021OneMember 2016-09-30 0001043961 tbio:VariousInstitutionalHoldersFebruary2020Member 2016-09-30 0001043961 tbio:VariousInstitutionalHoldersFebruary2017Member 2016-09-30 0001043961 tbio:VariousInstitutionalHoldersApril2020Member 2016-09-30 0001043961 tbio:SeriesBWarrantsMember 2015-07-07 2015-07-07 0001043961 tbio:AttheMarketOfferingMember 2016-01-01 2016-09-30 0001043961 us-gaap:SeriesBPreferredStockMember 2016-01-06 0001043961 tbio:A2016WarrantLiabilityMember 2016-01-01 2016-09-30 0001043961 tbio:A2012WarrantLiabilityMember 2016-01-01 2016-09-30 0001043961 tbio:A2016WarrantLiabilityMember 2016-01-01 2016-01-31 0001043961 tbio:A2016WarrantLiabilityMember 2016-09-30 0001043961 tbio:A2012WarrantLiabilityMember 2016-09-30 0001043961 tbio:A2012WarrantLiabilityMember 2012-02-01 2012-02-28 0001043961 tbio:A2012WarrantLiabilityMember 2015-07-01 2015-09-30 0001043961 tbio:A2012WarrantLiabilityMember 2015-09-30 0001043961 tbio:A2012WarrantLiabilityMember 2016-07-01 2016-09-30 0001043961 tbio:A2012WarrantLiabilityMember 2015-06-30 0001043961 tbio:A2012WarrantLiabilityMember 2016-06-30 0001043961 tbio:A2016WarrantLiabilityMember 2016-06-30 0001043961 tbio:A2016WarrantLiabilityMember 2016-07-01 2016-09-30 0001043961 tbio:A2012WarrantLiabilityMember 2014-12-31 0001043961 tbio:A2012WarrantLiabilityMember 2015-12-31 0001043961 tbio:A2012WarrantLiabilityMember 2015-01-01 2015-09-30 0001043961 tbio:A2016WarrantLiabilityMember 2015-12-31 0001043961 us-gaap:EmployeeStockOptionMember 2016-09-30 0001043961 us-gaap:EmployeeStockOptionMember 2015-12-31 0001043961 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001043961 us-gaap:StockAppreciationRightsSARSMember 2016-09-30 0001043961 us-gaap:StockAppreciationRightsSARSMember 2015-12-31 0001043961 tbio:EquityIncentivePlan2006Member 2016-01-01 2016-09-30 0001043961 tbio:PrecipioMember us-gaap:SubsequentEventMember 2016-10-12 2016-10-12 0001043961 tbio:PrecipioMember us-gaap:MinimumMember us-gaap:SubsequentEventMember 2016-10-12 0001043961 tbio:PrecipioMember us-gaap:SubsequentEventMember 2016-10-12 0001043961 tbio:PrecipioMember us-gaap:SubsequentEventMember 2016-10-12 0001043961 tbio:PrecipioMember us-gaap:MaximumMember us-gaap:SubsequentEventMember 2016-10-12 xbrli:pure iso4217:USD iso4217:USD xbrli:shares tbio:investor xbrli:shares iso4217:USD tbio:unit tbio:operating_segments false --12-31 Q3 2016 2016-09-30 10-Q 0001043961 24786244 Smaller Reporting Company TRANSGENOMIC INC P30D 1200000 1800000 3466841 2666349 800492 3055555 3400000 1881456 1174099 98333 9.00 1436882 1436882 941197 941197 0.50 0.50 P90D P90D P5Y P5Y6M P5Y6M P5Y P5Y P5Y P6M P5Y 1.95 1.8135 3500000 250000 125000 0.85 0.5 3000000 0.05 0.05 120000 7 0.01 264000 0 168000 2419000 5192000 9394000 1052000 3782000 0 0 106000 330000 98000 166000 1910000 8325000 252000 1621000 7927000 8406000 9290000 14664000 10462000 5270000 4400000 0 1 100000 1565000 1565000 385000 -30000 12000 357000 -174000 -550000 -285000 -782000 0 0 0 0 P0Y4M28D 205000 -599000 -274000 -426000 1500000 0.07 0.07 0.07 0.0325 31666 107033 107527 0.02 0.34 1.00 1.075269 148000 6200000 3000000 22000000 50000 50000 2000 72000 92558 4.20 125000 50000 50000 1 1 0.3333 1 -17400000 3781000 6273000 264000 180000 3734000 2704000 6899000 6985000 10000 0 200403000 201522000 140000 140000 20000 20000 70000 87000 157000 140000 0 0 19000 19000 100000 200000 10392728 10701453 4816000 2078000 3282000 866000 1987000 265000 1987000 265000 7000000 3000000 256500 1609000 2787000 444000 71000 1178000 -373000 1910000 1052000 -3010000 381000 15.00 10.25 4.23 9 1.21 4.00 1.66 0.01 4.23 2.24 9 1.21 1.21 4.23 15.00 12.96 12.96 11.73 11.73 4.00 10.86 2.24 7.56 9.59 1.66 0.01 1.66 6.50 1.21 1.21 4.39 0.20 948333 1387685 3262088 3362276 823333 250000 1097600 691655 1097600 1212665 1212665 365388 9230 1309785 714780 1881396 1483161 1200000.0 700000.0 2188177 1773929 2873765 2873765 1882395 1882395 1161972 3239827 8976354 443233 250000 161026 374618 122433 667164 2919043 714780 441655 1161972 1720430 4474825 3681590 793235 0.01 0.01 150000000 150000000 13915691 24139130 1583333 13915691 24139130 139000 241000 -7321000 -13629000 -1926000 -6187000 2150538 862057 1443297 2305354 445000 1375000 430000 1477000 7596000 3025000 4000000 571000 7814000 3243000 4000000 571000 400000 502786 281023 0.03 2.20 P20D P15D 750000 4000000 46250 925000 750000 0.0650 0.06 0.0625 0.06 P3Y 217000 200000 176000 200000 100000 200000 100000 100000 343000 264000 1532000 1532000 -1700000 1500000 90000 1053000 -5204000 -6259000 -34000 -25000 -6736000 -7791000 -124000 -1078000 44000 133000 0 0 1905000 244000 2100000 300000 3203000 9980000 57000 1251000 2304000 7888000 226000 709000 82000 21000 5507000 17868000 283000 1960000 4475000 4475000 -0.55 -0.17 -0.38 -1.24 -0.70 -0.54 -0.08 -0.08 0.00 -0.28 -0.28 0.00 2000 0 321000 225000 100000 25000000 30000 -357000 P1Y0M 0.67 0.86 0.0042 0.0104 385000 -30000 0 12000 350000 7000 1437000 145000 560000 175000 350000 0 0 1442000 0 1430000 P7Y 481000 207000 274000 370000 290000 80000 100000 100000 100000 100000 1651000 671000 980000 1352000 672000 680000 1170000 464000 706000 982000 382000 600000 -14000 0 -115000 147000 27000 -279000 7024000 7024000 0 0 -2051000 -7223000 -1892000 -6162000 -2051000 -7224000 -1892000 -6162000 -5248000 -5248000 -6392000 -6392000 -34000 -34000 -25000 -25000 1100000 0 0 -1000 0 0 0 0 -162000 2492000 -158000 -12000 0 0 61000 47000 0 -14000 78000 -728000 214000 -280000 1170000 982000 400000 365000 0 50000 36000 100000 0 0 0 63000 63000 63000 0 0 0 0 17636000 19902000 4816000 2078000 16981000 18260000 264000 0 264000 0 20000 4000000 4000000 3000000 2300000 0.005 7596000 7814000 0 0 0.091 700000 700000 700000 700000 700000 700000 5593000 5592000 0.80 0.62 8991000 2195000 1621000 1006000 -289000 -46000 -9436000 -3574000 -6426000 -3955000 -7299000 -13615000 -1926000 -6187000 -6187000 -7630000 -2382000 -5248000 -14608000 -8216000 -6392000 -1926000 -1892000 -34000 -6208000 -6183000 -25000 2 1 2141000 6772000 1645000 5457000 -2256000 -6625000 -1618000 -5736000 700000 700000 700000 700000 400000 200000 200000 200000 537000 314000 105000 58000 -22000 -14000 0 0 -10000 10000 1068000 1068000 305000 212000 -6000 -19000 -1000 -1000 200000 9000 27000 718441 470599 1330000 212783 140000 280000 19000 3681591.90 793236.17 331000 993000 0 21000 0.01 0.01 0.01 0.01 15000000 15000000 4029502 214705 2365243 4029502 2586205 1443297 214705 214705 0 0 40000 2000 100000 8977000 500000 468000 100000 2200000 4000000 0 1779000 50 3000000 923000 500000 7158000 7157000 259000 172000 P7Y P3Y P7Y P3Y P10Y P1Y P7Y P2Y P7Y P3Y 0 72000 100000 35000 2000 700000 874000 550000 455000 1374000 393000 1065000 -213412000 -219589000 12 330000 1522000 457000 1198000 1686000 5398000 1252000 4392000 200000 489000 500000 0 111000 100000 P3Y P3Y 98333 4.14 4.14 P1Y1M1D 0 0.85 0.0156 98333 98333 574650 4.08 252589 641560 11250 25250 25250 25250 1107794 880455 3.45 3.39 0 860411 3.28 0.84 0.84 0.28 0.28 0.42 6.00 4.85 3.25 1.42 0.25 0.25 0 P10Y P6Y0M0D 0.93 13915691 4029502 24139130 214705 2150538 8930717 -6180040 64153 78000 500000 1383333 1443297 730776 3573899 1500000 6780179 1035255 1292722 1150569 2365243 4475000 4447000 90000 -62000 89000 8300000 7000000 2400000 500000 488000 519000 12000 24000 543000 -12820000 10000 200403000 139000 40000 -213412000 -17824000 0 201522000 241000 2000 -219589000 350000 1430000 13763240 11784583 23551869 21896943 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of activity for the allowance for obsolete inventory during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Ending</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrants.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our issued and outstanding warrants to purchase common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability (&#8220;Common Stock Warrant Liability&#8221;). We are required to present these instruments at fair value at each reporting date and any changes in fair values are recorded as an adjustment to earnings. The Common Stock Warrant Liabilities are considered Level Three financial instruments for purposes of fair value measurement.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Cash.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INTANGIBLES AND OTHER ASSETS</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We review our amortizable long-lived assets for impairment annually or whenever events indicate that the carrying amount of the asset (group) may not be recoverable. An impairment loss may be needed if the sum of the future undiscounted cash flows is less than the carrying amount of the asset (group). The amount of the loss would be determined by comparing the fair market value of the asset to the carrying amount of the asset (group).</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-lived intangible assets as of September 30, 2016 and December 31, 2015 consisted of the following: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net&#160;Book</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">672</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,352</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">370</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">982</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net&#160;Book</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">671</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">464</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,651</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,170</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.3046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated&#160;Useful&#160;Life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Life of the patent</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets include U.S. security deposits and deferred tax assets, net of applicable valuation allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense for intangible assets was </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> during the nine month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. Amortization expense for intangible assets is expected to be </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for each of the years ending December 31, 2016, 2017, 2018, 2019 and 2020.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risks and Uncertainties.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-lived intangible assets as of September 30, 2016 and December 31, 2015 consisted of the following: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net&#160;Book</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">680</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">672</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">382</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,352</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">370</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">982</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net&#160;Book</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">706</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">671</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">464</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,651</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,170</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.3046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated&#160;Useful&#160;Life</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Life of the patent</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intellectual property</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of activity for the allowance for doubtful accounts from continuing operations during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Ending</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are presented in conformity with GAAP. All amounts are presented in U.S. Dollars (&#8220;$&#8221;). Supplemental cash flows from discontinued operations are presented in Note 3 - &#8220;Discontinued Operations&#8221;. We have evaluated events occurring subsequent to September 30, 2016 for potential recognition or disclosure in the consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2015. The accompanying condensed consolidated financial statements as of and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;"> are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 14, 2016. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BUSINESS DESCRIPTION</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Description.</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Transgenomic, Inc. (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, the &#8220;Company&#8221; or &#8220;Transgenomic&#8221;) is a biotechnology company advancing personalized medicine for the detection and treatment of cancer and inherited diseases through our proprietary molecular technologies and clinical and research services. A key goal is to bring our Multiplexed ICE COLD-PCR (&#8220;MX-ICP&#8221;) product to the clinical market through strategic partnerships and licensing agreements, enabling the use of blood and other bodily fluids for more effective and patient-friendly diagnosis, monitoring and treatment of cancer.</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MX-ICP is technology proprietary to Transgenomic. It is a reagent that improves the ability to detect genetic mutations. This technology has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing and Digital PCR. By enhancing the level of detection of genetic mutations and suppressing the normal or wild-type DNA, several benefits are provided.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, our operations were organized and reviewed by management along our major product lines and presented in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> business segments: Laboratory Services and Genetic Assays and Platforms. Beginning with the quarter ended September 30, 2015, our operations are now organized as </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> business segment, our Laboratory Services segment, and during the second half of 2015, we began presenting our Genetic Assays and Platforms segment and a portion of our Laboratory Services segment in discontinued operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our current Laboratory Services business consists of our laboratory in Omaha, Nebraska, which is focused on providing genetic analytical services related to Oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. Our laboratory employs a variety of genomic testing service technologies, including our proprietary MX-ICP technology. Our laboratory in Omaha is certified under the Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;) as a high complexity laboratory and is accredited by the College of American Pathologists.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed consolidated balance sheets, statements of operations and statements of cash flows for all periods presented reflect our former Genetic Assays and Platforms activities and Patient Testing business as discontinued operations (See Note 3 - &#8220;Discontinued Operations&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Going Concern.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) applicable for a going concern, which assume that we will realize our assets and discharge our liabilities in the ordinary course of business. We have incurred substantial operating losses and have used cash in our operating activities for the past few years. As of September 30, 2016, we had negative working capital of </font><font style="font-family:inherit;font-size:10pt;">$17.4 million</font><font style="font-family:inherit;font-size:10pt;">. Our ability to continue as a going concern is dependent upon a combination of generating additional revenue, improving cash collections, potentially selling underutilized assets and, if necessary, raising additional financing to meet our obligations and pay our liabilities arising from normal business operations when they come due. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. We cannot be certain that additional financing will be available on acceptable terms, or at all, and our failure to raise capital when needed could limit our ability to continue our operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents and Other Current Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to a number of claims of various amounts that arise out of the normal course of our business. In our opinion, the disposition of pending claims, in excess of recorded accruals, could have a material adverse effect on our financial position, results of operations or cash flows. On February 25, 2016, the Board of Regents of the University of Nebraska (&#8220;UNMC&#8221;) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> owed by us to UNMC. We and UNMC are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded at December 31, 2015 and September 30, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In addition, on April 13, 2016, Fox Chase Cancer Center (&#8220;Fox Chase&#8221;) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the &#8220;Court of Common Pleas&#8221;), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the &#8220;License Agreement&#8221;), as well as the assignment of certain of our rights under the License Agreement to Integrated DNA Technologies, Inc. (&#8220;IDT&#8221;) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the &#8220;IDT Agreement&#8221;). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase&#8217;s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney&#8217;s fees.&#160; Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. We are unable to determine whether any loss will occur or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by us as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 23, 2016, the Icahn School of Medicine at Mount Sinai (&#8220;Mount Sinai&#8221;) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> owed by us to Mount Sinai for services rendered. We and Mount Sinai are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded at December 31, 2015 and September 30, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The outcome of legal proceedings and claims brought against us are subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts in excess of management&#8217;s expectations, our financial statements for such reporting period could be materially adversely affected. In general, the resolution of a legal matter could prevent us from offering our services or products to others, could be material to our financial condition or cash flows, or both, or could otherwise adversely affect our operating results.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We lease certain equipment, vehicles and operating facilities under non-cancellable operating leases that expire on various dates through 2022. The future minimum lease payments required under these leases are </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> for the remainder of </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">thereafter</font><font style="font-family:inherit;font-size:10pt;">. Rent expense for each of the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">. At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, firm commitments to vendors totaled </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DEBT</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dollars&#160;in&#160;Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revolving Line of Credit</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term Loan</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible Promissory Notes </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,814</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,596</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,814</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net of current maturities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revolving Line of Credit.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6.25%</font><font style="font-family:inherit;font-size:10pt;"> or (b) the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wall Street Journal</font><font style="font-family:inherit;font-size:10pt;"> prime rate plus </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3%</font><font style="font-family:inherit;font-size:10pt;">. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;">6.50%</font><font style="font-family:inherit;font-size:10pt;">. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20,000</font><font style="font-family:inherit;font-size:10pt;"> on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line. In addition, a fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on November 1, 2017.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Term Loan.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">We received </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">9.1%</font><font style="font-family:inherit;font-size:10pt;">. </font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will pay the Lenders an additional final payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$120,000</font><font style="font-family:inherit;font-size:10pt;"> at maturity or prepayment of the Term Loan. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1%</font><font style="font-family:inherit;font-size:10pt;"> of the total outstanding balance under the Term Loan.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Additional Terms.</font></div><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement contains affirmative and negative covenants. Under the Term Loan, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders&#8217; consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of September 30, 2016, we were not in compliance with the Loan Agreement, as amended by the Ninth Amendment, due to the fact that we did not make the required monthly interest payments during the third quarter and have not received a waiver for the non-compliance and as such all debt has been classified as current at September 30, 2016.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. As of the date these financials were available for release, the Lenders have not exercised the remedies under the Loan Agreement.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> Convertible Promissory Notes. </font><font style="font-family:inherit;font-size:10pt;">The Notes accrue interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> per year and mature on December 31, 2016. </font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revolving Line and Term Loan.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 13, 2013 (the &#8220;Effective Date&#8221;), we entered into a Loan and Security Agreement with affiliates of Third Security, LLC (the &#8220;Lenders&#8221;) for (a) a revolving line of credit (the &#8220;Revolving Line&#8221;) with borrowing availability of up to </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">, subject to reduction based on our eligible accounts receivable, and (b) a term loan (the &#8220;Term Loan&#8221; and, together with the Revolving Line, the &#8220;Loan Agreement&#8221;) of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">. Proceeds were used to pay off a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> year senior secured promissory note payable to PGxHealth, LLC, which was entered into on December 29, 2010 in conjunction with our acquisition of the FAMILION family of genetic tests, and for general corporate and working capital purposes.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 2, 2013, we entered into an amendment to the Loan Agreement (the &#8220;Amendment&#8221;). The Amendment, which became effective as of June&#160;30, 2013, reduced our future minimum revenue covenants under the Loan Agreement and modified the interest rates applicable to the amounts advanced under the Revolving Line. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 14, 2013, we entered into a second amendment to the Loan Agreement (the &#8220;Second Amendment&#8221;). The Second Amendment, which became effective as of October 31, 2013, reduced our future minimum revenue covenants under the Loan Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 27, 2014, we entered into a third amendment to the Loan Agreement (the &#8220;Third Amendment&#8221;). Pursuant to the Third Amendment, the Lenders agreed to waive certain events of default under the Loan Agreement, and the parties amended certain provisions of the Loan Agreement, including the minimum liquidity ratio that we must maintain during the term of the Loan Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 3, 2014, we entered into a fourth amendment to the Loan Agreement (the &#8220;Fourth Amendment&#8221;). Pursuant to the terms of the Fourth Amendment, we were not required to make any principal or interest payments under the Term Loan for the period from March 1, 2014 through March 31, 2015. The interest on the debt that was deferred and not paid was capitalized as part of the Term Loan. The amount of interest that was capitalized from March 1, 2014 to March 31, 2015 was </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 22, 2014, we entered into a fifth amendment to the Loan Agreement (the &#8220;Fifth Amendment&#8221;). Pursuant to the Fifth Amendment, the parties amended certain provisions of the Loan Agreement, including reducing the minimum liquidity and revenue covenants under the Loan Agreement. The Fifth Amendment also reduced the aggregate amount that we may borrow under the Revolving Line from </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 1, 2015, we entered into a sixth amendment to the Loan Agreement (the &#8220;Sixth Amendment&#8221;). Pursuant to the Sixth Amendment, among other things, (a) the Lenders waived specified events of default under the terms of the Loan Agreement, (b) commencing April 1, 2015, we began making monthly interest payments with respect to the Term Loan to the Lenders, (c) we were not be obligated to make monthly payments of principal under the Term Loan to the Lenders until April 1, 2016, (d) we made an initial prepayment of a portion of the Term Loan balance in the amount of approximately </font><font style="font-family:inherit;font-size:10pt;">$148,000</font><font style="font-family:inherit;font-size:10pt;"> on April 1, 2015 and will make one or more additional prepayments to the Lenders under the Loan Agreement upon the occurrence of certain events, as defined in the Loan Agreement, and (e) we were not required to comply with the minimum liquidity ratio under the terms of the Loan Agreement until the earliest to occur of a specified event, as defined in the Loan Agreement, or March 31, 2016. The Sixth Amendment also extends the time period in which we must provide certain reports and statements to the Lenders and amends the circumstances pursuant to which we may engage in certain sales or transfers of our business or property without the consent of the Lenders. </font></div><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of June 30, 2015, we were in compliance with all financial covenants of the Loan Agreement, but were not in compliance with the restrictions limiting the amount that we may borrow under the Revolving Line. Accordingly, on August 10, 2015, we received a waiver from the Lenders relating to this non-compliance and paid the Lenders an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">, which brought us back into compliance with the terms of the Revolving Line. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 4, 2015, we entered into a seventh amendment to the Loan Agreement (the &#8220;Seventh Amendment&#8221;). The Seventh Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) reduced our borrowing availability under the Revolving Line to approximately </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">, and (d) limited our borrowing base under the Loan Agreement to the amount of the Revolving Line.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 6, 2016, we entered into an eighth amendment to the Loan Agreement (the &#8220;Eighth Amendment&#8221;). The Eighth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) extended the maturity date of the Loan Agreement until November 1, 2017, and (d) provided for the repayment of an overadvance of </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;"> previously provided by the Lenders to us pursuant to the Loan Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 6, 2016, we entered into a ninth amendment to the Loan Agreement (the &#8220;Ninth Amendment&#8221;). The Ninth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) amended the prepayment terms of the Loan Agreement, (c) provided for the reduction of amounts available under the Revolving Line upon the prepayment or repayment of certain amounts by us, (d) removed the minimum liquidity ratio and minimum net revenue financial covenants applicable to us under the Loan Agreement, (e) amended the circumstances pursuant to which we may engage in certain sales or transfers of our business or property without the consent of the Lenders, and (f) capitalized certain amounts owed by us to the Lenders and added such overdue amounts to the outstanding principal amount of the Revolving Line. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the Ninth Amendment, the overadvance that existed at March 31, 2016 was added to the outstanding principal amount of the Revolving Line and no overadvance existed as of September 30, 2016.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Promissory Notes.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 31, 2014, we entered into an Unsecured Convertible Promissory Note Purchase Agreement (the &#8220;Note Purchase Agreement&#8221;) with an accredited investor (the &#8220;Investor&#8221;), pursuant to which we agreed to issue and sell to the Investor in a private placement an unsecured convertible promissory note (the &#8220;Initial Note&#8221;). We issued the Initial Note in the aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;"> to the Investor on December 31, 2014. Pursuant to the terms of the Initial Note, interest accrued at a rate of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> per year and the Initial Note was set to mature on December 31, 2016. Under the Initial Note, the outstanding principal and unpaid interest accrued was convertible into shares of our common stock as follows: (i) commencing upon the date of issuance of the Initial Note (but no earlier than January 1, 2015), the Investor was entitled to convert, on a one-time basis, up to </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding principal and unpaid interest accrued under the Initial Note, into shares of our common stock at a conversion price equal to the lesser of (a) the average closing price of the common stock on the principal securities exchange or securities market on which our common stock is then traded (the &#8220;Market&#8221;) for the </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days immediately preceding the date of conversion, and (b) </font><font style="font-family:inherit;font-size:10pt;">$2.20</font><font style="font-family:inherit;font-size:10pt;"> (subject to adjustment for stock splits, stock dividends, other distributions, recapitalizations and the like); and (ii) commencing February 15, 2015, the Investor was entitled to convert, on a one-time basis, any or all of the remaining outstanding principal and unpaid interest accrued under the Initial Note, into shares of our common stock at a conversion price equal to </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the average closing price of our common stock on the Market for the </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days immediately preceding the date of conversion. The Initial Note has been converted in full into </font><font style="font-family:inherit;font-size:10pt;">502,786</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, in accordance with the terms of the Initial Note. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 15, 2015, we entered into the Note Purchase Agreement with </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> accredited investors (the &#8220;Additional Investors&#8221;) and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, notes (the &#8220;Additional Notes&#8221;) in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$925,000</font><font style="font-family:inherit;font-size:10pt;">. The Additional Notes have the same terms and conditions as the Initial Note. As of September 30, 2016, </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;"> of the aggregate principal amount of the Additional Notes, and accrued interest thereon, has been converted into an aggregate of </font><font style="font-family:inherit;font-size:10pt;">281,023</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCK OPTIONS </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Options.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,107,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(252,589</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">880,455</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">574,650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.08</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we granted options to purchase </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">25,250</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at a weighted-average exercise price of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.84</font><font style="font-family:inherit;font-size:10pt;"> per share under our 2006 Equity Incentive Plan, as amended (the &#8220;Plan&#8221;). Options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">641,560</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock were granted during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">574,650</font><font style="font-family:inherit;font-size:10pt;"> options exercisable and </font><font style="font-family:inherit;font-size:10pt;">860,411</font><font style="font-family:inherit;font-size:10pt;"> options that were vested or expected to vest with an aggregate intrinsic value of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Appreciation Rights (</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">SARs</font><font style="font-family:inherit;font-size:10pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes SARs activity under the Plan during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">SARs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,558</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All outstanding SARs were issued solely to our executive officers.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">92,558</font><font style="font-family:inherit;font-size:10pt;"> shares subject to outstanding SARs were exercisable and </font><font style="font-family:inherit;font-size:10pt;">98,333</font><font style="font-family:inherit;font-size:10pt;"> shares were vested or expected to vest. The weighted-average exercise price of these SARs was </font><font style="font-family:inherit;font-size:10pt;">$4.14</font><font style="font-family:inherit;font-size:10pt;"> per share and the aggregate intrinsic value was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,107,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(252,589</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">880,455</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">574,650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.08</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DISCONTINUED OPERATIONS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 8, 2015, we entered into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with Edge BioSystems, Inc. (&#8220;Edge Bio&#8221;), pursuant to which we sold our manufacturing, marketing and selling of high quality polymer and silica based beads and resin and chromatography columns business (collectively, the &#8220;Columns Business&#8221;). The Columns Business was part of our former segment, Genetic Assays and Platforms. Pursuant to the Asset Purchase Agreement, Edge Bio acquired substantially all of the assets used solely in connection with the Columns Business and assumed certain liabilities of the Columns Business for a total cash purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Asset Sale&#8221;), which was paid on September 8, 2015 upon the closing of the Asset Sale. During the year ended December 31, 2015, we recorded a gain on the sale of the Columns Business of </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 25, 2015, we entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with ADSTEC Corporation (&#8220;ADSTEC&#8221;) and ADS Biotec Inc., a wholly-owned subsidiary of ADSTEC (&#8220;Buyer&#8221;), pursuant to which we sold (1) to ADSTEC our facilities located in Glasgow, Scotland and on Irvington Road in Omaha, Nebraska (together, the &#8220;Facilities&#8221;) and all of our stock, inventory and raw materials located at the Facilities (collectively, the &#8220;Inventory&#8221;), and (2) to Buyer (a) all of the remaining assets relating to our Genetic Assays and Platforms business segment (the &#8220;Business&#8221;), other than the Inventory (the &#8220;Purchased Assets&#8221;), and (b) all of the ordinary shares of Transgenomic Limited, a wholly-owned subsidiary of ours (the &#8220;Shares&#8221;). </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Purchase Agreement, ADSTEC and Buyer acquired the Facilities, the Inventory, the Purchased Assets and the Shares for an aggregate purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$300,000</font><font style="font-family:inherit;font-size:10pt;">, and Buyer assumed our financial and human resources commitments related to the Business (the &#8220;Transaction&#8221;). During the year ended December 31, 2015, we recorded a loss on the Transaction of </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Together, the Asset Sale and the Transaction represent the divestiture of our Genetic Assays and Platforms business, resulting in a strategic shift that had a major effect on our operations and financial results. Therefore, the divested operations of our Genetic Assays and Platforms business meet the criteria to be reported as discontinued operations.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the fourth quarter of 2015, our Board of Directors took actions to begin the process of divesting our Patient Testing business in New Haven, Connecticut. In March 2016, we announced that we had suspended testing services in our Patient Testing laboratory as we review and evaluate various strategic alternatives for that business. As a result of these actions, as of December 31, 2015, our Patient Testing business met the criteria to be reported as discontinued operations. We anticipate that we will complete the divestiture of the Patient Testing business during 2016.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The related assets, liabilities, results of operations and cash flows for both the Genetic Assays and Platforms business and Patient Testing business are classified as assets held for sale, liabilities held for sale and discontinued operations for all periods presented.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Results of the discontinued operations consisted of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three months ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Dollars in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,960</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,203</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,251</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,980</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,888</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,910</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,325</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of long-lived assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,024</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,024</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss) from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,736</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,078</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on sale of business/assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,532</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,053</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,532</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,392</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The loss from discontinued operations for the nine month period ended September 30, 2016, includes approximately </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> in proceeds received from the sale of assets of our discontinued Patient Testing business.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities of the discontinued operations are classified as assets held for sale and liabilities held for sale in the condensed consolidated balance sheets and consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,905</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,987</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of activity for the allowance for doubtful accounts from discontinued operations during the three and nine months ended September 30, 2016 and 2015. The allowance for doubtful accounts from discontinued operations is included in the assets held for sale in the condensed consolidated balance sheets.</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Ending</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,406</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,052</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(168</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,290</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,664</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,927</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,782</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,419</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,290</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loss Per Share.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at July 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(385</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and nine months ended September 30, 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.9140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at July 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,430</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.9140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine Months Ended</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,430</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise specified, book value approximates fair market value. The common stock warrant liability is recorded at fair value.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FAIR VALUE</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities;</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2&#8212;Observable inputs other than those included in Level&#160;1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets;&#160;and</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3&#8212;Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our long term debt book value approximates fair market value due to the variable interest rate it bears. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrant Liabilities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2012 Warrant Liability</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2012 Warrant Liability represents the fair value of the </font><font style="font-family:inherit;font-size:10pt;">1.2 million</font><font style="font-family:inherit;font-size:10pt;"> warrants issued in February 2012, which, through a series of changes in exercise price since February 2012, are now exercisable for </font><font style="font-family:inherit;font-size:10pt;">3.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our Statement of Operations. Management does not believe that this liability will be settled by a use of cash.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2012 Warrant Liability is considered a Level 3 financial instrument and is valued using a Monte Carlo simulation model. This method is well suited to valuing options with non-standard features, such as anti-dilution protection. A Monte Carlo simulation model uses repeated random sampling to simulate significant uncertainty in inputs. Assumptions and inputs used in the valuation of the common stock warrants are broken down into four sections: Static Business Inputs; Static Technical Inputs; Simulated Business Inputs; and Simulated Technical Inputs.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Static Business Inputs include: our equity value, which was estimated using our stock price of </font><font style="font-family:inherit;font-size:10pt;">$0.28</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">; the amount of the down-round financing; the timing of the down-round financing; and the expected exercise period of </font><font style="font-family:inherit;font-size:10pt;">0.41</font><font style="font-family:inherit;font-size:10pt;"> years from the valuation date.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Static Technical Inputs include: volatility of </font><font style="font-family:inherit;font-size:10pt;">67%</font><font style="font-family:inherit;font-size:10pt;"> and the risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">0.42%</font><font style="font-family:inherit;font-size:10pt;"> based on the </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;">-year U.S. Treasury yield interpolated from the six-month and one-year U.S. Treasury bonds. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Simulated Business Inputs include: the probability of down-round financing, which was estimated to be </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> for simulated equity values below the down-round financing cut-off point.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Simulated Technical Inputs include: our equity value follows a geometric Brownian motion and is simulated over weekly periods; and a down-round financing event that was randomly simulated in an iteration based on the </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> discrete probability of a down-round financing for those iterations where our simulated equity value at the expected timing of a down-round financing event was below the down-round financing cut-off point.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at July 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(385</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">350</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(350</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 Warrant Liability</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrant Liability represents the fair value of the </font><font style="font-family:inherit;font-size:10pt;">1.8 million</font><font style="font-family:inherit;font-size:10pt;"> warrants issued in January 2016. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our Statement of Operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Common Stock Warrant Liability is considered a Level 3 financial instrument and is valued using a binomial lattice simulation model. This method is well suited to valuing options with non-standard features. Assumptions and inputs used in the valuation of the common stock warrants include; our equity value, which was estimated using our stock price of </font><font style="font-family:inherit;font-size:10pt;">$0.28</font><font style="font-family:inherit;font-size:10pt;"> as of September 30, 2016; volatility of </font><font style="font-family:inherit;font-size:10pt;">86%</font><font style="font-family:inherit;font-size:10pt;">; and a risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">1.04%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and nine months ended September 30, 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.9140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at July 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,430</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.9140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Nine Months Ended</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at January 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,437</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,430</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in unrealized gains or losses of Level 3 liabilities was included in earnings and was reported in other income (expense) in our Statement of Operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets include intellectual property and patents.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:57px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. Intellectual Property.&#160;&#160;&#160;&#160;Initial costs paid to license intellectual property from independent third parties are capitalized and amortized using the straight-line method over the license period. Ongoing royalties related to such licenses are expensed as incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:57px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Patents.&#160;&#160;&#160;&#160;We capitalize legal costs, filing fees and other expenses associated with obtaining patents on new discoveries and amortize these costs using the straight-line method over the shorter of the legal life of the patent or its economic life beginning on the date the patent is issued.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCOME TAXES</font></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Annually, we file U.S. Federal, state and foreign income tax returns.&#160; All U.S. Federal and most state loss carryforwards remain subject to adjustment in the event of an income tax examination.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense from continuing operations was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. Income tax expense was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended September 30, 2015 and for the nine months ended September 30, 2015, we had an income tax benefit of approximately </font><font style="font-family:inherit;font-size:10pt;">one thousand</font><font style="font-family:inherit;font-size:10pt;"> dollars. We maintain a full valuation allowance on our net deferred tax assets,&#160;having concluded that we are not more likely than not going to realize the benefit of our deferred tax assets, including our net operating loss carryforwards.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During each of the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, there were no material changes to the liability for uncertain tax positions.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost or market net of allowance for obsolete inventory. Cost is computed using standard costs for finished goods and average or latest actual cost for raw materials and work in process, which approximates the first-in, first-out (FIFO) method.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, Revenue from Contracts with Customers (&#8220;ASU No. 2014-09&#8221;). This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year. As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40)(&#8220;ASU No. 2014-15&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">. </font><font style="font-family:inherit;font-size:10pt;">This guidance addresses management&#8217;s responsibility to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern and to provide related footnote disclosures. The standard will be effective for the first interim period within annual reporting periods beginning after December&#160;15, 2016. Early adoption is permitted. We do not expect to early adopt this guidance and do not believe that the adoption of this guidance will have a material impact on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016; however, early adoption is permitted. We do not expect to early adopt this guidance and are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain prior year amounts have been reclassified to conform to the current year presentation in our condensed consolidated financial statements, which consists of the effects of reclassifications from the presentation of our discontinued operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#160;to&#160;10&#160;years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Production equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2 to 7 years</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation is computed using the straight-line method over the estimated useful lives of the related assets as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#160;to&#160;10&#160;years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Production equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2 to 7 years</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Sales Recognition.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:66px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue is realized and earned when all of the following criteria are met:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persuasive evidence of an arrangement exists;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delivery has occurred or services have been rendered;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The seller&#8217;s price to the buyer is fixed or determinable; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collectability is reasonably assured.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In our Biomarker Identification laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year. At each of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and December 31, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue was </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:174%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales from Patient Testing laboratories, reported as part of discontinued operations, are recognized on an individual test basis and take place when the test report is completed, reviewed and sent to the client less the reserve for insurance, Medicare and Medicaid contractual adjustments. There are no deferred net sales associated with our Patient Testing services. Adjustments to the allowances, based on actual receipts from third party payers, are reflected in the estimated contractual allowance applied prospectively. In the fourth quarter of 2015, we adjusted our contractual allowance rates to better reflect the reimbursement level we expect to achieve on Patient Testing billings. The adjustment negatively impacted our Patient Testing revenues for all periods after the third quarter of 2015. (See Note 3 - &#8220;Discontinued Operations&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales of Genetic Assays and Platforms products, reported as discontinued operations (See Note 3 - &#8220;Discontinued Operations&#8221;) are recognized in accordance with the terms of the sales arrangement. Such recognition is based on receipt of an unconditional customer order and transfer of title and risk of ownership to the customer, typically upon shipment of the product under a purchase order. Our sales terms do not provide for the right of return unless the product is damaged or defective. Net sales from certain services associated with the analytical instruments, to be performed subsequent to shipment of the products, is deferred and recognized when the services are provided. Such services, mainly limited to installation and training services that are not essential to the functionality of the instruments, typically are performed in a timely manner subsequent to shipment of the instrument. We also enter into various service contracts that cover installed instruments. These contracts cover specific time periods and net sales associated with these contracts are deferred and recognized ratably over the service period.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dollars&#160;in&#160;Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revolving Line of Credit</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,025</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term Loan</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible Promissory Notes </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,814</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,596</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,814</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,596</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net of current maturities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revolving Line of Credit.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6.25%</font><font style="font-family:inherit;font-size:10pt;"> or (b) the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wall Street Journal</font><font style="font-family:inherit;font-size:10pt;"> prime rate plus </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3%</font><font style="font-family:inherit;font-size:10pt;">. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;">6.50%</font><font style="font-family:inherit;font-size:10pt;">. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20,000</font><font style="font-family:inherit;font-size:10pt;"> on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line. In addition, a fee of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">0.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on November 1, 2017.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Term Loan.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">We received </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">9.1%</font><font style="font-family:inherit;font-size:10pt;">. </font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will pay the Lenders an additional final payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$120,000</font><font style="font-family:inherit;font-size:10pt;"> at maturity or prepayment of the Term Loan. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1%</font><font style="font-family:inherit;font-size:10pt;"> of the total outstanding balance under the Term Loan.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Additional Terms.</font></div><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Loan Agreement contains affirmative and negative covenants. Under the Term Loan, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders&#8217; consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of September 30, 2016, we were not in compliance with the Loan Agreement, as amended by the Ninth Amendment, due to the fact that we did not make the required monthly interest payments during the third quarter and have not received a waiver for the non-compliance and as such all debt has been classified as current at September 30, 2016.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. As of the date these financials were available for release, the Lenders have not exercised the remedies under the Loan Agreement.</font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> Convertible Promissory Notes. </font><font style="font-family:inherit;font-size:10pt;">The Notes accrue interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> per year and mature on December 31, 2016. </font></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Results of the discontinued operations consisted of the following:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three months ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Dollars in thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,960</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of goods sold</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,203</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,251</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,980</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,304</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,888</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,910</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,325</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of long-lived assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,024</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,024</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating income (loss) from discontinued operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,736</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,078</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on sale of business/assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,532</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,053</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,532</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,204</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from discontinued operations, net of taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,248</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,392</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities of the discontinued operations are classified as assets held for sale and liabilities held for sale in the condensed consolidated balance sheets and consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,905</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,987</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">264</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of activity for the allowance for doubtful accounts from discontinued operations during the three and nine months ended September 30, 2016 and 2015. The allowance for doubtful accounts from discontinued operations is included in the assets held for sale in the condensed consolidated balance sheets.</font></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:42%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Ending</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,406</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,052</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(168</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,290</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,664</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,927</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,782</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,419</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,290</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes SARs activity under the Plan during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">SARs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.14</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,558</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.20</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrant Holder</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Issue&#160;Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,919,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.23</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">443,233</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.23</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">374,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,780</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.24</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.66</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">667,164</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.01</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,161,972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(7)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(7)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,720,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,976,354</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the Private Placement completed in February 2012 and are classified as a liability in our financial statements. See Note 9 - &#8220;Fair Value&#8221; for additional information. These warrants also contain certain anti-dilution provisions that provide for an adjustment to the exercise price and number of shares issuable upon exercise of the warrant in the event that we engage in certain issuances of shares of our common stock at a price lower than the exercise price of the warrant.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the 2013 Offering, which was completed in January 2013. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the 2014 Private Placement, which was completed in October 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the February 2015 Offering, which was completed in February 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the July 2015 Offering, which was completed in July 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were originally issued in connection with the July 2015 Offering, which was completed in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(7)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All stock-based awards to date have exercise prices equal to the market value of the shares at the date of grant and have </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">-year contractual terms. Unvested awards as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> had vesting periods of up to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. None of the awards outstanding at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> are subject to performance or market-based vesting conditions.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We measure and recognize compensation expense for all stock-based awards made to employees and directors. Compensation expense, net of estimated forfeitures, is based on the calculated fair value of the awards as measured at the grant date and is expensed over the service period of the awards.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are presented in conformity with GAAP. All amounts are presented in U.S. Dollars (&#8220;$&#8221;). Supplemental cash flows from discontinued operations are presented in Note 3 - &#8220;Discontinued Operations&#8221;. We have evaluated events occurring subsequent to September 30, 2016 for potential recognition or disclosure in the consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2015. The accompanying condensed consolidated financial statements as of and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;"> are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 14, 2016. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain prior year amounts have been reclassified to conform to the current year presentation in our condensed consolidated financial statements, which consists of the effects of reclassifications from the presentation of our discontinued operations.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risks and Uncertainties.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. In addition, estimates and assumptions associated with the determination of the fair value of certain assets and related impairments require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise specified, book value approximates fair market value. The common stock warrant liability is recorded at fair value. See Note 9 - &#8220;Fair Value&#8221; for additional information.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents and Other Current Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less. Other current assets as of September 30, 2016 of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> include prepaid assets of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and other receivables of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Cash.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits. We have not experienced any losses on such accounts as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of activity for the allowance for doubtful accounts from continuing operations during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Ending</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:4px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While payment terms are generally </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;">, we have also provided extended payment terms in certain cases. Accounts receivable are carried at original invoice amount and shown net of allowance for doubtful accounts. The estimate made for doubtful accounts is based on a review of all outstanding amounts on a quarterly basis. We determine the allowance for doubtful accounts by regularly evaluating individual payor receivables and considering a payor&#8217;s financial condition, credit history, reimbursement rates and current economic conditions. Accounts receivable are written off when deemed uncollectible and after all collection efforts have been exhausted. Recoveries of accounts receivable previously written off are recorded as a reduction in bad debt expense when received.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Inventories.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost or market net of allowance for obsolete inventory. Cost is computed using standard costs for finished goods and average or latest actual cost for raw materials and work in process, which approximates the first-in, first-out (FIFO) method. At September 30, 2016, our net inventories were less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and were comprised predominantly of raw materials. </font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of activity for the allowance for obsolete inventory during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Ending</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Three Months Ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:4px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We determine the allowance for obsolescence by evaluating inventory quarterly for items deemed to be slow moving or obsolete.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets as follows:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1&#160;to&#160;10&#160;years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Production equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 7 years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2 to 7 years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense in continuing operations related to property and equipment was less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for each of the three month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">. Depreciation expense was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> month periods ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively. Depreciation expense during each period includes depreciation related to equipment acquired under capital leases. </font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets include intellectual property and patents.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:57px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. Intellectual Property.&#160;&#160;&#160;&#160;Initial costs paid to license intellectual property from independent third parties are capitalized and amortized using the straight-line method over the license period. Ongoing royalties related to such licenses are expensed as incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:57px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. Patents.&#160;&#160;&#160;&#160;We capitalize legal costs, filing fees and other expenses associated with obtaining patents on new discoveries and amortize these costs using the straight-line method over the shorter of the legal life of the patent or its economic life beginning on the date the patent is issued.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All stock-based awards to date have exercise prices equal to the market value of the shares at the date of grant and have </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">-year contractual terms. Unvested awards as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> had vesting periods of up to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. None of the awards outstanding at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> are subject to performance or market-based vesting conditions.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We measure and recognize compensation expense for all stock-based awards made to employees and directors. Compensation expense, net of estimated forfeitures, is based on the calculated fair value of the awards as measured at the grant date and is expensed over the service period of the awards.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, we recorded compensation expense for all stock awards of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, within selling, general and administrative expense. During the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2015</font><font style="font-family:inherit;font-size:10pt;">, we recorded compensation expense for all stock awards of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the unrecognized compensation expense related to unvested stock awards was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">1.1 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We granted stock options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">11,250</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">25,250</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock during the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. The fair value of the stock options granted during the year was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions: risk-free interest rates of </font><font style="font-family:inherit;font-size:10pt;">1.56%</font><font style="font-family:inherit;font-size:10pt;"> based on the U.S. Treasury yield in effect at the time of grant; dividend yields of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> percent; expected lives of </font><font style="font-family:inherit;font-size:10pt;">6.00</font><font style="font-family:inherit;font-size:10pt;"> years, based on expected exercise activity behavior; and volatility of </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> based on the historical volatility of our common stock over a time that is consistent with the expected life of the options. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in our stock awards outstanding as of September 30, 2016 were stock appreciation rights (&#8220;SARs&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">to purchase </font><font style="font-family:inherit;font-size:10pt;">98,333</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. The SARs were issued solely to our executive officers and will vest over </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. </font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Sales Recognition.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:66px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue is realized and earned when all of the following criteria are met:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persuasive evidence of an arrangement exists;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delivery has occurred or services have been rendered;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The seller&#8217;s price to the buyer is fixed or determinable; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collectability is reasonably assured.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> In our Biomarker Identification laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year. At each of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and December 31, </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue was </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:174%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales from Patient Testing laboratories, reported as part of discontinued operations, are recognized on an individual test basis and take place when the test report is completed, reviewed and sent to the client less the reserve for insurance, Medicare and Medicaid contractual adjustments. There are no deferred net sales associated with our Patient Testing services. Adjustments to the allowances, based on actual receipts from third party payers, are reflected in the estimated contractual allowance applied prospectively. In the fourth quarter of 2015, we adjusted our contractual allowance rates to better reflect the reimbursement level we expect to achieve on Patient Testing billings. The adjustment negatively impacted our Patient Testing revenues for all periods after the third quarter of 2015. (See Note 3 - &#8220;Discontinued Operations&#8221;).</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales of Genetic Assays and Platforms products, reported as discontinued operations (See Note 3 - &#8220;Discontinued Operations&#8221;) are recognized in accordance with the terms of the sales arrangement. Such recognition is based on receipt of an unconditional customer order and transfer of title and risk of ownership to the customer, typically upon shipment of the product under a purchase order. Our sales terms do not provide for the right of return unless the product is damaged or defective. Net sales from certain services associated with the analytical instruments, to be performed subsequent to shipment of the products, is deferred and recognized when the services are provided. Such services, mainly limited to installation and training services that are not essential to the functionality of the instruments, typically are performed in a timely manner subsequent to shipment of the instrument. We also enter into various service contracts that cover installed instruments. These contracts cover specific time periods and net sales associated with these contracts are deferred and recognized ratably over the service period.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrants.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our issued and outstanding warrants to purchase common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability (&#8220;Common Stock Warrant Liability&#8221;). We are required to present these instruments at fair value at each reporting date and any changes in fair values are recorded as an adjustment to earnings. The Common Stock Warrant Liabilities are considered Level Three financial instruments for purposes of fair value measurement. See Note 9 - &#8220;Fair Value&#8221; for additional information.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loss Per Share.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to </font><font style="font-family:inherit;font-size:10pt;">10,701,453</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">10,392,728</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock have been excluded from the computation of diluted loss per share at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, because the effect is anti-dilutive due to the net loss. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, Revenue from Contracts with Customers (&#8220;ASU No. 2014-09&#8221;). This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year. As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40)(&#8220;ASU No. 2014-15&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">. </font><font style="font-family:inherit;font-size:10pt;">This guidance addresses management&#8217;s responsibility to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern and to provide related footnote disclosures. The standard will be effective for the first interim period within annual reporting periods beginning after December&#160;15, 2016. Early adoption is permitted. We do not expect to early adopt this guidance and do not believe that the adoption of this guidance will have a material impact on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016; however, early adoption is permitted. We do not expect to early adopt this guidance and are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCKHOLDERS&#8217; EQUITY</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">150,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock authorized for issuance.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 2, 2012, we entered into definitive agreements with institutional and other accredited investors and raised approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$22.0 million</font><font style="font-family:inherit;font-size:10pt;"> in a private placement financing (the &#8220;Private Placement&#8221;), which included an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> in convertible notes issued in December 2011 to entities affiliated with Third Security, LLC, a related party, that automatically converted into shares of our common stock and warrants to purchase such common stock on the same terms as all investors in the Private Placement. Pursuant to the purchase agreement, we issued an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">1,583,333</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12.00</font><font style="font-family:inherit;font-size:10pt;">, as well as </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;">-year warrants to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">823,333</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;"> per share. In connection with the conversion of the convertible notes issued by us to the entities affiliated with Third Security, LLC, the entities received an aggregate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">250,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock and </font><font style="font-family:inherit;font-size:10pt;">125,000</font><font style="font-family:inherit;font-size:10pt;"> warrants on the same terms as all investors in the Private Placement. Craig-Hallum Capital Group LLC (&#8220;Craig-Hallum&#8221;) served as the sole placement agent for the offering. In consideration for services rendered as the placement agent in the offering, we agreed to (a) pay to the placement agent cash commissions equal to </font><font style="font-family:inherit;font-size:10pt;">$1,330,000</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">7.0%</font><font style="font-family:inherit;font-size:10pt;"> of the gross proceeds received in the offering; (b) issue to the placement agent a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year warrant to purchase up to </font><font style="font-family:inherit;font-size:10pt;">31,666</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock (representing </font><font style="font-family:inherit;font-size:10pt;">2%</font><font style="font-family:inherit;font-size:10pt;"> of the shares sold in the Private Placement) with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;"> per share and other terms that are the same as the terms of the warrants issued in the Private Placement; and (c) reimburse the placement agent for reasonable out-of-pocket expenses, including fees paid to the placement agent&#8217;s legal counsel, incurred in connection with the offering, which reimbursable expenses were not to exceed </font><font style="font-family:inherit;font-size:10pt;">$125,000</font><font style="font-family:inherit;font-size:10pt;">. The costs incurred to complete the Private Placement were recorded as a reduction in equity in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">. Net proceeds from this offering were used for general corporate and working capital purposes, primarily to accelerate development of several of our key initiatives.</font></div><div style="line-height:120%;padding-top:15px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 24, 2013, we entered into a Securities Purchase Agreement with certain institutional and other accredited investors pursuant to which we: (a) sold to the investors an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,383,333</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$6.00</font><font style="font-family:inherit;font-size:10pt;"> for aggregate gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$8.3 million</font><font style="font-family:inherit;font-size:10pt;">; and (b) issued to the investors warrants to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">691,655</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$9.00</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;2013 Offering&#8221;). The warrants may be exercised, in whole or in part, at any time from January 30, 2013 until January 30, 2018 and contain both cash and &#8220;cashless exercise&#8221; features. Affiliates of Third Security, LLC purchased an aggregate of </font><font style="font-family:inherit;font-size:10pt;">500,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">250,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock in the 2013 Offering on the same terms as the other investors. Net proceeds from the 2013 Offering were used for general corporate and working capital purposes.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the 2013 Offering, we entered into a registration rights agreement with the investors (the &#8220;Registration Rights Agreement&#8221;). The Registration Rights Agreement required that we file with the SEC a registration statement to register for resale the shares of common stock sold and the shares of common stock issuable upon exercise of the warrants (the &#8220;Warrant Shares&#8221;) by March 16, 2013. The registration statement was filed with the SEC on March 15, 2013 and was declared effective by the SEC on March 29, 2013.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2013 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of the warrants decreased from </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;"> per share to </font><font style="font-family:inherit;font-size:10pt;">$12.96</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">948,333</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1,097,600</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 22, 2014, we entered into a Securities Purchase Agreement with certain accredited investors (the &#8220;October 2014 Investors&#8221;), pursuant to which we, in a private placement, issued and sold to the October 2014 Investors (the &#8220;2014 Private Placement&#8221;) an aggregate of </font><font style="font-family:inherit;font-size:10pt;">730,776</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$3.25</font><font style="font-family:inherit;font-size:10pt;"> for an aggregate purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">, and warrants to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">365,388</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock with an initial exercise price of </font><font style="font-family:inherit;font-size:10pt;">$4.00</font><font style="font-family:inherit;font-size:10pt;"> per share that are exercisable for the period from April 22, 2015 through April 22, 2020. In connection with the 2014 Private Placement, we also issued a warrant to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">9,230</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock to one advisor. The warrants issued in the 2014 Private Placement include both cash and &#8220;cashless exercise&#8221; features.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2014 Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale. The exercise price of the warrants decreased from </font><font style="font-family:inherit;font-size:10pt;">$11.73</font><font style="font-family:inherit;font-size:10pt;"> per share to </font><font style="font-family:inherit;font-size:10pt;">$10.86</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">1,212,665</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1,309,785</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 31, 2014, we entered into the Note Purchase Agreement with the Investor pursuant to which we agreed to issue and sell the Initial Note to the Investor (the &#8220;Note Private Placement&#8221;). See Note 5 - &#8220;Debt-</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Promissory Notes</font><font style="font-family:inherit;font-size:10pt;">&#8221; for additional information regarding the terms of the Initial Note. Pursuant to the terms of the Note Purchase Agreement, we are subject to certain registration obligations and we may be required to effect one or more other registrations to register for resale the shares of our common stock issued or issuable under the Initial Note in connection with certain &#8220;piggy-back&#8221; registration rights granted to the Investor.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Note Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale. The exercise price of the 2012 warrants decreased from </font><font style="font-family:inherit;font-size:10pt;">$10.86</font><font style="font-family:inherit;font-size:10pt;"> per share to </font><font style="font-family:inherit;font-size:10pt;">$10.25</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">1,309,785</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1,387,685</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 15, 2015, we entered into the Note Purchase Agreement with the Additional Investors and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, the Additional Notes in an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$925,000</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Additional Note Private Placement&#8221;). The Additional Notes have the same terms and conditions as the Initial Note.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Craig-Hallum acted as the sole placement agent for the sale and issuance of the Additional Notes. In connection with the sale and issuance of the Additional Notes, we issued to Craig-Hallum an unsecured convertible promissory note, upon the same terms and conditions as the Notes, in an aggregate principal amount equal to </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> of the proceeds received by us pursuant to the sale and issuance of the Additional Notes, or </font><font style="font-family:inherit;font-size:10pt;">$46,250</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;Placement Agent Note&#8221;). As of the date of filing of this Quarterly Report on form 10-Q, the Placement Agent Note remains outstanding.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Additional Note Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from </font><font style="font-family:inherit;font-size:10pt;">$10.25</font><font style="font-family:inherit;font-size:10pt;"> per share to </font><font style="font-family:inherit;font-size:10pt;">$9.59</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">1,387,685</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1,483,161</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 27, 2015, we entered into a purchase agreement with Craig-Hallum (the &#8220;Underwriter&#8221;) relating to our sale and issuance of </font><font style="font-family:inherit;font-size:10pt;">3,573,899</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock and corresponding warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;">714,780</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock (the &#8220;February 2015 Offering&#8221;). Each share of common stock was sold in combination with a warrant to purchase </font><font style="font-family:inherit;font-size:10pt;">0.20</font><font style="font-family:inherit;font-size:10pt;"> of a share of common stock. The purchase price to the public for each share of common stock and accompanying warrant was </font><font style="font-family:inherit;font-size:10pt;">$1.95</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The purchase price paid by the Underwriter to us for the common stock and accompanying warrants was </font><font style="font-family:inherit;font-size:10pt;">$1.8135</font><font style="font-family:inherit;font-size:10pt;">. The net proceeds from the February 2015 Offering, after deducting the Underwriter&#8217;s discount and other estimated February 2015 Offering expenses, were approximately </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying warrants are exercisable immediately upon their initial issuance date at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.24</font><font style="font-family:inherit;font-size:10pt;"> per share and will expire </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years from the date of issuance. The exercise price will also be subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The February 2015 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from </font><font style="font-family:inherit;font-size:10pt;">$9.59</font><font style="font-family:inherit;font-size:10pt;"> per share to </font><font style="font-family:inherit;font-size:10pt;">$7.56</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">1,483,161</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1,881,396</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 30, 2015, we entered into a Securities Purchase Agreement with certain accredited investors (the &#8220;July 2015 Investors&#8221;) pursuant to which, on July 7, 2015, we sold to the July 2015 Investors (a) an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">1.5 million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$1.42</font><font style="font-family:inherit;font-size:10pt;">, (b) warrants (the &#8220;Series B Warrants&#8221;) to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">0.7 million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share, and (c) warrants (the &#8220;Series A Warrants&#8221; and, together with the Series B Warrants, the &#8220;July 2015 Warrants&#8221;) to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.66</font><font style="font-family:inherit;font-size:10pt;"> per share (collectively, the &#8220;July 2015 Offering&#8221;). Each of the July 2015 Warrants has a term of </font><font style="font-family:inherit;font-size:10pt;">5 and 1/2 years</font><font style="font-family:inherit;font-size:10pt;">. The Series B Warrants were immediately exercisable upon issuance. The Series A Warrants became exercisable on January 7, 2016, </font><font style="font-family:inherit;font-size:10pt;">six months</font><font style="font-family:inherit;font-size:10pt;"> from the date of issuance. The aggregate gross proceeds to us from the July 2015 Offering were approximately </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Craig-Hallum (the &#8220;2015 Placement Agent&#8221;) served as the sole placement agent for the July 2015 Offering. In consideration for services rendered as the placement agent in the July 2015 Offering, we (a) paid to the 2015 Placement Agent cash commissions equal to approximately </font><font style="font-family:inherit;font-size:10pt;">$212,783</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">7.0%</font><font style="font-family:inherit;font-size:10pt;"> of the gross proceeds received in the July 2015 Offering; (b) issued to the 2015 Placement Agent a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year warrant to purchase up to </font><font style="font-family:inherit;font-size:10pt;">107,033</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock with an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.66</font><font style="font-family:inherit;font-size:10pt;"> per share and which is subject to other terms that are the same as the terms of the Series A Warrants; and (c) reimbursed the 2015 Placement Agent for reasonable out-of-pocket expenses, including fees paid to the 2015 Placement Agent&#8217;s legal counsel, incurred in connection with the July 2015 Offering, which reimbursable expenses did not exceed </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The July 2015 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from </font><font style="font-family:inherit;font-size:10pt;">$7.56</font><font style="font-family:inherit;font-size:10pt;"> per share to </font><font style="font-family:inherit;font-size:10pt;">$6.50</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">1,881,396</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">2,188,177</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 6, 2016, we entered into a Securities Purchase Agreement (the &#8220;SPA&#8221;) with certain accredited investors (the &#8220;2016 Investors&#8221;), pursuant to which, on January 8, 2016, we sold to the 2016 Investors, and the 2016 Investors purchased from us (the &#8220;January 2016 Offering&#8221;), an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> of units (the &#8220;Units&#8221;) consisting of (a) an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,365,243</font><font style="font-family:inherit;font-size:10pt;"> shares (the &#8220;A-1 Preferred Shares&#8221;) of our Series A-1 Convertible Preferred Stock (the &#8220;A-1 Preferred&#8221;), and (b) warrants (the &#8220;2016 Warrants&#8221;) to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,773,929</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. Each Unit was sold to the 2016 Investors at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$0.93</font><font style="font-family:inherit;font-size:10pt;"> per Unit. The A-1 Preferred Shares are convertible into shares of our common stock at an initial rate of 1-for-1, which conversion rate is subject to further adjustment as set forth in our Certificate of Designation of Series A-1 Convertible Preferred Stock, which was filed with the Secretary of State of the State of Delaware on January 8, 2016 (the &#8220;Series A-1 Certificate of Designation&#8221;). Pursuant to the terms of the Series A-1 Certificate of Designation, the holders of the A-1 Preferred Shares will generally be entitled to that number of votes as is equal to the product obtained by multiplying: (i) the number of whole shares of our common stock into which the A-1 Preferred may be converted as of the record date of such vote or consent, by (ii) 0.93, rounded down to the nearest whole number. Therefore, every </font><font style="font-family:inherit;font-size:10pt;">1.075269</font><font style="font-family:inherit;font-size:10pt;"> shares of A-1 Preferred will generally initially be entitled to one vote. In May 2016, </font><font style="font-family:inherit;font-size:10pt;">2,150,538</font><font style="font-family:inherit;font-size:10pt;"> of the A-1 Preferred Shares were converted into </font><font style="font-family:inherit;font-size:10pt;">2,150,538</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. At June 30, 2016, there were </font><font style="font-family:inherit;font-size:10pt;">214,705</font><font style="font-family:inherit;font-size:10pt;"> A-1 Preferred Shares outstanding.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrants were immediately exercisable upon issuance, have a term of </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years and have an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.21</font><font style="font-family:inherit;font-size:10pt;"> per share of our common stock. Each 2016 Warrant includes both cash and &#8220;cashless exercise&#8221; features and an exchange feature whereby the holder of the 2016 Warrant may exchange (the &#8220;Exchange Right&#8221;) all or any portion of the 2016 Warrant for a number of shares of our common stock equal to the quotient obtained by dividing the &#8220;Exchange Amount&#8221; by the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged (the &#8220;Exchange Price&#8221;). Under the 2016 Warrants, the &#8220;Exchange Amount&#8221; is based upon a Black Scholes option pricing model, and the aggregate Exchange Amount under all of the 2016 Warrants will be </font><font style="font-family:inherit;font-size:10pt;">$1,436,882</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged. Each 2016 Warrant provides that the number of shares that may be issued upon exercise of the Exchange Right is limited to the number of shares that may be purchased pursuant to the terms of the 2016 Warrant, unless we have previously obtained stockholder approval or approval from The Nasdaq Stock Market LLC to issue any additional shares of our common stock (the &#8220;Additional Shares&#8221;) pursuant to the Exchange Right (the &#8220;Required Approvals&#8221;). For any Exchange Right exercised more than </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days following the issuance of the 2016 Warrants, if we have not obtained either of the Required Approvals, we will be required to pay the 2016 Warrant holder an amount in cash for any Additional Shares that we cannot issue without the Required Approvals based on the Exchange Amount.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrants further provide that, to the extent the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged is less than </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, the Exchange Price will be deemed to be equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, and, in addition to issuing shares of our common stock based on this Exchange Price, we will be required to pay to the 2016 Warrant holder an amount in cash equal to the product obtained by multiplying (a) </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;"> minus the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the 2016 Warrant holder by the Company in such exchange at an Exchange Price equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">. Therefore, if the Required Approvals are obtained, based on the Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$1,436,882</font><font style="font-family:inherit;font-size:10pt;"> (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of the issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the 2016 Warrants will be </font><font style="font-family:inherit;font-size:10pt;">2,873,765</font><font style="font-family:inherit;font-size:10pt;">. In addition, if, for example, assuming an Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$1,436,882</font><font style="font-family:inherit;font-size:10pt;">, the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrants are exchanged is </font><font style="font-family:inherit;font-size:10pt;">$0.25</font><font style="font-family:inherit;font-size:10pt;">, we would be required to pay to the 2016 Warrant holders cash in an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$718,441</font><font style="font-family:inherit;font-size:10pt;"> in addition to issuing the 2016 Warrant holders </font><font style="font-family:inherit;font-size:10pt;">2,873,765</font><font style="font-family:inherit;font-size:10pt;"> shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the terms of the SPA, we amended that certain Series A Warrant to purchase up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,161,972</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock previously issued by us to an affiliate of one of the 2016 Investors on July 7, 2015 (the &#8220;Original Warrant&#8221;), as previously reported by us on our Amendment No. 1 to Current Report on Form 8-K/A, filed with the SEC on July 7, 2015 (as so amended, the &#8220;Amended Warrant&#8221;). The Amended Warrant amends the Original Warrant to provide that the Amended Warrant is subject to the same terms and conditions as the 2016 Warrants and, therefore, includes both cash and &#8220;cashless exercise&#8221; features and an Exchange Right whereby the number of shares issuable pursuant to the Exchange Right is equal to the &#8220;Amended Warrant Exchange Amount&#8221;, which is based on a Black Scholes option pricing model, and will be </font><font style="font-family:inherit;font-size:10pt;">$941,197</font><font style="font-family:inherit;font-size:10pt;">, subject to adjustment to the extent that the risk-free U.S. treasury rate fluctuates between the date of issuance of the Amended Warrant and the date the Amended Warrant is exchanged. The Amended Warrant is exercisable for up to </font><font style="font-family:inherit;font-size:10pt;">1,161,972</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock in the event we have obtained either of the Required Approvals with respect to the Amended Warrant. In the event the Amended Warrant holder exercises the Amended Warrant more than </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days following the issuance of the Amended Warrant, if we have not obtained either of the Required Approvals, we will be required to pay the Amended Warrant holder an amount in cash for the shares of our common stock that we cannot issue under the Amended Warrant pursuant to such exercise without the Required Approvals based on the Amended Warrant Exchange Amount.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Amended Warrant also provides that, to the extent the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is less than </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, the Exchange Price will be deemed to be equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">, and, in addition to issuing shares of our common stock based on this Exchange Price (assuming receipt of the Required Approvals), we will be required to pay to the Amended Warrant holder an amount in cash equal to the product obtained by multiplying (a) </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;"> minus the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the Amended Warrant holder by us in such exchange at an Exchange Price equal to </font><font style="font-family:inherit;font-size:10pt;">$0.50</font><font style="font-family:inherit;font-size:10pt;">. Therefore, if the Required Approvals are obtained, based on the Amended Warrant Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$941,197</font><font style="font-family:inherit;font-size:10pt;"> (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the issuance of the Amended Warrant and the date the Amended Warrant is exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the Amended Warrant will be </font><font style="font-family:inherit;font-size:10pt;">1,882,395</font><font style="font-family:inherit;font-size:10pt;">. In addition, if, for example, assuming an Amended Warrant Exchange Amount of </font><font style="font-family:inherit;font-size:10pt;">$941,197</font><font style="font-family:inherit;font-size:10pt;">, the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is </font><font style="font-family:inherit;font-size:10pt;">$0.25</font><font style="font-family:inherit;font-size:10pt;">, we would be required to pay to the Amended Warrant holder cash in an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$470,599</font><font style="font-family:inherit;font-size:10pt;"> in addition to issuing the Amended Warrant holder </font><font style="font-family:inherit;font-size:10pt;">1,882,395</font><font style="font-family:inherit;font-size:10pt;"> shares.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with entering into the SPA, we also entered into a Registration Rights Agreement, dated January 8, 2016, with the 2016 Investors. Pursuant to the terms of the Registration Rights Agreement, we were required to file with the SEC a registration statement to register for resale the shares of our common stock issuable upon conversion of the A-1 Preferred Shares and the shares of our common stock issuable upon exercise of the 2016 Warrants and the Amended Warrant by January 25, 2016. We filed the required registration statement with the SEC on January 25, 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Craig-Hallum (the &#8220;Placement Agent&#8221;) served as the sole placement agent for the January 2016 Offering. In consideration for services rendered as the Placement Agent in the January 2016 Offering, we (1) paid to the Placement Agent cash commissions equal to approximately </font><font style="font-family:inherit;font-size:10pt;">$140,000</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">7.0%</font><font style="font-family:inherit;font-size:10pt;"> of the gross proceeds received in the January 2016 Offering, excluding any proceeds received from Third Security, LLC or any of its affiliates; (2) issued to the Placement Agent, for a price of </font><font style="font-family:inherit;font-size:10pt;">$50</font><font style="font-family:inherit;font-size:10pt;">, a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year warrant to purchase up to </font><font style="font-family:inherit;font-size:10pt;">107,527</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.21</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Agent Warrant&#8221;), which is subject to the same terms as the 2016 Warrants except that the Agent Warrant was not exercisable until July 8, 2016 and does not contain the Exchange Right; and (3) reimbursed the Placement Agent for reasonable out-of-pocket expenses, including fees paid to the Placement Agent&#8217;s legal counsel, incurred in connection with the January 2016 Offering, which reimbursable expenses did not exceed </font><font style="font-family:inherit;font-size:10pt;">$50,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The January 2016 Offering and the payment of all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock in the form of shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">$1.00</font><font style="font-family:inherit;font-size:10pt;"> per share of our common stock discussed under &#8220;-Conversion of Preferred Stock&#8221; below required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased to </font><font style="font-family:inherit;font-size:10pt;">$4.39</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">2,188,177</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">3,239,827</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 31, 2016, we issued to a vendor an aggregate of </font><font style="font-family:inherit;font-size:10pt;">78,000</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock and, on June 14, 2016, we issued to a second vendor an aggregate of </font><font style="font-family:inherit;font-size:10pt;">64,153</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. Such shares of common stock were issued to the vendors in lieu of an aggregate cash amount of approximately </font><font style="font-family:inherit;font-size:10pt;">$89,000</font><font style="font-family:inherit;font-size:10pt;"> owed by us to such vendors for services previously performed by such vendors. We issued the shares to the vendors in transactions exempt from registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The offering of the shares to the vendors did not involve a public offering, and no general solicitation or advertisement was made in connection with the offering of the shares to the vendors.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 7, 2016, we entered into an At the Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with Craig-Hallum, as sales agent, pursuant to which we may offer and sell, from time to time, through Craig-Hallum, up to </font><font style="font-family:inherit;font-size:10pt;">$3,500,000</font><font style="font-family:inherit;font-size:10pt;"> of shares (the &#8220;Shares&#8221;) of our common stock. Any Shares offered and sold in the offering will be issued pursuant to our effective shelf registration statement on Form S-3 (File No. 333-201907) and the related prospectus previously declared effective by the SEC on February 13, 2015, as supplemented by a prospectus supplement, dated June 7, 2016, that we filed with the SEC pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The number of shares eligible for sale under the ATM Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the ATM Agreement, we will pay Craig-Hallum a placement fee of </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> of the gross sales price of the Shares, unless Craig-Hallum acts as principal, in which case we may sell Shares to Craig-Hallum as principal at a price to be agreed upon by us and Craig-Hallum. We will also reimburse Craig-Hallum for certain expenses incurred in connection with the ATM Agreement, and agreed to provide indemnification and contribution to Craig-Hallum with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and nine months ended September 30, 2016, we sold </font><font style="font-family:inherit;font-size:10pt;">1,035,255</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">1,150,569</font><font style="font-family:inherit;font-size:10pt;"> shares under the ATM Agreement.&#160; For the nine months ended September 30, 2016, the average sales price per common share was </font><font style="font-family:inherit;font-size:10pt;">$0.42</font><font style="font-family:inherit;font-size:10pt;"> and the aggregate net proceeds from the sales totaled </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended September 30, 2016, the sale of shares under the ATM Agreement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased to </font><font style="font-family:inherit;font-size:10pt;">$4.23</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">3,262,088</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">3,362,276</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrants.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and 2015, we issued warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">3,055,555</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">3,466,841</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, respectively. None of the issued warrants were exercised during such periods. The warrants issued in the nine months ended September 30, 2016 included </font><font style="font-family:inherit;font-size:10pt;">1,174,099</font><font style="font-family:inherit;font-size:10pt;"> warrants issued due to repricing requirements of the Private Placement and </font><font style="font-family:inherit;font-size:10pt;">1,881,456</font><font style="font-family:inherit;font-size:10pt;"> warrants issued in connection with the January 2016 Offering. The warrants issued in the nine months ended September 30, 2015 included </font><font style="font-family:inherit;font-size:10pt;">800,492</font><font style="font-family:inherit;font-size:10pt;"> warrants issued due to repricing requirements of the Private Placement and </font><font style="font-family:inherit;font-size:10pt;">2,666,349</font><font style="font-family:inherit;font-size:10pt;"> warrants issued in connection with the February 2015 Offering and the July 2015 Offering. Warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">8,976,354</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock were outstanding at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Warrant Holder</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Issue&#160;Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,919,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.23</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2012</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">443,233</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.23</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">441,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.00</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">374,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$4.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,780</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$2.24</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.66</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(5)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">667,164</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$0.01</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(6)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,161,972</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Affiliates of Third Security, LLC</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(7)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">161,026</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various Institutional Holders</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(7)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,720,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.21</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,976,354</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the Private Placement completed in February 2012 and are classified as a liability in our financial statements. See Note 9 - &#8220;Fair Value&#8221; for additional information. These warrants also contain certain anti-dilution provisions that provide for an adjustment to the exercise price and number of shares issuable upon exercise of the warrant in the event that we engage in certain issuances of shares of our common stock at a price lower than the exercise price of the warrant.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the 2013 Offering, which was completed in January 2013. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the 2014 Private Placement, which was completed in October 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the February 2015 Offering, which was completed in February 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the July 2015 Offering, which was completed in July 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were originally issued in connection with the July 2015 Offering, which was completed in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(7)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.</font></div></td></tr></table><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Issuance of Series B Preferred Stock.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 5, 2014, we entered into a Series B Convertible Preferred Stock Purchase Agreement (the &#8220;Series B Purchase Agreement&#8221;) with affiliates of Third Security, LLC (the &#8220;2014 Third Security Investors&#8221;), pursuant to which we, in a private placement, sold and issued an aggregate of </font><font style="font-family:inherit;font-size:10pt;">1,443,297</font><font style="font-family:inherit;font-size:10pt;"> shares of our Series B Preferred Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Series B Preferred Stock&#8221;), at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$4.85</font><font style="font-family:inherit;font-size:10pt;"> for an aggregate purchase price of approximately </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">. Each share of Series B Preferred Stock issued pursuant to the Series B Purchase Agreement was initially convertible into shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;">-for-1, which conversion rate was subject to further adjustment as set forth in the Certificate of Designation of Series B Convertible Preferred Stock.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Series B financing, we also entered into a Registration Rights Agreement, dated March 5, 2014, with the 2014 Third Security Investors, pursuant to which we granted certain demand, &#8220;piggy-back&#8221; and S-3 registrations rights covering the resale of the shares of common stock underlying the Series B Preferred Stock issued pursuant to the Series B Purchase Agreement and all shares of common stock issuable upon any dividend or other distribution with respect thereto.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Series B financing required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of the warrants decreased from </font><font style="font-family:inherit;font-size:10pt;">$12.96</font><font style="font-family:inherit;font-size:10pt;"> per share to </font><font style="font-family:inherit;font-size:10pt;">$11.73</font><font style="font-family:inherit;font-size:10pt;"> per share and the number of shares issuable upon exercise of the warrants increased from </font><font style="font-family:inherit;font-size:10pt;">1,097,600</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">1,212,665</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Conversion of Preferred Stock.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 6, 2016, the Company entered into a Conversion Agreement (the &#8220;Conversion Agreement&#8221;) with the holders (the &#8220;Preferred Holders&#8221;) of all of the Company&#8217;s outstanding shares of Series A Convertible Preferred Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Series A Preferred Stock&#8221;), and Series B Preferred Stock, pursuant to which, among other things, the Preferred Holders: (a) elected to convert all of the outstanding shares of Series A Preferred Stock and Series B Preferred Stock into shares of our common stock, in each case in accordance with the terms thereof, and (b) agreed that all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock would be paid by the Company in shares of our common stock at a rate of </font><font style="font-family:inherit;font-size:10pt;">$1.00</font><font style="font-family:inherit;font-size:10pt;"> per share of our common stock (collectively, the &#8220;Conversion&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The outstanding shares of Series A Preferred Stock were convertible into shares of our common stock at a rate of 1-for-3, and the outstanding shares of Series B Preferred Stock were convertible into shares of our common stock at a rate of 1-for-1. Prior to the entry into the Conversion Agreement, there were </font><font style="font-family:inherit;font-size:10pt;">2,586,205</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock outstanding, which were converted into </font><font style="font-family:inherit;font-size:10pt;">862,057</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, and </font><font style="font-family:inherit;font-size:10pt;">1,443,297</font><font style="font-family:inherit;font-size:10pt;"> shares of Series B Preferred Stock outstanding, which were converted into </font><font style="font-family:inherit;font-size:10pt;">1,443,297</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, for an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,305,354</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock issued upon conversion of the Series A Preferred Stock and Series B Preferred Stock (the &#8220;Conversion Shares&#8221;). At the time of the entry into the Conversion Agreement, there were </font><font style="font-family:inherit;font-size:10pt;">$3,681,591.90</font><font style="font-family:inherit;font-size:10pt;"> in accrued and unpaid dividends on the outstanding shares of Series A Preferred Stock, which were converted, in accordance with the Conversion Agreement, into </font><font style="font-family:inherit;font-size:10pt;">3,681,590</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, and </font><font style="font-family:inherit;font-size:10pt;">$793,236.17</font><font style="font-family:inherit;font-size:10pt;"> in accrued and unpaid dividends on the outstanding shares of Series B Preferred Stock, which were converted, in accordance with the terms of the Conversion Agreement, into </font><font style="font-family:inherit;font-size:10pt;">793,235</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock, for an aggregate of </font><font style="font-family:inherit;font-size:10pt;">4,474,825</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock issued pursuant to the accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock. Therefore, in connection with the full conversion of the Series A Preferred Stock and Series B Preferred Stock, plus the conversion of all accrued and unpaid dividends thereon, we issued an aggregate of </font><font style="font-family:inherit;font-size:10pt;">6,780,179</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock to the Preferred Holders on January 6, 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following the conversion of the shares of Series A Preferred Stock and Series B Preferred Stock into common stock, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Preferred Stock or Series B Preferred Stock remain outstanding.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock Dividends.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> We had cumulative undeclared dividends on our Series A Preferred Stock and Series B Preferred Stock of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;"> at September 30, 2016 and December 31, 2015, respectively. Since dividends should generally not be recognized as a liability until declared, we had a recorded liability of zero for these undeclared dividends.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had no undeclared dividends for the three months ended September 30, 2016. For the three months ended September 30, 2015 and the nine months ended September 30, 2016 and 2015, we had undeclared dividends. In accordance with the FASB&#8217;s Accounting Standards Codification Topic 260-10-45-11, &#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Earnings per Share</font><font style="font-family:inherit;font-size:10pt;">&#8221;, these dividends were added to the net loss per share calculation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUBSEQUENT EVENTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Merger Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 12, 2016, Transgenomic, New Haven Labs Inc., a wholly owned subsidiary of Transgenomic (&#8220;Merger Sub&#8221; and, together with Transgenomic, the &#8220;Transgenomic Parties&#8221;), and Precipio Diagnostics, LLC (&#8220;Precipio&#8221;) entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) pursuant to which Precipio will become a wholly owned subsidiary of Transgenomic (the &#8220;Merger&#8221;), on the terms and subject to the conditions set forth in the Merger Agreement. Following the Merger, Transgenomic will change its name to Precipio, Inc. (&#8220;New Precipio&#8221;). The parties expect the Merger to close in 2016.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When the Merger is completed, (i)&#160;each outstanding common unit of Precipio will be converted into the right to receive an amount of shares of New Precipio common stock based on an exchange ratio set forth in the Merger Agreement, which is dependent on the relative amount of outstanding liabilities of each of the parties at the time of the Merger, together with cash in lieu of fractional units, which will result in Precipio unit holders owning between </font><font style="font-family:inherit;font-size:10pt;">62%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">80%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding shares of New Precipio common stock (not taking into account the issuance of New Precipio preferred stock in the Merger or the private placement discussed below) and (ii) each outstanding preferred unit of Precipio will be converted into the right to receive shares of New Precipio preferred stock in an aggregate amount equal to </font><font style="font-family:inherit;font-size:10pt;">$3 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, at the effective time of the Merger, New Precipio also will issue shares of New Precipio preferred stock in a private placement, whereby: </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">holders of indebtedness of Transgenomic will receive </font><font style="font-family:inherit;font-size:10pt;">$3 million</font><font style="font-family:inherit;font-size:10pt;"> in New Precipio preferred stock in exchange for such indebtedness; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Precipio will issue for cash up to </font><font style="font-family:inherit;font-size:10pt;">$7 million</font><font style="font-family:inherit;font-size:10pt;"> in New Precipio preferred stock to investors in a private placement.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Precipio preferred stock will be issued based on a pre-money valuation of New Precipio of </font><font style="font-family:inherit;font-size:10pt;">$25 million</font><font style="font-family:inherit;font-size:10pt;"> and will represent, in the aggregate, approximately </font><font style="font-family:inherit;font-size:10pt;">34%</font><font style="font-family:inherit;font-size:10pt;"> of the outstanding shares of New Precipio common stock on an as-converted basis, including New Precipio preferred stock issued in the Merger and the private placement.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The board of managers of Precipio and the boards of directors of Transgenomic and Merger Sub, and Transgenomic, in its capacity as the sole stockholder of Merger Sub, have each approved the Merger Agreement and the board of managers of Precipio and the board of directors of Transgenomic have each recommended that their respective equity holders approve the transactions contemplated by the Merger Agreement. Transgenomic will hold a special meeting of its stockholders to approve the issuance of shares of Transgenomic common stock pursuant to the Merger, as required by Nasdaq Listing Rules, as well as certain other matters (the &#8220;Special Meeting&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Merger Agreement contains various representations, warranties and covenants of the Transgenomic Parties and Precipio, including, among others, covenants (i) by each of Precipio and Transgenomic to operate its business in the ordinary course, (ii) by each of Precipio and Transgenomic not to engage in certain kinds of transactions during the period between the execution of the Merger Agreement and the completion of the Merger, (iii) by Precipio to have its members approve the Merger and (iv) by Transgenomic to hold the Special Meeting.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Merger Agreement, Precipio and Transgenomic are subject to customary &#8220;no shop&#8221; provisions that limit their respective abilities to solicit alternative acquisition proposals from third parties or to provide confidential information to third parties, subject to a &#8220;fiduciary out&#8221; provision that allows Precipio and Transgenomic to provide information and participate in discussions with respect to certain unsolicited written proposals and to terminate the Merger Agreement and enter into an acquisition agreement with respect to a superior proposal in compliance with the terms of the Merger Agreement (a &#8220;Superior Proposal&#8221;).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Completion of the Merger is subject to various conditions, including, among others: (i) approval of the holders of a majority of Transgenomic&#8217;s shares of outstanding common stock, (ii) approval of the requisite amount of the members of Precipio, (iii) approval of an amendment to the Certificate of Incorporation of Transgenomic contemplating the New Preferred Stock Financing (described below) and changing the name of Transgenomic to Precipio, Inc. or such other name as determined by Precipio, (iv) obtaining certain third party consents, (v) the absence of any judgment, injunction, order or decree prohibiting or enjoining the completion of the Merger, (vi) consummation of the New Preferred Stock Financing, (vii) approval of listing of the Parent Common Stock on NASDAQ, (viii) completion of the Common Unit Recapitalization (described above), (ix) increase in the size of the Transgenomic board by two members and the appointment of designees in accordance with the Merger Agreement and (x) the lock-up of certain Transgenomic stockholders and Precipio members.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the obligation of the parties to complete the Merger is subject to certain other conditions, including (i) subject to the standards set forth in the Merger Agreement, the accuracy of the representations and warranties of the other party, (ii)&#160;compliance of each party with its covenants in all material respects and (iii)&#160;no material adverse effect of either party.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Merger Agreement contains certain termination rights for both the Transgenomic Parties and Precipio. Either may terminate the Merger Agreement if the Merger is not completed on or before the date that is six months following the date of the Merger Agreement. Moreover, either party may terminate the Merger Agreement if the other party changes its recommendation to its security holders to approve the Merger and the related transactions or enter into an agreement with a third party regarding a Superior Proposal (as defined in the Merger Agreement).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Merger Agreement also provides that, upon termination of the Merger Agreement under certain circumstances, Transgenomic will be required to pay to Precipio a termination payment of </font><font style="font-family:inherit;font-size:10pt;">$256,500</font><font style="font-family:inherit;font-size:10pt;">. If the Merger Agreement is terminated for certain other reasons, Precipio will be required to pay Transgenomic a termination payment of </font><font style="font-family:inherit;font-size:10pt;">$256,500</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, which is attached hereto as Exhibit 2.1 and incorporated by reference herein. The Merger Agreement has been included as an exhibit hereto solely to provide investors and security holders with information regarding its terms. It is not intended to be a source of financial, business or operational information about Transgenomic, Precipio or their respective subsidiaries or affiliates. The representations, warranties and covenants contained in the Merger Agreement are made only for purposes of the Merger Agreement and are made as of specific dates; are solely for the benefit of the parties; may be subject to qualifications and limitations agreed upon by the parties in connection with negotiating the terms of the Merger Agreement, including being qualified by confidential disclosures made for the purpose of allocating contractual risk between the parties rather than establishing matters as facts; and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors or security holders. Investors and security holders should not rely on the representations, warranties and covenants or any description thereof as characterizations of the actual state of facts or condition of Transgenomic, Precipio or their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in public disclosures.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, the Supporting Stockholders and Supporting Members (as defined in the Merger Agreement) are obligated to enter into a lock-up agreement with the combined company at the Effective Time pursuant to which the Supporting Stockholders will agree, among other things, not to sell shares of Transgenomic common stock for the six month period beginning at the Effective Time.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Merger Agreement also provides that the combined company will enter into employment agreements with certain employees of Precipio at the Effective Time and that the officers of the combined company will be agreed to by the parties prior to the Effective Time.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:174%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Special Meeting of Stockholders </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At our 2016 Special Meeting of Stockholders (the &#8220;Special Meeting&#8221;) held on October 31, 2016, our stockholders approved the proposal to authorize our Board of Directors to, in its discretion, amend our Third Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio of between one-for-ten to one-for-thirty, such ratio to be determined by our Board of Directors (the &#8220;Reverse Split Proposal&#8221;). The Reverse Split Proposal was described in detail in our definitive proxy statement filed with the Securities and Exchange Commission on September 22, 2016, as supplemented on October 13, 2016. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The approval of the Reverse Split Proposal by our stockholders provides our Board of Directors with the authority to carry out the reverse stock split, but our Board of Directors is not obligated to do so. If our Board of Directors determines to effect the reverse stock split, it intends to select a reverse stock split ratio that it believes would be most likely to achieve the anticipated benefits of the reverse stock split. Notwithstanding approval of the Reverse Split Proposal by our stockholders, our Board of Directors may, in its sole discretion, abandon the Reverse Split Proposal and determine, prior to the effectiveness of any filing with the Secretary of State of the State of Delaware, not to effect the reverse stock split. If our Board of Directors fails to implement the reverse stock split on or prior to the first anniversary date of the Special Meeting, stockholder approval again would be required prior to implementing any reverse stock split.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:4px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While payment terms are generally </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;">, we have also provided extended payment terms in certain cases. Accounts receivable are carried at original invoice amount and shown net of allowance for doubtful accounts. The estimate made for doubtful accounts is based on a review of all outstanding amounts on a quarterly basis. We determine the allowance for doubtful accounts by regularly evaluating individual payor receivables and considering a payor&#8217;s financial condition, credit history, reimbursement rates and current economic conditions. Accounts receivable are written off when deemed uncollectible and after all collection efforts have been exhausted. Recoveries of accounts receivable previously written off are recorded as a reduction in bad debt expense when received.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. In addition, estimates and assumptions associated with the determination of the fair value of certain assets and related impairments require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these condensed consolidated financial statements.</font></div></div> EX-101.SCH 6 tbio-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - BUSINESS DESCRIPTION link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - BUSINESS DESCRIPTION (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - DEBT (Convertible Promissory Notes) (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - DEBT (Revolving Line and Term Loan) (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - DEBT (Schedule of Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - DISCONTINUED OPERATIONS link:presentationLink link:calculationLink link:definitionLink 2405405 - Disclosure - DISCONTINUED OPERATIONS (Allowance for Doubtful Accounts) (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - DISCONTINUED OPERATIONS (Assets and Liabilities Held for Sale) (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - DISCONTINUED OPERATIONS (Narratives) (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - DISCONTINUED OPERATIONS (Revenues and Net Income (Loss)) (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - DISCONTINUED OPERATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - DOCUMENT AND ENTITY INFORMATION link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - FAIR VALUE link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - FAIR VALUE (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2409401 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - INTANGIBLES AND OTHER ASSETS link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - INTANGIBLES AND OTHER ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - INTANGIBLES AND OTHER ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - STOCK OPTIONS link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - STOCK OPTIONS (Stock Appreciation Rights) (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - STOCK OPTIONS (Stock Options) (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - STOCK OPTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock) (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - STOCKHOLDERS' EQUITY (Conversion of Preferred Stock) (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - STOCKHOLDERS' EQUITY (Issuance of Series B Preferred Stock) (Details) link:presentationLink link:calculationLink link:definitionLink 2410406 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Dividends) (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Accounts Receivable) (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Inventories) (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narratives) (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 tbio-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 tbio-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 tbio-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Accounting Policies [Abstract] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Reclassification Reclassification, Policy [Policy Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Risks and Uncertainties Risks and Uncertainties [Policy Text Block] Risks and Uncertainties [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Fair Value Fair Value Measurement, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Concentrations of Cash Concentration of Cash Policy [Policy Text Block] Concentration of Cash Policy [Policy Text Block] Accounts Receivable Trade and Other Accounts Receivable, Policy [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Net Sales Recognition Revenue Recognition, Policy [Policy Text Block] Common Stock Warrants Common stock warrants [Policy Text Block] Common stock warrants [Policy Text Block] Loss Per Share Earnings Per Share, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Discontinued Operations and Disposal Groups [Abstract] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Genetic Assays and Platforms and Patient Testing Genetic Assays and Platforms and Patient Testing [Member] Genetic Assays and Platforms and Patient Testing [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Discontinued operations Discontinued Operations [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Disposal Group, Including Discontinued Operations, Allowance for Doubtful Accounts [Roll Forward] Disposal Group, Including Discontinued Operations, Allowance for Doubtful Accounts [Roll Forward] Disposal Group, Including Discontinued Operations, Allowance for Doubtful Accounts [Roll Forward] Beginning Balance Disposal Group, Including Discontinued Operations, Allowance for Doubtful Accounts Receivable Disposal Group, Including Discontinued Operations, Allowance for Doubtful Accounts Receivable Additions Disposal Group, Including Discontinued Operation, Provision for Doubtful Accounts Disposal Group, Including Discontinued Operation, Provision for Doubtful Accounts Deductions Disposal Group, Including Discontinued Operation, Allowance for Doubtful Accounts Receivable, Write-offs Disposal Group, Including Discontinued Operation, Allowance for Doubtful Accounts Receivable, Write-offs Ending Balance Schedule of discontinued operations impact on income statement and balance sheets Disposal Groups, Including Discontinued Operations [Table Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving credit facility Revolving Credit Facility [Member] Lender Name [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Third Security LLC and affiliates Third Security LLC And Affiliates [Member] Third Security LLC And Affiliates [Member] PGxHealth, LLC PGxHealth, LLC [Member] PGxHealth, LLC [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Line of credit Line of Credit [Member] Term loan Term Loan [Member] Term Loan [Member] Senior secured promissory note Senior Notes [Member] Convertible notes payable Convertible Notes Payable [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Face amount Debt Instrument, Face Amount Debt term of note payable that was paid off Debt Instrument, Term Interest costs capitalized Interest Costs Capitalized Initial prepayment of a portion of the loan balance Principal Amount Outstanding of Loans, Initial Prepayment Principal Amount Outstanding of Loans, Initial Prepayment Payment to lenders to support the amount advanced Repayments of Long-term Lines of Credit Overadvance on Loan Agreement Long-term Debt, Current Maturities Stockholders' Equity Note [Abstract] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Preferred stock Preferred Stock [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Series B preferred stock Series B Preferred Stock [Member] Class of Stock [Line Items] Class of Stock [Line Items] Private placement, net (in shares) Stock Issued During Period, Shares, New Issues Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Share price (in dollars per share) Share Price Private placement, net Stock Issued During Period, Value, New Issues Conversion ratio Stockholders' Equity Note, Conversion Ratio Stockholders' Equity Note, Conversion Ratio Common stock warrant, exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Common stock warrant, common stock called (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Conversion of Stock [Table] Conversion of Stock [Table] Series A Preferred Stock Series A Preferred Stock [Member] Series A-1 Convertible Preferred Stock and Warrants Series A-1 Convertible Preferred Stock and Warrants [Member] Series A-1 Convertible Preferred Stock and Warrants [Member] Common Stock Common Stock [Member] Conversion of Stock [Line Items] Conversion of Stock [Line Items] Dividend conversion rate per share Preferred Stock, Dividend Conversion Rate, Per Share Preferred Stock, Dividend Conversion Rate, Per Share Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Number of common stock converted Conversion of Stock, Shares Issued Amount of preferred dividends in arrears Preferred Stock, Amount of Preferred Dividends in Arrears Number of shares of common stock dividends Common Stock Dividends, Shares Income Tax Disclosure [Abstract] INCOME TAXES Income Tax Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Indefinite-Lived and Finite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived and Finite-Lived Intangible Assets [Table] [Table] Schedule of Indefinite-Lived and Finite-Lived Intangible Assets [Table] [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Patents Patents [Member] Intellectual property Intellectual Property [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Net [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Cost Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Book Value Finite-Lived Intangible Assets, Net Estimated Useful Life Finite-Lived Intangible Asset, Useful Life Amortization expense for intangible assets Amortization of Intangible Assets Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Amortization expense, 2016 Finite-Lived Intangible Assets, Amortization Expense, Current Fiscal Year Finite-Lived Intangible Assets, Amortization Expense, Current Fiscal Year Amortization expense, 2017 Finite-Lived Intangible Assets, Amortization Expense, Year Two Amortization expense, 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Three Amortization expense, 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Four Amortization expense, 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Five Genetic Assays and Platforms business Genetic Assays And Platforms Business [Member] Genetic Assays And Platforms Business [Member] Patient Testing Patient Testing [Member] Patient Testing [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] ADSTEC Corporation ADSTEC Corporation [Member] ADSTEC Corporation [Member] Purchase price Disposal Group, Including Discontinued Operation, Consideration (Loss) gain on sale of business Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax LOSS FROM DISCONTINUED OPERATIONS, NET OF TAXES Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent DISCONTINUED OPERATIONS Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] CURRENT ASSETS: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accounts receivable, net Accounts Receivable, Net, Current Inventories, net Inventory, Net Other current assets Other Assets, Current Assets held for sale Disposal Group, Including Discontinued Operation, Assets, Current Total current assets Assets, Current PROPERTY AND EQUIPMENT: Property, Plant and Equipment [Abstract] Equipment Machinery and Equipment, Gross Furniture, fixtures & leasehold improvements Furniture Fixtures And Leasehold Improvements Gross Furniture Fixtures And Leasehold Improvements Gross Property and equipment, gross Property, Plant and Equipment, Gross Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net OTHER ASSETS: Assets, Noncurrent [Abstract] Intangibles, net Intangible Assets, Net (Excluding Goodwill) Other assets Other Assets, Noncurrent Assets Assets LIABILITIES AND STOCKHOLDERS’ DEFICIT Liabilities and Equity [Abstract] CURRENT LIABILITIES: Liabilities, Current [Abstract] Current maturities of long-term debt Accounts payable Accounts Payable, Current Accrued compensation Employee-related Liabilities, Current Accrued expenses Accrued Liabilities, Current Deferred revenue Deferred Revenue, Current Other liabilities Other Liabilities, Current Liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities, Current Total current liabilities Liabilities, Current LONG TERM LIABILITIES: Liabilities, Noncurrent [Abstract] Common stock warrant liability Warrants and Rights Outstanding Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities STOCKHOLDERS’ DEFICIT: Stockholders' Equity Attributable to Parent [Abstract] Convertible preferred stock, $0.01 par value, 15,000,000 shares authorized, 214,705 and 4,029,502 shares issued and outstanding, respectively Preferred Stock, Value, Issued Common stock, $0.01 par value, 150,000,000 shares authorized, 24,139,130 and 13,915,691 shares issued and outstanding, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders’ deficit Stockholders' Equity Attributable to Parent Liabilities and stockholders' equity Liabilities and Equity Convertible promissory notes Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Wall Street Journal prime rate Wall Street Journal Prime Rate [Member] Wall Street Journal Prime Rate [Member] Total debt Debt and Capital Lease Obligations Current portion of long-term debt Long-term debt, net of current maturities Long-term Debt, Excluding Current Maturities Annual interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Basis spread on variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Effective interest rate (as a percent) Debt Instrument, Interest Rate, Effective Percentage Commitment fee amount Line of Credit Facility, Commitment Fee Amount Commitment fee (as a percent) Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Proceeds from issuance of long-term debt Proceeds from Issuance of Long-term Debt Current interest rate (as a percent) Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate Future debt extinguishment costs Debt Instrument, Future Debt Extinguishment Costs Debt Instrument, Future Debt Extinguishment Costs Prepayment penalty percentage of outstanding balance (as a percent) Debt Instrument, Prepayment Penalty Percent Debt Instrument, Prepayment Penalty Percent Increase in interest rate in case of debt default (as a percent) Debt Instrument, Debt Default, Interest Rate, Stated Percentage Increase Debt Instrument, Debt Default, Interest Rate, Stated Percentage Increase Disclosure of Compensation Related Costs, Share-based Payments [Abstract] STOCK OPTIONS Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Debt Instrument, Conversion, Period [Axis] Debt Instrument, Conversion, Period [Axis] Debt Instrument, Conversion, Period [Axis] Debt Instrument, Conversion, Period [Domain] Debt Instrument, Conversion, Period [Domain] [Domain] for Debt Instrument, Conversion, Period [Axis] Conversion, period one Debt Instrument, Conversion, Period One [Member] Debt Instrument, Conversion, Period One [Member] Conversion, period two Debt Instrument, Conversion, Period Two [Member] Debt Instrument, Conversion, Period Two [Member] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Additional notes Additional Note Private Placement [Member] Additional Note Private Placement [Member] Interest rate (as a percent) Percentage of debt convertible Debt Instrument, Convertible, Percentage of Debt Debt Instrument, Convertible, Percentage of Debt Threshold consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Conversion price as percentage of average closing price Debt Instrument, Convertible, Conversion Percentage of Average Closing Price Debt Instrument, Convertible, Conversion Percentage of Average Closing Price Number of shares converted Debt Conversion, Converted Instrument, Shares Issued Number of additional accredited investors Debt Instrument, Number of Additional Accredited Investors Debt Instrument, Number of Additional Accredited Investors Conversion of convertible promissory notes Debt Conversion, Converted Instrument, Amount Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Leasehold Improvements Leasehold Improvements [Member] Furniture and Fixtures Furniture and Fixtures [Member] Production Equipment Other Machinery and Equipment [Member] Computer Equipment Computer Equipment [Member] Research and Development Equipment Other Capitalized Property Plant and Equipment [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and equipment, estimated useful lives Property, Plant and Equipment, Useful Life Depreciation expense Depreciation Fair Value Disclosures [Abstract] Schedule of changes in fair value of liability Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Statement of Comprehensive Income [Abstract] Net Loss Net Income (Loss) Attributable to Parent Other comprehensive loss - foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Comprehensive Loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent INTANGIBLES AND OTHER ASSETS Intangibles And Other Assets [Text Block] Intangibles And Other Assets [Text Block] Schedule of long-lived intangible assets Schedule of Indefinite-Lived and Finite-Lived Intangible Assets [Table Text Block] Schedule of Indefinite-Lived and Finite-Lived Intangible Assets [Table Text Block] Allowance for Doubtful Accounts Receivable [Roll Forward] Allowance for Doubtful Accounts Receivable [Roll Forward] Beginning balance Allowance for Doubtful Accounts Receivable Additions Provision for Doubtful Accounts, Excluding Amounts Not Included in Provision Provision for Doubtful Accounts, Excluding Amounts Not Included in Provision Deductions Allowance for Doubtful Accounts Receivable, Write-offs Ending balance Accounts receivable, general payment terms Accounts Receivable, General Payment Terms1 Accounts Receivable, General Payment Terms1 Net raw materials inventory Inventory, Raw Materials, Net of Reserves Obsolete inventory [Roll Forward] Obsolete inventory [Roll Forward] Obsolete inventory [Roll Forward] Beginning Balance Inventory Valuation Reserves Additions Inventory, Additions Inventory, Additions Deductions Inventory Write-down Ending Balance ASSETS Disposal Group, Including Discontinued Operation, Assets [Abstract] Accounts receivable, net Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Other current assets Disposal Group, Including Discontinued Operation, Other Assets, Current Total Assets Disposal Group, Including Discontinued Operation, Assets LIABILITIES Disposal Group, Including Discontinued Operation, Liabilities [Abstract] Accrued compensation Disposal Group, Including Discontinued Operation, Accrued Employee-Related Liabilities, Current Disposal Group, Including Discontinued Operation, Accrued Employee-related Liabilities, Current Total Liabilities Disposal Group, Including Discontinued Operation, Liabilities Cumulative undeclared dividends, preferred stock Dividends, Preferred Stock, Cash, Not Declared Dividends, Preferred Stock, Cash, Not Declared Private Placement Private Placement [Member] Offering Offering [Member] Offering [Member] Warranty Holders and Issuance [Axis] Warranty Holders and Issuance [Axis] Warranty Holders and Issuance [Axis] Warranty Holders and Issuance [Domain] Warranty Holders and Issuance [Domain] Warranty Holders and Issuance [Domain] Various Institutional Holders; February 2017 Various Institutional Holders; February 2017 [Member] Various Institutional Holders; February 2017 [Member] Affiliates of Third Security, LLC; February 2017 Affiliates of Third Security, LLC; February 2017 [Member] Affiliates of Third Security, LLC; February 2017 [Member] Various Institutional Holders; January 2018 Various Institutional Holders; January 2018 [Member] Various Institutional Holders; January 2018 [Member] Affiliates of Third Security, LLC; January 2018 Affiliates of Third Security, LLC; January 2018 [Member] Affiliates of Third Security, LLC; January 2018 [Member] Various Institutional Holders; April 2020 Various Institutional Holders; April 2020 [Member] Various Institutional Holders; April 2020 [Member] Various Institutional Holders; February 2020 Various Institutional Holders; February 2020 [Member] Various Institutional Holders; February 2020 [Member] Various Institutional Holders; December 2020 Various Institutional Holders; December 2020 One [Member] Various Institutional Holders; December 2020 One [Member] Various Institutional Holders; December 2020 Various Institutional Holders; December 2020 Two [Member] Various Institutional Holders; December 2020 Two [Member] Various Institutional Holders; January 2021 Various Institutional Holders; January 2021 One [Member] Various Institutional Holders; January 2021 One [Member] Affiliates of Third Security, LLC; January 2021 Affiliates of Third Security, LLC; January 2021 [Member] Affiliates of Third Security, LLC; January 2021 [Member] Various Institutional Holders; January 2021 Various Institutional Holders; January 2021 Two [Member] Various Institutional Holders; January 2021 Two [Member] Common stock warrants issued (in shares) Class of Warrant or Right, Number of Issued Warrants or Rights Class of Warrant or Right, Number of Issued Warrants or Rights Underlying Shares Class of Warrant or Right, Outstanding Exercise Price (in dollars per share) Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Executive Officers Executive Officer [Member] Business segments Segments [Axis] Segments Segments [Domain] Pharmacogenomic Services Pharmacogenomic services [Member] Pharmacogenomic services [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Current prepaid expense Prepaid Expense, Current Other current receivables Other Receivables, Net, Current Share-based compensation arrangement by share-based payment award, expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Stock options, unvested options, vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Stock-based compensation expense Share-based Compensation Unrecognized compensation expense related to unvested stock awards, not yet recognized Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unvested stock options, unrecognized compensation expense weighted average recognition period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Stock options, granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Stock options, fair value assumptions, risk free interest rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Stock options, fair value assumptions, dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Stock options, fair value assumptions, expected life Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Stock options, fair value assumptions, historical volatility rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Common stock rights issued (in shares) Deferred revenue Options, warrants and conversion rights, common stock callable and antidilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] SARs Stock Appreciation Rights (SARs) [Member] Number of SARs Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Number Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Outstanding (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Exercisable (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Weighted Average Grant Date Fair Value Stock appreciation rights, nonvested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Stock appreciation rights, aggregate intrinsic value, outstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Threatened Litigation Threatened Litigation [Member] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Breach of contract Performance Guarantee [Member] UNMC University of Nebraska [Member] University of Nebraska [Member] Mount Sinai Icahn School of Medicine [Member] Icahn School of Medicine [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Damages sought in a lawsuit Loss Contingency, Damages Sought, Value Accrual of possible loss in a lawsuit Loss Contingency, Estimate of Possible Loss Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Future minimum payments due, remainder of 2016 Operating Leases, Future Minimum Payments, Remainder of Fiscal Year Future minimum payments due, 2017 Operating Leases, Future Minimum Payments, Due in Two Years Future minimum payments due, 2018 Operating Leases, Future Minimum Payments, Due in Three Years Future minimum payments due, 2019 Operating Leases, Future Minimum Payments, Due in Four Years Future minimum payments due, 2020 Operating Leases, Future Minimum Payments, Due in Five Years Future minimum payments, due thereafter Operating Leases, Future Minimum Payments, Due Thereafter Rent expense Operating Leases, Rent Expense, Net Firm commitments to vendors Purchase Commitment, Remaining Minimum Amount Committed Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Private Placement Preferred Stock Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Deficit Retained Earnings [Member] Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance at beginning of period Balance at beginning of period (in shares) Shares, Outstanding Net loss Foreign currency translation adjustment Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock issued during period (in shares) Stock issued during period Dividends on preferred stock Dividends, Preferred Stock, Cash Conversion of preferred stock and preferred stock dividends Stock Issued During Period, Value, Conversion of Convertible Securities Conversion of preferred stock and preferred stock dividends (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Balance at end of period Balance at end of period (in shares) COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Employee Stock Option Employee Stock Option [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Equity Incentive Plan 2006 Equity Incentive Plan 2006 [Member] Equity Incentive Plan 2006 [Member] Number of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Outstanding at end of period (in shares) Exercisable at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding at beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Outstanding at end of period (in dollars per share) Exercisable at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Stock options, expected to vest, outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Stock options, expected to vest, outstanding, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Organization, Consolidation and Presentation of Financial Statements [Abstract] BUSINESS DESCRIPTION Business Description and Basis of Presentation [Text Block] Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Precipio Precipio [Member] Precipio [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Subsequent Event [Line Items] Subsequent Event [Line Items] Projected ownership interest in parent Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Business acquisition costs, projected Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Debt instrument, convertible, value of exchanged shares Debt Instrument, Convertible, Value of Stock Exchanged Debt Instrument, Convertible, Value of Stock Exchanged Equity Issued in Business Combination, Fair Value Disclosure Equity Issued in Business Combination, Fair Value Disclosure Percentage of shares issued Percentage of Shares Issued Percentage of Shares Issued Business termination cost Business Combination, Contingent Consideration, Liability 2014 Private Placement Two Thousand Fourteen Private Placement [Member] Two Thousand Fourteen Private Placement [Member] At the Market Offering At the Market Offering [Member] At the Market Offering [Member] Additional Note Private Placement 2015 Offering Two Thousand Fifteen Offering [Member] Two Thousand Fifteen Offering [Member] Series A Warrants Series A Warrants [Member] Series A Warrants [Member] Series A Warrant, Cashless Exchange Series A Warrant, Cashless Exchange [Member] Series A Warrant, Cashless Exchange [Member] Series A-1 Warrant Series A-1 Warrant [Member] Series A-1 Warrant [Member] Series B Warrants Series B Warrants [Member] Series B Warrants [Member] Warrants Series A and Series B Warrants [Member] Series A and Series B Warrants [Member] Advisor Advisor [Member] Advisor [Member] Series A-1 Convertible Preferred Stock Series A-1 Convertible Preferred Stock [Member] Series A-1 Convertible Preferred Stock [Member] Weighted Average Weighted Average [Member] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Pro Forma Pro Forma [Member] Craig-Hallum Capital Group LLC Craig-Hallum Capital Group LLC [Member] Craig-Hallum Capital Group LLC [Member] Proceeds from issuance of common stock and convertible notes Proceeds from issuance of common stock and convertible notes Proceeds from issuance of common stock and convertible notes Common stock, sale price per share (in dollars per share) Sale of Stock, Price Per Share Warrants term Class of Warrant or Right, Exercise Term1 Class of Warrant or Right, Exercise Term1 Convertible notes, common stock callable (in shares) Convertible notes, Number of Securities Called by Note Convertible notes, Number of Securities Called by Note Convertible notes, warrants callable (in shares) Convertible Notes, Number of Warrants Called by Notes Convertible Notes, Number of Warrants Called by Notes Payments of stock issuance costs Payments of Stock Issuance Costs Payments of stock issuance costs, percentage of gross offering proceeds Payments of Stock Issuance Costs, Percentage of Gross Offering Proceeds Payments of Stock Issuance Costs, Percentage of Gross Offering Proceeds Payments of stock issuance costs, warrant right to purchase common stock shares Payments of Stock Issuance Costs, Warrant Right To Purchase Common Stock Shares Payments of Stock Issuance Costs, Warrant Right To Purchase Common Stock Shares Payments of stock issuance costs, warrant right to purchase common stock shares, percentage of shares in offering Payments of Stock Issuance Costs, Warrant Right To Purchase Common Stock Shares, Percentage of Shares in Offering Payments of Stock Issuance Costs, Warrant Right To Purchase Common Stock Shares, Percentage of Shares in Offering Stock issuance costs, reimbursable expenses (not to exceed) Stock Issuance Costs, Reimbursable Expenses Stock Issuance Costs, Reimbursable Expenses Payments of stock issuance costs, reduction to equity Payments of Stock Issuance Costs, Reduction To Equity Payments of Stock Issuance Costs, Reduction To Equity Issuance of common stock, net Proceeds from Issuance of Common Stock Payments for repurchase of warrants Payments for Repurchase of Warrants Class of warrant or right, number of securities called by warrants or rights, price per share (in dollars per share) Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Price Per Share Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Price Per Share Face amount as percentage of proceeds from debt issuance Debt Instrument, Face Amount, Percentage of Proceeds from Debt Issuance Debt Instrument, Face Amount, Percentage of Proceeds from Debt Issuance Class of warrant or right, number of securities called by each warrant or right (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Class of warrant or right, purchase price per share, public (in dollars per share) Class of Warrant or Right, Purchase Price Per Unit, Public Class of Warrant or Right, Purchase Price Per Unit, Public Class of warrant or right, purchase price per share, underwriter (in dollars per share) Class of Warrant or Right, Purchase Price Per Unit, Underwriter Class of Warrant or Right, Purchase Price Per Unit, Underwriter Proceeds from issuance of common stock and warrants, net Proceeds from Issuance of Common Stock and Warrants, Net Proceeds from Issuance of Common Stock and Warrants, Net Class of warrant or right, expiration period Class of Warrant or Right, Expiration Period Class of Warrant or Right, Expiration Period Warrants, period exercisable Class of Warrant or Right, Period from which Warrants or Rights Exercisable Class of Warrant or Right, Period from which Warrants or Rights Exercisable Proceeds from issuance of common stock and warrants Proceeds from Issuance or Sale of Equity Proceeds from issuance of convertible preferred stock Proceeds from Issuance of Convertible Preferred Stock Price per share of shares issued (in dollars per share) Shares Issued, Price Per Share Voting rights, number of shares per one vote Preferred Stock, Voting Rights, Number of Shares Per One Vote Preferred Stock, Voting Rights, Number of Shares Per One Vote Number of shares converted Conversion of Stock, Shares Converted Shares issued upon conversion of preferred stock (in shares) Warrant exchange amount Class of Warrant or Right, Exchange Amount Class of Warrant or Right, Exchange Amount Warrant exercise period not subject to cash payment Class of Warrant or Right, Exercise Period Not Subject to Cash Payment Class of Warrant or Right, Exercise Period Not Subject to Cash Payment Warrant exchange price threshold (in dollars per share) Class of Warrant or Right, Exchange Price Threshold Class of Warrant or Right, Exchange Price Threshold Proceeds from issuance of warrants Proceeds from Issuance of Warrants Stock issued during period for services (in shares) Stock Issued During Period, Shares, Issued for Services Stock issued during period for services Stock Issued During Period, Value, Issued for Services Aggregate authorized amount under At the Market Offering Agreement Common Stock, Aggregate Authorized Amount Common Stock, Aggregate Authorized Amount Net sales Disposal Group, Including Discontinued Operation, Revenue Cost of goods sold Disposal Group, Including Discontinued Operation, Costs of Goods Sold Gross profit Disposal Group, Including Discontinued Operation, Gross Profit (Loss) Selling, general and administrative expense Disposal Group, Including Discontinued Operation, Selling, General And Administrative Expense Disposal Group, Including Discontinued Operation, Selling, General And Administrative Expense Research and development expense Disposal Group, Including Discontinued Operation, Research and Development Expense Disposal Group, Including Discontinued Operation, Research and Development Expense Impairment of long-lived assets Impairment of Long-Lived Assets Held-for-use Operating income (loss) from discontinued operations Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax Gain on sale of business/assets Income (loss) from discontinued operations before income taxes Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Income tax expense Discontinued Operation, Tax Effect of Discontinued Operation Income (loss) from discontinued operations, net of taxes Summary of stock option activity Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Summary of SARs activity Schedule of Other Share-based Compensation, Activity [Table Text Block] Subsequent Events Subsequent Events [Text Block] Number of operating segments Number of Operating Segments Working capital Working Capital (Deficiency) Working Capital (Deficiency) Summary of activity for the allowance for doubtful accounts Allowance for Credit Losses on Financing Receivables [Table Text Block] Activity for the allowance for obsolete inventory Activity for the allowance for obsolete inventory [Table Text Block] Activity for the allowance for obsolete inventory [Table Text Block] Schedule of property and equipment, useful lives Property, Plant and Equipment [Table Text Block] Income Statement [Abstract] Operating Activities [Axis] Operating Activities [Axis] Operating Activities [Domain] Operating Activities [Domain] Continuing operations Continuing Operations [Member] NET SALES Revenue, Net COST OF GOODS SOLD Cost of Goods and Services Sold Gross profit Gross Profit OPERATING EXPENSES: Operating Expenses [Abstract] Selling, general and administrative Selling, General and Administrative Expense Research and development Research and Development Expense Operating Expenses Operating Expenses OPERATING LOSS FROM CONTINUING OPERATIONS Operating Income (Loss) OTHER INCOME (EXPENSE): Nonoperating Income (Expense) [Abstract] Interest expense, net Interest income and (expense), net Interest income and (expense), net Warrant revaluation Gain (Loss) On Stock Warrants Revaluation Other, net Other Nonoperating Income (Expense) Other Income (Expense) Other Income (Expense) Other Income (Expense) LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest INCOME TAX BENEFIT Income Tax Expense (Benefit) LOSS FROM CONTINUING OPERATIONS Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent NET LOSS PREFERRED STOCK DIVIDENDS Preferred Stock Dividends, Income Statement Impact NET LOSS AVAILABLE TO COMMON STOCKHOLDERS Net Income (Loss) Available to Common Stockholders, Basic BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE) Earnings Per Share, Basic and Diluted BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES) Weighted Average Number of Shares Outstanding, Basic and Diluted Income tax expense (benefit) DEBT Debt Disclosure [Text Block] Schedule of stockholders' equity, including warrants and rights Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] FAIR VALUE Financial Instruments Disclosure [Text Block] STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] Statement of Cash Flows [Abstract] CASH FLOWS USED IN OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Less loss from discontinued operations, net of tax Loss from continuing operations Adjustments to reconcile net loss to net cash flows used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Stock-based compensation Provision for losses on doubtful accounts Provision for Doubtful Accounts Warrant revaluation Fair Value Adjustment of Warrants Loss on sale of fixed assets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Deferred interest Increase (Decrease) in Interest Payable, Net Deferred tax provision Increase (Decrease) in Deferred Income Taxes Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses and other liabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Net cash used in continuing operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash provided by (used in) discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Other assets Payments for (Proceeds from) Other Investing Activities Net cash used in continuing operations Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash provided by discontinued operations Cash Provided by (Used in) Investing Activities, Discontinued Operations Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities CASH FLOWS PROVIDED BY FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Principal payments on capital lease obligations Repayments of Long-term Capital Lease Obligations Issuance of preferred stock, net Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds from borrowings Proceeds from Notes Payable Principal payment on note payable Repayments of Notes Payable Net cash flows provided by financing activities Net Cash Provided by (Used in) Financing Activities EFFECT OF FOREIGN CURRENCY EXCHANGE RATE CHANGES ON CASH Effect of Exchange Rate on Cash and Cash Equivalents NET CHANGE IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS AT END OF PERIOD SUPPLEMENTAL CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Cash paid during the period for: Cash Paid During The Period For: [Abstract] Cash Paid During The Period For: [Abstract] Interest Interest Paid Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] 2012 Warrant Liability 2012 Warrant Liability [Member] 2012 Warrant Liability [Member] 2016 Warrant Liability 2016 Warrant Liability [Member] 2016 Warrant Liability [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Stock options, fair value assumptions, expected life Issuance of Warrants, Expected Exercise Period Issuance of Warrants, Expected Exercise Period Volatility (as a percent) Fair Value Assumptions, Expected Volatility Rate Risk-free interest rate (as a percent) Fair Value Assumptions, Risk Free Interest Rate Fair value assumptions, expected term Fair Value Assumptions, Expected Term Percentage of simulated equity values below the down-round financing cut-off point Fair Value Assumptions, Percentage of Simulated Equity Values Below the Down-Round Financing Cut-Off Point Fair Value Assumptions, Percentage of Simulated Equity Values Below the Down-Round Financing Cut-Off Point Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Beginning balance Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Additions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Total (gains) or losses: Total gains or losses [Abstract] Total gains or losses [Abstract] Recognized in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Balance at end of period Schedule of debt Schedule of Debt [Table Text Block] Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding EX-101.PRE 10 tbio-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
DOCUMENT AND ENTITY INFORMATION - shares
 9 Months Ended
Sep. 30, 2016
Oct. 31, 2016
Document and Entity Information [Abstract]    
Entity Registrant Name TRANSGENOMIC INC  
Entity Central Index Key 0001043961  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Document Type 10-Q  
Document Period End Date Sep. 30, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   24,786,244
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
CURRENT ASSETS:    
Cash and cash equivalents $ 71 $ 444
Accounts receivable, net 180 264
Inventories, net 36 50
Other current assets 314 537
Assets held for sale 265 1,987
Total current assets 866 3,282
PROPERTY AND EQUIPMENT:    
Equipment 5,592 5,593
Furniture, fixtures & leasehold improvements 1,565 1,565
Property and equipment, gross 7,157 7,158
Less: accumulated depreciation (6,985) (6,899)
Property and equipment, net 172 259
OTHER ASSETS:    
Intangibles, net 982 1,170
Other assets 58 105
Assets 2,078 4,816
CURRENT LIABILITIES:    
Current maturities of long-term debt 7,814 7,596
Accounts payable 6,273 3,781
Accrued compensation 225 321
Accrued expenses 2,704 3,734
Deferred revenue 176 217
Other liabilities 1,068 1,068
Liabilities held for sale 0 264
Total current liabilities 18,260 16,981
LONG TERM LIABILITIES:    
Common stock warrant liability 1,430 350
Other long-term liabilities 212 305
Total liabilities 19,902 17,636
STOCKHOLDERS’ DEFICIT:    
Convertible preferred stock, $0.01 par value, 15,000,000 shares authorized, 214,705 and 4,029,502 shares issued and outstanding, respectively 2 40
Common stock, $0.01 par value, 150,000,000 shares authorized, 24,139,130 and 13,915,691 shares issued and outstanding, respectively 241 139
Additional paid-in capital 201,522 200,403
Accumulated other comprehensive income 0 10
Accumulated deficit (219,589) (213,412)
Total stockholders’ deficit (17,824) (12,820)
Liabilities and stockholders' equity $ 2,078 $ 4,816
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS) - $ / shares
Sep. 30, 2016
Dec. 31, 2015
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 15,000,000 15,000,000
Preferred stock, shares issued (in shares) 214,705 4,029,502
Preferred stock, shares outstanding (in shares) 214,705 4,029,502
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 150,000,000 150,000,000
Common stock, shares issued (in shares) 24,139,130 13,915,691
Common stock, shares outstanding (in shares) 24,139,130 13,915,691
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
NET SALES $ 457,000 $ 330,000 $ 1,198,000 $ 1,522,000
COST OF GOODS SOLD 430,000 445,000 1,477,000 1,375,000
Gross profit 27,000 (115,000) (279,000) 147,000
OPERATING EXPENSES:        
Selling, general and administrative 1,252,000 1,686,000 4,392,000 5,398,000
Research and development 393,000 455,000 1,065,000 1,374,000
Operating Expenses 1,645,000 2,141,000 5,457,000 6,772,000
OPERATING LOSS FROM CONTINUING OPERATIONS (1,618,000) (2,256,000) (5,736,000) (6,625,000)
OTHER INCOME (EXPENSE):        
Interest expense, net (285,000) (174,000) (782,000) (550,000)
Warrant revaluation 12,000 385,000 357,000 (30,000)
Other, net (1,000) (6,000) (1,000) (19,000)
Other Income (Expense) (274,000) 205,000 (426,000) (599,000)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES (1,892,000) (2,051,000) (6,162,000) (7,224,000)
INCOME TAX BENEFIT 0 0 0 (1,000)
LOSS FROM CONTINUING OPERATIONS (1,892,000) (2,051,000) (6,162,000) (7,223,000)
LOSS FROM DISCONTINUED OPERATIONS, NET OF TAXES (34,000) (5,248,000) (25,000) (6,392,000)
NET LOSS (1,926,000) (7,299,000) (6,187,000) (13,615,000)
PREFERRED STOCK DIVIDENDS 0 (331,000) (21,000) (993,000)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS $ (1,926,000) $ (7,630,000) $ (6,208,000) $ (14,608,000)
BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE) $ (0.08) $ (0.55) $ (0.28) $ (1.24)
BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES) 23,551,869 13,763,240 21,896,943 11,784,583
Continuing operations        
OTHER INCOME (EXPENSE):        
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS $ (1,892,000) $ (2,382,000) $ (6,183,000) $ (8,216,000)
BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE) $ (0.08) $ (0.17) $ (0.28) $ (0.70)
Discontinued operations        
OTHER INCOME (EXPENSE):        
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS $ (34,000) $ (5,248,000) $ (25,000) $ (6,392,000)
BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE) $ 0.00 $ (0.38) $ 0.00 $ (0.54)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Statement of Comprehensive Income [Abstract]        
Net Loss $ (1,926) $ (7,299) $ (6,187) $ (13,615)
Other comprehensive loss - foreign currency translation adjustment 0 (22) 0 (14)
Comprehensive Loss $ (1,926) $ (7,321) $ (6,187) $ (13,629)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - 9 months ended Sep. 30, 2016 - USD ($)
$ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income
Private Placement
Private Placement
Preferred Stock
Private Placement
Additional Paid-in Capital
Balance at beginning of period at Dec. 31, 2015 $ (12,820) $ 40 $ 139 $ 200,403 $ (213,412) $ 10      
Balance at beginning of period (in shares) at Dec. 31, 2015   4,029,502 13,915,691            
Increase (Decrease) in Stockholders' Equity                  
Net loss (6,187)       (6,187)        
Foreign currency translation adjustment 0       10 (10)      
Stock-based compensation 140     140          
Stock issued during period (in shares)     1,292,722         2,365,243  
Stock issued during period 500   $ 12 488     $ 543 $ 24 $ 519
Dividends on preferred stock (4,475)     (4,475)          
Conversion of preferred stock and preferred stock dividends 4,475 $ (62) $ 90 4,447          
Conversion of preferred stock and preferred stock dividends (in shares)   (6,180,040) 8,930,717            
Balance at end of period at Sep. 30, 2016 $ (17,824) $ 2 $ 241 $ 201,522 $ (219,589) $ 0      
Balance at end of period (in shares) at Sep. 30, 2016   214,705 24,139,130            
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
CASH FLOWS USED IN OPERATING ACTIVITIES:    
NET LOSS $ (6,187) $ (13,615)
Less loss from discontinued operations, net of tax (25) (6,392)
Loss from continuing operations (6,162) (7,223)
Adjustments to reconcile net loss to net cash flows used in operating activities:    
Depreciation and amortization 264 343
Stock-based compensation 111 489
Provision for losses on doubtful accounts 72 0
Warrant revaluation (357) 30
Loss on sale of fixed assets 0 14
Deferred interest 47 61
Deferred tax provision 0 0
Changes in operating assets and liabilities:    
Accounts receivable 12 158
Inventories 14 0
Other current assets 280 (214)
Accounts payable 2,492 (162)
Accrued expenses and other liabilities (728) 78
Net cash used in continuing operations (3,955) (6,426)
Net cash provided by (used in) discontinued operations 381 (3,010)
Net cash used in operating activities (3,574) (9,436)
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:    
Purchases of property and equipment (19) (280)
Other assets (27) (9)
Net cash used in continuing operations (46) (289)
Net cash provided by discontinued operations 1,052 1,910
Net cash provided by investing activities 1,006 1,621
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:    
Principal payments on capital lease obligations (2) (35)
Issuance of preferred stock, net 1,779 0
Issuance of common stock, net 468 8,977
Proceeds from borrowings 500 923
Principal payment on note payable (550) (874)
Net cash flows provided by financing activities 2,195 8,991
EFFECT OF FOREIGN CURRENCY EXCHANGE RATE CHANGES ON CASH 0 2
NET CHANGE IN CASH AND CASH EQUIVALENTS (373) 1,178
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 444 1,609
CASH AND CASH EQUIVALENTS AT END OF PERIOD 71 2,787
Cash paid during the period for:    
Interest $ 0 $ 365
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
BUSINESS DESCRIPTION
 9 Months Ended
Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS DESCRIPTION
BUSINESS DESCRIPTION
Business Description.

Transgenomic, Inc. (“we”, “us”, “our”, the “Company” or “Transgenomic”) is a biotechnology company advancing personalized medicine for the detection and treatment of cancer and inherited diseases through our proprietary molecular technologies and clinical and research services. A key goal is to bring our Multiplexed ICE COLD-PCR (“MX-ICP”) product to the clinical market through strategic partnerships and licensing agreements, enabling the use of blood and other bodily fluids for more effective and patient-friendly diagnosis, monitoring and treatment of cancer.

MX-ICP is technology proprietary to Transgenomic. It is a reagent that improves the ability to detect genetic mutations. This technology has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing and Digital PCR. By enhancing the level of detection of genetic mutations and suppressing the normal or wild-type DNA, several benefits are provided.

Historically, our operations were organized and reviewed by management along our major product lines and presented in two business segments: Laboratory Services and Genetic Assays and Platforms. Beginning with the quarter ended September 30, 2015, our operations are now organized as one business segment, our Laboratory Services segment, and during the second half of 2015, we began presenting our Genetic Assays and Platforms segment and a portion of our Laboratory Services segment in discontinued operations.

Our current Laboratory Services business consists of our laboratory in Omaha, Nebraska, which is focused on providing genetic analytical services related to Oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. Our laboratory employs a variety of genomic testing service technologies, including our proprietary MX-ICP technology. Our laboratory in Omaha is certified under the Clinical Laboratory Improvement Amendments (“CLIA”) as a high complexity laboratory and is accredited by the College of American Pathologists.

Our condensed consolidated balance sheets, statements of operations and statements of cash flows for all periods presented reflect our former Genetic Assays and Platforms activities and Patient Testing business as discontinued operations (See Note 3 - “Discontinued Operations”).

Going Concern.

The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (“GAAP”) applicable for a going concern, which assume that we will realize our assets and discharge our liabilities in the ordinary course of business. We have incurred substantial operating losses and have used cash in our operating activities for the past few years. As of September 30, 2016, we had negative working capital of $17.4 million. Our ability to continue as a going concern is dependent upon a combination of generating additional revenue, improving cash collections, potentially selling underutilized assets and, if necessary, raising additional financing to meet our obligations and pay our liabilities arising from normal business operations when they come due. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. We cannot be certain that additional financing will be available on acceptable terms, or at all, and our failure to raise capital when needed could limit our ability to continue our operations.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation.
The accompanying condensed consolidated financial statements are presented in conformity with GAAP. All amounts are presented in U.S. Dollars (“$”). Supplemental cash flows from discontinued operations are presented in Note 3 - “Discontinued Operations”. We have evaluated events occurring subsequent to September 30, 2016 for potential recognition or disclosure in the consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.
The condensed consolidated balance sheet as of December 31, 2015 was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2015. The accompanying condensed consolidated financial statements as of and for the three and nine months ended September 30, 2016 and 2015 are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2015 contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on April 14, 2016. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2016.
Certain prior year amounts have been reclassified to conform to the current year presentation in our condensed consolidated financial statements, which consists of the effects of reclassifications from the presentation of our discontinued operations.
Principles of Consolidation.
The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.
Risks and Uncertainties.
Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.
Use of Estimates.
The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. In addition, estimates and assumptions associated with the determination of the fair value of certain assets and related impairments require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these condensed consolidated financial statements.
Fair Value.
Unless otherwise specified, book value approximates fair market value. The common stock warrant liability is recorded at fair value. See Note 9 - “Fair Value” for additional information.
Cash and Cash Equivalents and Other Current Assets.
Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less. Other current assets as of September 30, 2016 of $0.3 million include prepaid assets of $0.1 million and other receivables of $0.2 million.
Concentrations of Cash.
From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits. We have not experienced any losses on such accounts as of September 30, 2016.
Accounts Receivable.
The following is a summary of activity for the allowance for doubtful accounts from continuing operations during the three and nine months ended September 30, 2016 and 2015: 
 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended September 30, 2016
$
157

 
$
2

 
$
(19
)
 
$
140

Three Months Ended September 30, 2015
$
20

 
$
50

 
$
—

 
$
70

Nine Months Ended September 30, 2016
$
87

 
$
72

 
$
(19
)
 
$
140

Nine Months Ended September 30, 2015
$
20

 
$
50

 
$
—

 
$
70


While payment terms are generally 30 days, we have also provided extended payment terms in certain cases. Accounts receivable are carried at original invoice amount and shown net of allowance for doubtful accounts. The estimate made for doubtful accounts is based on a review of all outstanding amounts on a quarterly basis. We determine the allowance for doubtful accounts by regularly evaluating individual payor receivables and considering a payor’s financial condition, credit history, reimbursement rates and current economic conditions. Accounts receivable are written off when deemed uncollectible and after all collection efforts have been exhausted. Recoveries of accounts receivable previously written off are recorded as a reduction in bad debt expense when received.
Inventories.
Inventories are stated at the lower of cost or market net of allowance for obsolete inventory. Cost is computed using standard costs for finished goods and average or latest actual cost for raw materials and work in process, which approximates the first-in, first-out (FIFO) method. At September 30, 2016, our net inventories were less than $0.1 million and were comprised predominantly of raw materials.
 
The following is a summary of activity for the allowance for obsolete inventory during the three and nine months ended September 30, 2016 and 2015: 
 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended September 30, 2016
$
63

 
$
—

 
$
—

 
$
63

Three Months Ended September 30, 2015
$
—

 
$
—

 
$
—

 
$
—

Nine Months Ended September 30, 2016
$
63

 
$
—

 
$
—

 
$
63

Nine Months Ended September 30, 2015
$
—

 
$
—

 
$
—

 
$
—


We determine the allowance for obsolescence by evaluating inventory quarterly for items deemed to be slow moving or obsolete.
Property and Equipment.
Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets as follows:
 
Leasehold improvements
1 to 10 years
Furniture and fixtures
3 to 7 years
Production equipment
3 to 7 years
Computer equipment
3 to 7 years
Research and development equipment
2 to 7 years

Depreciation expense in continuing operations related to property and equipment was less than $0.1 million for each of the three month periods ended September 30, 2016 and 2015. Depreciation expense was $0.1 million and $0.2 million for the nine month periods ended September 30, 2016 and 2015, respectively. Depreciation expense during each period includes depreciation related to equipment acquired under capital leases.
Intangible Assets.
Intangible assets include intellectual property and patents.
1. Intellectual Property.    Initial costs paid to license intellectual property from independent third parties are capitalized and amortized using the straight-line method over the license period. Ongoing royalties related to such licenses are expensed as incurred.
2. Patents.    We capitalize legal costs, filing fees and other expenses associated with obtaining patents on new discoveries and amortize these costs using the straight-line method over the shorter of the legal life of the patent or its economic life beginning on the date the patent is issued.
Stock-Based Compensation.
All stock-based awards to date have exercise prices equal to the market value of the shares at the date of grant and have 10-year contractual terms. Unvested awards as of September 30, 2016 had vesting periods of up to three years from the date of grant. None of the awards outstanding at September 30, 2016 are subject to performance or market-based vesting conditions.
We measure and recognize compensation expense for all stock-based awards made to employees and directors. Compensation expense, net of estimated forfeitures, is based on the calculated fair value of the awards as measured at the grant date and is expensed over the service period of the awards.
During the three and nine months ended September 30, 2016, we recorded compensation expense for all stock awards of zero and $0.1 million, respectively, within selling, general and administrative expense. During the three and nine months ended September 30, 2015, we recorded compensation expense for all stock awards of $0.2 million and $0.5 million, respectively. As of September 30, 2016, the unrecognized compensation expense related to unvested stock awards was $0.1 million, which is expected to be recognized over a weighted-average period of 1.1 years.
We granted stock options to purchase an aggregate of 11,250 and 25,250 shares of our common stock during the three and nine months ended September 30, 2016, respectively. The fair value of the stock options granted during the year was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions: risk-free interest rates of 1.56% based on the U.S. Treasury yield in effect at the time of grant; dividend yields of zero percent; expected lives of 6.00 years, based on expected exercise activity behavior; and volatility of 85% based on the historical volatility of our common stock over a time that is consistent with the expected life of the options.
Included in our stock awards outstanding as of September 30, 2016 were stock appreciation rights (“SARs”) to purchase 98,333 shares of our common stock. The SARs were issued solely to our executive officers and will vest over three years from the date of grant.
Net Sales Recognition.
Revenue is realized and earned when all of the following criteria are met:
•
Persuasive evidence of an arrangement exists;
•
Delivery has occurred or services have been rendered;
•
The seller’s price to the buyer is fixed or determinable; and
•
Collectability is reasonably assured.

In our Biomarker Identification laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year. At each of September 30, 2016 and December 31, 2015, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue was $0.2 million.

Net sales from Patient Testing laboratories, reported as part of discontinued operations, are recognized on an individual test basis and take place when the test report is completed, reviewed and sent to the client less the reserve for insurance, Medicare and Medicaid contractual adjustments. There are no deferred net sales associated with our Patient Testing services. Adjustments to the allowances, based on actual receipts from third party payers, are reflected in the estimated contractual allowance applied prospectively. In the fourth quarter of 2015, we adjusted our contractual allowance rates to better reflect the reimbursement level we expect to achieve on Patient Testing billings. The adjustment negatively impacted our Patient Testing revenues for all periods after the third quarter of 2015. (See Note 3 - “Discontinued Operations”).

Net sales of Genetic Assays and Platforms products, reported as discontinued operations (See Note 3 - “Discontinued Operations”) are recognized in accordance with the terms of the sales arrangement. Such recognition is based on receipt of an unconditional customer order and transfer of title and risk of ownership to the customer, typically upon shipment of the product under a purchase order. Our sales terms do not provide for the right of return unless the product is damaged or defective. Net sales from certain services associated with the analytical instruments, to be performed subsequent to shipment of the products, is deferred and recognized when the services are provided. Such services, mainly limited to installation and training services that are not essential to the functionality of the instruments, typically are performed in a timely manner subsequent to shipment of the instrument. We also enter into various service contracts that cover installed instruments. These contracts cover specific time periods and net sales associated with these contracts are deferred and recognized ratably over the service period.
Common Stock Warrants.
Certain of our issued and outstanding warrants to purchase common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability (“Common Stock Warrant Liability”). We are required to present these instruments at fair value at each reporting date and any changes in fair values are recorded as an adjustment to earnings. The Common Stock Warrant Liabilities are considered Level Three financial instruments for purposes of fair value measurement. See Note 9 - “Fair Value” for additional information.
Loss Per Share.
Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to 10,701,453 and 10,392,728 shares of our common stock have been excluded from the computation of diluted loss per share at September 30, 2016 and 2015, respectively, because the effect is anti-dilutive due to the net loss.
Recent Accounting Pronouncements.
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“ASU No. 2014-09”). This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year. As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40)(“ASU No. 2014-15”). This guidance addresses management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted. We do not expect to early adopt this guidance and do not believe that the adoption of this guidance will have a material impact on our consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016; however, early adoption is permitted. We do not expect to early adopt this guidance and are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
DISCONTINUED OPERATIONS
 9 Months Ended
Sep. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATIONS
DISCONTINUED OPERATIONS

On September 8, 2015, we entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Edge BioSystems, Inc. (“Edge Bio”), pursuant to which we sold our manufacturing, marketing and selling of high quality polymer and silica based beads and resin and chromatography columns business (collectively, the “Columns Business”). The Columns Business was part of our former segment, Genetic Assays and Platforms. Pursuant to the Asset Purchase Agreement, Edge Bio acquired substantially all of the assets used solely in connection with the Columns Business and assumed certain liabilities of the Columns Business for a total cash purchase price of approximately $2.1 million (the “Asset Sale”), which was paid on September 8, 2015 upon the closing of the Asset Sale. During the year ended December 31, 2015, we recorded a gain on the sale of the Columns Business of $1.5 million.

On November 25, 2015, we entered into an Asset Purchase Agreement (the “Purchase Agreement”) with ADSTEC Corporation (“ADSTEC”) and ADS Biotec Inc., a wholly-owned subsidiary of ADSTEC (“Buyer”), pursuant to which we sold (1) to ADSTEC our facilities located in Glasgow, Scotland and on Irvington Road in Omaha, Nebraska (together, the “Facilities”) and all of our stock, inventory and raw materials located at the Facilities (collectively, the “Inventory”), and (2) to Buyer (a) all of the remaining assets relating to our Genetic Assays and Platforms business segment (the “Business”), other than the Inventory (the “Purchased Assets”), and (b) all of the ordinary shares of Transgenomic Limited, a wholly-owned subsidiary of ours (the “Shares”).

Pursuant to the Purchase Agreement, ADSTEC and Buyer acquired the Facilities, the Inventory, the Purchased Assets and the Shares for an aggregate purchase price of approximately $300,000, and Buyer assumed our financial and human resources commitments related to the Business (the “Transaction”). During the year ended December 31, 2015, we recorded a loss on the Transaction of $1.7 million.

Together, the Asset Sale and the Transaction represent the divestiture of our Genetic Assays and Platforms business, resulting in a strategic shift that had a major effect on our operations and financial results. Therefore, the divested operations of our Genetic Assays and Platforms business meet the criteria to be reported as discontinued operations.
During the fourth quarter of 2015, our Board of Directors took actions to begin the process of divesting our Patient Testing business in New Haven, Connecticut. In March 2016, we announced that we had suspended testing services in our Patient Testing laboratory as we review and evaluate various strategic alternatives for that business. As a result of these actions, as of December 31, 2015, our Patient Testing business met the criteria to be reported as discontinued operations. We anticipate that we will complete the divestiture of the Patient Testing business during 2016.
The related assets, liabilities, results of operations and cash flows for both the Genetic Assays and Platforms business and Patient Testing business are classified as assets held for sale, liabilities held for sale and discontinued operations for all periods presented.
Results of the discontinued operations consisted of the following:
 
Three months ended September 30,
 
Nine months ended September 30,
(Dollars in thousands)
2016
 
2015
 
2016
 
2015
Net sales
$
283

 
$
5,507

 
$
1,960

 
$
17,868

Cost of goods sold
57

 
3,203

 
1,251

 
9,980

Gross profit
226

 
2,304

 
709

 
7,888

Selling, general and administrative expense
252

 
1,910

 
1,621

 
8,325

Research and development expense
98

 
106

 
166

 
330

Impairment of long-lived assets
—

 
7,024

 
—

 
7,024

Operating income (loss) from discontinued operations
(124
)
 
(6,736
)
 
(1,078
)
 
(7,791
)
Gain on sale of business/assets
90

 
1,532

 
1,053

 
1,532

Income (loss) from discontinued operations before income taxes
(34
)
 
(5,204
)
 
(25
)
 
(6,259
)
Income tax expense
—

 
44

 
—

 
133

Income (loss) from discontinued operations, net of taxes
$
(34
)
 
$
(5,248
)
 
$
(25
)
 
$
(6,392
)


The loss from discontinued operations for the nine month period ended September 30, 2016, includes approximately $1.1 million in proceeds received from the sale of assets of our discontinued Patient Testing business.
Assets and liabilities of the discontinued operations are classified as assets held for sale and liabilities held for sale in the condensed consolidated balance sheets and consisted of the following:
 
Dollars in Thousands
 
September 30,
2016
 
December 31,
2015
ASSETS
 
 
 
Accounts receivable, net
$
244

 
$
1,905

Other current assets
21

 
82

Total Assets
$
265

 
$
1,987

 
 
 
 
LIABILITIES
 
 
 
Accrued compensation
$
—

 
$
264

Total Liabilities
$
—

 
$
264

 
 
 
 

The following is a summary of activity for the allowance for doubtful accounts from discontinued operations during the three and nine months ended September 30, 2016 and 2015. The allowance for doubtful accounts from discontinued operations is included in the assets held for sale in the condensed consolidated balance sheets.
 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended September 30, 2016
$
10,462

 
$
—

 
$
(5,192
)
 
$
5,270

Three Months Ended September 30, 2015
$
8,406

 
$
1,052

 
$
(168
)
 
$
9,290

Nine Months Ended September 30, 2016
$
14,664

 
$
—

 
$
(9,394
)
 
$
5,270

Nine Months Ended September 30, 2015
$
7,927

 
$
3,782

 
$
(2,419
)
 
$
9,290
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
INTANGIBLES AND OTHER ASSETS
 9 Months Ended
Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLES AND OTHER ASSETS
INTANGIBLES AND OTHER ASSETS
We review our amortizable long-lived assets for impairment annually or whenever events indicate that the carrying amount of the asset (group) may not be recoverable. An impairment loss may be needed if the sum of the future undiscounted cash flows is less than the carrying amount of the asset (group). The amount of the loss would be determined by comparing the fair market value of the asset to the carrying amount of the asset (group).
Long-lived intangible assets as of September 30, 2016 and December 31, 2015 consisted of the following:
 
Dollars in Thousands
 
September 30, 2016
 
Cost
 
Accumulated
Amortization
 
Net Book
Value
Patents
680

 
80

 
600

Intellectual property
672

 
290

 
382

 
$
1,352

 
$
370

 
$
982




 
Dollars in Thousands
 
December 31, 2015
 
Cost
 
Accumulated
Amortization
 
Net Book
Value
Patents
980

 
274

 
706

Intellectual property
671

 
207

 
464

 
$
1,651

 
$
481

 
$
1,170


 
 
 
Estimated Useful Life
Patents
Life of the patent
Intellectual property
7 years

Other assets include U.S. security deposits and deferred tax assets, net of applicable valuation allowances.
Amortization expense for intangible assets was $0.2 million and $0.1 million during the nine month periods ended September 30, 2016 and 2015, respectively. Amortization expense for intangible assets is expected to be $0.1 million for each of the years ending December 31, 2016, 2017, 2018, 2019 and 2020.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
DEBT
 9 Months Ended
Sep. 30, 2016
Debt Disclosure [Abstract]  
DEBT
DEBT
 
 
Dollars in Thousands
 
 
September 30, 2016
 
December 31, 2015
Revolving Line of Credit(1)
 
$
3,243

 
$
3,025

Term Loan(2)
 
4,000

 
4,000

Convertible Promissory Notes (3)
 
571

 
571

Total debt
 
7,814

 
7,596

Current portion of long-term debt
 
(7,814
)
 
(7,596
)
Long-term debt, net of current maturities
 
$
—

 
$
—

 
(1)
Revolving Line of Credit. Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) 6.25% or (b) the Wall Street Journal prime rate plus 3%. The current interest rate is 6.50%. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of $20,000 on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line. In addition, a fee of 0.5% per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on November 1, 2017.

(2)
Term Loan. We received $4.0 million under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is 9.1%.

We will pay the Lenders an additional final payment of $120,000 at maturity or prepayment of the Term Loan. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of 1% of the total outstanding balance under the Term Loan.

Additional Terms.
The Loan Agreement contains affirmative and negative covenants. Under the Term Loan, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders’ consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of September 30, 2016, we were not in compliance with the Loan Agreement, as amended by the Ninth Amendment, due to the fact that we did not make the required monthly interest payments during the third quarter and have not received a waiver for the non-compliance and as such all debt has been classified as current at September 30, 2016.

To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by 5% and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. As of the date these financials were available for release, the Lenders have not exercised the remedies under the Loan Agreement.

(3) Convertible Promissory Notes. The Notes accrue interest at a rate of 6% per year and mature on December 31, 2016.

Revolving Line and Term Loan.

On March 13, 2013 (the “Effective Date”), we entered into a Loan and Security Agreement with affiliates of Third Security, LLC (the “Lenders”) for (a) a revolving line of credit (the “Revolving Line”) with borrowing availability of up to $4.0 million, subject to reduction based on our eligible accounts receivable, and (b) a term loan (the “Term Loan” and, together with the Revolving Line, the “Loan Agreement”) of $4.0 million. Proceeds were used to pay off a three year senior secured promissory note payable to PGxHealth, LLC, which was entered into on December 29, 2010 in conjunction with our acquisition of the FAMILION family of genetic tests, and for general corporate and working capital purposes.
On August 2, 2013, we entered into an amendment to the Loan Agreement (the “Amendment”). The Amendment, which became effective as of June 30, 2013, reduced our future minimum revenue covenants under the Loan Agreement and modified the interest rates applicable to the amounts advanced under the Revolving Line.

On November 14, 2013, we entered into a second amendment to the Loan Agreement (the “Second Amendment”). The Second Amendment, which became effective as of October 31, 2013, reduced our future minimum revenue covenants under the Loan Agreement.

On January 27, 2014, we entered into a third amendment to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment, the Lenders agreed to waive certain events of default under the Loan Agreement, and the parties amended certain provisions of the Loan Agreement, including the minimum liquidity ratio that we must maintain during the term of the Loan Agreement.

On March 3, 2014, we entered into a fourth amendment to the Loan Agreement (the “Fourth Amendment”). Pursuant to the terms of the Fourth Amendment, we were not required to make any principal or interest payments under the Term Loan for the period from March 1, 2014 through March 31, 2015. The interest on the debt that was deferred and not paid was capitalized as part of the Term Loan. The amount of interest that was capitalized from March 1, 2014 to March 31, 2015 was $0.4 million.

On October 22, 2014, we entered into a fifth amendment to the Loan Agreement (the “Fifth Amendment”). Pursuant to the Fifth Amendment, the parties amended certain provisions of the Loan Agreement, including reducing the minimum liquidity and revenue covenants under the Loan Agreement. The Fifth Amendment also reduced the aggregate amount that we may borrow under the Revolving Line from $4.0 million to $3.0 million.

On April 1, 2015, we entered into a sixth amendment to the Loan Agreement (the “Sixth Amendment”). Pursuant to the Sixth Amendment, among other things, (a) the Lenders waived specified events of default under the terms of the Loan Agreement, (b) commencing April 1, 2015, we began making monthly interest payments with respect to the Term Loan to the Lenders, (c) we were not be obligated to make monthly payments of principal under the Term Loan to the Lenders until April 1, 2016, (d) we made an initial prepayment of a portion of the Term Loan balance in the amount of approximately $148,000 on April 1, 2015 and will make one or more additional prepayments to the Lenders under the Loan Agreement upon the occurrence of certain events, as defined in the Loan Agreement, and (e) we were not required to comply with the minimum liquidity ratio under the terms of the Loan Agreement until the earliest to occur of a specified event, as defined in the Loan Agreement, or March 31, 2016. The Sixth Amendment also extends the time period in which we must provide certain reports and statements to the Lenders and amends the circumstances pursuant to which we may engage in certain sales or transfers of our business or property without the consent of the Lenders.
As of June 30, 2015, we were in compliance with all financial covenants of the Loan Agreement, but were not in compliance with the restrictions limiting the amount that we may borrow under the Revolving Line. Accordingly, on August 10, 2015, we received a waiver from the Lenders relating to this non-compliance and paid the Lenders an aggregate of $0.7 million, which brought us back into compliance with the terms of the Revolving Line.

On September 4, 2015, we entered into a seventh amendment to the Loan Agreement (the “Seventh Amendment”). The Seventh Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) reduced our borrowing availability under the Revolving Line to approximately $2.3 million, and (d) limited our borrowing base under the Loan Agreement to the amount of the Revolving Line.

On January 6, 2016, we entered into an eighth amendment to the Loan Agreement (the “Eighth Amendment”). The Eighth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) reduced our future minimum revenue covenants under the Loan Agreement, (c) extended the maturity date of the Loan Agreement until November 1, 2017, and (d) provided for the repayment of an overadvance of $750,000 previously provided by the Lenders to us pursuant to the Loan Agreement.

On June 6, 2016, we entered into a ninth amendment to the Loan Agreement (the “Ninth Amendment”). The Ninth Amendment, among other things, (a) provided that the Lenders waived specified events of default under the terms of the Loan Agreement, (b) amended the prepayment terms of the Loan Agreement, (c) provided for the reduction of amounts available under the Revolving Line upon the prepayment or repayment of certain amounts by us, (d) removed the minimum liquidity ratio and minimum net revenue financial covenants applicable to us under the Loan Agreement, (e) amended the circumstances pursuant to which we may engage in certain sales or transfers of our business or property without the consent of the Lenders, and (f) capitalized certain amounts owed by us to the Lenders and added such overdue amounts to the outstanding principal amount of the Revolving Line.
 
As a result of the Ninth Amendment, the overadvance that existed at March 31, 2016 was added to the outstanding principal amount of the Revolving Line and no overadvance existed as of September 30, 2016.

Convertible Promissory Notes.

On December 31, 2014, we entered into an Unsecured Convertible Promissory Note Purchase Agreement (the “Note Purchase Agreement”) with an accredited investor (the “Investor”), pursuant to which we agreed to issue and sell to the Investor in a private placement an unsecured convertible promissory note (the “Initial Note”). We issued the Initial Note in the aggregate principal amount of $750,000 to the Investor on December 31, 2014. Pursuant to the terms of the Initial Note, interest accrued at a rate of 6% per year and the Initial Note was set to mature on December 31, 2016. Under the Initial Note, the outstanding principal and unpaid interest accrued was convertible into shares of our common stock as follows: (i) commencing upon the date of issuance of the Initial Note (but no earlier than January 1, 2015), the Investor was entitled to convert, on a one-time basis, up to 50% of the outstanding principal and unpaid interest accrued under the Initial Note, into shares of our common stock at a conversion price equal to the lesser of (a) the average closing price of the common stock on the principal securities exchange or securities market on which our common stock is then traded (the “Market”) for the 20 consecutive trading days immediately preceding the date of conversion, and (b) $2.20 (subject to adjustment for stock splits, stock dividends, other distributions, recapitalizations and the like); and (ii) commencing February 15, 2015, the Investor was entitled to convert, on a one-time basis, any or all of the remaining outstanding principal and unpaid interest accrued under the Initial Note, into shares of our common stock at a conversion price equal to 85% of the average closing price of our common stock on the Market for the 15 consecutive trading days immediately preceding the date of conversion. The Initial Note has been converted in full into 502,786 shares of our common stock, in accordance with the terms of the Initial Note.

On January 15, 2015, we entered into the Note Purchase Agreement with seven accredited investors (the “Additional Investors”) and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, notes (the “Additional Notes”) in an aggregate principal amount of $925,000. The Additional Notes have the same terms and conditions as the Initial Note. As of September 30, 2016, $400,000 of the aggregate principal amount of the Additional Notes, and accrued interest thereon, has been converted into an aggregate of 281,023 shares of our common stock.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES
We are subject to a number of claims of various amounts that arise out of the normal course of our business. In our opinion, the disposition of pending claims, in excess of recorded accruals, could have a material adverse effect on our financial position, results of operations or cash flows. On February 25, 2016, the Board of Regents of the University of Nebraska (“UNMC”) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of $0.7 million owed by us to UNMC. We and UNMC are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A $0.7 million liability has been recorded at December 31, 2015 and September 30, 2016.
In addition, on April 13, 2016, Fox Chase Cancer Center (“Fox Chase”) filed a lawsuit against us in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the “Court of Common Pleas”), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement we entered into with Fox Chase in August 2000, as amended (the “License Agreement”), as well as the assignment of certain of our rights under the License Agreement to Integrated DNA Technologies, Inc. (“IDT”) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement we entered into with IDT effective as of July 1, 2014 (the “IDT Agreement”). Pursuant to the terms of the IDT Agreement, we agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained our preliminary objections to several of Fox Chase’s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney’s fees.  Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remain pending against us. We believe that we have good and substantial defenses to the claims asserted by Fox Chase. We are unable to determine whether any loss will occur or to estimate the range of such potential loss; therefore, no amount of loss has been accrued by us as of the date of filing of this Quarterly Report on Form 10-Q. Furthermore, there is no guarantee that we will prevail in this suit or receive any damages or other relief if we do prevail.
On June 23, 2016, the Icahn School of Medicine at Mount Sinai (“Mount Sinai”) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of $0.7 million owed by us to Mount Sinai for services rendered. We and Mount Sinai are currently in discussions to determine a mutually agreeable means by which to settle the outstanding liability. A $0.7 million liability has been recorded at December 31, 2015 and September 30, 2016.
The outcome of legal proceedings and claims brought against us are subject to significant uncertainty. Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts in excess of management’s expectations, our financial statements for such reporting period could be materially adversely affected. In general, the resolution of a legal matter could prevent us from offering our services or products to others, could be material to our financial condition or cash flows, or both, or could otherwise adversely affect our operating results.
We lease certain equipment, vehicles and operating facilities under non-cancellable operating leases that expire on various dates through 2022. The future minimum lease payments required under these leases are $0.2 million for the remainder of 2016, $0.7 million in 2017, $0.7 million in 2018, $0.7 million in 2019, $0.7 million in 2020 and $0.4 million thereafter. Rent expense for each of the nine month periods ended September 30, 2016 and 2015 was $0.2 million. At September 30, 2016, firm commitments to vendors totaled $0.1 million.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
INCOME TAXES
 9 Months Ended
Sep. 30, 2016
Income Tax Disclosure [Abstract]  
INCOME TAXES
INCOME TAXES

Annually, we file U.S. Federal, state and foreign income tax returns.  All U.S. Federal and most state loss carryforwards remain subject to adjustment in the event of an income tax examination.
Income tax expense from continuing operations was zero for the three and nine months ended September 30, 2016. Income tax expense was zero for the three months ended September 30, 2015 and for the nine months ended September 30, 2015, we had an income tax benefit of approximately one thousand dollars. We maintain a full valuation allowance on our net deferred tax assets, having concluded that we are not more likely than not going to realize the benefit of our deferred tax assets, including our net operating loss carryforwards.
During each of the three and nine month periods ended September 30, 2016 and 2015, there were no material changes to the liability for uncertain tax positions.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY
 9 Months Ended
Sep. 30, 2016
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS' EQUITY
STOCKHOLDERS’ EQUITY
Common Stock.

Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have 150,000,000 shares of common stock authorized for issuance.
On February 2, 2012, we entered into definitive agreements with institutional and other accredited investors and raised approximately $22.0 million in a private placement financing (the “Private Placement”), which included an aggregate of $3.0 million in convertible notes issued in December 2011 to entities affiliated with Third Security, LLC, a related party, that automatically converted into shares of our common stock and warrants to purchase such common stock on the same terms as all investors in the Private Placement. Pursuant to the purchase agreement, we issued an aggregate of 1,583,333 shares of our common stock at a price per share of $12.00, as well as five-year warrants to purchase up to an aggregate of 823,333 shares of our common stock with an exercise price of $15.00 per share. In connection with the conversion of the convertible notes issued by us to the entities affiliated with Third Security, LLC, the entities received an aggregate of 250,000 shares of our common stock and 125,000 warrants on the same terms as all investors in the Private Placement. Craig-Hallum Capital Group LLC (“Craig-Hallum”) served as the sole placement agent for the offering. In consideration for services rendered as the placement agent in the offering, we agreed to (a) pay to the placement agent cash commissions equal to $1,330,000, or 7.0% of the gross proceeds received in the offering; (b) issue to the placement agent a five-year warrant to purchase up to 31,666 shares of our common stock (representing 2% of the shares sold in the Private Placement) with an exercise price of $15.00 per share and other terms that are the same as the terms of the warrants issued in the Private Placement; and (c) reimburse the placement agent for reasonable out-of-pocket expenses, including fees paid to the placement agent’s legal counsel, incurred in connection with the offering, which reimbursable expenses were not to exceed $125,000. The costs incurred to complete the Private Placement were recorded as a reduction in equity in the amount of $1.5 million. Net proceeds from this offering were used for general corporate and working capital purposes, primarily to accelerate development of several of our key initiatives.
On January 24, 2013, we entered into a Securities Purchase Agreement with certain institutional and other accredited investors pursuant to which we: (a) sold to the investors an aggregate of 1,383,333 shares of our common stock at a price per share of $6.00 for aggregate gross proceeds of approximately $8.3 million; and (b) issued to the investors warrants to purchase up to an aggregate of 691,655 shares of our common stock with an exercise price of $9.00 per share (the “2013 Offering”). The warrants may be exercised, in whole or in part, at any time from January 30, 2013 until January 30, 2018 and contain both cash and “cashless exercise” features. Affiliates of Third Security, LLC purchased an aggregate of 500,000 shares of common stock and warrants to purchase an aggregate of 250,000 shares of common stock in the 2013 Offering on the same terms as the other investors. Net proceeds from the 2013 Offering were used for general corporate and working capital purposes.
In connection with the 2013 Offering, we entered into a registration rights agreement with the investors (the “Registration Rights Agreement”). The Registration Rights Agreement required that we file with the SEC a registration statement to register for resale the shares of common stock sold and the shares of common stock issuable upon exercise of the warrants (the “Warrant Shares”) by March 16, 2013. The registration statement was filed with the SEC on March 15, 2013 and was declared effective by the SEC on March 29, 2013.
The 2013 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of the warrants decreased from $15.00 per share to $12.96 per share and the number of shares issuable upon exercise of the warrants increased from 948,333 to 1,097,600.
On October 22, 2014, we entered into a Securities Purchase Agreement with certain accredited investors (the “October 2014 Investors”), pursuant to which we, in a private placement, issued and sold to the October 2014 Investors (the “2014 Private Placement”) an aggregate of 730,776 shares of our common stock at a price per share of $3.25 for an aggregate purchase price of approximately $2.4 million, and warrants to purchase up to an aggregate of 365,388 shares of our common stock with an initial exercise price of $4.00 per share that are exercisable for the period from April 22, 2015 through April 22, 2020. In connection with the 2014 Private Placement, we also issued a warrant to purchase up to an aggregate of 9,230 shares of our common stock to one advisor. The warrants issued in the 2014 Private Placement include both cash and “cashless exercise” features.
The 2014 Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale. The exercise price of the warrants decreased from $11.73 per share to $10.86 per share and the number of shares issuable upon exercise of the warrants increased from 1,212,665 to 1,309,785.
On December 31, 2014, we entered into the Note Purchase Agreement with the Investor pursuant to which we agreed to issue and sell the Initial Note to the Investor (the “Note Private Placement”). See Note 5 - “Debt-Convertible Promissory Notes” for additional information regarding the terms of the Initial Note. Pursuant to the terms of the Note Purchase Agreement, we are subject to certain registration obligations and we may be required to effect one or more other registrations to register for resale the shares of our common stock issued or issuable under the Initial Note in connection with certain “piggy-back” registration rights granted to the Investor.

The Note Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the February 2012 common stock and warrant sale. The exercise price of the 2012 warrants decreased from $10.86 per share to $10.25 per share and the number of shares issuable upon exercise of the warrants increased from 1,309,785 to 1,387,685.

On January 15, 2015, we entered into the Note Purchase Agreement with the Additional Investors and, on January 20, 2015, issued and sold to the Additional Investors, in a private placement, the Additional Notes in an aggregate principal amount of $925,000 (the “Additional Note Private Placement”). The Additional Notes have the same terms and conditions as the Initial Note.

Craig-Hallum acted as the sole placement agent for the sale and issuance of the Additional Notes. In connection with the sale and issuance of the Additional Notes, we issued to Craig-Hallum an unsecured convertible promissory note, upon the same terms and conditions as the Notes, in an aggregate principal amount equal to 5% of the proceeds received by us pursuant to the sale and issuance of the Additional Notes, or $46,250 (the “Placement Agent Note”). As of the date of filing of this Quarterly Report on form 10-Q, the Placement Agent Note remains outstanding.

The Additional Note Private Placement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from $10.25 per share to $9.59 per share and the number of shares issuable upon exercise of the warrants increased from 1,387,685 to 1,483,161.

On February 27, 2015, we entered into a purchase agreement with Craig-Hallum (the “Underwriter”) relating to our sale and issuance of 3,573,899 shares of our common stock and corresponding warrants to purchase up to 714,780 shares of our common stock (the “February 2015 Offering”). Each share of common stock was sold in combination with a warrant to purchase 0.20 of a share of common stock. The purchase price to the public for each share of common stock and accompanying warrant was $1.95.
The purchase price paid by the Underwriter to us for the common stock and accompanying warrants was $1.8135. The net proceeds from the February 2015 Offering, after deducting the Underwriter’s discount and other estimated February 2015 Offering expenses, were approximately $6.2 million.
The accompanying warrants are exercisable immediately upon their initial issuance date at an exercise price of $2.24 per share and will expire five years from the date of issuance. The exercise price will also be subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock.
The February 2015 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from $9.59 per share to $7.56 per share and the number of shares issuable upon exercise of the warrants increased from 1,483,161 to 1,881,396.
On June 30, 2015, we entered into a Securities Purchase Agreement with certain accredited investors (the “July 2015 Investors”) pursuant to which, on July 7, 2015, we sold to the July 2015 Investors (a) an aggregate of approximately 1.5 million shares of our common stock at a price per share of $1.42, (b) warrants (the “Series B Warrants”) to purchase up to an aggregate of 0.7 million shares of our common stock with an exercise price of $0.01 per share, and (c) warrants (the “Series A Warrants” and, together with the Series B Warrants, the “July 2015 Warrants”) to purchase up to an aggregate of 1.2 million shares of our common stock, with an exercise price of $1.66 per share (collectively, the “July 2015 Offering”). Each of the July 2015 Warrants has a term of 5 and 1/2 years. The Series B Warrants were immediately exercisable upon issuance. The Series A Warrants became exercisable on January 7, 2016, six months from the date of issuance. The aggregate gross proceeds to us from the July 2015 Offering were approximately $3.0 million.
Craig-Hallum (the “2015 Placement Agent”) served as the sole placement agent for the July 2015 Offering. In consideration for services rendered as the placement agent in the July 2015 Offering, we (a) paid to the 2015 Placement Agent cash commissions equal to approximately $212,783, or 7.0% of the gross proceeds received in the July 2015 Offering; (b) issued to the 2015 Placement Agent a five-year warrant to purchase up to 107,033 shares of our common stock with an exercise price of $1.66 per share and which is subject to other terms that are the same as the terms of the Series A Warrants; and (c) reimbursed the 2015 Placement Agent for reasonable out-of-pocket expenses, including fees paid to the 2015 Placement Agent’s legal counsel, incurred in connection with the July 2015 Offering, which reimbursable expenses did not exceed $50,000.
The July 2015 Offering required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased from $7.56 per share to $6.50 per share and the number of shares issuable upon exercise of the warrants increased from 1,881,396 to 2,188,177.
On January 6, 2016, we entered into a Securities Purchase Agreement (the “SPA”) with certain accredited investors (the “2016 Investors”), pursuant to which, on January 8, 2016, we sold to the 2016 Investors, and the 2016 Investors purchased from us (the “January 2016 Offering”), an aggregate of approximately $2.2 million of units (the “Units”) consisting of (a) an aggregate of 2,365,243 shares (the “A-1 Preferred Shares”) of our Series A-1 Convertible Preferred Stock (the “A-1 Preferred”), and (b) warrants (the “2016 Warrants”) to purchase up to an aggregate of 1,773,929 shares of our common stock. Each Unit was sold to the 2016 Investors at a purchase price of $0.93 per Unit. The A-1 Preferred Shares are convertible into shares of our common stock at an initial rate of 1-for-1, which conversion rate is subject to further adjustment as set forth in our Certificate of Designation of Series A-1 Convertible Preferred Stock, which was filed with the Secretary of State of the State of Delaware on January 8, 2016 (the “Series A-1 Certificate of Designation”). Pursuant to the terms of the Series A-1 Certificate of Designation, the holders of the A-1 Preferred Shares will generally be entitled to that number of votes as is equal to the product obtained by multiplying: (i) the number of whole shares of our common stock into which the A-1 Preferred may be converted as of the record date of such vote or consent, by (ii) 0.93, rounded down to the nearest whole number. Therefore, every 1.075269 shares of A-1 Preferred will generally initially be entitled to one vote. In May 2016, 2,150,538 of the A-1 Preferred Shares were converted into 2,150,538 shares of our common stock. At June 30, 2016, there were 214,705 A-1 Preferred Shares outstanding.

The 2016 Warrants were immediately exercisable upon issuance, have a term of five years and have an exercise price of $1.21 per share of our common stock. Each 2016 Warrant includes both cash and “cashless exercise” features and an exchange feature whereby the holder of the 2016 Warrant may exchange (the “Exchange Right”) all or any portion of the 2016 Warrant for a number of shares of our common stock equal to the quotient obtained by dividing the “Exchange Amount” by the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged (the “Exchange Price”). Under the 2016 Warrants, the “Exchange Amount” is based upon a Black Scholes option pricing model, and the aggregate Exchange Amount under all of the 2016 Warrants will be $1,436,882, subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged. Each 2016 Warrant provides that the number of shares that may be issued upon exercise of the Exchange Right is limited to the number of shares that may be purchased pursuant to the terms of the 2016 Warrant, unless we have previously obtained stockholder approval or approval from The Nasdaq Stock Market LLC to issue any additional shares of our common stock (the “Additional Shares”) pursuant to the Exchange Right (the “Required Approvals”). For any Exchange Right exercised more than 90 days following the issuance of the 2016 Warrants, if we have not obtained either of the Required Approvals, we will be required to pay the 2016 Warrant holder an amount in cash for any Additional Shares that we cannot issue without the Required Approvals based on the Exchange Amount.

The 2016 Warrants further provide that, to the extent the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged is less than $0.50, the Exchange Price will be deemed to be equal to $0.50, and, in addition to issuing shares of our common stock based on this Exchange Price, we will be required to pay to the 2016 Warrant holder an amount in cash equal to the product obtained by multiplying (a) $0.50 minus the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the 2016 Warrant holder by the Company in such exchange at an Exchange Price equal to $0.50. Therefore, if the Required Approvals are obtained, based on the Exchange Amount of $1,436,882 (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the date of the issuance of the 2016 Warrants and the date the 2016 Warrants are exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the 2016 Warrants will be 2,873,765. In addition, if, for example, assuming an Exchange Amount of $1,436,882, the closing bid price of our common stock on the second trading day prior to the date the 2016 Warrants are exchanged is $0.25, we would be required to pay to the 2016 Warrant holders cash in an aggregate amount of $718,441 in addition to issuing the 2016 Warrant holders 2,873,765 shares.

In accordance with the terms of the SPA, we amended that certain Series A Warrant to purchase up to an aggregate of 1,161,972 shares of our common stock previously issued by us to an affiliate of one of the 2016 Investors on July 7, 2015 (the “Original Warrant”), as previously reported by us on our Amendment No. 1 to Current Report on Form 8-K/A, filed with the SEC on July 7, 2015 (as so amended, the “Amended Warrant”). The Amended Warrant amends the Original Warrant to provide that the Amended Warrant is subject to the same terms and conditions as the 2016 Warrants and, therefore, includes both cash and “cashless exercise” features and an Exchange Right whereby the number of shares issuable pursuant to the Exchange Right is equal to the “Amended Warrant Exchange Amount”, which is based on a Black Scholes option pricing model, and will be $941,197, subject to adjustment to the extent that the risk-free U.S. treasury rate fluctuates between the date of issuance of the Amended Warrant and the date the Amended Warrant is exchanged. The Amended Warrant is exercisable for up to 1,161,972 shares of our common stock in the event we have obtained either of the Required Approvals with respect to the Amended Warrant. In the event the Amended Warrant holder exercises the Amended Warrant more than 90 days following the issuance of the Amended Warrant, if we have not obtained either of the Required Approvals, we will be required to pay the Amended Warrant holder an amount in cash for the shares of our common stock that we cannot issue under the Amended Warrant pursuant to such exercise without the Required Approvals based on the Amended Warrant Exchange Amount.

The Amended Warrant also provides that, to the extent the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is less than $0.50, the Exchange Price will be deemed to be equal to $0.50, and, in addition to issuing shares of our common stock based on this Exchange Price (assuming receipt of the Required Approvals), we will be required to pay to the Amended Warrant holder an amount in cash equal to the product obtained by multiplying (a) $0.50 minus the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged, by (b) the aggregate number of shares of our common stock issued to the Amended Warrant holder by us in such exchange at an Exchange Price equal to $0.50. Therefore, if the Required Approvals are obtained, based on the Amended Warrant Exchange Amount of $941,197 (which, as noted above, is subject to adjustment to the extent that the risk-free U.S. Treasury rate fluctuates between the issuance of the Amended Warrant and the date the Amended Warrant is exchanged), the maximum number of shares of our common stock issuable pursuant to the Exchange Right in the Amended Warrant will be 1,882,395. In addition, if, for example, assuming an Amended Warrant Exchange Amount of $941,197, the closing bid price of our common stock on the second trading day prior to the date the Amended Warrant is exchanged is $0.25, we would be required to pay to the Amended Warrant holder cash in an aggregate amount of $470,599 in addition to issuing the Amended Warrant holder 1,882,395 shares.

In connection with entering into the SPA, we also entered into a Registration Rights Agreement, dated January 8, 2016, with the 2016 Investors. Pursuant to the terms of the Registration Rights Agreement, we were required to file with the SEC a registration statement to register for resale the shares of our common stock issuable upon conversion of the A-1 Preferred Shares and the shares of our common stock issuable upon exercise of the 2016 Warrants and the Amended Warrant by January 25, 2016. We filed the required registration statement with the SEC on January 25, 2016.

Craig-Hallum (the “Placement Agent”) served as the sole placement agent for the January 2016 Offering. In consideration for services rendered as the Placement Agent in the January 2016 Offering, we (1) paid to the Placement Agent cash commissions equal to approximately $140,000, or 7.0% of the gross proceeds received in the January 2016 Offering, excluding any proceeds received from Third Security, LLC or any of its affiliates; (2) issued to the Placement Agent, for a price of $50, a five-year warrant to purchase up to 107,527 shares of our common stock at an exercise price of $1.21 per share (the “Agent Warrant”), which is subject to the same terms as the 2016 Warrants except that the Agent Warrant was not exercisable until July 8, 2016 and does not contain the Exchange Right; and (3) reimbursed the Placement Agent for reasonable out-of-pocket expenses, including fees paid to the Placement Agent’s legal counsel, incurred in connection with the January 2016 Offering, which reimbursable expenses did not exceed $50,000.

The January 2016 Offering and the payment of all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock in the form of shares of our common stock at a rate of $1.00 per share of our common stock discussed under “-Conversion of Preferred Stock” below required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased to $4.39 per share and the number of shares issuable upon exercise of the warrants increased from 2,188,177 to 3,239,827.

On May 31, 2016, we issued to a vendor an aggregate of 78,000 shares of our common stock and, on June 14, 2016, we issued to a second vendor an aggregate of 64,153 shares of our common stock. Such shares of common stock were issued to the vendors in lieu of an aggregate cash amount of approximately $89,000 owed by us to such vendors for services previously performed by such vendors. We issued the shares to the vendors in transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The offering of the shares to the vendors did not involve a public offering, and no general solicitation or advertisement was made in connection with the offering of the shares to the vendors.

On June 7, 2016, we entered into an At the Market Offering Agreement (the “ATM Agreement”) with Craig-Hallum, as sales agent, pursuant to which we may offer and sell, from time to time, through Craig-Hallum, up to $3,500,000 of shares (the “Shares”) of our common stock. Any Shares offered and sold in the offering will be issued pursuant to our effective shelf registration statement on Form S-3 (File No. 333-201907) and the related prospectus previously declared effective by the SEC on February 13, 2015, as supplemented by a prospectus supplement, dated June 7, 2016, that we filed with the SEC pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the “Securities Act”). The number of shares eligible for sale under the ATM Agreement will be subject to the limitations of General Instruction I.B.6 of Form S-3.

Under the terms of the ATM Agreement, we will pay Craig-Hallum a placement fee of 3.25% of the gross sales price of the Shares, unless Craig-Hallum acts as principal, in which case we may sell Shares to Craig-Hallum as principal at a price to be agreed upon by us and Craig-Hallum. We will also reimburse Craig-Hallum for certain expenses incurred in connection with the ATM Agreement, and agreed to provide indemnification and contribution to Craig-Hallum with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended.
 
During the three and nine months ended September 30, 2016, we sold 1,035,255 and 1,150,569 shares under the ATM Agreement.  For the nine months ended September 30, 2016, the average sales price per common share was $0.42 and the aggregate net proceeds from the sales totaled $0.5 million.    

During the three months ended September 30, 2016, the sale of shares under the ATM Agreement required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of these warrants decreased to $4.23 per share and the number of shares issuable upon exercise of the warrants increased from 3,262,088 to 3,362,276.
Common Stock Warrants.
During the nine months ended September 30, 2016 and 2015, we issued warrants to purchase 3,055,555 and 3,466,841 shares of common stock, respectively. None of the issued warrants were exercised during such periods. The warrants issued in the nine months ended September 30, 2016 included 1,174,099 warrants issued due to repricing requirements of the Private Placement and 1,881,456 warrants issued in connection with the January 2016 Offering. The warrants issued in the nine months ended September 30, 2015 included 800,492 warrants issued due to repricing requirements of the Private Placement and 2,666,349 warrants issued in connection with the February 2015 Offering and the July 2015 Offering. Warrants to purchase an aggregate of 8,976,354 shares of common stock were outstanding at September 30, 2016.
 
Warrant Holder
 
Issue Year
 
Expiration
 
Underlying
Shares
 
Exercise
Price
Various Institutional Holders(1)
 
2012
 
February 2017
 
2,919,043
 
$4.23
Affiliates of Third Security, LLC(1)
 
2012
 
February 2017
 
443,233
 
$4.23
Various Institutional Holders(2)
 
2013
 
January 2018
 
441,655
 
$9.00
Affiliates of Third Security, LLC(2)
 
2013
 
January 2018
 
250,000
 
$9.00
Various Institutional Holders(3)
 
2014
 
April 2020
 
374,618
 
$4.00
Various Institutional Holders(4)
 
2015
 
February 2020
 
714,780
 
$2.24
Various Institutional Holders(5)
 
2015
 
December 2020
 
122,433
 
$1.66
Various Institutional Holders(5)
 
2015
 
December 2020
 
667,164
 
$0.01
Various Institutional Holders(6)
 
2015
 
January 2021
 
1,161,972
 
$1.21
Affiliates of Third Security, LLC(7)
 
2016
 
January 2021
 
161,026
 
$1.21
Various Institutional Holders(7)
 
2016
 
January 2021
 
1,720,430
 
$1.21
 
 
 
 
 
 
8,976,354
 
 


(1)
These warrants were issued in connection with the Private Placement completed in February 2012 and are classified as a liability in our financial statements. See Note 9 - “Fair Value” for additional information. These warrants also contain certain anti-dilution provisions that provide for an adjustment to the exercise price and number of shares issuable upon exercise of the warrant in the event that we engage in certain issuances of shares of our common stock at a price lower than the exercise price of the warrant.
(2)
These warrants were issued in connection with the 2013 Offering, which was completed in January 2013.
(3)
These warrants were issued in connection with the 2014 Private Placement, which was completed in October 2014.
(4)
These warrants were issued in connection with the February 2015 Offering, which was completed in February 2015.
(5)
These warrants were issued in connection with the July 2015 Offering, which was completed in July 2015.
(6)
These warrants were originally issued in connection with the July 2015 Offering, which was completed in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.
(7)
These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.
Issuance of Series B Preferred Stock.

On March 5, 2014, we entered into a Series B Convertible Preferred Stock Purchase Agreement (the “Series B Purchase Agreement”) with affiliates of Third Security, LLC (the “2014 Third Security Investors”), pursuant to which we, in a private placement, sold and issued an aggregate of 1,443,297 shares of our Series B Preferred Stock, par value $0.01 per share (the “Series B Preferred Stock”), at a price per share of $4.85 for an aggregate purchase price of approximately $7.0 million. Each share of Series B Preferred Stock issued pursuant to the Series B Purchase Agreement was initially convertible into shares of our common stock at a rate of 1-for-1, which conversion rate was subject to further adjustment as set forth in the Certificate of Designation of Series B Convertible Preferred Stock.

In connection with the Series B financing, we also entered into a Registration Rights Agreement, dated March 5, 2014, with the 2014 Third Security Investors, pursuant to which we granted certain demand, “piggy-back” and S-3 registrations rights covering the resale of the shares of common stock underlying the Series B Preferred Stock issued pursuant to the Series B Purchase Agreement and all shares of common stock issuable upon any dividend or other distribution with respect thereto.

The Series B financing required the repricing and issuance of additional common stock warrants to the holders of warrants issued in the Private Placement. The exercise price of the warrants decreased from $12.96 per share to $11.73 per share and the number of shares issuable upon exercise of the warrants increased from 1,097,600 to 1,212,665.

Conversion of Preferred Stock.

On January 6, 2016, the Company entered into a Conversion Agreement (the “Conversion Agreement”) with the holders (the “Preferred Holders”) of all of the Company’s outstanding shares of Series A Convertible Preferred Stock, par value $0.01 per share (the “Series A Preferred Stock”), and Series B Preferred Stock, pursuant to which, among other things, the Preferred Holders: (a) elected to convert all of the outstanding shares of Series A Preferred Stock and Series B Preferred Stock into shares of our common stock, in each case in accordance with the terms thereof, and (b) agreed that all accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock would be paid by the Company in shares of our common stock at a rate of $1.00 per share of our common stock (collectively, the “Conversion”).

The outstanding shares of Series A Preferred Stock were convertible into shares of our common stock at a rate of 1-for-3, and the outstanding shares of Series B Preferred Stock were convertible into shares of our common stock at a rate of 1-for-1. Prior to the entry into the Conversion Agreement, there were 2,586,205 shares of Series A Preferred Stock outstanding, which were converted into 862,057 shares of our common stock, and 1,443,297 shares of Series B Preferred Stock outstanding, which were converted into 1,443,297 shares of our common stock, for an aggregate of 2,305,354 shares of our common stock issued upon conversion of the Series A Preferred Stock and Series B Preferred Stock (the “Conversion Shares”). At the time of the entry into the Conversion Agreement, there were $3,681,591.90 in accrued and unpaid dividends on the outstanding shares of Series A Preferred Stock, which were converted, in accordance with the Conversion Agreement, into 3,681,590 shares of our common stock, and $793,236.17 in accrued and unpaid dividends on the outstanding shares of Series B Preferred Stock, which were converted, in accordance with the terms of the Conversion Agreement, into 793,235 shares of our common stock, for an aggregate of 4,474,825 shares of our common stock issued pursuant to the accrued and unpaid dividends on the Series A Preferred Stock and Series B Preferred Stock. Therefore, in connection with the full conversion of the Series A Preferred Stock and Series B Preferred Stock, plus the conversion of all accrued and unpaid dividends thereon, we issued an aggregate of 6,780,179 shares of our common stock to the Preferred Holders on January 6, 2016.

Following the conversion of the shares of Series A Preferred Stock and Series B Preferred Stock into common stock, no shares of Series A Preferred Stock or Series B Preferred Stock remain outstanding.
Preferred Stock Dividends.
We had cumulative undeclared dividends on our Series A Preferred Stock and Series B Preferred Stock of zero and $4.4 million at September 30, 2016 and December 31, 2015, respectively. Since dividends should generally not be recognized as a liability until declared, we had a recorded liability of zero for these undeclared dividends.
We had no undeclared dividends for the three months ended September 30, 2016. For the three months ended September 30, 2015 and the nine months ended September 30, 2016 and 2015, we had undeclared dividends. In accordance with the FASB’s Accounting Standards Codification Topic 260-10-45-11, “Earnings per Share”, these dividends were added to the net loss per share calculation.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
FAIR VALUE
 9 Months Ended
Sep. 30, 2016
Fair Value Disclosures [Abstract]  
FAIR VALUE
FAIR VALUE

FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our consolidated financial statements.
FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:
Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities;
Level 2—Observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets; and
Level 3—Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.

Debt.
Our long term debt book value approximates fair market value due to the variable interest rate it bears.

Common Stock Warrant Liabilities.

Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.

2012 Warrant Liability
The 2012 Warrant Liability represents the fair value of the 1.2 million warrants issued in February 2012, which, through a series of changes in exercise price since February 2012, are now exercisable for 3.4 million shares of common stock. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our Statement of Operations. Management does not believe that this liability will be settled by a use of cash.
The 2012 Warrant Liability is considered a Level 3 financial instrument and is valued using a Monte Carlo simulation model. This method is well suited to valuing options with non-standard features, such as anti-dilution protection. A Monte Carlo simulation model uses repeated random sampling to simulate significant uncertainty in inputs. Assumptions and inputs used in the valuation of the common stock warrants are broken down into four sections: Static Business Inputs; Static Technical Inputs; Simulated Business Inputs; and Simulated Technical Inputs.
Static Business Inputs include: our equity value, which was estimated using our stock price of $0.28 as of September 30, 2016; the amount of the down-round financing; the timing of the down-round financing; and the expected exercise period of 0.41 years from the valuation date.
Static Technical Inputs include: volatility of 67% and the risk-free interest rate of 0.42% based on the 1-year U.S. Treasury yield interpolated from the six-month and one-year U.S. Treasury bonds.
Simulated Business Inputs include: the probability of down-round financing, which was estimated to be 100% for simulated equity values below the down-round financing cut-off point.
Simulated Technical Inputs include: our equity value follows a geometric Brownian motion and is simulated over weekly periods; and a down-round financing event that was randomly simulated in an iteration based on the 100% discrete probability of a down-round financing for those iterations where our simulated equity value at the expected timing of a down-round financing event was below the down-round financing cut-off point.

During the three and nine months ended September 30, 2016 and 2015, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:
 
 
Dollars in Thousands
 
 
For the Three Months Ended
 
 
September 30, 2016
 
September 30, 2015
Beginning balance at July 1
 
$
—

 
$
560

Total (gains) or losses:
 

 
 
Recognized in earnings
 
—

 
(385
)
Balance at September 30
 
$
—

 
$
175


 
 
Dollars in Thousands
 
 
For the Nine Months Ended
 
 
September 30, 2016
 
September 30, 2015
Beginning balance at January 1
 
$
350

 
$
145

Total (gains) or losses:
 
 
 
 
Recognized in earnings
 
(350
)
 
30

Balance at September 30
 
$
—

 
$
175



2016 Warrant Liability
The 2016 Warrant Liability represents the fair value of the 1.8 million warrants issued in January 2016. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our Statement of Operations.
The Common Stock Warrant Liability is considered a Level 3 financial instrument and is valued using a binomial lattice simulation model. This method is well suited to valuing options with non-standard features. Assumptions and inputs used in the valuation of the common stock warrants include; our equity value, which was estimated using our stock price of $0.28 as of September 30, 2016; volatility of 86%; and a risk-free interest rate of 1.04%.
During the three and nine months ended September 30, 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:
 
 
Dollars in Thousands
 
 
 
For the Three Months Ended
 
 
 
September 30, 2016
 
Beginning balance at July 1
 
$
1,442

 
Total (gains) or losses:
 
 
 
Recognized in earnings
 
(12
)
 
Balance at September 30
 
$
1,430

 
 
 
Dollars in Thousands
 
 
 
For the Nine Months Ended
 
 
 
September 30, 2016
 
Beginning balance at January 1
 
$
—

 
Additions
 
1,437

 
Total (gains) or losses:
 
 
 
Recognized in earnings
 
(7
)
 
Balance at September 30
 
$
1,430

 

The change in unrealized gains or losses of Level 3 liabilities was included in earnings and was reported in other income (expense) in our Statement of Operations.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCK OPTIONS
 9 Months Ended
Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
STOCK OPTIONS
STOCK OPTIONS
 
Stock Options.

The following table summarizes stock option activity during the nine months ended September 30, 2016:
 
 
Number of
Options
 
Weighted-Average
Exercise Price
Outstanding at January 1, 2016
1,107,794

 
$
3.45

Granted
25,250

 
0.84

Forfeited
(252,589
)
 
3.28

Outstanding at September 30, 2016
880,455

 
$
3.39

Exercisable at September 30, 2016
574,650

 
$
4.08


    
During the nine months ended September 30, 2016, we granted options to purchase 25,250 shares of our common stock at a weighted-average exercise price of $0.84 per share under our 2006 Equity Incentive Plan, as amended (the “Plan”). Options to purchase an aggregate of 641,560 shares of our common stock were granted during the nine months ended September 30, 2015.

As of September 30, 2016, there were 574,650 options exercisable and 860,411 options that were vested or expected to vest with an aggregate intrinsic value of zero.

Stock Appreciation Rights (“SARs”)

The following table summarizes SARs activity under the Plan during the nine months ended September 30, 2016:
 
Number of
SARs
 
Weighted-Average
Exercise Price
Outstanding at January 1, 2016
98,333

 
$
4.14

Outstanding at September 30, 2016
98,333

 
$
4.14

Exercisable at September 30, 2016
92,558

 
$
4.20



All outstanding SARs were issued solely to our executive officers.

As of September 30, 2016, 92,558 shares subject to outstanding SARs were exercisable and 98,333 shares were vested or expected to vest. The weighted-average exercise price of these SARs was $4.14 per share and the aggregate intrinsic value was zero.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUBSEQUENT EVENTS
 9 Months Ended
Sep. 30, 2016
Subsequent Events [Abstract]  
Subsequent Events
SUBSEQUENT EVENTS

Merger Agreement

On October 12, 2016, Transgenomic, New Haven Labs Inc., a wholly owned subsidiary of Transgenomic (“Merger Sub” and, together with Transgenomic, the “Transgenomic Parties”), and Precipio Diagnostics, LLC (“Precipio”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which Precipio will become a wholly owned subsidiary of Transgenomic (the “Merger”), on the terms and subject to the conditions set forth in the Merger Agreement. Following the Merger, Transgenomic will change its name to Precipio, Inc. (“New Precipio”). The parties expect the Merger to close in 2016.
 
When the Merger is completed, (i) each outstanding common unit of Precipio will be converted into the right to receive an amount of shares of New Precipio common stock based on an exchange ratio set forth in the Merger Agreement, which is dependent on the relative amount of outstanding liabilities of each of the parties at the time of the Merger, together with cash in lieu of fractional units, which will result in Precipio unit holders owning between 62% and 80% of the outstanding shares of New Precipio common stock (not taking into account the issuance of New Precipio preferred stock in the Merger or the private placement discussed below) and (ii) each outstanding preferred unit of Precipio will be converted into the right to receive shares of New Precipio preferred stock in an aggregate amount equal to $3 million.

In connection with the Merger, at the effective time of the Merger, New Precipio also will issue shares of New Precipio preferred stock in a private placement, whereby:

•
holders of indebtedness of Transgenomic will receive $3 million in New Precipio preferred stock in exchange for such indebtedness; and

•
New Precipio will issue for cash up to $7 million in New Precipio preferred stock to investors in a private placement.

New Precipio preferred stock will be issued based on a pre-money valuation of New Precipio of $25 million and will represent, in the aggregate, approximately 34% of the outstanding shares of New Precipio common stock on an as-converted basis, including New Precipio preferred stock issued in the Merger and the private placement.

The board of managers of Precipio and the boards of directors of Transgenomic and Merger Sub, and Transgenomic, in its capacity as the sole stockholder of Merger Sub, have each approved the Merger Agreement and the board of managers of Precipio and the board of directors of Transgenomic have each recommended that their respective equity holders approve the transactions contemplated by the Merger Agreement. Transgenomic will hold a special meeting of its stockholders to approve the issuance of shares of Transgenomic common stock pursuant to the Merger, as required by Nasdaq Listing Rules, as well as certain other matters (the “Special Meeting”).
 
The Merger Agreement contains various representations, warranties and covenants of the Transgenomic Parties and Precipio, including, among others, covenants (i) by each of Precipio and Transgenomic to operate its business in the ordinary course, (ii) by each of Precipio and Transgenomic not to engage in certain kinds of transactions during the period between the execution of the Merger Agreement and the completion of the Merger, (iii) by Precipio to have its members approve the Merger and (iv) by Transgenomic to hold the Special Meeting.
 
Under the Merger Agreement, Precipio and Transgenomic are subject to customary “no shop” provisions that limit their respective abilities to solicit alternative acquisition proposals from third parties or to provide confidential information to third parties, subject to a “fiduciary out” provision that allows Precipio and Transgenomic to provide information and participate in discussions with respect to certain unsolicited written proposals and to terminate the Merger Agreement and enter into an acquisition agreement with respect to a superior proposal in compliance with the terms of the Merger Agreement (a “Superior Proposal”).
 
Completion of the Merger is subject to various conditions, including, among others: (i) approval of the holders of a majority of Transgenomic’s shares of outstanding common stock, (ii) approval of the requisite amount of the members of Precipio, (iii) approval of an amendment to the Certificate of Incorporation of Transgenomic contemplating the New Preferred Stock Financing (described below) and changing the name of Transgenomic to Precipio, Inc. or such other name as determined by Precipio, (iv) obtaining certain third party consents, (v) the absence of any judgment, injunction, order or decree prohibiting or enjoining the completion of the Merger, (vi) consummation of the New Preferred Stock Financing, (vii) approval of listing of the Parent Common Stock on NASDAQ, (viii) completion of the Common Unit Recapitalization (described above), (ix) increase in the size of the Transgenomic board by two members and the appointment of designees in accordance with the Merger Agreement and (x) the lock-up of certain Transgenomic stockholders and Precipio members.
 
In addition, the obligation of the parties to complete the Merger is subject to certain other conditions, including (i) subject to the standards set forth in the Merger Agreement, the accuracy of the representations and warranties of the other party, (ii) compliance of each party with its covenants in all material respects and (iii) no material adverse effect of either party.
 
The Merger Agreement contains certain termination rights for both the Transgenomic Parties and Precipio. Either may terminate the Merger Agreement if the Merger is not completed on or before the date that is six months following the date of the Merger Agreement. Moreover, either party may terminate the Merger Agreement if the other party changes its recommendation to its security holders to approve the Merger and the related transactions or enter into an agreement with a third party regarding a Superior Proposal (as defined in the Merger Agreement).
 
The Merger Agreement also provides that, upon termination of the Merger Agreement under certain circumstances, Transgenomic will be required to pay to Precipio a termination payment of $256,500. If the Merger Agreement is terminated for certain other reasons, Precipio will be required to pay Transgenomic a termination payment of $256,500.
 
The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, which is attached hereto as Exhibit 2.1 and incorporated by reference herein. The Merger Agreement has been included as an exhibit hereto solely to provide investors and security holders with information regarding its terms. It is not intended to be a source of financial, business or operational information about Transgenomic, Precipio or their respective subsidiaries or affiliates. The representations, warranties and covenants contained in the Merger Agreement are made only for purposes of the Merger Agreement and are made as of specific dates; are solely for the benefit of the parties; may be subject to qualifications and limitations agreed upon by the parties in connection with negotiating the terms of the Merger Agreement, including being qualified by confidential disclosures made for the purpose of allocating contractual risk between the parties rather than establishing matters as facts; and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors or security holders. Investors and security holders should not rely on the representations, warranties and covenants or any description thereof as characterizations of the actual state of facts or condition of Transgenomic, Precipio or their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in public disclosures.
 
In connection with the Merger, the Supporting Stockholders and Supporting Members (as defined in the Merger Agreement) are obligated to enter into a lock-up agreement with the combined company at the Effective Time pursuant to which the Supporting Stockholders will agree, among other things, not to sell shares of Transgenomic common stock for the six month period beginning at the Effective Time.
 
The Merger Agreement also provides that the combined company will enter into employment agreements with certain employees of Precipio at the Effective Time and that the officers of the combined company will be agreed to by the parties prior to the Effective Time.

Special Meeting of Stockholders
At our 2016 Special Meeting of Stockholders (the “Special Meeting”) held on October 31, 2016, our stockholders approved the proposal to authorize our Board of Directors to, in its discretion, amend our Third Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio of between one-for-ten to one-for-thirty, such ratio to be determined by our Board of Directors (the “Reverse Split Proposal”). The Reverse Split Proposal was described in detail in our definitive proxy statement filed with the Securities and Exchange Commission on September 22, 2016, as supplemented on October 13, 2016.
The approval of the Reverse Split Proposal by our stockholders provides our Board of Directors with the authority to carry out the reverse stock split, but our Board of Directors is not obligated to do so. If our Board of Directors determines to effect the reverse stock split, it intends to select a reverse stock split ratio that it believes would be most likely to achieve the anticipated benefits of the reverse stock split. Notwithstanding approval of the Reverse Split Proposal by our stockholders, our Board of Directors may, in its sole discretion, abandon the Reverse Split Proposal and determine, prior to the effectiveness of any filing with the Secretary of State of the State of Delaware, not to effect the reverse stock split. If our Board of Directors fails to implement the reverse stock split on or prior to the first anniversary date of the Special Meeting, stockholder approval again would be required prior to implementing any reverse stock split.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation.
The accompanying condensed consolidated financial statements are presented in conformity with GAAP. All amounts are presented in U.S. Dollars (“$”). Supplemental cash flows from discontinued operations are presented in Note 3 - “Discontinued Operations”. We have evaluated events occurring subsequent to September 30, 2016 for potential recognition or disclosure in the consolidated financial statements and concluded there were no subsequent events that required recognition or disclosure.
The condensed consolidated balance sheet as of December 31, 2015 was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2015. The accompanying condensed consolidated financial statements as of and for the three and nine months ended September 30, 2016 and 2015 are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2015 contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on April 14, 2016. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2016.
Reclassification
Certain prior year amounts have been reclassified to conform to the current year presentation in our condensed consolidated financial statements, which consists of the effects of reclassifications from the presentation of our discontinued operations.
Principles of Consolidation
Principles of Consolidation.
The condensed consolidated financial statements include the accounts of Transgenomic, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.
Risks and Uncertainties
Risks and Uncertainties.
Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.
Use of Estimates
Use of Estimates.
The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. In addition, estimates and assumptions associated with the determination of the fair value of certain assets and related impairments require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these condensed consolidated financial statements.
Fair Value
Fair Value.
Unless otherwise specified, book value approximates fair market value. The common stock warrant liability is recorded at fair value.
Cash and Cash Equivalents
Cash and Cash Equivalents and Other Current Assets.
Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less.
Concentrations of Cash
Concentrations of Cash.
From time to time, we may maintain a cash position with financial institutions in amounts that exceed federally insured limits.
Accounts Receivable
While payment terms are generally 30 days, we have also provided extended payment terms in certain cases. Accounts receivable are carried at original invoice amount and shown net of allowance for doubtful accounts. The estimate made for doubtful accounts is based on a review of all outstanding amounts on a quarterly basis. We determine the allowance for doubtful accounts by regularly evaluating individual payor receivables and considering a payor’s financial condition, credit history, reimbursement rates and current economic conditions. Accounts receivable are written off when deemed uncollectible and after all collection efforts have been exhausted. Recoveries of accounts receivable previously written off are recorded as a reduction in bad debt expense when received.
Inventory
Inventories.
Inventories are stated at the lower of cost or market net of allowance for obsolete inventory. Cost is computed using standard costs for finished goods and average or latest actual cost for raw materials and work in process, which approximates the first-in, first-out (FIFO) method.
Property and Equipment
Property and Equipment.
Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets as follows:
 
Leasehold improvements
1 to 10 years
Furniture and fixtures
3 to 7 years
Production equipment
3 to 7 years
Computer equipment
3 to 7 years
Research and development equipment
2 to 7 years
Intangible Assets
Intangible Assets.
Intangible assets include intellectual property and patents.
1. Intellectual Property.    Initial costs paid to license intellectual property from independent third parties are capitalized and amortized using the straight-line method over the license period. Ongoing royalties related to such licenses are expensed as incurred.
2. Patents.    We capitalize legal costs, filing fees and other expenses associated with obtaining patents on new discoveries and amortize these costs using the straight-line method over the shorter of the legal life of the patent or its economic life beginning on the date the patent is issued.
Stock-Based Compensation
Stock-Based Compensation.
All stock-based awards to date have exercise prices equal to the market value of the shares at the date of grant and have 10-year contractual terms. Unvested awards as of September 30, 2016 had vesting periods of up to three years from the date of grant. None of the awards outstanding at September 30, 2016 are subject to performance or market-based vesting conditions.
We measure and recognize compensation expense for all stock-based awards made to employees and directors. Compensation expense, net of estimated forfeitures, is based on the calculated fair value of the awards as measured at the grant date and is expensed over the service period of the awards.
Net Sales Recognition
Net Sales Recognition.
Revenue is realized and earned when all of the following criteria are met:
•
Persuasive evidence of an arrangement exists;
•
Delivery has occurred or services have been rendered;
•
The seller’s price to the buyer is fixed or determinable; and
•
Collectability is reasonably assured.

In our Biomarker Identification laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year. At each of September 30, 2016 and December 31, 2015, deferred net sales associated with pharmacogenomics research projects included in the balance sheet in deferred revenue was $0.2 million.

Net sales from Patient Testing laboratories, reported as part of discontinued operations, are recognized on an individual test basis and take place when the test report is completed, reviewed and sent to the client less the reserve for insurance, Medicare and Medicaid contractual adjustments. There are no deferred net sales associated with our Patient Testing services. Adjustments to the allowances, based on actual receipts from third party payers, are reflected in the estimated contractual allowance applied prospectively. In the fourth quarter of 2015, we adjusted our contractual allowance rates to better reflect the reimbursement level we expect to achieve on Patient Testing billings. The adjustment negatively impacted our Patient Testing revenues for all periods after the third quarter of 2015. (See Note 3 - “Discontinued Operations”).

Net sales of Genetic Assays and Platforms products, reported as discontinued operations (See Note 3 - “Discontinued Operations”) are recognized in accordance with the terms of the sales arrangement. Such recognition is based on receipt of an unconditional customer order and transfer of title and risk of ownership to the customer, typically upon shipment of the product under a purchase order. Our sales terms do not provide for the right of return unless the product is damaged or defective. Net sales from certain services associated with the analytical instruments, to be performed subsequent to shipment of the products, is deferred and recognized when the services are provided. Such services, mainly limited to installation and training services that are not essential to the functionality of the instruments, typically are performed in a timely manner subsequent to shipment of the instrument. We also enter into various service contracts that cover installed instruments. These contracts cover specific time periods and net sales associated with these contracts are deferred and recognized ratably over the service period.
Common Stock Warrants
Common Stock Warrants.
Certain of our issued and outstanding warrants to purchase common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability (“Common Stock Warrant Liability”). We are required to present these instruments at fair value at each reporting date and any changes in fair values are recorded as an adjustment to earnings. The Common Stock Warrant Liabilities are considered Level Three financial instruments for purposes of fair value measurement.
Loss Per Share
Loss Per Share.
Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock.
Recent Accounting Pronouncements
Recent Accounting Pronouncements.
In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“ASU No. 2014-09”). This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in GAAP when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year. As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40)(“ASU No. 2014-15”). This guidance addresses management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted. We do not expect to early adopt this guidance and do not believe that the adoption of this guidance will have a material impact on our consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016; however, early adoption is permitted. We do not expect to early adopt this guidance and are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Summary of activity for the allowance for doubtful accounts
The following is a summary of activity for the allowance for doubtful accounts from continuing operations during the three and nine months ended September 30, 2016 and 2015: 
 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended September 30, 2016
$
157

 
$
2

 
$
(19
)
 
$
140

Three Months Ended September 30, 2015
$
20

 
$
50

 
$
—

 
$
70

Nine Months Ended September 30, 2016
$
87

 
$
72

 
$
(19
)
 
$
140

Nine Months Ended September 30, 2015
$
20

 
$
50

 
$
—

 
$
70
Activity for the allowance for obsolete inventory
The following is a summary of activity for the allowance for obsolete inventory during the three and nine months ended September 30, 2016 and 2015: 
 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended September 30, 2016
$
63

 
$
—

 
$
—

 
$
63

Three Months Ended September 30, 2015
$
—

 
$
—

 
$
—

 
$
—

Nine Months Ended September 30, 2016
$
63

 
$
—

 
$
—

 
$
63

Nine Months Ended September 30, 2015
$
—

 
$
—

 
$
—

 
$
—
Schedule of property and equipment, useful lives
Depreciation is computed using the straight-line method over the estimated useful lives of the related assets as follows:
 
Leasehold improvements
1 to 10 years
Furniture and fixtures
3 to 7 years
Production equipment
3 to 7 years
Computer equipment
3 to 7 years
Research and development equipment
2 to 7 years
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
DISCONTINUED OPERATIONS (Tables)
 9 Months Ended
Sep. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of discontinued operations impact on income statement and balance sheets
Results of the discontinued operations consisted of the following:
 
Three months ended September 30,
 
Nine months ended September 30,
(Dollars in thousands)
2016
 
2015
 
2016
 
2015
Net sales
$
283

 
$
5,507

 
$
1,960

 
$
17,868

Cost of goods sold
57

 
3,203

 
1,251

 
9,980

Gross profit
226

 
2,304

 
709

 
7,888

Selling, general and administrative expense
252

 
1,910

 
1,621

 
8,325

Research and development expense
98

 
106

 
166

 
330

Impairment of long-lived assets
—

 
7,024

 
—

 
7,024

Operating income (loss) from discontinued operations
(124
)
 
(6,736
)
 
(1,078
)
 
(7,791
)
Gain on sale of business/assets
90

 
1,532

 
1,053

 
1,532

Income (loss) from discontinued operations before income taxes
(34
)
 
(5,204
)
 
(25
)
 
(6,259
)
Income tax expense
—

 
44

 
—

 
133

Income (loss) from discontinued operations, net of taxes
$
(34
)
 
$
(5,248
)
 
$
(25
)
 
$
(6,392
)
Assets and liabilities of the discontinued operations are classified as assets held for sale and liabilities held for sale in the condensed consolidated balance sheets and consisted of the following:
 
Dollars in Thousands
 
September 30,
2016
 
December 31,
2015
ASSETS
 
 
 
Accounts receivable, net
$
244

 
$
1,905

Other current assets
21

 
82

Total Assets
$
265

 
$
1,987

 
 
 
 
LIABILITIES
 
 
 
Accrued compensation
$
—

 
$
264

Total Liabilities
$
—

 
$
264

 
 
 
 

The following is a summary of activity for the allowance for doubtful accounts from discontinued operations during the three and nine months ended September 30, 2016 and 2015. The allowance for doubtful accounts from discontinued operations is included in the assets held for sale in the condensed consolidated balance sheets.
 
Dollars in Thousands
 
Beginning
Balance
 
Additions
 
Deductions
 
Ending
Balance
Three Months Ended September 30, 2016
$
10,462

 
$
—

 
$
(5,192
)
 
$
5,270

Three Months Ended September 30, 2015
$
8,406

 
$
1,052

 
$
(168
)
 
$
9,290

Nine Months Ended September 30, 2016
$
14,664

 
$
—

 
$
(9,394
)
 
$
5,270

Nine Months Ended September 30, 2015
$
7,927

 
$
3,782

 
$
(2,419
)
 
$
9,290
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
INTANGIBLES AND OTHER ASSETS (Tables)
 9 Months Ended
Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of long-lived intangible assets
Long-lived intangible assets as of September 30, 2016 and December 31, 2015 consisted of the following:
 
Dollars in Thousands
 
September 30, 2016
 
Cost
 
Accumulated
Amortization
 
Net Book
Value
Patents
680

 
80

 
600

Intellectual property
672

 
290

 
382

 
$
1,352

 
$
370

 
$
982




 
Dollars in Thousands
 
December 31, 2015
 
Cost
 
Accumulated
Amortization
 
Net Book
Value
Patents
980

 
274

 
706

Intellectual property
671

 
207

 
464

 
$
1,651

 
$
481

 
$
1,170


 
 
 
Estimated Useful Life
Patents
Life of the patent
Intellectual property
7 years
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
DEBT (Tables)
 9 Months Ended
Sep. 30, 2016
Debt Disclosure [Abstract]  
Schedule of debt
 
 
Dollars in Thousands
 
 
September 30, 2016
 
December 31, 2015
Revolving Line of Credit(1)
 
$
3,243

 
$
3,025

Term Loan(2)
 
4,000

 
4,000

Convertible Promissory Notes (3)
 
571

 
571

Total debt
 
7,814

 
7,596

Current portion of long-term debt
 
(7,814
)
 
(7,596
)
Long-term debt, net of current maturities
 
$
—

 
$
—

 
(1)
Revolving Line of Credit. Amounts advanced under the Revolving Line accrue interest at an annual rate equal to the greater of (a) 6.25% or (b) the Wall Street Journal prime rate plus 3%. The current interest rate is 6.50%. Interest is payable on a monthly basis, with the balance payable at the maturity of the Revolving Line. Under the Loan Agreement, we pay the Lenders a commitment fee of $20,000 on each one-year anniversary of March 13, 2013, the Effective Date, during the term of the Revolving Line. In addition, a fee of 0.5% per annum is payable quarterly on the unused portion of the Revolving Line. The Revolving Line matures on November 1, 2017.

(2)
Term Loan. We received $4.0 million under the Term Loan on the Effective Date. Pursuant to the terms of the Loan Agreement, as amended, the maturity date of the Loan Agreement was extended until November 1, 2017 and no principal payments on the Term Loan are due until such date. The current interest rate is 9.1%.

We will pay the Lenders an additional final payment of $120,000 at maturity or prepayment of the Term Loan. In addition, if we repay the Term Loan prior to maturity, we will pay the Lenders a prepayment penalty of 1% of the total outstanding balance under the Term Loan.

Additional Terms.
The Loan Agreement contains affirmative and negative covenants. Under the Term Loan, we agreed not to (i) pledge or otherwise encumber our assets other than to the Lenders, (ii) enter into additional borrowings or guarantees, (iii) repurchase our capital stock, or (iv) enter into certain mergers or acquisitions without the Lenders’ consent. Additionally, the Loan Agreement contains a subjective acceleration clause at the discretion of the Lenders. As of September 30, 2016, we were not in compliance with the Loan Agreement, as amended by the Ninth Amendment, due to the fact that we did not make the required monthly interest payments during the third quarter and have not received a waiver for the non-compliance and as such all debt has been classified as current at September 30, 2016.

To secure the repayment of any amounts borrowed under the Revolving Line and the Term Loan, we granted the Lenders a security interest in all of our assets. The occurrence of an event of default under the Loan Agreement could result in the acceleration of our obligations under the Loan Agreement, would increase the applicable interest rate under the Revolving Line or Term Loan (or both) by 5% and would permit the Lenders to exercise remedies with respect to the collateral under the Loan Agreement. As of the date these financials were available for release, the Lenders have not exercised the remedies under the Loan Agreement.

(3) Convertible Promissory Notes. The Notes accrue interest at a rate of 6% per year and mature on December 31, 2016.

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY (Tables)
 9 Months Ended
Sep. 30, 2016
Stockholders' Equity Note [Abstract]  
Schedule of stockholders' equity, including warrants and rights
Warrant Holder
 
Issue Year
 
Expiration
 
Underlying
Shares
 
Exercise
Price
Various Institutional Holders(1)
 
2012
 
February 2017
 
2,919,043
 
$4.23
Affiliates of Third Security, LLC(1)
 
2012
 
February 2017
 
443,233
 
$4.23
Various Institutional Holders(2)
 
2013
 
January 2018
 
441,655
 
$9.00
Affiliates of Third Security, LLC(2)
 
2013
 
January 2018
 
250,000
 
$9.00
Various Institutional Holders(3)
 
2014
 
April 2020
 
374,618
 
$4.00
Various Institutional Holders(4)
 
2015
 
February 2020
 
714,780
 
$2.24
Various Institutional Holders(5)
 
2015
 
December 2020
 
122,433
 
$1.66
Various Institutional Holders(5)
 
2015
 
December 2020
 
667,164
 
$0.01
Various Institutional Holders(6)
 
2015
 
January 2021
 
1,161,972
 
$1.21
Affiliates of Third Security, LLC(7)
 
2016
 
January 2021
 
161,026
 
$1.21
Various Institutional Holders(7)
 
2016
 
January 2021
 
1,720,430
 
$1.21
 
 
 
 
 
 
8,976,354
 
 


(1)
These warrants were issued in connection with the Private Placement completed in February 2012 and are classified as a liability in our financial statements. See Note 9 - “Fair Value” for additional information. These warrants also contain certain anti-dilution provisions that provide for an adjustment to the exercise price and number of shares issuable upon exercise of the warrant in the event that we engage in certain issuances of shares of our common stock at a price lower than the exercise price of the warrant.
(2)
These warrants were issued in connection with the 2013 Offering, which was completed in January 2013.
(3)
These warrants were issued in connection with the 2014 Private Placement, which was completed in October 2014.
(4)
These warrants were issued in connection with the February 2015 Offering, which was completed in February 2015.
(5)
These warrants were issued in connection with the July 2015 Offering, which was completed in July 2015.
(6)
These warrants were originally issued in connection with the July 2015 Offering, which was completed in July 2015, and were amended in connection with the January 2016 Offering, which was completed in January 2016.
(7)
These warrants were issued in connection with the January 2016 Offering, which was completed in January 2016.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
FAIR VALUE (Tables)
 9 Months Ended
Sep. 30, 2016
Fair Value Disclosures [Abstract]  
Schedule of changes in fair value of liability
During the three and nine months ended September 30, 2016 and 2015, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:
 
 
Dollars in Thousands
 
 
For the Three Months Ended
 
 
September 30, 2016
 
September 30, 2015
Beginning balance at July 1
 
$
—

 
$
560

Total (gains) or losses:
 

 
 
Recognized in earnings
 
—

 
(385
)
Balance at September 30
 
$
—

 
$
175


 
 
Dollars in Thousands
 
 
For the Nine Months Ended
 
 
September 30, 2016
 
September 30, 2015
Beginning balance at January 1
 
$
350

 
$
145

Total (gains) or losses:
 
 
 
 
Recognized in earnings
 
(350
)
 
30

Balance at September 30
 
$
—

 
$
175

During the three and nine months ended September 30, 2016, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:
 
 
Dollars in Thousands
 
 
 
For the Three Months Ended
 
 
 
September 30, 2016
 
Beginning balance at July 1
 
$
1,442

 
Total (gains) or losses:
 
 
 
Recognized in earnings
 
(12
)
 
Balance at September 30
 
$
1,430

 
 
 
Dollars in Thousands
 
 
 
For the Nine Months Ended
 
 
 
September 30, 2016
 
Beginning balance at January 1
 
$
—

 
Additions
 
1,437

 
Total (gains) or losses:
 
 
 
Recognized in earnings
 
(7
)
 
Balance at September 30
 
$
1,430

 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCK OPTIONS (Tables)
 9 Months Ended
Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summary of stock option activity
The following table summarizes stock option activity during the nine months ended September 30, 2016:
 
 
Number of
Options
 
Weighted-Average
Exercise Price
Outstanding at January 1, 2016
1,107,794

 
$
3.45

Granted
25,250

 
0.84

Forfeited
(252,589
)
 
3.28

Outstanding at September 30, 2016
880,455

 
$
3.39

Exercisable at September 30, 2016
574,650

 
$
4.08
Summary of SARs activity
The following table summarizes SARs activity under the Plan during the nine months ended September 30, 2016:
 
Number of
SARs
 
Weighted-Average
Exercise Price
Outstanding at January 1, 2016
98,333

 
$
4.14

Outstanding at September 30, 2016
98,333

 
$
4.14

Exercisable at September 30, 2016
92,558

 
$
4.20
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
BUSINESS DESCRIPTION (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2016
USD ($)
operating_segments
Sep. 30, 2015
operating_segments
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Number of operating segments | operating_segments 1 2
Working capital | $ $ (17.4)  
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narratives) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Other current assets $ 314,000   $ 314,000   $ 537,000
Current prepaid expense 100,000   100,000    
Other current receivables 200,000   $ 200,000    
Share-based compensation arrangement by share-based payment award, expiration period     10 years    
Stock-based compensation expense     $ 111,000 $ 489,000  
Unrecognized compensation expense related to unvested stock awards, not yet recognized $ 100,000   $ 100,000    
Unvested stock options, unrecognized compensation expense weighted average recognition period     1 year 1 month 1 day    
Stock options, granted (in shares) 11,250   25,250 641,560  
Stock options, fair value assumptions, risk free interest rate (as a percent)     1.56%    
Stock options, fair value assumptions, dividend yield     0.00%    
Stock options, fair value assumptions, expected life     6 years    
Stock options, fair value assumptions, historical volatility rate (as a percent)     85.00%    
Common stock rights issued (in shares)     3,055,555 3,466,841  
Deferred revenue $ 176,000   $ 176,000   217,000
Options, warrants and conversion rights, common stock callable and antidilutive (in shares)     10,701,453 10,392,728  
Pharmacogenomic Services          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Deferred revenue 200,000   $ 200,000   $ 200,000
Executive Officers          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock options, unvested options, vesting period     3 years    
Common stock rights issued (in shares)     98,333    
Selling, General and Administrative Expenses          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock-based compensation expense $ 0 $ 200,000 $ 100,000 $ 500,000  
Maximum          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock options, unvested options, vesting period     3 years    
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Accounts Receivable) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Allowance for Doubtful Accounts Receivable [Roll Forward]        
Beginning balance $ 157 $ 20 $ 87 $ 20
Additions 2 50 72 50
Deductions (19) 0 (19) 0
Ending balance $ 140 $ 70 $ 140 $ 70
Accounts receivable, general payment terms     30 days  
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Inventories) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Accounting Policies [Abstract]        
Net raw materials inventory $ 100   $ 100  
Obsolete inventory [Roll Forward]        
Beginning Balance 63 $ 0 63 $ 0
Additions 0 0 0 0
Deductions 0 0 0 0
Ending Balance $ 63 $ 0 $ 63 $ 0
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Property, Plant and Equipment [Line Items]        
Depreciation expense $ 0.1 $ 0.1 $ 0.1 $ 0.2
Leasehold Improvements | Minimum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     1 year  
Leasehold Improvements | Maximum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     10 years  
Furniture and Fixtures | Minimum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     3 years  
Furniture and Fixtures | Maximum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     7 years  
Production Equipment | Minimum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     3 years  
Production Equipment | Maximum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     7 years  
Computer Equipment | Minimum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     3 years  
Computer Equipment | Maximum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     7 years  
Research and Development Equipment | Minimum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     2 years  
Research and Development Equipment | Maximum        
Property, Plant and Equipment [Line Items]        
Property and equipment, estimated useful lives     7 years  
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
DISCONTINUED OPERATIONS (Narratives) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Nov. 25, 2015
Sep. 08, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
LOSS FROM DISCONTINUED OPERATIONS, NET OF TAXES $ (34) $ (5,248) $ (25) $ (6,392)      
Genetic Assays and Platforms business              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Purchase price             $ 2,100
(Loss) gain on sale of business         $ 1,500    
Genetic Assays and Platforms business | ADSTEC Corporation              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Purchase price           $ 300  
(Loss) gain on sale of business         $ (1,700)    
Patient Testing | Discontinued operations              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
LOSS FROM DISCONTINUED OPERATIONS, NET OF TAXES     $ 1,100        
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
DISCONTINUED OPERATIONS (Revenues and Net Income (Loss)) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Income (loss) from discontinued operations, net of taxes $ (34) $ (5,248) $ (25) $ (6,392)
Discontinued operations | Genetic Assays and Platforms and Patient Testing        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Net sales 283 5,507 1,960 17,868
Cost of goods sold 57 3,203 1,251 9,980
Gross profit 226 2,304 709 7,888
Selling, general and administrative expense 252 1,910 1,621 8,325
Research and development expense 98 106 166 330
Impairment of long-lived assets 0 7,024 0 7,024
Operating income (loss) from discontinued operations (124) (6,736) (1,078) (7,791)
Gain on sale of business/assets 90 1,532 1,053 1,532
Income (loss) from discontinued operations before income taxes (34) (5,204) (25) (6,259)
Income tax expense 0 44 0 133
Income (loss) from discontinued operations, net of taxes $ (34) $ (5,248) $ (25) $ (6,392)
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
DISCONTINUED OPERATIONS (Assets and Liabilities Held for Sale) (Details) - Discontinued operations - Genetic Assays and Platforms and Patient Testing - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
ASSETS    
Accounts receivable, net $ 244 $ 1,905
Other current assets 21 82
Total Assets 265 1,987
LIABILITIES    
Accrued compensation 0 264
Total Liabilities $ 0 $ 264
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
DISCONTINUED OPERATIONS (Allowance for Doubtful Accounts) (Details) - Genetic Assays and Platforms and Patient Testing - Discontinued operations - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Disposal Group, Including Discontinued Operations, Allowance for Doubtful Accounts [Roll Forward]        
Beginning Balance $ 10,462 $ 8,406 $ 14,664 $ 7,927
Additions 0 1,052 0 3,782
Deductions (5,192) (168) (9,394) (2,419)
Ending Balance $ 5,270 $ 9,290 $ 5,270 $ 9,290
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
INTANGIBLES AND OTHER ASSETS (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Finite-Lived Intangible Assets, Net [Abstract]      
Cost $ 1,352   $ 1,651
Accumulated Amortization 370   481
Net Book Value 982   1,170
Amortization expense for intangible assets 200 $ 100  
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]      
Amortization expense, 2016 100    
Amortization expense, 2017 100    
Amortization expense, 2018 100    
Amortization expense, 2019 100    
Amortization expense, 2020 100    
Patents      
Finite-Lived Intangible Assets, Net [Abstract]      
Cost 680   980
Accumulated Amortization 80   274
Net Book Value 600   706
Intellectual property      
Finite-Lived Intangible Assets, Net [Abstract]      
Cost 672   671
Accumulated Amortization 290   207
Net Book Value $ 382   $ 464
Estimated Useful Life 7 years    
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
DEBT (Schedule of Debt) (Details) - USD ($)
 9 Months Ended
Sep. 30, 2016
Dec. 31, 2015
Dec. 31, 2014
Debt Instrument [Line Items]      
Total debt $ 7,814,000 $ 7,596,000  
Current portion of long-term debt (7,814,000) (7,596,000)  
Long-term debt, net of current maturities 0 0  
Line of credit | Revolving credit facility      
Debt Instrument [Line Items]      
Total debt $ 3,243,000 3,025,000  
Annual interest rate (as a percent) 6.25%    
Effective interest rate (as a percent) 6.50%    
Commitment fee amount $ 20,000    
Commitment fee (as a percent) 0.50%    
Line of credit | Revolving credit facility | Wall Street Journal prime rate      
Debt Instrument [Line Items]      
Basis spread on variable rate (as a percent) 3.00%    
Term loan      
Debt Instrument [Line Items]      
Total debt $ 4,000,000 4,000,000  
Proceeds from issuance of long-term debt $ 4,000,000    
Current interest rate (as a percent) 9.10%    
Future debt extinguishment costs $ 120,000    
Prepayment penalty percentage of outstanding balance (as a percent) 1.00%    
Increase in interest rate in case of debt default (as a percent) 5.00%    
Convertible promissory notes      
Debt Instrument [Line Items]      
Total debt $ 571,000 $ 571,000  
Annual interest rate (as a percent) 6.00%   6.00%
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
DEBT (Revolving Line and Term Loan) (Details) - USD ($)
 13 Months Ended
Aug. 10, 2015
Mar. 13, 2013
Mar. 31, 2015
Sep. 30, 2016
Jan. 06, 2016
Dec. 31, 2015
Sep. 04, 2015
Apr. 01, 2015
Dec. 31, 2014
Oct. 22, 2014
Oct. 21, 2014
Debt Instrument [Line Items]                      
Overadvance on Loan Agreement       $ 7,814,000   $ 7,596,000          
Term loan                      
Debt Instrument [Line Items]                      
Interest costs capitalized     $ 400,000                
Initial prepayment of a portion of the loan balance               $ 148,000      
Convertible notes payable                      
Debt Instrument [Line Items]                      
Face amount         $ 750,000       $ 750,000    
Third Security LLC and affiliates | Term loan                      
Debt Instrument [Line Items]                      
Face amount   $ 4,000,000                  
PGxHealth, LLC | Senior secured promissory note                      
Debt Instrument [Line Items]                      
Debt term of note payable that was paid off   3 years                  
Revolving credit facility | Line of credit                      
Debt Instrument [Line Items]                      
Current borrowing capacity             $ 2,300,000     $ 3,000,000 $ 4,000,000
Payment to lenders to support the amount advanced $ 700,000                    
Revolving credit facility | Third Security LLC and affiliates | Line of credit                      
Debt Instrument [Line Items]                      
Current borrowing capacity   $ 4,000,000                  
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
DEBT (Convertible Promissory Notes) (Details)
 9 Months Ended
Dec. 31, 2014
USD ($)
$ / shares
Sep. 30, 2016
USD ($)
shares
Jan. 06, 2016
USD ($)
Jan. 20, 2015
USD ($)
Jan. 15, 2015
investor
Additional notes          
Debt Instrument [Line Items]          
Number of additional accredited investors | investor         7
Convertible notes payable          
Debt Instrument [Line Items]          
Face amount $ 750,000   $ 750,000    
Interest rate (as a percent) 6.00% 6.00%      
Number of shares converted | shares   502,786      
Convertible notes payable | Additional notes          
Debt Instrument [Line Items]          
Face amount       $ 925,000  
Number of shares converted | shares   281,023      
Conversion of convertible promissory notes   $ 400,000      
Convertible notes payable | Conversion, period one          
Debt Instrument [Line Items]          
Percentage of debt convertible 50.00%        
Threshold consecutive trading days 20 days        
Conversion price (in dollars per share) | $ / shares $ 2.20        
Convertible notes payable | Conversion, period two          
Debt Instrument [Line Items]          
Threshold consecutive trading days 15 days        
Conversion price as percentage of average closing price 85.00%        
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)
$ in Millions
 9 Months Ended
Jun. 23, 2016
Feb. 25, 2016
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]          
Future minimum payments due, remainder of 2016     $ 0.2    
Future minimum payments due, 2017     0.7    
Future minimum payments due, 2018     0.7    
Future minimum payments due, 2019     0.7    
Future minimum payments due, 2020     0.7    
Future minimum payments, due thereafter     0.4    
Rent expense     0.2 $ 0.2  
Firm commitments to vendors     0.1    
Threatened Litigation | Breach of contract | UNMC          
Loss Contingencies [Line Items]          
Damages sought in a lawsuit   $ 0.7      
Accrual of possible loss in a lawsuit     0.7   $ 0.7
Threatened Litigation | Breach of contract | Mount Sinai          
Loss Contingencies [Line Items]          
Damages sought in a lawsuit $ 0.7        
Accrual of possible loss in a lawsuit     $ 0.7   $ 0.7
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
INCOME TAXES (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Income Tax Disclosure [Abstract]        
Income tax expense (benefit) $ 0 $ 0 $ 0 $ (1,000)
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY (Common Stock) (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Jun. 14, 2016
shares
Jun. 07, 2016
USD ($)
May 31, 2016
shares
Jan. 06, 2016
USD ($)
$ / shares
shares
Jul. 07, 2015
USD ($)
$ / shares
shares
Feb. 27, 2015
USD ($)
$ / shares
$ / unit
shares
Oct. 22, 2014
USD ($)
$ / shares
shares
Jan. 24, 2013
USD ($)
$ / shares
shares
Feb. 02, 2012
USD ($)
$ / shares
shares
May 31, 2016
shares
Dec. 31, 2011
USD ($)
Sep. 30, 2016
USD ($)
$ / shares
shares
Sep. 30, 2016
USD ($)
$ / shares
shares
Sep. 30, 2015
USD ($)
Jun. 30, 2016
shares
Dec. 31, 2015
$ / shares
shares
Jan. 20, 2015
USD ($)
Jan. 15, 2015
USD ($)
$ / shares
shares
Dec. 31, 2014
USD ($)
$ / shares
shares
Oct. 21, 2014
$ / shares
shares
Mar. 05, 2014
$ / shares
shares
Dec. 31, 2012
$ / shares
shares
Class of Stock [Line Items]                                            
Common stock, shares authorized (in shares)                       150,000,000 150,000,000     150,000,000            
Common stock, shares issued (in shares)                       24,139,130 24,139,130     13,915,691            
Private placement, net (in shares)       6,780,179 1,500,000                                  
Share price (in dollars per share) | $ / shares         $ 1.42                                  
Stock issued during period | $                         $ 500,000                  
Issuance of common stock, net | $                         $ 468,000 $ 8,977,000                
Proceeds from issuance of common stock and warrants | $         $ 3,000,000                                  
Preferred stock, shares issued (in shares)                       214,705 214,705     4,029,502            
Preferred stock, par value (in dollars per share) | $ / shares                       $ 0.01 $ 0.01     $ 0.01            
Preferred stock, shares outstanding (in shares)                       214,705 214,705     4,029,502            
Common Stock                                            
Class of Stock [Line Items]                                            
Private placement, net (in shares)                         1,292,722                  
Stock issued during period | $                         $ 12,000                  
Shares issued upon conversion of preferred stock (in shares)                         8,930,717                  
Stock issued during period for services (in shares) 64,153   78,000                                      
Stock issued during period for services | $                       $ 89,000                    
Craig-Hallum Capital Group LLC                                            
Class of Stock [Line Items]                                            
Warrants term       5 years 5 years                                  
Common stock warrant, exercise price (in dollars per share) | $ / shares       $ 1.21 $ 1.66                                  
Payments of stock issuance costs | $       $ 140,000 $ 212,783                                  
Payments of stock issuance costs, percentage of gross offering proceeds       7.00% 7.00%                                  
Payments of stock issuance costs, warrant right to purchase common stock shares       107,527 107,033                                  
Stock issuance costs, reimbursable expenses (not to exceed) | $       $ 50,000 $ 50,000                                  
Proceeds from issuance of warrants | $       50                                    
Convertible notes payable                                            
Class of Stock [Line Items]                                            
Face amount | $       750,000                             $ 750,000      
Series A-1 Convertible Preferred Stock and Warrants                                            
Class of Stock [Line Items]                                            
Proceeds from issuance of convertible preferred stock | $       $ 2,200,000                                    
Price per share of shares issued (in dollars per share) | $ / shares       $ 0.93                                    
Series A-1 Convertible Preferred Stock                                            
Class of Stock [Line Items]                                            
Preferred stock, shares issued (in shares)       2,365,243                                    
Voting rights, number of shares per one vote       1.075269                                    
Number of shares converted                   2,150,538                        
Preferred stock, shares outstanding (in shares)                       214,705 214,705                  
Common Stock                                            
Class of Stock [Line Items]                                            
Shares issued upon conversion of preferred stock (in shares)                   2,150,538                        
Series A Preferred Stock                                            
Class of Stock [Line Items]                                            
Preferred stock, par value (in dollars per share) | $ / shares       $ 0.01                                    
Preferred stock, shares outstanding (in shares)       0                       2,586,205            
Third Security LLC and affiliates                                            
Class of Stock [Line Items]                                            
Common stock warrant, common stock called (in shares)               1,097,600                         1,212,665  
Common stock warrant, exercise price (in dollars per share) | $ / shares               $ 12.96                         $ 11.73  
Series A Warrants                                            
Class of Stock [Line Items]                                            
Warrants term         5 years 6 months                                  
Warrants, period exercisable         6 months                                  
Warrant exchange amount | $       $ 941,197                                    
Warrant exercise period not subject to cash payment       90 days                                    
Warrant exchange price threshold (in dollars per share) | $ / shares       $ 0.50                                    
Series A Warrants | Pro Forma                                            
Class of Stock [Line Items]                                            
Share price (in dollars per share) | $ / shares       $ 0.25                                    
Payments for repurchase of warrants | $       $ 470,599                                    
Warrant exchange amount | $       $ 941,197                                    
Series A Warrants | Maximum                                            
Class of Stock [Line Items]                                            
Common stock warrant, common stock called (in shares)       1,161,972                                    
Series A Warrant, Cashless Exchange | Maximum                                            
Class of Stock [Line Items]                                            
Common stock warrant, common stock called (in shares)       1,882,395                                    
Series A Warrant, Cashless Exchange | Maximum | Pro Forma                                            
Class of Stock [Line Items]                                            
Common stock warrant, common stock called (in shares)       1,882,395                                    
Series A-1 Warrant                                            
Class of Stock [Line Items]                                            
Common stock warrant, common stock called (in shares)       1,773,929                                    
Common stock warrant, exercise price (in dollars per share) | $ / shares       $ 1.21                                    
Warrants, period exercisable       5 years                                    
Warrant exchange amount | $       $ 1,436,882                                    
Warrant exercise period not subject to cash payment       90 days                                    
Warrant exchange price threshold (in dollars per share) | $ / shares       $ 0.50                                    
Series A-1 Warrant | Pro Forma                                            
Class of Stock [Line Items]                                            
Share price (in dollars per share) | $ / shares       $ 0.25                                    
Payments for repurchase of warrants | $       $ 718,441                                    
Warrant exchange amount | $       $ 1,436,882                                    
Series A-1 Warrant | Maximum                                            
Class of Stock [Line Items]                                            
Common stock warrant, common stock called (in shares)       2,873,765                                    
Series A-1 Warrant | Maximum | Pro Forma                                            
Class of Stock [Line Items]                                            
Common stock warrant, common stock called (in shares)       2,873,765                                    
Series B Warrants                                            
Class of Stock [Line Items]                                            
Warrants term         5 years 6 months                                  
Common stock warrant, exercise price (in dollars per share) | $ / shares         $ 0.01                                  
Series B Warrants | Maximum                                            
Class of Stock [Line Items]                                            
Common stock warrant, common stock called (in shares)         700,000.0                                  
Warrants                                            
Class of Stock [Line Items]                                            
Common stock warrant, exercise price (in dollars per share) | $ / shares         $ 1.66                                  
Warrants | Maximum                                            
Class of Stock [Line Items]                                            
Common stock warrant, common stock called (in shares)         1,200,000.0                                  
Private Placement                                            
Class of Stock [Line Items]                                            
Proceeds from issuance of common stock and convertible notes | $                 $ 22,000,000   $ 3,000,000                      
Common stock, shares issued (in shares)                 1,583,333                          
Common stock, sale price per share (in dollars per share) | $ / shares                 $ 12                          
Warrants term                 5 years                          
Common stock warrant, common stock called (in shares)       3,239,827 2,188,177 1,881,396 1,309,785 1,097,600 823,333     3,362,276 3,362,276   3,262,088     1,483,161 1,387,685 1,212,665   948,333
Common stock warrant, exercise price (in dollars per share) | $ / shares       $ 4.39 $ 6.50 $ 7.56 $ 10.86 $ 12.96 $ 15.00     $ 4.23 $ 4.23         $ 9.59 $ 10.25 $ 11.73   $ 15.00
Payments of stock issuance costs | $                 $ 1,330,000                          
Payments of stock issuance costs, percentage of gross offering proceeds                 7.00%                          
Payments of stock issuance costs, warrant right to purchase common stock shares                 31,666                          
Payments of stock issuance costs, warrant right to purchase common stock shares, percentage of shares in offering                 2.00%                          
Stock issuance costs, reimbursable expenses (not to exceed) | $                 $ 125,000                          
Payments of stock issuance costs, reduction to equity | $                 $ 1,500,000                          
Stock issued during period | $                         $ 543,000                  
Private Placement | Third Security LLC and affiliates                                            
Class of Stock [Line Items]                                            
Convertible notes, common stock callable (in shares)                 250,000                          
Convertible notes, warrants callable (in shares)                 125,000                          
2014 Private Placement                                            
Class of Stock [Line Items]                                            
Common stock warrant, common stock called (in shares)             365,388                              
Common stock warrant, exercise price (in dollars per share) | $ / shares             $ 4.00                              
Private placement, net (in shares)             730,776                              
Share price (in dollars per share) | $ / shares             $ 3.25                              
Stock issued during period | $             $ 2,400,000                              
2014 Private Placement | Advisor                                            
Class of Stock [Line Items]                                            
Common stock warrant, common stock called (in shares)             9,230                              
At the Market Offering                                            
Class of Stock [Line Items]                                            
Issuance of common stock, net | $                       $ 500,000 $ 100,000                  
At the Market Offering | Common Stock                                            
Class of Stock [Line Items]                                            
Private placement, net (in shares)                       1,035,255 1,150,569                  
Aggregate authorized amount under At the Market Offering Agreement | $   $ 3,500,000                                        
At the Market Offering | Craig-Hallum Capital Group LLC | Common Stock                                            
Class of Stock [Line Items]                                            
Payments of stock issuance costs, percentage of gross offering proceeds   3.25%                                        
At the Market Offering | Weighted Average | Common Stock                                            
Class of Stock [Line Items]                                            
Share price (in dollars per share) | $ / shares                       $ 0.42 $ 0.42                  
Offering                                            
Class of Stock [Line Items]                                            
Common stock warrant, common stock called (in shares)               691,655                            
Private placement, net (in shares)               1,383,333                            
Share price (in dollars per share) | $ / shares               $ 6.00                            
Stock issued during period | $               $ 8,300,000                            
Class of warrant or right, number of securities called by warrants or rights, price per share (in dollars per share) | $ / shares               $ 9.00                            
Offering | Affiliates of Third Security, LLC; January 2018                                            
Class of Stock [Line Items]                                            
Common stock warrant, common stock called (in shares)               250,000                            
Private placement, net (in shares)               500,000                            
Additional Note Private Placement | Convertible notes payable                                            
Class of Stock [Line Items]                                            
Face amount | $                                 $ 925,000          
Additional Note Private Placement | Convertible notes payable | Craig-Hallum Capital Group LLC                                            
Class of Stock [Line Items]                                            
Face amount | $                                   $ 46,250        
Face amount as percentage of proceeds from debt issuance                                   5.00%        
2015 Offering | Craig-Hallum Capital Group LLC                                            
Class of Stock [Line Items]                                            
Common stock warrant, common stock called (in shares)           714,780                                
Common stock warrant, exercise price (in dollars per share) | $ / shares           $ 2.24                                
Private placement, net (in shares)           3,573,899                                
Class of warrant or right, number of securities called by each warrant or right (in shares)           0.20                                
Class of warrant or right, purchase price per share, public (in dollars per share) | $ / unit           1.95                                
Class of warrant or right, purchase price per share, underwriter (in dollars per share) | $ / unit           1.8135                                
Proceeds from issuance of common stock and warrants, net | $           $ 6,200,000                                
Class of warrant or right, expiration period           5 years                                
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details) - $ / shares
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Jan. 06, 2016
Jul. 07, 2015
Feb. 27, 2015
Jan. 15, 2015
Dec. 31, 2014
Oct. 22, 2014
Oct. 21, 2014
Jan. 24, 2013
Dec. 31, 2012
Feb. 02, 2012
Class of Stock [Line Items]                        
Common stock warrants issued (in shares) 3,055,555 3,466,841                    
Underlying Shares 8,976,354                      
Various Institutional Holders; February 2017                        
Class of Stock [Line Items]                        
Underlying Shares 2,919,043                      
Exercise Price (in dollars per share) $ 4.23                      
Affiliates of Third Security, LLC; February 2017                        
Class of Stock [Line Items]                        
Underlying Shares 443,233                      
Exercise Price (in dollars per share) $ 4.23                      
Various Institutional Holders; January 2018                        
Class of Stock [Line Items]                        
Underlying Shares 441,655                      
Exercise Price (in dollars per share) $ 9                      
Affiliates of Third Security, LLC; January 2018                        
Class of Stock [Line Items]                        
Underlying Shares 250,000                      
Exercise Price (in dollars per share) $ 9                      
Various Institutional Holders; April 2020                        
Class of Stock [Line Items]                        
Underlying Shares 374,618                      
Exercise Price (in dollars per share) $ 4.00                      
Various Institutional Holders; February 2020                        
Class of Stock [Line Items]                        
Underlying Shares 714,780                      
Exercise Price (in dollars per share) $ 2.24                      
Various Institutional Holders; December 2020                        
Class of Stock [Line Items]                        
Underlying Shares 122,433                      
Exercise Price (in dollars per share) $ 1.66                      
Various Institutional Holders; December 2020                        
Class of Stock [Line Items]                        
Underlying Shares 667,164                      
Exercise Price (in dollars per share) $ 0.01                      
Various Institutional Holders; January 2021                        
Class of Stock [Line Items]                        
Underlying Shares 1,161,972                      
Exercise Price (in dollars per share) $ 1.21                      
Affiliates of Third Security, LLC; January 2021                        
Class of Stock [Line Items]                        
Underlying Shares 161,026                      
Exercise Price (in dollars per share) $ 1.21                      
Various Institutional Holders; January 2021                        
Class of Stock [Line Items]                        
Underlying Shares 1,720,430                      
Exercise Price (in dollars per share) $ 1.21                      
Private Placement                        
Class of Stock [Line Items]                        
Common stock warrants issued (in shares) 1,174,099 800,492                    
Exercise Price (in dollars per share) $ 4.23   $ 4.39 $ 6.50 $ 7.56 $ 9.59 $ 10.25 $ 10.86 $ 11.73 $ 12.96 $ 15.00 $ 15.00
Offering                        
Class of Stock [Line Items]                        
Common stock warrants issued (in shares) 1,881,456 2,666,349                    
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY (Issuance of Series B Preferred Stock) (Details)
$ / shares in Units, $ in Thousands
 9 Months Ended
Jan. 06, 2016
shares
Jul. 07, 2015
$ / shares
shares
Mar. 05, 2014
USD ($)
$ / shares
shares
Sep. 30, 2016
USD ($)
$ / shares
Dec. 31, 2015
$ / shares
Jan. 24, 2013
$ / shares
shares
Class of Stock [Line Items]            
Private placement, net (in shares) | shares 6,780,179 1,500,000        
Preferred stock, par value (in dollars per share)       $ 0.01 $ 0.01  
Share price (in dollars per share)   $ 1.42        
Private placement, net | $       $ 500    
Series B preferred stock            
Class of Stock [Line Items]            
Conversion ratio 1          
Third Security LLC and affiliates            
Class of Stock [Line Items]            
Common stock warrant, exercise price (in dollars per share)     $ 11.73     $ 12.96
Common stock warrant, common stock called (in shares) | shares     1,212,665     1,097,600
Third Security LLC and affiliates | Preferred stock | Series B preferred stock            
Class of Stock [Line Items]            
Private placement, net (in shares) | shares     1,443,297      
Preferred stock, par value (in dollars per share)     $ 0.01      
Share price (in dollars per share)     $ 4.85      
Private placement, net | $     $ 7,000      
Conversion ratio     1      
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY (Conversion of Preferred Stock) (Details)
 9 Months Ended
Jan. 06, 2016
USD ($)
$ / shares
shares
Jul. 07, 2015
shares
Sep. 30, 2016
$ / shares
shares
Dec. 31, 2015
$ / shares
shares
Conversion of Stock [Line Items]        
Preferred stock, par value (in dollars per share) | $ / shares     $ 0.01 $ 0.01
Preferred stock, shares outstanding (in shares)     214,705 4,029,502
Number of shares of common stock dividends 4,474,825      
Private placement, net (in shares) 6,780,179 1,500,000    
Common Stock        
Conversion of Stock [Line Items]        
Number of common stock converted 2,305,354      
Private placement, net (in shares)     1,292,722  
Series A Preferred Stock        
Conversion of Stock [Line Items]        
Preferred stock, par value (in dollars per share) | $ / shares $ 0.01      
Conversion ratio 0.3333      
Dividend conversion rate per share | $ / shares $ 1.00      
Preferred stock, shares outstanding (in shares) 0     2,586,205
Number of common stock converted 862,057      
Amount of preferred dividends in arrears | $ $ 3,681,591.90      
Number of shares of common stock dividends 3,681,590      
Series B preferred stock        
Conversion of Stock [Line Items]        
Conversion ratio 1      
Preferred stock, shares outstanding (in shares) 0     1,443,297
Number of common stock converted 1,443,297      
Amount of preferred dividends in arrears | $ $ 793,236.17      
Number of shares of common stock dividends 793,235      
Series A-1 Convertible Preferred Stock and Warrants        
Conversion of Stock [Line Items]        
Conversion ratio 1      
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY (Preferred Stock Dividends) (Details) - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Stockholders' Equity Note [Abstract]    
Cumulative undeclared dividends, preferred stock $ 0 $ 4,400,000
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.5.0.2
FAIR VALUE (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Jan. 31, 2016
Feb. 28, 2012
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Jul. 07, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]              
Common stock warrants issued (in shares)         3,055,555 3,466,841  
Share price (in dollars per share)             $ 1.42
Percentage of simulated equity values below the down-round financing cut-off point         100.00%    
2012 Warrant Liability              
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]              
Common stock warrants issued (in shares)   1,200,000     3,400,000    
Share price (in dollars per share)     $ 0.28   $ 0.28    
Stock options, fair value assumptions, expected life         4 months 28 days    
Volatility (as a percent)         67.00%    
Risk-free interest rate (as a percent)         0.42%    
Fair value assumptions, expected term         1 year    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]              
Beginning balance $ 350   $ 0 $ 560 $ 350 $ 145  
Total (gains) or losses:              
Recognized in earnings     0 (385) (350) 30  
Balance at end of period     $ 0 $ 175 $ 0 $ 175  
2016 Warrant Liability              
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]              
Common stock warrants issued (in shares) 1,800,000            
Share price (in dollars per share)     $ 0.28   $ 0.28    
Volatility (as a percent)         86.00%    
Risk-free interest rate (as a percent)         1.04%    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]              
Beginning balance $ 0   $ 1,442   $ 0    
Additions         1,437    
Total (gains) or losses:              
Recognized in earnings     (12)   (7)    
Balance at end of period     $ 1,430   $ 1,430    
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCK OPTIONS (Stock Options) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2016
Sep. 30, 2015
Number of Options      
Granted (in shares) 11,250 25,250 641,560
Weighted-Average Exercise Price      
Stock options, expected to vest, outstanding (in shares) 860,411 860,411  
Stock options, expected to vest, outstanding, aggregate intrinsic value $ 0 $ 0  
Equity Incentive Plan 2006      
Number of Options      
Granted (in shares)   25,250  
Weighted-Average Exercise Price      
Granted (in dollars per share)   $ 0.84  
Employee Stock Option      
Number of Options      
Outstanding at beginning of period (in shares)   1,107,794  
Granted (in shares)   25,250  
Forfeited (in shares)   (252,589)  
Outstanding at end of period (in shares) 880,455 880,455  
Exercisable at end of period (in shares) 574,650 574,650  
Weighted-Average Exercise Price      
Outstanding at beginning of period (in dollars per share)   $ 3.45  
Granted (in dollars per share)   0.84  
Forfeited (in dollars per share)   3.28  
Outstanding at end of period (in dollars per share) $ 3.39 3.39  
Exercisable at end of period (in dollars per share) $ 4.08 $ 4.08  
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCK OPTIONS (Stock Appreciation Rights) (Details) - SARs - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Number of SARs    
Outstanding (in shares) 98,333 98,333
Exercisable (in shares) 92,558  
Weighted-Average Exercise Price    
Outstanding (in dollars per share) $ 4.14 $ 4.14
Exercisable (in dollars per share) $ 4.20  
Stock appreciation rights, nonvested (in shares) 98,333  
Stock appreciation rights, aggregate intrinsic value, outstanding $ 0  
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUBSEQUENT EVENTS (Details) - Subsequent Event
Oct. 12, 2016
USD ($)
Precipio  
Subsequent Event [Line Items]  
Business acquisition costs, projected $ 7,000,000
Equity Issued in Business Combination, Fair Value Disclosure $ 25,000,000
Percentage of shares issued 34.00%
Precipio  
Subsequent Event [Line Items]  
Business acquisition costs, projected $ 3,000,000
Debt instrument, convertible, value of exchanged shares 3,000,000
Business termination cost $ 256,500
Precipio | Minimum  
Subsequent Event [Line Items]  
Projected ownership interest in parent 62.00%
Precipio | Maximum  
Subsequent Event [Line Items]  
Projected ownership interest in parent 80.00%
EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 228 306 1 false 79 0 false 7 false false R1.htm 0001000 - Document - DOCUMENT AND ENTITY INFORMATION Sheet http://www.transgenomic.com/role/DocumentAndEntityInformation DOCUMENT AND ENTITY INFORMATION Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS) Sheet http://www.transgenomic.com/role/CondensedConsolidatedBalanceSheetsParentheticals CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS) Statements 3 false false R4.htm 1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfOperations UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1003000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveLoss UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 1004000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT Sheet http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersDeficit UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT Statements 6 false false R7.htm 1005000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.transgenomic.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101100 - Disclosure - BUSINESS DESCRIPTION Sheet http://www.transgenomic.com/role/BusinessDescription BUSINESS DESCRIPTION Notes 8 false false R9.htm 2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 2105100 - Disclosure - DISCONTINUED OPERATIONS Sheet http://www.transgenomic.com/role/DiscontinuedOperations DISCONTINUED OPERATIONS Notes 10 false false R11.htm 2106100 - Disclosure - INTANGIBLES AND OTHER ASSETS Sheet http://www.transgenomic.com/role/IntangiblesAndOtherAssets INTANGIBLES AND OTHER ASSETS Notes 11 false false R12.htm 2107100 - Disclosure - DEBT Sheet http://www.transgenomic.com/role/Debt DEBT Notes 12 false false R13.htm 2108100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.transgenomic.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 2109100 - Disclosure - INCOME TAXES Sheet http://www.transgenomic.com/role/IncomeTaxes INCOME TAXES Notes 14 false false R15.htm 2110100 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.transgenomic.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 15 false false R16.htm 2111100 - Disclosure - FAIR VALUE Sheet http://www.transgenomic.com/role/FairValue FAIR VALUE Notes 16 false false R17.htm 2112100 - Disclosure - STOCK OPTIONS Sheet http://www.transgenomic.com/role/StockOptions STOCK OPTIONS Notes 17 false false R18.htm 2114100 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.transgenomic.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 18 false false R19.htm 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.transgenomic.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 2305301 - Disclosure - DISCONTINUED OPERATIONS (Tables) Sheet http://www.transgenomic.com/role/DiscontinuedOperationsTables DISCONTINUED OPERATIONS (Tables) Tables http://www.transgenomic.com/role/DiscontinuedOperations 21 false false R22.htm 2306301 - Disclosure - INTANGIBLES AND OTHER ASSETS (Tables) Sheet http://www.transgenomic.com/role/IntangiblesAndOtherAssetsTables INTANGIBLES AND OTHER ASSETS (Tables) Tables http://www.transgenomic.com/role/IntangiblesAndOtherAssets 22 false false R23.htm 2307301 - Disclosure - DEBT (Tables) Sheet http://www.transgenomic.com/role/DebtTables DEBT (Tables) Tables http://www.transgenomic.com/role/Debt 23 false false R24.htm 2310301 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.transgenomic.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.transgenomic.com/role/StockholdersEquity 24 false false R25.htm 2311301 - Disclosure - FAIR VALUE (Tables) Sheet http://www.transgenomic.com/role/FairValueTables FAIR VALUE (Tables) Tables http://www.transgenomic.com/role/FairValue 25 false false R26.htm 2312301 - Disclosure - STOCK OPTIONS (Tables) Sheet http://www.transgenomic.com/role/StockOptionsTables STOCK OPTIONS (Tables) Tables http://www.transgenomic.com/role/StockOptions 26 false false R27.htm 2401401 - Disclosure - BUSINESS DESCRIPTION (Details) Sheet http://www.transgenomic.com/role/BusinessDescriptionDetails BUSINESS DESCRIPTION (Details) Details http://www.transgenomic.com/role/BusinessDescription 27 false false R28.htm 2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narratives) (Details) Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesNarrativesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narratives) (Details) Details http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesTables 28 false false R29.htm 2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Accounts Receivable) (Details) Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Accounts Receivable) (Details) Details http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesTables 29 false false R30.htm 2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Inventories) (Details) Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesInventoriesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Inventories) (Details) Details http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesTables 30 false false R31.htm 2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details) Sheet http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details) Details http://www.transgenomic.com/role/SummaryOfSignificantAccountingPoliciesTables 31 false false R32.htm 2405402 - Disclosure - DISCONTINUED OPERATIONS (Narratives) (Details) Sheet http://www.transgenomic.com/role/DiscontinuedOperationsNarrativesDetails DISCONTINUED OPERATIONS (Narratives) (Details) Details http://www.transgenomic.com/role/DiscontinuedOperationsTables 32 false false R33.htm 2405403 - Disclosure - DISCONTINUED OPERATIONS (Revenues and Net Income (Loss)) (Details) Sheet http://www.transgenomic.com/role/DiscontinuedOperationsRevenuesAndNetIncomeLossDetails DISCONTINUED OPERATIONS (Revenues and Net Income (Loss)) (Details) Details http://www.transgenomic.com/role/DiscontinuedOperationsTables 33 false false R34.htm 2405404 - Disclosure - DISCONTINUED OPERATIONS (Assets and Liabilities Held for Sale) (Details) Sheet http://www.transgenomic.com/role/DiscontinuedOperationsAssetsAndLiabilitiesHeldForSaleDetails DISCONTINUED OPERATIONS (Assets and Liabilities Held for Sale) (Details) Details http://www.transgenomic.com/role/DiscontinuedOperationsTables 34 false false R35.htm 2405405 - Disclosure - DISCONTINUED OPERATIONS (Allowance for Doubtful Accounts) (Details) Sheet http://www.transgenomic.com/role/DiscontinuedOperationsAllowanceForDoubtfulAccountsDetails DISCONTINUED OPERATIONS (Allowance for Doubtful Accounts) (Details) Details http://www.transgenomic.com/role/DiscontinuedOperationsTables 35 false false R36.htm 2406402 - Disclosure - INTANGIBLES AND OTHER ASSETS (Details) Sheet http://www.transgenomic.com/role/IntangiblesAndOtherAssetsDetails INTANGIBLES AND OTHER ASSETS (Details) Details http://www.transgenomic.com/role/IntangiblesAndOtherAssetsTables 36 false false R37.htm 2407402 - Disclosure - DEBT (Schedule of Debt) (Details) Sheet http://www.transgenomic.com/role/DebtScheduleOfDebtDetails DEBT (Schedule of Debt) (Details) Details http://www.transgenomic.com/role/DebtTables 37 false false R38.htm 2407403 - Disclosure - DEBT (Revolving Line and Term Loan) (Details) Sheet http://www.transgenomic.com/role/DebtRevolvingLineAndTermLoanDetails DEBT (Revolving Line and Term Loan) (Details) Details http://www.transgenomic.com/role/DebtTables 38 false false R39.htm 2407404 - Disclosure - DEBT (Convertible Promissory Notes) (Details) Notes http://www.transgenomic.com/role/DebtConvertiblePromissoryNotesDetails DEBT (Convertible Promissory Notes) (Details) Details http://www.transgenomic.com/role/DebtTables 39 false false R40.htm 2408401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.transgenomic.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.transgenomic.com/role/CommitmentsAndContingencies 40 false false R41.htm 2409401 - Disclosure - INCOME TAXES (Details) Sheet http://www.transgenomic.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://www.transgenomic.com/role/IncomeTaxes 41 false false R42.htm 2410402 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock) (Details) Sheet http://www.transgenomic.com/role/StockholdersEquityCommonStockDetails STOCKHOLDERS' EQUITY (Common Stock) (Details) Details http://www.transgenomic.com/role/StockholdersEquityTables 42 false false R43.htm 2410403 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details) Sheet http://www.transgenomic.com/role/StockholdersEquityCommonStockWarrantsDetails STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details) Details http://www.transgenomic.com/role/StockholdersEquityTables 43 false false R44.htm 2410404 - Disclosure - STOCKHOLDERS' EQUITY (Issuance of Series B Preferred Stock) (Details) Sheet http://www.transgenomic.com/role/StockholdersEquityIssuanceOfSeriesBPreferredStockDetails STOCKHOLDERS' EQUITY (Issuance of Series B Preferred Stock) (Details) Details http://www.transgenomic.com/role/StockholdersEquityTables 44 false false R45.htm 2410405 - Disclosure - STOCKHOLDERS' EQUITY (Conversion of Preferred Stock) (Details) Sheet http://www.transgenomic.com/role/StockholdersEquityConversionOfPreferredStockDetails STOCKHOLDERS' EQUITY (Conversion of Preferred Stock) (Details) Details http://www.transgenomic.com/role/StockholdersEquityTables 45 false false R46.htm 2410406 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Dividends) (Details) Sheet http://www.transgenomic.com/role/StockholdersEquityPreferredStockDividendsDetails STOCKHOLDERS' EQUITY (Preferred Stock Dividends) (Details) Details http://www.transgenomic.com/role/StockholdersEquityTables 46 false false R47.htm 2411402 - Disclosure - FAIR VALUE (Details) Sheet http://www.transgenomic.com/role/FairValueDetails FAIR VALUE (Details) Details http://www.transgenomic.com/role/FairValueTables 47 false false R48.htm 2412402 - Disclosure - STOCK OPTIONS (Stock Options) (Details) Sheet http://www.transgenomic.com/role/StockOptionsStockOptionsDetails STOCK OPTIONS (Stock Options) (Details) Details http://www.transgenomic.com/role/StockOptionsTables 48 false false R49.htm 2412403 - Disclosure - STOCK OPTIONS (Stock Appreciation Rights) (Details) Sheet http://www.transgenomic.com/role/StockOptionsStockAppreciationRightsDetails STOCK OPTIONS (Stock Appreciation Rights) (Details) Details http://www.transgenomic.com/role/StockOptionsTables 49 false false R50.htm 2414401 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.transgenomic.com/role/SubsequentEventsDetails SUBSEQUENT EVENTS (Details) Details http://www.transgenomic.com/role/SubsequentEvents 50 false false All Reports Book All Reports tbio-20160930.xml tbio-20160930.xsd tbio-20160930_cal.xml tbio-20160930_def.xml tbio-20160930_lab.xml tbio-20160930_pre.xml true true ZIP 67 0001043961-16-000037-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001043961-16-000037-xbrl.zip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�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end